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	ABSTRACT	
Macrophages are key players in both regulatory and inflammatory immune responses. 
They are implicated in the pathogenesis of rheumatoid arthritis (RA) where they 
accumulate in the synovium and produce pro-inflammatory cytokines including TNFα 
and IL-6. The rheumatoid synovium is metabolically distinctive, with low oxygen 
perfusion and high concentrations of lactate and reactive oxygen species (ROS). 
Macrophages are known to respond to metabolic signals, therefore we wanted to 
explore whether metabolic phenotypes of differentiated macrophages could play a role 
in the persistence of RA. We used an in vitro model of pro-inflammatory “classically 
activated” and “alternatively activated” macrophages to study macrophage behaviour 
using metabolomic and transcriptomic techniques. Differentiation with GM-CSF and 
M-CSF produced macrophages with distinctive profiles. GM-CSF macrophages were 
metabolically active, metabolising glucose, glutamine and fatty acids, while M-CSF 
macrophages utilised fatty acid β-oxidation alone. Activation of macrophages with 
LPS, LPS+IFNγ or IL-4 produced metabolic changes, however, differences between 
M-CSF groups were modest. LPS activation of GM-CSF macrophages drove both 
depletion of intracellular metabolites and transcriptional downregulation. In contrast, 
IL-4 activation of M-CSF macrophages was metabolically activating. We propose that 
the metabolic adaptability of GM-CSF macrophages may put them at an energetic 
advantage in the hypoxic, ROS-enriched rheumatoid synovium.  
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(NADPH) and oxidised (NADP+) forms 
NK Natural Killer cells 
NMR Nuclear magnetic resonance (spectroscopy) 
NO Nitric Oxide 
OA Osteoarthritis; non-inflammatory joint disease resulting from the 
mechanical breakdown of cartilage and underlying bone 
PADI Peptidylarginine deiminase; enzyme catalysing the conversion of 
protein arginine residues to citrulline 
PBMC Peripheral Blood Mononuclear Cells 
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PBS Phosphate buffered saline 
PCA Principal Component Analysis; a unsupervised clustering method 
PLS Partial least squares –R regression, -DA discriminant analysis; a set of 
supervised clustering methods 
PMN Polymorphonuclear leukocytes; a descriptive name for granulocytes - 
including neutrophils, eosinophils, basophils and mast cells - but 
commonly refers to neutrophils alone due to their relative high 
abundance 
PPP Pentose Phosphate Pathway 
PQN Probabilistic Quotient Normalisation 
PRIDE Proteomics Identifications Database; a public data repository of mass 
spectrometry (MS) based proteomics data 
RA Rheumatoid Arthritis 
RANTES 
(CCL5) 
Regulated on activation, normal T cell expressed and secreted 
RASF Rheumatoid Arthritis Synovial Fibroblasts 
ROS Reactive Oxygen Species; chemically reactive molecules containing 
oxygen, a normal byproduct of metabolism but also as an anti-
microbial defence 
RPMI 1640 Roswell Park Memorial Institute culture media 1640 
SF Synovial Fluid 
SLE Systemic Lupus Erythematosus 
STAT Signal Transducer and Activator of Transcription; intracellular 
transcription factors mediating cellular immunity, proliferation, 
differentiation and apoptosis, primarily activated by JAKs 
TCA Tricarboxylic acid cycle; also known as Citric Acid or Krebs cycle 
TGF Transforming Growth Factor 
Th1 Type 1 helper T cells; associated with immunity against intracellular 
bacteria and protozoa 
Th2 Type 2 helper T cells; associated with immunity against extracellular 
parasites, including helminths 
TLR Toll-Like Receptor 
TMA Trimethylamine 
TMB 3,3',5,5'-Tetramethylbenzidine; substrate used as a visualising agent 
in ELISA 
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TMSP 
(TSP) 
Trimethylsilyl Propanoic acid; a pH indicator commonly used in 
NMR spectroscopy 
TNF Tumour Necrosis Factor 
TSA Total Spectral Area; used as a basis for spectral normalisation 
VEGF Vascular endothelial growth factor 
VLDL Very Low Density Lipoprotein 
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1 INTRODUCTION	
Chronic inflammatory diseases are complex conditions which manifest with both 
localised and systemic pathology. They commonly feature an autoimmune component 
and involve both humoral and cellular facets of the immune system. Disease prevalence 
and onset is affected by multiple factors including genetic polymorphisms, gender, age 
and environmental components. Given the inherent complexity of these conditions 
systems biology approaches have increasingly been favoured due to their potential to 
both take into account these many aetiological factors but also to give new insights into 
the pathology at the cellular and molecular level. The work described in this thesis set 
out to apply the systems biology approach metabolomics to the investigation of chronic 
inflammatory disease rheumatoid arthritis (RA) at the cellular level, through the 
analysis of metabolic pathways in differentiated macrophages. RA is the most common 
of the chronic autoimmune diseases, affecting up to 1% of the population, and it 
provides an exemplar of the complexity of the molecular and cellular processes driving 
inflammatory diseases [1]. Some key features of rheumatoid arthritis are described 
below, as an illustration of the condition and to set in context the molecular and cellular 
studies that form the basis of this thesis. 
1.1 Rheumatoid	arthritis	
Rheumatoid arthritis is a debilitating systemic inflammatory disease, characterised by 
autoimmune destruction of the synovial joints. First characterised in the 1800’s  RA is 
the most common form of inflammatory arthritis, estimated to affect 1.2% of women 
and 0.4% of men in the United Kingdom— a risk ratio for women of 3:1 [1,2]. This 
difference between the sexes diminishes with age,  meaning the absolute risk for women 
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earlier in life is actually higher [3]. The onset of disease typically occurs between 30 
and 50 years of age [4]. RA is a complex disease with multiple clinical features, making 
diagnosis and classification difficult. The latest diagnostic criteria (2010 American 
College of Rheumatology/European League Against Rheumatism) identified 3 key 
features of the disease — symptomatic joints, symptom duration and the presence of 
antibodies or other protein markers — that were required for diagnosis of RA [5]. 
Swollen joints are the characteristic feature of the disease, and result from increased 
synovial fluid volume driven by the infiltration of immune cells and thickening of the 
synovial membrane, angiogenesis and hyperplasia with increased numbers of both 
fibroblasts and macrophages [6] (Figure 1.1).  
1.2 Autoantibodies	 in	 RA	 indicate	 immune	 processes	 are	
involved	
Rheumatoid factor (RF), an immunoglobulin M (IgM) class antibody against the 
fragment crystallisable (Fc) region of immunoglobulin G (IgG), is the classic marker 
of rheumatoid disease, but is also seen in other autoimmune conditions such as primary 
Sjögrens syndrome and systemic lupus erythematosus (SLE) [6,7]. It is normally 
present in healthy individuals — the synovium itself is a source of RF — where it binds 
with low affinity and has roles in complement fixation and immune complex clearance 
[8–10]. However, in certain conditions RF may undergo affinity maturation and 
become pathogenic [11]. RF was first proposed as a mediator of immune complex (IC) 
disease in RA during the 1960s [8]. However, many immune-mediated and infectious 
diseases also show the presence of immune complexes, therefore ICs alone are not 
sufficient to explain RA [12]. Importantly, while current diagnostic criteria include RF 
(and other RA-associated antibodies) their presence is neither necessary nor sufficient 
for the diagnosis of RA [5,13]. 
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Antibodies against citrullinated proteins have received particular attention as possible 
markers of disease. Citrullination is the process by which arginine residues in peptides 
are converted to cyclic citrullinated proteins (CCPs) by peptidylarginine deiminase 
(PADI) enzymes [14]. These altered peptides may present novel epitopes allowing 
presentation and recognition by the host immune system [15]. Anti-citrullinated protein 
antibodies (ACPA) are detectable up to ten years before the onset of disease [16]. Other 
auto-antigens implicated in RA include carbamylated proteins occurring from the 
reaction of lysine residues with cyanate to form homocitrulline [17]. Myeloperoxidase 
(MPO) catalyses the conversion of thiocyanate to cyanate, providing the source of 
cyanate for the carbamylation reaction. Auto-antibodies to carbamylated proteins are 
present in the sera of 50% of RA patients, including those with the more aggressive 
ACPA-negative form of the disease [18]. Autoantibodies targeting joint-associated 
proteoglycans and collagens, glucose-6-phosphate isomerase and heat shock proteins 
have all been identified as potential biomarkers of active disease. 
Figure 1.1. The healthy and the rheumatoid joint. In the diseased jointimmune cell infiltrate, including macrophages, dendritic, T and B cells,invade the synovial membrane releasing pro-inflammatory cytokines.Hyperplasia of the synovial lining and local angiogenesis leads to swellingof the joint. As disease progresses synoviocytes and osteoclasts co-operateto degrade the adjacent bone surface, leading to loss of function.
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1.3 Cellular	and	molecular	drivers	of	pathology	in	RA	
While diagnostic criteria and markers of disease are well defined, the mechanism 
underlying RA remains unclear. Multiple cell types have been implicated in the 
progression of disease, including fibroblast-like synoviocytes, osteoclasts, dendritic 
cells, macrophages, neutrophils and B & T lymphocytes, and it is likely that each plays 
a role in the initiation or development of active disease. In one established model of 
disease development it is suggested that the onset of disease may start through innate 
immune activation of dendritic cells, macrophages, fibroblasts and mast cells by 
complement, immune complexes and toll-like receptors (TLRs) [6]. This innate 
activation triggers the release of cytokines and chemokines, creating chemoattractant 
gradients for the infiltration of further macrophages, neutrophils, B cells and T cells 
[19]. Both chemokines and chemokine receptors are involved in regulating the process 
of leukocyte invasion [20,21]. The complexity of this process is highlighted by the fact 
that more than 50 chemokines, and 19 chemokine receptors have been identified with 
putative roles in this process [22,23]. Progression of the disease leads to the formation 
of pannus tissue — containing activated synoviocytes, osteoclasts and macrophages — 
across articular joint surfaces, driving proteinase-dependent destruction of cartilage and 
bone matrix [24]. The subsequent fusion of articular bone occurs as a result of scar 
tissue formation in a process termed ankylosis, leading to the characteristic joint 
deformity [25]. Activated synoviocytes may themselves produce pro-inflammatory 
cytokine IL-6 and matrix metallo-proteinases (MMPs) therefore driving persistent local 
inflammation [6]. During the destructive phase of the disease, receptor activator of 
nuclear factor kappa-B ligand (RANKL) driven osteoclast activation drives bone 
resorption while synoviocytes invade cartilage [6]. 
 
	 7	
Early treatment of RA is associated with better long-term patient prognosis [26]. 
Disease-modifying anti-rheumatic drugs (DMARDs) are a class of therapeutic agents 
with proven ability to reduce synovitis, lower systemic inflammation and improve joint 
function [19]. The most commonly used DMARD, methotrexate, is a folate analogue 
which inhibits folate and purine metabolism [27]. Low dose methotrexate suppresses 
proliferation of lymphocytes and leukocytes and drives leukocyte apoptosis [27,28]. 
Second line DMARDs include antibody-based biologic drugs that bind and block 
immunological targets. Both etanercept and infliximab are anti-tumour necrosis factor-
alpha (TNFα) agents, which directly neutralise pro-inflammatory TNFα and thereby 
reduce inflammation [29]. Rituximab is chimeric monoclonal antibody against cluster 
of differentiation 20 (CD20), a B cell surface marker which acts to severely deplete 
peripheral B cell populations and lower antibody titre [30]. Anti-interleukin 6 receptor 
(IL-6R) antibody Tocilizumab competitively binds both soluble and membrane-bound 
forms of the receptor, inhibiting the inflammatory effects of interleukin 6 (IL-6) [31]. 
While these treatments are all able to regulate and slow progression of disease, none 
can bring about complete remission and not all patients respond. Biologic treatments 
are expensive and there has been interest in finding prognostic biomarkers. 
1.4 Genetic	and	environmental	factors	increase	risk	of	RA	
Early commencement of therapy has beneficial effects on patient outcomes, however 
prediction of disease onset and progression remains poor. Genome-wide association 
studies have identified single-nucleotide polymorphisms in immunologically related 
genes associated with an increased risk of disease. These include the human leukocyte 
antigen (HLA) alleles involved in antigen recognition, peptidyl-arginine deiminase 
type IV (PAD4) controlling production of immunogenic cyclic citrullinated proteins 
(CCPs) and tyrosine phosphatase Lyp (PTPN22) variants with a role in T cell 
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signalling. Single nucleotide polymorphism (SNPs) in these genes have been associated 
with increased incidence of RA [32]. However, twin concordance studies give an upper 
limit on the contribution of genetic factors of only 60% [33].  
 
Studies have also demonstrated a role for environmental triggers in the development of 
disease [34]. Smoking is associated with anti-citrulline immunity and ACPA-positive 
RA [35]. Proposed mechanisms include the induction of reactive oxygen species 
(ROS), decreased circulating antioxidants and lipopolysaccharide (LPS) in inhaled 
smoke [35–38]. Smoking activates macrophages and dendritic cells via TLRs, 
promotes migration of neutrophils, induces necrosis with associated damage-
associated molecular pattern (DAMP) release and impairs macrophage engulfment of 
apoptotic cells [39–42]. The presence of RA-associated antibodies before joint 
inflammation and their association with mucosal insults such as smoking suggest that 
RA immune reactions may originate at extra-articular locations, including particularly 
respiratory, oral intestinal mucosal sites [16,43,44]. Following activation of adaptive 
immunity at mucosal sites, antibodies are circulated via the lymphatics and blood to the 
joints [16,43]. Subsequent migration of B and T cells to the synovium drives 
organisation into discrete lymphoid-like aggregates and leads to adaptive immune 
responses in individuals with genetic predisposition [6]. Gene-environment interactions 
compound this risk, for example an interaction between human leukocyte antigen  
DRB1 (HLA-DRB1), PTPN22 and smoking has been demonstrated in RA [45]. In 
individuals with both genetic risk factors the odds ratio (OR) of developing RA is 13.2, 
with genetic risk factors and a history of smoking this rises to 23.4. However, while 
these gene variants and environmental triggers quantify risk, they cannot predict onset 
of disease, subsequent disease severity or response to treatment [46]. The mechanism 
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that drives an individual from high risk yet healthy to active and progressive disease is 
unknown. Due to the complexity of the disease there has been an increasing interest in 
the use of ‘—omics’ approaches, such as metabolomics, proteomics or transcriptomics, 
to study the disease. 
1.5 Metabolomics	
Metabolomics is the systematic study of the small molecular weight chemical 
fingerprints that result from cellular processes. In clinical metabolomics the goal is 
typically the identification of predictive diagnostic biomarkers that can be measured 
non-invasively from patient urine, plasma or serum. This approach has met with success 
in the analysis of inflammatory diseases, with specific metabolite profiles having 
predictive ability for a number of conditions including ulcerative colitis, rheumatoid 
arthritis and multiple sclerosis, as previously reviewed by our group (Table 1) [47–50]. 
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Metabolite  Fluids Associations References 
Amino acids 
Glycine   pRA† [51] 
Essential Protein 
breakdown 
Serum pOA [52] 
Citric acid cycle intermediates 
Oxaloacetate  CSF, VF pIIH, pLIU [49] 
Citrate  CSF qIIH [49] 
Malate  Urine pOA† [53] 
Creatinine  CSF pMS [54] 
Ketone bodies Acetyl-CoA, 
fatty acid, 
amino acid 
breakdown.  
SF, CSF pRA, pMS [55–57] 
Lactate Hypoxia, 
oxidative 
damage. 
SF, 
Urine, 
CSF 
pRA, pOA†, 
pIIH, pMS 
[48,53,54] 
Lipids     
Oxylipids   NSAIDs [58,59] 
Phospholipid metabolites and esters  Simvastatin [60] 
Lipoprotein-
associated fatty 
acids 
Resting energy 
source 
SF, 
Blood 
pIA, pOA [61] 
Organic acids 
Acetate  Faecal qCD [62] 
Butyrate  Faecal qCD, qT1D [62,63] 
Formate  Urine pCD [62] 
Purine and pyrimidine derivatives    
Uracil   pRA† [51] 
Xanthine   pRA† [51] 
Trimethylamine  Urine pIBD, 
pIBD†, qCD 
[62,64] 
Urea  VF p LIU [65] 
Xanthurenic acid   pCD [66] 
Table	1.	Key	metabolites	and	their	association	with	inflammatory	diseases.	Selected	from	current	literature	arranged	according	to	the	major	themes	discussed.	RA	–	Rheumatoid	arthritis;	IA	–	Inflammatory	arthritis;	OA	–	Osteoarthritis;	IIH	–	idiopathic	intracranial	hypertension;	MS	–	Multiple	sclerosis;	LIU	–	Lens	induced	uveitis;	CD	–	Crohn’s	disease.	CSF	–	Cerebrospinal	fluid,	VF-	Vitreous	fluid,	SF	-	Synovial	fluid.	†Animal	model.	Adapted	from	[50].		
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Due to the complex nature of metabolomic data, typically containing measurements for 
hundreds or thousands of metabolites, multivariate analysis methods are preferred. The 
most commonly used methods are principal component analysis (PCA) (Figure 1.2) 
and partial least squares (PLS) which are unsupervised and supervised methods 
respectively [67].  
 
In unsupervised analyses no influence is given to the development of the statistical 
model outside of the measured variables. The resulting model describes the largest 
metabolite variation between samples without regard to sample classifications. The 
output of PCA is a projection of the original data into a series of correlated orthogonal 
principal components, which attempt to describe variation within the original dataset. 
The variables selected in principal component (PC) 1 describe the largest correlated 
variation in the data, PC 2 describes the next largest after subtraction of PC1 and so on 
for each subsequent PC. Samples are projected into the new component space using 
relative scores derived from their individual metabolite profiles. Separation between 
samples in the projected space represents true differences between the samples original 
data, and the transformation is reversible. If the largest source of variation is between 
experimental groups PCA can be sufficient to answer experimental questions. 
However, in noisy or heavily confounded data — often the case with biological samples 
— it may be necessary to adjust the statistical model to isolate variation of interest. 
Supervised methods therefore use specific variation in the dataset to predict another 
property. In a metabolomic context for example, it is possible to perform PLS 
regression to explore relationships between metabolites and other features such as 
disease activity, progression or severity. The related technique partial least squares 
discriminant analysis (PLS-DA) is an adaptation of PLS regression for binary 
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classification. Both unsupervised and supervised approaches result in statistical models 
which describe the relationships between samples in the training set, but can also be 
applied to new data for classification purposes. Because they include covariate 
variables models derived using PCA or PLS are often unnecessarily complex, including 
variables which do not contribute to the power of the model. Selection may be applied 
to iteratively simplify models while retaining accuracy. This can be of particular value 
when applying the statistical model to subsequent data.   
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Figure 1.2. Principal component analysis is a statistical approach usingorthogonal transformations to extract information from complex data. (A)An example dataset with 2 variables (x, y) where the variation betweensamples is best described by a combination of both variables (red line) or
principal component (PC) 1. (B) By transforming the dataset, this variationcan be projected as PC1, while orthogonal variation lies in the secondcomponent. (C) In complex data multiple variables contribute to each PCwith variable weights reflecting the contribution of a given variable to thecomponent. High weights in a PC reflect variables that are high in sampleswith high scores, or low in samples with low scores.
CPC2
PC1
A B
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In clinical metabolomics, where the goal is the development of reusable biomarkers, 
biological interpretation of the resulting metabolomic profile is often unnecessary. 
Further, as metabolite markers have typically been metabolised en route from the site 
of disease there is limited potential for functional understanding. This has been 
demonstrated in metabolomic studies of ulcerative colitis where distinct metabolomic 
profiles were found in urinary and serum, and urinary and faecal analysis [47,62,68]. 
The synovium exhibits similar compartmentalisation effects and substantial differences 
have been measured between the synovial and systemic metabolome measured with 
synovial fluid and matched serum profiles respectively [55].  
1.6 Metabolomics	of	rheumatoid	arthritis	
Rheumatoid arthritis is particularly interesting from a metabolomic perspective due to 
the combination of local and systemic involvement, the compartmentalisation of the 
synovial site and the evidence of tissue hypoxia during active disease [69]. Chronic 
inflammation drives significant alterations in systemic metabolism in a process known 
as rheumatoid cachexia. Changes in lipids are seen in the years prior to the 
manifestation of any RA symptoms which may relate to the pre-disease immune 
activity which leads to the development of autoantibodies against citrullinated proteins 
[16,70,71]. Systemically RA patients exhibit a perturbed resting metabolic rate up to 
8% higher than healthy controls [72]. Although the mechanism for the increased 
metabolic rate seen in RA is yet to be elucidated, it is reasonable to suggest that the 
inflammatory process is a major contributor. The fact that joints are hot in inflammatory 
arthritis is a strong indicator of increased local metabolism. Raised synovial glycolytic 
activity has been demonstrated in RA patients, with a radiolabelled, non-degradable, 
glucose analogue (18-F-deoxyglucose) shown to accumulate preferentially in the joints 
via positron emission tomography (PET) scan [73]. The same technique has also been 
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used to demonstrate enhanced metabolic activity in extra-articular sites, including 
subcutaneous nodules and lymph nodes, in active RA [74]. Metabolic dysregulation 
itself  has been implicated in RA comorbidity with up to 40% of patients with long 
standing RA also displaying insulin resistance, atherosclerosis and other features of 
metabolic syndrome [75]. These metabolic effects contribute greatly to the impact of 
the disease. Male RA mortality from cardiovascular disease is 1.5x higher than the 
general population, while women are 3.10x more likely to suffer a myocardial 
infarction after 10 years of disease [76,77]. Insulin resistance in RA patients is thought 
to relate directly to impaired glucose metabolism in these patients [78]. 
 
Synovial fluid of patients with active RA has been reported to contain high levels of 
lactate, low levels of glucose and lower very low density lipoprotein (VLDL) 
cholesterol and higher ketone bodies indicating increased utilisation of fats for energy 
[48,55]. Synovial inflammation is accompanied by angiogenesis, yet the raised synovial 
cavity pressure inhibits perfusion while the intermittent occlusion of vessels resulting 
in reduced total O2 perfusion and reperfusion injury leading to the production of 
reactive oxygen species and local tissue damage [79,80]. Reactive oxygen species 
resulting from both reperfusion and infiltrating leukocytes depolymerise synovial 
hyaluronic acid leading to cartilage destruction [81]. In a study comparing the plasma 
of RA patients with active disease to those with controlled disease and healthy controls 
it was shown that patients with active RA had higher levels of plasma cholesterol, 
lactate, acetylated-glycoprotein and lipids [61]. Metabolites associated with 
tricarboxylic acid  (TCA) cycle, urea, fatty acid and amino acid metabolism have all 
been identified as potential biomarkers for RA [82]. Synovial fibroblast cells show a 
metabolic shift in RA from oxidative phosphorylation to glycolysis, while fibroblast 
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cytokine secretion, proliferation and migration correlate with glucose transporter 
expression [83]. Glucose starvation or glycolytic inhibition have both been shown to 
reduce disease severity in animal models of arthritis [83]. These are encouraging 
indications that metabolomics may be a useful approach to study RA. 
 
The classical signs of inflammation — dolor, calor, rubor and tumor— are all 
indicative of local changes in the tissue, both influencing and under the influence of 
metabolism. Redness and heat are caused by the increase in flow of core-temperature 
blood to the site, which itself affects the local nutrient supply and oxygenation of 
tissues. Cytokines released by immune cells alter blood vessel permeability, leading to 
swelling, while the production of reactive oxygen species and reactive nitrogen species 
by macrophages and neutrophils irritates nerve endings causing pain. Infiltrating cells 
also raise the metabolic load on the tissues. The production of reactive oxygen species 
consumes considerable oxygen, adenosine 5’-triphosphate (ATP) and reduced 
nicotinamide adenine dinucleotide phosphate (NADPH), while neutralisation of free 
radicals consumes glutathione, putting metabolic stress on surrounding tissues [84].  
 
Inflammation is an energy-intensive process with the production of phagocytes alone 
consuming approximately 7.9x105 J [85–87] during an infectious episode, while 
infiltration, differentiation and activation of leukocytes all put metabolic demands on 
local tissues. The relationship between inflammation and metabolism is most clearly 
demonstrated in cachexia, where the loss of tissue mass is driven by TNFα, a mediator 
of the inflammatory response [88,89]. However, the link between the mammalian 
systems of metabolic and immune control extends far beyond acute inflammation. Both 
metabolic and immune systems share a common evolutionary precursor — the fat body 
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organ — and this association persists in mammalian biology [90]. Lymph nodes are 
embedded in adipose tissue and visceral fat is heavily infiltrated with macrophages, 
with both visceral fat macrophages and adipocytes contributing to systemic 
inflammation through the production of inflammatory cytokines [88,91]. 
 
Metabolomic analysis of synovial fluid and fibroblasts has identified multiple altered 
metabolites associated with RA, including increases in citrulline, succinate, glutamine, 
octadecanol, isopalmitic acid, lactate glycerol, taurine and cholesterol ester and 
decreases in the tryptophan pathway comprising kynurenine, indoleacetic acid, indole 
acetaldehyde, and N-formylkynurenine [82,92,93]. The reported changes are associated 
with the urea cycle, tricarboxylic acid cycle (TCA) cycle, fatty acid metabolism 
(including β-oxidation) and amino acid metabolism [82]. There are also differences 
between genders, with choline levels in RA females increased compared to those in RA 
males [93]. An increased lactate:glucose ratio has been observed in both plasma and 
synovial fluid of patients with rheumatoid arthritis and has been shown to correlate with 
active inflammation and oxidative damage [48]. In aerobic conditions oxidative 
phosphorylation is the most energetically efficient mechanism to generate ATP. 
However, while glycolysis is energetically inefficient, proliferating cells may still 
preferentially use it to support biomass and amino acid production [94,95]. During this 
aerobic glycolysis the majority of carbon, nitrogen and energy for cell growth and 
division may be met by glucose and glutamine.  
 
Oxidative phosphorylation is the mitochondrial process whereby NADH and succinate 
from the tricarboxylic acid (TCA) cycle are oxidised, releasing electrons which are 
transferred through a series of redox reactions from donors to acceptors. These redox 
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reactions release energy, which is used to transfer protons across the inner 
mitochondrial membrane, creating a proton (pH) gradient which is in turn used to 
regenerate ATP from adenosine 5’-diphosphate (ADP) by ATP synthase. The ATP 
generation from oxidative phosphorylation is therefore dependent on the TCA cycle to 
function. The TCA cycle however also has other important roles in cellular 
biosynthesis, with intermediate metabolites depleted — in a process termed 
cataplerosis —primarily for the synthesis of fatty acids and non-essential amino acids. 
This balance between biomass and energy is one of the key regulatory processes in the 
cell. Replenishment of metabolites in the TCA cycle — anaplerosis — occurs from 
multiple sources. The cardinal route for glycolytic carbon to enter the TCA cycle is via 
conversion of pyruvate to acetyl-coenzyme A (acetyl-coA) or oxaloacetate [96]. 
However, pyruvate from the glycolytic pathway may also be metabolised to malate in 
the cytosol, being subsequently metabolised to oxaloacetate in the mitochondria. 
Amino acids may replenish the TCA cycle, with aspartate metabolised directly to 
oxaloacetate and glutamate metabolised to α-ketoglutarate. This latter route offers the 
mechanism whereby glutamine, converted to glutamate by glutaminolysis, can enter 
the TCA cycle during anaerobic glycolysis to support biomass generation. Other amino 
acids, including leucine, isoleucine, lysine, phenylalanine, tryptophan, and tyrosine 
may be converted into acetyl-CoA for metabolism. Beta-oxidation of fatty acids may 
also be used to generate acetyl-coA. Metabolites of the citric acid cycle have been found 
to be diagnostic in a number of non-inflammatory diseases. For example, raised urine 
malate is a predictor of disease progression in the Hartley guinea pig model of OA, 
while raised oxaloacetate and reduced citrate are seen in idiopathic intracranial 
hypertension [49] [53]. 
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Energy requirements for non-proliferative tissues are predominantly met by the 
oxidation of free fatty acids [97]. Part-metabolism of fatty acids in the liver forms 
ketone bodies, which are subsequently re-circulated to the tissues as an energy source 
[98]. Inflammatory arthritis has been associated with raised synovial fatty acids, while 
systemic reduction of chylomicron and VLDL triglycerides suggests utilisation of fats 
as an energy source [61]. Ketone bodies have also been associated with inflammatory 
disease, including raised synovial fluid concentrations of ketone bodies, particularly 
3-hydroxybutyrate, in patients with rheumatoid arthritis [55–57]. Similar observations 
in the rat air pouch model of localised inflammation [99] suggest that presence of 3-
hydroxybutyrate may be a signature of immune cell metabolism of lipids under the 
hypoxic conditions. 
1.7 Hypoxia	and	the	inflamed	joint.	
Physiological levels of oxygen are between 1-12% depending on tissue location and 
perfusion [100,101]. Inflamed sites are often more hypoxic than healthy tissues, due a 
combination of increased metabolic demands of local tissues, invading leukocytes, 
blood vessel occlusion resulting from inflammation or tissue structure, as in the 
rheumatoid synovium. In chronically inflamed or sclerotic tissues oxygen perfusion can 
be held as low as 0.5-2.5% [102,103]. Synovial fluid of RA patients is hypoxic with a 
median partial pressure of O2 (pp02) of 2-4% compared to 9-12% in non-RA patients 
[104,105]. This is further supported by the detection of low-molecular-weight 
metabolites consistent with an anaerobic metabolism [106]. An inverse correlation 
between inflammatory cell infiltration and synovial oxygen tension has been 
demonstrated [107,108]. Tissue hypoxia has been most extensively studied in cancer, 
where tumour growth and cellular metabolism exceed the capacity of the local blood 
supply [109]. The mechanism in RA is thought to be similar, with inflammation 
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expanding the synovial lining from 1-2 cells thick to several layers through 
hyperproliferation and immune cell infiltration [110]. This increase in synovial tissue 
mass results in increased local oxygen consumption but reduced perfusion [111].  
 
The ‘master regulators’ of responses to cellular responses to hypoxia are the hypoxia-
inducible factor (HIF) family of transcription factors [109,112]. By this mechanism 
cells are able to adapt their metabolism to the local oxygen saturation. HIF is stabilised 
in low oxygen, resulting in induction of transcription of a number of genes including a 
number of glycolytic enzymes [113,114]. HIF signalling activation leads to changes in 
expression of ~1% of human genes, including genes related to metabolism (e.g. 
glyceraldehyde-3-phosphate dehydrogenase GAPDH and glucose transporters 
GLUT1), pH regulation, erythropoiesis, angiogenesis and apoptosis [109,112,115]. 
Inactivation of hypoxia-inducible factor 1-alpha (HIF-1α) in mouse has been shown to 
lead to macrophages with reduced bactericidal capacity [116]. Further, in the collagen 
induced arthritis (CIA) mouse model of RA, HIF-1α deficiency led to reduced 
infiltration of macrophages [117]. HIF-1α has also been shown to promote TLR-
signalling induced inflammation in rheumatoid arthritis synovial fibroblasts (RASFs) 
[118] and promote the expression of inflammatory cytokines [119]. Neutrophils and 
macrophages in contrast have been considered intrinsically adapted to low oxygen 
conditions, making preferential use of glycolysis for their ATP requirements under 
normal physiological oxygen conditions [113]. Direct effects of stimulation with TLR 
ligands on RA synovial fibroblasts (RASF) have also been reported, including 
increased expression inflammatory cytokines, metalloproteinases and vascular 
endothelial growth factor (VEGF) [118]. HIF-1α has been shown to promote 
interactions between RASFs and T & B cells and overexpression of HIF-1α enhances 
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RASF mediated T helper 1 (Th1) and T helper 17 (Th17) cell expansion [118,119]. 
However, the effects of hypoxia are not through HIF-1α alone. Hypoxia also drives 
activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), 
thereby regulating the release of pro-inflammatory cytokines and growth factors 
through HIF-α-dependent and HIF‑α-independent mechanisms [120,121]. Hypoxia 
and reperfusion may also indirectly lead to oxidative damage via generation of reactive 
oxygen species (ROS) [107,122,123]. 
 
Tissue homeostasis is dependent on the regulated uptake and excretion of energy 
sources and waste. Inflammation can upset this balance through the combination of 
local tissue damage and the influx of inflammatory cells. This is seen in models of 
inflammation where expression of inflammatory interleukin 1-beta (IL-1β) is associated 
with increases in leucine, isoleucine, valine, n-butyrate and glucose [124]. Conversely, 
supplementation with branch chain amino acids has also been shown to drive an 
increase in Th1-like responses via IL-1β [125]. The catabolism of amino acids produces 
ammonia that must be converted to urea for excretion via the urine. In poorly perfused 
tissues, urea and other nitrogenous base carries can accumulate. For example, analysis 
of vitreous humour from patients with ocular inflammation has shown raised urea in 
lens-induced uveitis (LIU) [65]. Similarly, trimethylamine (TMA) has been shown to 
correlate with disease progression in inflammatory bowel disease (IBD) by urine and 
faecal metabolomic analysis [62]. Tissue-derived metabolites can also provide specific 
indicators of damage. For example, hyaluronic acid is released following the 
breakdown of articular cartilage proteoglycans by reactive oxygen species [81]. 
Hypoxia induces profound changes in metabolism of joint fibroblasts including 
increased output of lactate, which may result from damage to mitochondria [126]. 
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Lactate has been shown to enhance cell migration and induce functional polarisation of 
the other major cell type in the RA synovium — the macrophage [127].	
1.8 Macrophages	
Many cells of the myelomonocytic lineage, including dendritic cells and osteoclasts, 
are implicated in RA. However, we considered macrophages to be of particular interest 
for a number of reasons. Firstly, macrophage infiltration and activation correlates 
directly with severity, radiological progression and with joint destruction in RA 
[128,129]. Secondly, multiple susceptibility loci for RA are associated with 
macrophage function or homeostasis including CD30, TNFα, interleukin 1 receptor 
associated kinase 1 (IRAK1), TNF-receptor associated factor 1 & 6 (TRAF1/TRAF6), 
interferon regulatory factor 5 (IRF5) and recombination signal binding protein for 
immunoglobulin kappa J (RBPJ) [130–132]. Thirdly, there is a direct association 
between clinical improvement and altered macrophage function independent of 
therapeutic strategy [133]. Methotrexate directly impairs blood monocyte chemotaxis 
and pro-inflammatory production [134,135]. Corticosteroids downregulate monocyte 
inflammatory cytokine production through both transcriptional and post-transcriptional 
mechanisms [136]. Efficacy of classical anti-rheumatic therapies, including 
leukapheresis and injection of intramuscular gold, is associated with reduced activity 
of the mononuclear phagocyte system and both treatments are shown to have 
macrophage-specific effects [137–139]. Biological therapies specifically targeting 
macrophage cytokine TNFα have also demonstrated remarkable efficacy in acute 
disease with long-term efficacy limiting radiological disease progression [140,141]. 
Finally, macrophages display remarkable adaptability with both pro- and anti- 
inflammatory phenotypes and ability to adapt to specialised functions in different 
tissues. Macrophages are considered unlikely candidates as initiators of disease yet 
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strong candidates as promoters and mediators of both acute and chronic inflammation 
[128]. The functional plasticity of macrophages and the availability of inhibitors for 
both signalling pathways and metabolic enzymes also make macrophages a promising 
target for novel drug treatment [142,143].  
 
Macrophages are a family of leukocytes with important roles in tissue homeostasis and 
innate and adaptive immune responses [144]. They form highly diverse populations in 
multiple tissues and organs where they have varied functions [144–147]. Until recently 
most tissue macrophages were thought to be derived from circulating monocytes, but 
recent fate-mapping experiments have challenged this concept [148–151]. 
Macrophages may derive from both yolk-sac, foetal liver or bone marrow-derived 
monocytes. The different precursor populations have been shown to be responsible for 
resident macrophage populations in different tissues, including yolk-sac macrophages 
for microglia in the brain, foetal liver macrophages for Kupffer cells in the liver and 
alveolar macrophages and bone marrow-derived for dermal, gut and cardiac resident 
populations [148]. Bone marrow-derived monocytes differentiate sequentially in the 
bone marrow from monoblasts to pro-monocytes which in turn migrate into the blood 
and circulate making up 5-10% of peripheral blood leukocytes [144,152]. Mature 
monocytes circulate for approximately 3 days before migrating into the tissues [153]. 
Two sub-populations are identified in the circulation, termed classical monocytes and 
non-classical monocytes [154]. The former are CD14hi CD16- and migrate from the 
blood shortly after maturation, differentiating to tissue-resident macrophages or 
dendritic cells. The latter are CD14+ CD16+ and remain resident in the blood, with a 
putative role in maintenance of the endothelial lining of blood vessels, as a pool for 
inflammatory recruitment, and as a reserve for tissue populations [155–157]. It is not 
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known whether these sub-populations of macrophages are predefined in the marrow, 
however evidence from animal models suggests that differentiation from classical to 
non-classical monocytes occurs in the blood and that tissue phenotypes are determined 
by timing [154,158]. The origin of synovial tissue macrophages remains an open 
question. Fate-mapping in mice has given conflicting evidence that populations are yolk 
sac or foetal liver derived [148–151]. Self-renewing populations have also been 
described and there is evidence for blood monocyte recruitment during inflammation 
leading to persistent populations [150,151,159–161]. Early in development 
macrophages appear in various organs, deriving from the yolk sac or hematopoietic 
stem cells and taking up key strategic positions in the organs with important roles in 
homeostasis, clearance of senescent cells, tissue remodelling and repair [147,148,162]. 
Tissue macrophage populations are maintained by proliferation in the tissues, with 
minimal contribution from circulating bone-marrow derived macrophages [151,163].  
 
Macrophages are broadly classified according to a binary ‘classical’ or ‘alternative’ 
activation system first proposed by Goerdt et al. in 1999 based on the differential effects 
of IFNγ and interleukin 4 (IL-4) on macrophage gene expression respectively [164–
166]. The ‘classical activation’ definition was later expanded from IFNγ alone to 
include activation with either IFNγ or TLR agonists including LPS [165,167]. Later an 
updated terminology defining M1/M2 classification was proposed by Mills et al. in 
[168] based on murine experiments, correlating these macrophage subsets directly to 
the T helper cell 1/2 (Th1/Th2) dichotomy and proposing that the balance between 
inflammation and healing was governed by the M1 to M2 transition [168,169]. More 
recently it has been suggested that the M1/M2 classification represents extremes on a 
spectrum of functional states and the M2 nomenclature was expanded to include 
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different activation scenarios (M2a-c) reflecting stimulation with IL-4/IL-13, immune 
complexes and IL-10 [144,155,165,170–174]. Confusingly, a further classification, 
which defines M1 and M2 macrophages as those differentiated under granulocyte 
macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating 
factor (M-CSF) respectively [175,176] has also been used. While the resulting 
macrophages are both polarised and distinctive, they do not fit comfortably in the 
M1/M2a-c nomenclature [177,178]. Due to the potential for confusion Murray et al. 
have proposed dispensing with the M1/M2a-c nomenclature and describing 
macrophages in terms of their differentiation background (M-CSF/GM-CSF) and 
activating stimulus, e.g. M(LPS) or M(IL-4) to remove ambiguity [178]. The use of 
GM-CSF/M-CSF as a basis of M1/M2 subsets was discouraged. 
 
In this study we were primarily interested in macrophages matching the M1 and M2a 
activation profiles — M(LPS) or M(LPS+IFNγ) and M(IL-4) using the Murray 
nomenclature — due the potential role for these subsets in RA inflammation and 
resolution. However, given the high concentrations of GM-CSF in the rheumatoid joint 
we also thought it prudent to explore the effect of GM-CSF vs. M-CSF on macrophage 
differentiation and subsequent activation, matching somewhat the Verreck M1-M2 
model [176,179]. There follows a brief review of current knowledge regarding M1 and 
M2/M2a macrophage activation at both the phenotypic and metabolic level.  
1.8.1 Classical	activation	(M1)		
Classically activated macrophages, also referred to as ‘M1’ macrophages, are pro-
inflammatory effector cells (Figure 1.3). In response to IFNγ produced by activated 
CD4+ Th1 cells, CD8+ cytotoxic cells and natural killer (NK) cells they exhibit 
microbicidal and tumoricidal effector functions and secrete pro-inflammatory 
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cytokines [155,180]. Progression from priming to activation is dependent on secondary 
stimulation of IFNγ primed macrophages with TNFα which drives transcriptional 
changes via NFkB to induce autocrine production of TNFα [180]. Autocrine production 
of TNFα allows macrophages to self-activate in the presence of conserved bacterial 
pathogen associated molecular patterns (PAMPs) such as LPS — a strong activator of 
macrophages through TLR4 [155]. Classical activation is canonically regulated by NF-
κB and IRFs following LPS bound TLR4 engagement of PI3K, which in turn drives 
protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) 
activation [181,182]. Other TLR ligands can drive gene transcriptional changes via 
NFkB or mitogen-activated protein kinase (MAPK) pathways in a myeloid 
differentiation primary response 88 (MyD88) dependent manner [180]. The mitogen-
activated protein kinase kinase (MAP2K/MEK),  extracellular signal–regulated kinases 
(ERK) and inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β) pathways 
have also been implicated suggesting the process of activation is more complex [183]. 
Activation results in surface upregulation of HLA class II, TLRs and CD86, promoting 
antigen presentation, further sensitivity to PAMPs and co-stimulatory signals for the 
activation of T cells, respectively. Increased phagocytosis is also observed [184–186].  
 
Classically activated macrophages produce a wide array of pro-inflammatory cytokines 
including TNFα, IL-1β, IL-6, IL-12 and IL-23 [165]. IL-12 drives naïve T cell 
differentiation to T0, stimulating production of IFNγ, which in turn primes monocytes 
for activation. IL-1β, IL-6 and IL-23 drive development and expansion of pro-
inflammatory Th17 populations. High levels of IL-1β are also produced by classically 
activated macrophages while IL-1R antagonist and the decoy IL-1 type II receptor are 
downregulated [155,180]. M1 macrophage production of chemokine (C-X-C motif) ligand 
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9, 10 & 11(CXCL9, CXCL10 & CXCL11) recruits NK and T cells to the locality, while 
IL-17 promotes recruitment of neutrophils.  
 
M1 differentiation and activation is associated with metabolic changes, including an 
increase in glycolytic metabolism, mediated at least in part by induced expression of 
pro-glycolytic 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) 
isoform 74 and the phosphorylation of hexokinase by activated Akt [84,187]. Activated 
Akt also upregulates endosomal recycling of glucose transporter 1 (Glut1) to increase 
cell surface expression and potential for glucose uptake [188]. This preferential use of 
glycolysis allows for dynamic upregulation of ATP generation in response to 
replicating bacteria and may provide M1 macrophages with an energetic advantage in 
hypoxic tissues [189,190]. Increases in expression of glycolytic enzymes have been 
reported during phagocytosis in murine macrophages [191]. Both aerobic and anaerobic 
metabolism of glucose, and the oxidation of both glutamine and glutamate have been 
shown to contribute to cellular ATP in activated macrophages [192]. In contrast 
oxidative phosphorylation is reported to be downregulated in M1 macrophages with 
minimal flux of TCA metabolites [193]. Reactions of oxidative phosphorylation are 
directly inhibited by nitric oxide production [194] while mitochondrial export of citrate 
is important for nitric oxide (NO) and reactive oxygen species (ROS) generation 
[84,193,195]. Therefore, the increase in glycolysis may be necessary to sustain ATP 
generation during phagocytosis. Oxidation of pyruvate in the absence of TCA cycle 
activity drives accumulation of isocitrate and citrate supporting the generation of 
antimicrobial itaconic acid [194,196]. This is further promoted by the upregulation of 
cis-aconitate decarboxylase (IRG1) which both catalyses the conversion of cis-
aconitate to itaconic acid and promotes the production of bactericidal ROS in 
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phagosomes [196,197]. Similarly, the accumulation of succinate from pyruvate 
oxidation and glutaminolysis has been shown to sustain IL-1β production via a HIF-1α 
dependent mechanism [193]. These effects are long-term with M1 macrophage oxygen 
consumption shown downregulated after ~12 h due to damage to the electron transport 
chain by inducible nitric oxide synthase (iNOS) generated NO [198]. Macrophage 
generation of ROS by NADPH oxidase consumes NADPH which must be regenerated 
by the pentose phosphate pathway or malic enzyme the latter of which is induced in 
response to LPS stimulation [84]. Macrophages protect themselves from ROS by 
antioxidant glutathione (GSH), itself produced by NADPH from the pentose phosphate 
pathway (PPP) [84]. The PPP is also upregulated following M1 macrophage 
differentiation [199].  
 
Activated M1 macrophages are motile, actively phagocytic and secretory cells. 
Pinocytosis and phagocytosis both result in considerable turnover of lipids, with an 
estimated equivalent of the entire plasma membrane internalised every 35 minutes 
during pinocytosis [200]. LPS stimulation of macrophages results in the production of 
considerable quantities of inflammatory cytokines and secretion of these requires 
increased production of phospholipids for the expansion of endoplasmic reticulum (ER) 
and Golgi [187]. The turnover and regeneration of membrane phospholipids for 
phagocytosis is promoted by increased phospholipid synthesis and a switch from 
cholesterol to phosphatidylcholine production in M1 activated macrophages [201]. 
Inhibition of fatty acid synthesis has been shown to prevent phagocytosis [201]. In 
absence of exogenous fatty acid, glucose metabolism may, via oxidation of pyruvate to 
acetyl-CoA, be indirectly used for de novo synthesis of fatty acids and phospholipids 
[202]. Metabolism during phagocytosis has been reported to see a 4-fold increase in 
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glucose oxidation by the TCA cycle for murine peritoneal resident and activated 
macrophages [192,203]. Glutamine consumption is suppressed 43% by the availability 
of fatty acid oleate, suggesting that a considerable portion of glutamine utilisation in 
macrophages is via oxidation [192]. Pro-inflammatory IL-1 production has been linked 
directly to glutamine availability and inhibition of glutamine metabolism reduces IL-
1β production in M1 macrophages [193,204]. Macrophages may also consume citrate 
for the synthesis of phospholipids with arachidonic acid specifically consumed for the 
production of pro-inflammatory prostaglandins [205]. 
 
Macrophage differentiation may also be affected by tissue oxygen concentrations. This 
behaviour has been most thoroughly investigated in cancer biology, where increased 
transcription of mitogenic, proangiogenic, and prometastatic genes is reported via the 
action of hypoxia inducible factors HIF-1α and HIF-2α [206]. HIF-1α mediates 
transcriptional changes and drives long term increases in glycolysis through induction 
of Glut1 transporter and glycolytic enzyme lactate dehydrogenase A (LDHA) and 
isoform switching to PFKFB2 from PFKFB3 and PFKFB1 [113,114]. Pyruvate kinase 
(PKM) isoform switching to PKM2 promotes HIF-1α nuclear localisation [207]. HIF-
1α deficient macrophages are impaired in multiple aspects of M1 activation, including 
glycolysis, glucose uptake and IL-1β production [113]. In inflammatory sites hypoxia 
is associated with upregulation of expression of CXCL12, CXCL8, VEGF, IL-1β, and 
TNFα [208]. Hypoxia in combination with fatty acid palmitate promotes pro-
inflammatory responses resulting in secretion of IL-6 and IL-1β, while hypoxia itself 
can directly drive activation of macrophages with associated upregulation of pro-
inflammatory IL-1, IL-6, IFNγ and TNFα [209–214]. Hypoxia has no effect on NF-kB 
activation, but increased activation of c-Jun N-terminal kinases (JNK) and p38 MAPK 
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signalling [209]. JNK inhibition has been shown to block the hypoxia amplification of 
both inflammatory cytokines, as did inhibition of reactive oxygen species generation 
[209]. Knockdown of HIF-1α or HIF-2a only reduced IL-1β moderately, and had no 
effect on IL-6. Silencing dual-specificity phosphatase 16 (DUSP16) increased levels of 
IL-6 and IL-1β produced under normoxia. HIF-1β has been suggested to promote 
glycolysis and increased pentose phosphate pathway activity in inflammatory (M1) 
macrophages. Interestingly, increased succinate also inhibits prolyl hydroxylase (PHD) 
resulting in increased HIF-1α stability [193]. This provides a mechanism for initial Akt-
induced glycolytic flux to be sustained by HIF-alpha mediated transcriptional 
upregulation of glycolysis. While upregulation of glycolysis leads to excretion of 
lactate, HIF itself promotes lactate accumulation by upregulation of lactate 
dehydrogenase A [215]. Macrophages primed with TLR ligands may become more 
responsive to subsequent encounters. This training is mediated by the Akt-mTORC1-
HIF1-alpha pathway, and the sustained glycolytic state that follows initial stimulus may 
support the heightened second response [216,217]. Blockade of both the Akt-
mTORC1-HIF-1α axis, or glycolysis directly, has been shown to inhibit training of 
activated macrophages [183,216,217]. 

Figure 1.3. Classically-activated macrophages (M1) are pro-inflammatory effector cells. In response to bacterial LPS and IFNγ fromactivated CD4, CD8 or NK cells they activate and release pro-inflammatorycytokines TNFα, IL-1β, IL-6 and IL-12. IL-12 drives naïve T celldifferentiation to T0, stimulating production of IFNγ which in turn primesmonocytes for activation. Up-regulation of MHC-II, TLRs and CD86 furtherincreases M1 macrophage sensitivity to pathogens. They exhibit exhibitmicrobicidal and tumoricidal effector functions and have been closelyassociatedwith inflammatory diseases such as rheumatoid arthritis.
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1.8.2 Alternative	activation	(M2a)	
Stimulation of undifferentiated monocytes with Th2 cytokines IL-4 and/or IL-13 has 
been shown to drive the development of this distinct macrophage subset [218]. M2a 
macrophages are considered the macrophage counterpart to the Th2 phenotype, in the 
Th1-Th2 axis, with roles in humoral immunity, revascularization of damaged tissues 
and resolution of inflammation [170,219] (Figure 1.4).  
 
The primary feature of the phenotype is the downregulation of pro-inflammatory 
cytokines. However, the M2a phenotype is not inactive, but rather targeted towards 
alternative pathogens. For example, M2a differentiated cells show inhibited respiratory 
burst and reduced production of inflammatory IL-1βeta and IL-8, yet upregulation of 
HLA class II expression, promoting antigen presentation. M2a activation is further 
associated with a IL-12lo, IL-23lon phenotype, low levels of caspase-1, and high levels 
of IL-1Rα and the decoy IL-1 type II [173,218]. Surface expression of mannose 
receptor MRC1, important in the recognition and endocytosis of viruses, bacteria and 
fungi, is also increased. IL-4 increases pinocytosis and MRC1 dependent endocytosis 
and MRC1 independent macro- micro- pinocytosis [220,221]. IL-4 increases 
trafficking and recycling of early endosomes, and together with PGE2 increases the 
size of early endosomes, ER and Golgi compartments [222]. In contrast phagocytosis 
is reduced following activation with IL-4 [223]. The trend therefore is towards 
increased antigen processing of soluble extracellular antigens and antigen presentation 
via HLA class II of pathogens that cannot enter the phagocytic pathway.  IL-4 has been 
shown to drive proliferation of tissue macrophages in vivo [224,225]. 
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M2a activation is canonically under the control of Stat6 [145]. IL-4 ligation of the IL-
4 receptor (IL-4R) leads to activation of Jak1 and Jak2 which in turn phosphorylate 
Stat6 [145,183]. However, IL-4R also acts non-canonically through a complex 
signalling cascade involving phosphoinositide 3-kinase (PI3K), Akt and serine-
threonine kinase mTOR 2 (mTORC2) to activate mTORC1 [183,226]. The influence of 
Akt on macrophage activation is likely through downstream effects including 
modulation of NF-κB and pro-inflammatory gene transcription factor Foxo1 [227]. Akt 
activation is associated with M2a-like gene responses in mice including upregulation 
of arginase 1 (Arg1) [183,226]. Loss of Akt signalling has been shown to result in 
upregulation of pro-inflammatory cytokines including TNFα, IL-6 and IL-12; and 
downregulation of anti-inflammatory IL-10 [183,226,228]. Both Akt1 and Akt2 were 
thought to promote M2a polarization however the effect is now thought to be Akt 
specific, with Akt1 inhibiting and Akt2 promoting M1 activation respectively 
[229,230]. Myc is also upregulated following IL-4 stimulation [231]. 
 
IL-4 and IL-13 signalling pathways overlap and interact with other pathways including 
peroxisome proliferator-activated receptors (PPARδ PPARγ) and glucocorticoid 
receptors (GCR) [232,233]. The effects of IL-4 & IL-13 combine both antagonistically 
and co-operatively with the balance of IL-4/type II and IL-13Ra receptors, together 
with other cell-cell interactions, ultimately determining the phenotype of alternatively 
activated macrophages. An interesting feature of M2a macrophages is the ability to fuse 
to form multinucleated giant cells (MGC). MGCs play a key role in the formation of 
granulomas and IL-4 and IL-13 have both been shown to induce fusion in vitro 
[234,235]. The MGC cell formation process also forms the basis of RANKL/M-CSF 
induced osteoclasts [236,237]. IL-4 and IL-13 are produced by many cell types 
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including CD4+ Th2, CD8+ T, basophils, mast cells and eosinophils allowing induction 
of M2a macrophages by both innate and antigen-specific immune responses. 
 
In contrast to M1 macrophages, M2a macrophage activation is associated with reduced 
glycolytic activity. M2a macrophages instead make extensive use of oxidative 
metabolism, oxidising both glucose and fatty acids in the mitochondria including both 
exogenous scavenged sources and de novo synthesised lipids [238,239]. M2a 
macrophages have no detectable PFKB3 levels and express weak glycolytic activator 
PFKFB1 [84]. The energy efficiency of fatty acid β-oxidation is more compatible with 
slow growth and responses to larger endemic parasites that M2a macrophages are 
thought to target [189]. Exogenous lipoproteins are therefore a valuable source of fatty 
acids for M2a macrophages. These are taken up via CD36 and broken down by 
lysosomal acid lipase (LAL) [239]. The β-oxidation of fatty acids produces acetyl-coA, 
which is fed into the TCA cycle, and co-enzymes NADH and FADH2 which are utilised 
by oxidative phosphorylation for ATP generation [239]. Inhibition of fatty acid β-
oxidation has been shown to attenuate the transcriptional induction of the M2a 
programme while IL-4 upregulates β-oxidation via transcriptional induction of PPAR-
γ and PPAR-δ and PGC1β [189,232,240]. Fatty acids may also directly activate the 
PPARγ and PPARδ nuclear receptors [232,240]. IL-4 also stimulates biogenesis of 
mitochondria through up-regulation of PGC-1β, further promoting the metabolic switch 
to fatty acid oxidation [189]. 
 
Other biosynthetic processes are thought to be maintained predominantly by glutamine 
metabolism [241]. Glutamine is oxidatively metabolised in the TCA cycle following 
conversion to α-ketoglutarate [194], together with acetyl-coA resulting from fatty acid 
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oxidation [84]. M2a macrophages also consume glutamine for the generation of uridine 
diphosphate N-acetylglucosamine (UDP-GlcNAc) for N-glycolyslated surface proteins 
[194]. M2a macrophages further promote tissue healing via the production of ornithine 
from arginine via arginase activity in mice [242,243] or from glutamate and glutamate-
5-semialdehyde in humans [244]. Proline generated from ornithine via ornithine amino 
transferase (OAT) is a key precursor of collagen formation [243,245].  
 
The mTORC1 axis associated with M2a activation is also used to regulate anabolic 
metabolism by growth factor signalling [183,246,247]. Two complexes mTORC1 and 
mTORC2 function antagonistically to regulate cellular metabolism, survival and 
cytoskeletal reorganisation. In growing and proliferating cells Akt activates mTORC1, 
which promotes synthesis of lipids, proteins and nucleotides [183]. mTORC2 
phosphorylates Akt, and other members of the AGC kinase group, including PKA/C. 
In proliferating cells mTORC1 also acts to drives feedback inhibition of both Akt and 
mTORC2 [183]. mTORC1 drives lipogenesis through activation of transcription 
factors sterol regulatory element-binding protein 1 & 2 (Srebp1/Srebp2) which regulate 
fatty acid and cholesterol synthesis respectively. Srebp1 upregulates PPP enzymes, 
providing reducing power (NADPH) during fatty acid synthesis [246]. mTORC1 also 
promotes nucleotide synthesis through carbamoyl-phosphate synthetase (CAD) 
activation and upregulation of the PPP [246].  
 
Results have suggested that hypoxia may polarise macrophages to a M2a phenotype via 
HIF1-alpha and lactic acid from both undifferentiated and M1 states [127,248]. 
Tumour-associated macrophages (TAMs) expressing prototypical M2a markers were 
found to reside in more hypoxic regions, and express hypoxia-regulated genes [209]. 
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The apparent contradiction between the M2-phenotype aerobic-metabolism and 
differentiation in hypoxia may be resolved by the promotion of angiogenesis by these 
cells [249]. M2a macrophages therefore appear to accumulate in hypoxic regions, such 
as those found in wounds or inflammation, and promote revascularisation [109]. 
 
 

Figure 1.4. Alternatively-activated macrophages (M2a) are consideredthe macrophage counterpart to Th2 in the T helper cell axis. Differentiatingfrom monocytes in response to stimulation with IL-4 and/or IL-13 theyhave roles in humoral immunity, revascularisation of damaged tissues andresolution of inflammation. These macrophages are not directly anti-inflammatory (compare withM2c, which produce anti-inflammatory IL-10)however they do express inflammatory regulator IL-1 receptor antagonist.They target extracellular pathogens with increased endocytosis, expressionof mannose receptor MRC1, binding extracellular bacteria and fungi, andantigen-presentation via HLA class II.
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1.9 Macrophages	in	rheumatoid	arthritis	
RA synovial macrophages have an activated phenotype, with increased expression of 
HLA-DR, co-stimulatory molecules (CD80, CD86 and CD40), adhesion molecules 
(CD54) and chemokine receptors and produce pro-inflammatory cytokines [128,250–
255]. Macrophages are the largest producer of TNFα in the synovium, the number of 
macrophages in the joint correlates with inflammation and activated macrophages 
secrete proteases which may damage joint architecture [256–258]. The production of 
monocyte chemotactic IL-8 and monocyte chemoattractant protein 1 (MCP-1) by 
activated synovial macrophages drives further recruitment [259,260]. Infiltrating 
monocytes differentiate to mature macrophages during migration with immature 
monocytes colonising the synovial sub-lining while mature macrophages concentrate 
in the lining layers [129,261]. Beneath the surface of the lining layer macrophages are 
found distributed among fibroblasts as lymphoid aggregates with CD4+ T cells or 
diffuse infiltrates adjacent to CD8+ T cells [251,262]. The degree of macrophage 
infiltration is correlated directly with joint pain, inflammatory status and radiological 
progression of joint damage [129,257] and ultimately patient quality of life. 
Macrophage populations in the RA synovium are predominantly CD68+ rather than 
CD14+. Interestingly, it has been shown that while CD68+ cell counts correlate with 
radiologic outcome, CD14+ macrophages correlate with radiologic outcome and 
disease progression [129].  
 
Macrophages synthesise significant amounts of pro-inflammatory cytokines including 
IL-1, IL-6, TNFα and GM-CSF in the rheumatoid synovium [134,250,256,263]. 
Secreted TNFα in turn promotes expression of cytokines, adhesion molecules, 
prostaglandin E2 and collagenase by synovial cells [134,256,263]. Levels of TNFα in 
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synovial fluid correlates directly with synovial macrophage infiltration and bone 
erosion [264]. TNFα receptors are found in synovial tissue and fluid of patients with 
the most severe disease [265]. TNFα and IL-1 together are potent promoters of 
synovitis in animal models with TNFα production preceding development of synovitis 
[266,267]. Transgenic overexpression of TNFα has been shown to drive chronic 
arthritis [268]. IL-1 expression in RA patients is predominantly in CD14+ macrophages 
with levels of the cytokine in synovial fluid correlating with inflammation [269,270]. 
Expression of IL-1 is thought to occur later in disease than TNFα and is implicated in 
the induction of joint damage through upregulation of proteoglycan degradation and 
inhibition of synthesis [256,270,271]. Secondary effects, including induction of 
metalloproteases stromelysin and collagenase, and bone resorption, contribute to this 
[270,272]. Following differentiation, macrophages express IL-1 receptor antagonist 
(IL-1Ra) to modulate responses to IL-1. This is further up-regulated in the presence of 
pro-inflammatory cytokines, including IL-1 or GM-CSF [270]. However, in RA the 
balance tips in favour of IL-1. Interestingly methotrexate, one of the most successful 
DMARDs, shifts the IL-1/IL-1Ra balance back towards IL1-Ra [273]. High levels of 
TNFα and IL-1β are associated with granulomatous synovitis and rheumatoid nodules, 
while both are only modestly elevated in the diffuse synovitis seen in seronegative RA 
[274]. This difference may explain variability in measured TNFα in the rheumatoid 
synovium of active patients and variable sensitivity to anti-TNFα therapy 
[140,256,275]. Potent pro-inflammatory cytokine IL-17 also works synergistically with 
TNFα to promote inflammation and joint damage [276]. Receptors for IL-17 are 
expressed on CD14+ monocytes/macrophages in the synovium and stimulation of RA 
synovium with IL-17 triggers IL-6 and MMP production [277–279]. Peripheral blood 
CD14+ monocytes from both healthy donors and RA patients have been shown to 
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promote Th17 responses in IL-1B and TNFα-dependent manner [280]. IL-17 is directly 
chemotactic for monocytes in vitro at RA synovial concentrations via IL-17RA/RC on 
monocytes [281]. IL-15 stimulated synovial T cells also induce IL-1B, TNFα, IL-8 and 
MCP-1 production in macrophages, but not IL-10 [282,283].  
 
Despite the important role of TNFα in RA, the most strongly elevated cytokine in active 
disease is IL-6 [284]. Its acute rise in synovial fluid is consistent with the role of pro-
inflammatory IL-6 in the acute-phase response. Like TNFα and IL-1, IL-6 levels also 
correlated with the degree of radiological joint damage, and IL-6 may therefore act to 
promote the generation of osteoclasts [285]. The majority of synovial IL-6 is produced 
by synovial fibroblasts [286]. However, a role for activated macrophages in driving 
fibroblast IL-6 production is suggested by the histological co-localisation of IL-6-
expressing fibroblasts with CD14+ macrophages in synovial tissue and in vitro results 
showing that IL-1 stimulates fibroblast IL-6 production directly [286,287]. Interaction 
between macrophages and fibroblasts also elicits the production of IL-6, GM-CSF and 
IL-8 and IL-17, detected in 90% of all RA synovial explant cultures, further stimulates 
macrophages to produce IL-1 and TNFα [135,287]. Notably, it also has effects on other 
cells of the mononuclear lineage, both inducing the formation osteoclasts from 
progenitor cells and promoting nitric oxide production in chondrocytes [288,289]. 
Seropositive RA is associated with the highest levels of secreted IL-8 acting as a 
powerful promoter of angiogenesis and providing a link between macrophage 
activation, infiltration and neovascularisation of the rheumatoid synovium [290,291]. 
Macrophage migration inhibitory factor (MIF) is also raised in serum and synovial fluid 
of RA patients and has been shown to influence the production of TNFα [292]. 
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Macrophages may also have a role in synovial tissue degradation and remodelling, with 
activated macrophages producing collagenase, stromelysin, gelatinase B and leucocyte 
elastase [293]. Levels of gelatinase B correlate positively with disease severity [294] 
but the direct effect of macrophages on matrix is thought to be minimal. TGFβ, the 
main regulator of connective tissue remodelling, and TGFβ receptors are differentially 
expressed by macrophages in the lining, sub-lining layer and pannus [287]. TGFβ has 
been shown to induce synovial inflammation, but also to suppresses both acute and 
chronic arthritis in animal models [295,296]. Activated macrophages are a source of 
nitric oxide (NO) within the synovium and exposure of mixed synoviocytes to NO 
further drives TNFα production [297]. NO may also have effects on bone remodelling 
[298]. The production of reactive oxygen species by macrophages is also correlated 
with plasma TNFα [299].  
 
Macrophages are also thought to contribute to synthesis of anti-inflammatory IL-10 in 
the rheumatoid synovium, with the relative balance of pro- and anti-inflammatory 
cytokines being critical to the progression of disease [270,300]. It has been shown that 
in vitro activation of macrophages with T cells pre-stimulated in an antigen-dependent 
manner stimulated drives TNFα and IL-10 production [301] while T cells stimulated in 
an antigen-independent manner induce TNFα but not IL-10 [282]. Macrophages co-
localise and form close contacts with CD4+ T cells in the synovium, at a ratio of 9:1 to 
CD8+ T cell interactions [302,303] which may also promote disease by providing a 
link to the adaptive immune system. Targeting these subpopulations for therapy has 
shown clinical and histopathological improvement in animal models [304]. IL-10 has 
been reported to be elevated in both serum and synovial compartments in RA patients 
but conversely has been reported to be deficient [305,306]. The relative lack of IL-10 
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in the late RA synovial membrane supports the idea that early RA is driven by antigen-
specific T cell-macrophage interactions, while chronic RA may reflect a switch to 
antigen-independent activation, with a preponderance of pro-inflammatory cytokines. 
Modulation of monocytes by T regulatory cells (Tregs) has been shown to occur 
through both soluble factors (IL-10, IL-4/13) and cell-cell contact [307]. Monocyte-
recruiting chemokines including MCP-1, macrophage inflammatory protein 1-alpha 
(MIP-1a) and regulated on activation, normal T cell expressed and secreted 
(RANTES/CCL5) are expressed in the RA synovium and blood monocytes from 
patients with RA express the receptors (CCR1, 2, 3 and 5) [253,308]. Monocyte 
recruitment to the inflamed joint has been shown to be unaltered 2 weeks after anti-
TNF treatment, despite the significant effect on disease activity [309]. This suggests 
that the rapid drop in numbers post-treatment cannot be attributed to effects on 
recruitment [133]. IL-4 which also drives a co-ordinated anti-inflammatory response 
by decreasing macrophage production of IL-1B while increasing IL-1Ra, is virtually 
absent from synovial samples of active disease, suggested a lack of protective 
regulation [310].  
 
Monocyte activation in RA is not restricted to the synovium, with increases in 
macrophage-associated cytokine (IL-1, IL-6, TNFα) and growth factors (GM-CSF) in 
the blood [137,311]. There is evidence that circulating monocytes are already activated 
in RA, with spontaneous production of cytokines, soluble CD14, prostanoid and 
prostaglandin E2 [134,312,313]. An analysis of gene patterns in RA circulating 
monocytes during therapeutic leukapheresis show increased expression of 
inflammatory cytokines (IL-1α, IL-1β, IL-6, TNFα), alongside ferritin, lysozyme and 
thromobospondin-1 suggesting that monocytes in RA express a rheumatoid phenotype 
	 49	
prior to migration into synovial tissue [311]. This is further supported by the expression 
of glycoprotein gp39, a macrophage differentiation marker, on circulating and synovial 
monocytes in RA [314]. RA peripheral blood and synovial monocytes have been found 
to be resistant to apoptosis via spontaneous cell death, Fas-ligations or CD8+ T cell 
[315,316]. This resistance may occur via a number of mechanisms including increased 
expression of anti-apoptotic cellular FLICE-like inhibitory protein (FLIP) and induced 
myeloid leukemia cell differentiation protein (Mcl-1); reduced expression of pro-
apoptotic Bcl-2 interacting mediator of cell death (Bim); increased expression of TNFα 
and IL-1; or T regulatory (Treg) cells in the RA joint [315,317–321]. The role of TNFα 
in the survival of monocytes is supported by the increased apoptosis of monocytes in 
co-culture with anti-TNF infliximab and adalimumab [322]. Similar defects in 
apoptosis pathways and Fas ligand lead to inflammatory arthritis and SLE-like disease 
in murine models [323].  
 
There are further alterations in macrophage physiology in the bone marrow with signs 
of activation including overexpression of HLA class II and both pro- and anti- 
inflammatory cytokines (TNFα), chemoattractants (MIP) chemokines and growth 
factors (GM-CSF) [134,262,324]. Patients with active or severe disease show faster 
generation and differentiation of CD14+ myelomonocytic cells in the bone marrow 
[325]. However, in vitro experiments have shown that bone marrow precursor cells 
become insensitive to GM-CSF in RA patients [325]. Bone marrow adjacent to 
rheumatoid joints also shows elevated myeloid precursors correlated with local IL-1 
[326]. Differentiation of macrophages also occurs in extra-articular rheumatoid nodules 
which is an indicator of clinical severity [274,327].  
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Macrophages in RA are therefore associated with a strongly pro- inflammatory 
phenotype in line with the classically activated M1 macrophage polarisation previously 
discussed. There is further evidence of the anti-inflammatory capabilities of IL-4 and 
IL-10 being overwhelmed or supressed during active disease. The role of the metabolic 
environment in biasing against or limiting these anti-inflammatory responses is unclear.  
1.10 	Hypotheses	
In summary, macrophages are a key cell in the pathology of RA, altered metabolism is 
associated with a number of inflammatory diseases and the rheumatoid synovium 
represents an unique metabolic environment. Further, macrophage differentiation is 
known to be influenced by metabolic environment, including tissue hypoxia and lactate. 
We sought to further explore the relationship between differentiated macrophages and 
metabolism and to determine whether metabolic features of differentiated macrophages 
may contribute to chronic inflammation in the rheumatoid synovium.  
 
We hypothesised that — 
• Differentiated	macrophages	display	distinct	metabolic	profiles	
• Metabolic	 profiles	 of	 differentiation	 (and	 activated)	 macrophages	 reflect	 their	unique	immunological	and	homeostatic	functions	
• Metabolic	 differences	 between	 pro-	 and	 anti-inflammatory	 macrophages	contribute	to	chronic	inflammation	in	the	synovium	
• Metabolic	alteration	of	the	synovium	could	–	by	shifting	the	balance	from	pro-	to	anti-inflammatory	macrophages	–	offer	a	mechanism	to	resolve	RA
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2 MATERIALS	AND	METHODS	
Standard methods were used throughout this thesis for the isolation of monocytes and 
the differentiation and activation of macrophages. These methods are described below 
in detail and repeated briefly, together with experimental numbers and unique 
conditions, in the relevant chapters and figures. Replicates used in macrophage 
differentiation experiments are biological replicates from unique NHS Blood 
Transfusion Service (NHSBTS) donors.  
2.1 PBMC	separation	from	whole	blood	
Enriched white blood cells were obtained via apheresis cones from NHSBTS donors. 
Cells were diluted in an equal volume of PBS and 20 ml layered on an equal volume of 
Ficoll Paque in a 50 ml tube. Samples were centrifuged at 400 g for 30 minutes at room 
temperature. Using a Pasteur pipette the interphase containing PBMCs was removed to 
a new 50 ml tube. Cells were washed twice in 50ml PBS at 400 g and re-suspended in 
10ml RPMI.  
2.2 Isolation	of	monocytes	from	PBMCs	
Isolation of monocytes from PBMCs was performed by Percoll density gradient or by 
magnetic activated cell sorting (MACS) as per instructions from Miltenyi Biotec. 
 
For magnetic bead separation, PBMCs were incubated with 80ul MACS buffer per 107 
cells, and MACS CD14+ beads added at 20 µl per 107 cells for 15 minutes at 4 °C. 
Cells were washed in 1ml MACS buffer per 107 cells then resuspended in 500ul MACS 
buffer per 108 cells (5 ml/107). The MACS column was placed in a magnetic field, 
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rinsed through with 3mls MACS buffer solution, and cell suspension was added. The 
column was washed with 3x 3 ml MACS buffer, and run-off collected as waste. Finally, 
the column was transferred to a collection tube and 5ml buffer syringed through to wash 
out the selected cells. Purity of resulting samples was confirmed by flow cytometry.  
 
For larger cell numbers Percoll density gradient was used. The PBMC fraction was 
isolated as described above and then washed in HBSS by centrifugation at 300 g for 5 
minutes. This was repeated until the phases of the preparation were clear, indicating 
complete removal of the Ficoll. The pellet was resuspended in RPMI up to 20 ml for 
counting. The solution was diluted to ~20x106 cells/ml in RPMI with 10% HiFCS and 
then layered on top of an equal volume of prepared Percoll solution at the required 
density (23 ml Percoll, 4.75 ml 10x PBS, 26.25 ml H20). The gradient was centrifuged 
at 400 g for 30 min with low acceleration and brake to prevent disruption of the 
gradient. Enriched monocytes appear as a thin line of cells at the interphase between 
culture media and Percoll gradient. These cells were extracted with a Pasteur pipette 
and washed at 400 g for 5 minutes before resuspension in RPMI. Enriched monocytes 
were plated to T75 culture flasks at 10x106 per flask or at a density of 6.25x104 cells/cm2 
for other dishes. Monocytes were cultured for 1 hr in RPMI (no FCS) during which 
time monocytes adhered, leaving contaminant cells in suspension. Culture media was 
removed and the plate washed 3x with plain RPMI. After the final wash, media was 
replaced with differentiation media for the target macrophage subset. 
 
 

Figure 2.1. Experimental design. Monocyte/macrophage differentiationand activation for all experiments followed a similar protocol, outlinedhere. Peripheral blood monocytes were isolated and seeded at 10x106 perT75 or 6.25x104 cells/cm2. Differentiation/activation experiments werecarried out over 7 days with activation on day 6. Standard concentrationsused for all cytokine treatments were 10 ng/ml M-CSF or GM-CSF fordifferentiation; 100 ng/ml LPS, 100 ng/ml LPS + 20 ng/ml IFNγ, or20 ng/ml IL-4 for activation. (A) Monocyte differentiation and activationunder normal conditions in T75 flasks. Media (20 μl) were collected daily.Following activation on day 6 cells were incubated for 18 h after whichendpoint differentiation media (1 ml), intracellular metabolites and RNAwere collected. (B) Monocyte differentiation and activation undernormoxia (20% O2), hypoxia (1% O2) and reperfusion conditions. Mediawas completely replaced in all cultures on day 3 and 5. Hypoxic cells werefed with media maintained at 1%O2. Reperfusion was modelled by feedinghypoxic cells with media conditioned at 20% O2. Following activation onday 6, cells were incubated for 18 h after which intracellular metaboliteswere collected.
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2.3 Primary	monocyte	differentiation	and	activation	
In this study we have focused our attention on macrophages matching the M1 and M2a 
classifications — M(LPS) or M(LPS+IFNγ) and M(IL-4) using the Murray 
nomenclature [155,178,218,328]. However, we have also investigated the effect on 
GM-CSF vs. M-CSF on differentiation and activation in line with the Verreck M1-M2 
model [176,329]. For clarity therefore the resulting macrophage populations will be 
referred to using both differentiation background and treatment, e.g. M-CSF+LPS/GM-
CSF+LPS. The complete set of macrophage differentiation and activation conditions 
were as follows — M-CSF (no activation), GM-CSF (no activation), M-CSF+LPS, M-
CSF+LPS+ IFNγ, M-CSF+IL-4 and GM-CSF+LPS. 
 
The differentiation of all macrophage subsets followed the same experimental protocol 
as described in Figure 2.1A. Monocytes were differentiated in T75 tissue culture flasks, 
6 well plates or 96 well plates for 5 days. Standard differentiation media used for all 
experiments was RPMI with 10% heat inactivated foetal calf serum (HiFCS) 1% L-
glutamine and 1% penicillin/streptomycin. Differentiation was performed at a standard 
density of 10x106 per T75 or 6.25x104 cells/cm2 (chosen at half-confluence to minimise 
cell-cell contact) in media with 10 ng/ml M-CSF or GM-CSF. Media (20 µl) was 
collected on each day during differentiation. On day 6 of differentiation macrophages 
were activated with 100 ng/ml LPS, 100 ng/ml LPS + 20 ng/ml IFNγ, or 20 ng/ml IL-
4 depending on the target subset. Cells were left to activate for 18 h after which endpoint 
differentiation media (1 ml), intracellular metabolites and RNA were collected. 
2.4 Normoxia,	hypoxia,	reperfusion	assays	
To assess the metabolic effects of hypoxia and reperfusion on macrophages and 
dendritic cells, peripheral blood monocytes were differentiated under normal, hypoxic 
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and reperfusion conditions.  An overview of the experimental design is given in Figure 
2.1B. Macrophages were differentiated as per the Verreck et al. M1/M2 model using 
GM-CSF and M-CSF respectively. Dendritic cells were differentiated using GM-
CSF+IL-4 — with the IL-4 included throughout the differentiation process in contrast 
to the M2a model. Hypoxia and reperfusion assays were performed in a Don Whitley 
H35 hypoxystation which allows consistent control of oxygen perfusion for the 
duration of the experiment. Access to the hypoxystation is via airlock and manipulation 
via isolated rubber sleeves to avoid influx of atmospheric oxygen.  
 
Experiments were performed using multiple donors. Peripheral blood monocytes were 
seeded and differentiated in 6 well plates at a density of 6.25x104 cells/cm2 in standard 
culture media (RPMI+GPS+10% FCS) containing 10 ng/ml M-CSF, 10 ng/ml GM-
CSF or 10 ng/ml GM-CSF+20 ng/ml IL-4 for 6 days. On day 6 differentiated 
macrophage cultures were activated with 100 ng/ml LPS and incubated for 18 h. 
Culture media was replaced on day 3 and 5. Hypoxia experiments were performed in 
normoxia (20% O2), hypoxia (1% O2) and reperfusion. Media for hypoxic cells was 
pre-exposed to 1% O2 conditions for 1 hour prior to use and kept in hypoxic conditions 
for the duration of the experiment. On day 3 and day 5 media was replaced. Feeding of 
hypoxic cells was carried out under hypoxia with hypoxic media. Normoxic cells were 
fed with media under normal conditions. Reperfusion cells removed from the hypoxic 
station and fed with oxygenated media, then returned to hypoxia. On day 6, 10 ng/ml 
lipopolysaccharide (LPS) was added to half of each group of cell cultures and then left 
to activate for 18 h. Endpoint media was removed from all cultures and intracellular 
metabolites were extracted. 
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2.5 Metabolite	spiking	assays	
Metabolites used for these experiments were based on literature reviewed in Table 1 
and established cellular energy sources. The full panel of metabolites included glucose, 
glutamine, lactate, the branched-chain amino acids (BCAA) and arginine. Top 
concentrations used for each were 20 gL-1 glucose, 3 gL-1 glutamine, 133 µM lactate, 
BCAA (containing 0.5 gL-1 leucine, 0.5 gL-1 valine, and 0.5 gL-1 isoleucine) and 0.2 
gL-1 arginine. Some of these are standard constituents of RPMI media and in these cases 
concentrations were calculated on top of the base media to give a top concentration of 
10x. For metabolites not in media concentrations were sourced from previous NMR 
measured quantities. This was then serial diluted to give test concentrations. Metabolite 
spiking experiments were carried out under normoxia with standard GM-CSF and M-
CSF differentiation media. Monocytes were seeded and resuspended in spiked media 
and cultured for 5 days before activation with LPS. Endpoint culture media were 
collected for analysis by ELISA. 
2.6 Cell	metabolite	extraction	for	metabolomic	analysis	
Final media was removed and stored for analysis. Cells were washed with 1ml PBS at 
4 °C. This was completely removed and replaced with 1ml -48 °C 60% CH3OH to 
remove salt. This was again removed and replaced with 400 µl methanol. Cells were 
scraped into methanol suspension, transferred to 2 ml microcentrifuge tubes then snap 
frozen in LN2. Tubes were thawed on dry ice and then repeatedly snap frozen 3x to 
ensure complete elimination of metabolism. Samples were dried overnight and then 
stored at -80 °C. Samples were suspended in 600 µl:540 µl methanol:water and 
transferred into glass vials. Next, 600 µl pre-chilled chloroform was added to each tube 
with a blunt-ended Hamilton syringe and the samples were vortexed for 30 seconds to 
mix thoroughly. Samples were placed on ice to allow phases to separate and then 
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centrifuged at 4 °C in swingout rotor at 300 g for a further 10 minutes. Once completed, 
vials were removed from the centrifuge to the bench and left to stand for 5 min. The 
upper (polar) layer 400 µl was transferred to microcentrifuge tubes and stored at -80 °C 
overnight. The following day samples were dried in vacuum dryer for 3-4 hr, and 
resulting tubes were re-frozen at -80 °C until required for NMR. 
2.7 Culture	media	preparation	for	metabolomic	analysis	
Culture media samples were centrifuged at 300 g to pellet any remaining cells in 
suspension and the resulting supernatant was transferred to a clean microcentrifuge tube 
and frozen at -80 °C until use. Frozen media samples were defrosted at room 
temperature from which small volumes were taken for analysis. Samples were filtered 
using 30 kD molecular weight filter to remove protein from solution. 
2.8 Sample	preparation	for	NMR	spectroscopy	
Phosphate NMR buffer was prepared at 4x concentration using 0.624 g 
NaH2PO4.2H2O, 40 mg NaN3, 3.44 mg TMSP in 4 mL D2O and 4 mL H2O. The pH 
was adjusted to 7.00 with HCl then made up to 10 ml with H2O. The resulting solution 
was filtered with a 0.2 µm filter to sterilise and frozen at -20 °C until use.  
 
Extract samples were prepared by adding 45 µl of NMR buffer with 15 µl of dH2O to 
give a final 1x concentration of buffer. Culture media samples were prepared by adding 
45 µl of NMR buffer to 15 µl of media to give a final 1x concentration of buffer. The 
resulting solution was transferred to glass champagne vials for automated loading by 
robot into NMR tubes for acquisition. 
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1D and 2D J-resolved (JRES) 1H NMR NOESY spectra were acquired on a 600 MHz 
B600 Bruker Avance III spectrometer with TCI 1.7 mm z-PFG cryogenic probe. 
2.9 Metabolomic	processing	and	identification	
1D NMR: Data collected were processed using NMRLab and MetaboLab [330] via 
MATLAB. Spectra were aligned, scaled to TMSP, scaled by probabilistic quotient 
normalization (PQN) to account for dilution or variability in cell numbers. Spectra were 
binned to 0.005 ppm bins to reduce the data size and exported as PLS_Toolbox dataset 
objects (DSO) for subsequent analysis with MATLAB and PLS_Toolbox. Post-
identification analysis of metabolites was performed from 1D spectra by manual 
matching of representative spectra, against the Chenomx database of known spectral 
signatures. Binned spectra were also used to graph relative quantities of metabolites in 
different samples. Where multiple resonant peaks or peaks exist, these were summed. 
 
Quantification of metabolites was performed using the Chenomx software, using 
manual peak fitting against representative spectra and automated quantification against 
spectra in the same experiment. Metabolites were fit against a representative spectrum 
from each experimental group in the experiment. Peak clusters were adjusted to match 
to account for pH variation in the samples and peaks scaled to maximize fit. Automated 
fitting was performed using these selected metabolites and adjusted clusters, and the 
resulting µM concentrations used for subsequent analysis. 
 
2D JRES NMR/FIMA: For experiments where 2D JRES spectra were available 
identification was automated via the Field Independent Metabolite Analysis service 
provided by the Birmingham Metabolite Library at bml-nmr.org. Identification and 
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millimolar concentration data, scaled relative to an internal TMSP standard, is output 
in a simple tabular format for further analysis.  
2.10 ELISA	
Cytokine production by differentiated, activated macrophages was quantified from 
collected culture media using READY-SET-Go! ELISA Kits (eBioscience) as per 
manufacturer instructions. An ELISA plate (Nunc Maxisorp) was coated with 100 
µL/well of capture antibody in coating buffer. The plate was sealed and incubated 
overnight at 4°C. The following day wells were aspirated and washed 3x 250 µL/well 
wash buffer (PBS, 0.05% Tween-20) using an automated washer. Wells were blocked 
with 200 µL/well of diluent and incubated at room temperature for 1 hour. Lyophilized 
standards were reconstituted in dH2O and 2-fold serially diluted onto plate at 100 
µL/well. The media samples were added at 100 µL/well while wells with 100 µL/well 
of diluent were used as blanks. The plate was sealed and incubated at room temperate 
for 2 hours, then rinsed with wash buffer as previously described (3x washes). Diluted 
detection antibody was added at 100 µL/well and then the plate was sealed and 
incubated for 1 hour. After a further 3x washes, 100 µL of diluted Avidin-HRP was 
added to each well and incubated at room temperature for 30 minutes. After the final 
wash (5x washes) the plate was developed by the addition of 100 µL/well of TMB 
solution to each well. The plate was incubated at room temperature for 15 minutes and 
then 50 µL of stop solution (H2SO4) was added to each well. The developed plate was 
read at 450 nm with subtraction of a simultaneous 570 nm measurement to remove 
background. Blank well background was subtracted from the final values and a standard 
curve generated from diluted standards. The resulting standard curve equation was used 
to calculate values for measured samples from measured intensities. 
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2.11 RNA	Sequencing	(RNA-seq)	transcriptomics	data	RNA	was	quantified	from	cultured,	differentiated	monocytes	derived	from	PBMCs	isolated	from	NHSBT	apheresis	cones	as	previously	described.	Monocytes	were	differentiated	 in	6	well	plates,	 in	parallel	 to	matched	metabolomic	experiments	and	under	identical	conditions	at	a	density	of	6.25x104	cells	/	cm2.	Experiments	were	performed	in	biological	triplicate	(3	donors)	for	each	condition.		RNA	extraction	was	performed	on	day	7	with	direct	lysis	in	the	cell	culture	plate	using	the	RNeasy	Mini	Kit.	350	μl	of	RLT	buffer	was	added	direct	the	tissue	culture	plate	 and	 cells	 scraped	 into	 the	 solution.	 Samples	 were	 transferred	 into	 a	QIAshredder	spin	column	in	a	2	ml	collection	tube	and	centrifuged	for	2	min	in	a	microcentrifuge	at	8000	g.	1	volume	of	70%	ethanol	was	added	to	the	lysate and 
mixed by pipetting. Up to 700 µl of the sample, including precipitate, was transferred 
to an RNeasy Mini spin column in a 2 ml collection tube and centrifuged at 8000 g for 
15 s. Flow through was discarded. Next, 700 µl of buffer RW1 was added to the column 
and centrifuged at 8000 g for 15 s. Then, 500 µl of buffer RPE was added to the RNeasy 
spin column and centrifuged at 8000 g for 15 s. Flow through was discarded. Finally, 
500 µl buffer RPE was added to the spin column and centrifuged at 8000 g for 2 min to 
dry the membrane completely. The RNeasy spin column was transferred to a new 1.5 
ml collection tube, adding 50 µl RNase-free water directly to the membrane. The 
column was spun for 1 min at 8000 g to elute the RNA. Resulting solution of RNA was 
aliquoted to PCR strips at 25 µl/well (x2). Extracted RNA was quantified by NanoDrop. 
Samples were stored at -80 °C until ready to acquire.  
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Transcriptomic data was acquired by Oxford Gene Technologies using an Agilent 
8x60K gene expression array against the human male reference transcription profile. 
Following hybridisation arrays were scanned to obtain the array image. Feature 
extraction software was used to derive the array data using no background, with 
background-detrend, linear lowess dye normalisation and active multiplicative detrend 
enabled. Feature extracted data were analysed using Agilent’s GeneSpring v12.6. The 
standard Biological significance workflow was applied to these using one-way 
ANOVA to identify significantly regulated genes in experimental groups. Regulated 
genes were filtered at p<0.05 and with a log2 fold-change of >1 relative to the human 
male reference transcriptional profile. The resulting gene list was exported from 
GeneSpring and used for all subsequent analyses. 
2.12 Statistical	analysis	
Biological replicates from unique NHSBTS donors were used for all differentiation 
experiments. Where technical replicates were also performed the measured values were 
combined (median) before subsequent analysis. Analysis of metabolite data was 
performed by principal components analysis (PCA), partial least squares analysis (PLS) 
and partial least squares discriminant analysis (PLS-DA) using Eigenvector 
PLS_Toolbox. Spectra were mean-centred before analysis and outliers were excluded 
from the model based on high Hotelling T2 values or Q residuals with reference to 
source spectra. 
 
PLS models were cross validated with a random subset selection approach. Cross 
validation is a model validation technique used to determine how generalizable a model 
is and therefore how well it would apply to an independent data set. In this approach, 
the experimental data is repeatedly partitioned into complementary training and testing 
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sets. On each iteration the training set is used to build a model using the same 
parameters as the larger model and tested against the test set. The sensitivity and 
specificity of the resulting model describes how well the training data can be used to 
describe the test data. By repeating this process an estimate can be made of how well 
the larger model will perform for unknown data. This is described by the sensitivity and 
specificity scores which describe the true positive and true negative rate respectively. 
2.13 Software	development		
Analysis scripts (including the Pathomx software) were developed in Python (v2.7). 
Pathway drawing was performed using the Graphviz (v2.12) layout engine via the 
pydot (v1.0.28) interface. Statistical functions are provided by numpy (v1.6) from the 
SciPy project where appropriate. Software is provided as both a cross-platform 
graphical user interface application built on the Qt cross-platform graphical user 
interface (GUI) framework and as a command-line application. The software is freely 
available and open source under the GPL. Pathway knowledge is derived from the 
HumanCyc family of databases via the open web REST interface [331]. In this paper 
we are using the HumanCyc subset of this data containing pathways involved in central 
metabolism, amino acid biosynthesis and degradation, among others. Pathomx is 
supplied with an up-to-date set of common pathways. This analysis is based on version 
0.5.1 of Pathomx with HumanCyc database downloaded on 01/02/2013. For 2D JRES 
analysis FIMA-identified metabolites were matched to HumanCyc database identifiers.  
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2.14 Chemicals	and	reagents	
A complete list of agents and chemicals used in the experiments outlined in this thesis 
is given below (Table 2). 
Product Source Batch No. Cat No. 
READY-SET-Go! ELISA Kit IL-6 eBioscience, USA E09367-1636 88-7066-86 
GM-CSF Peprotech, USA 0202B301 081230 300-03 
M-CSF Peprotech, USA 110885 061285 300-25 
IL-4 Peprotech, USA 1007B14 100414-3 200-4 
IFNγ Peprotech, USA 101227 041027 300-02 
L-(+)-Lactic acid Sigma Aldrich  L1750 
L-isoleucine Sigma Aldrich  I2752 
Glucose Sigma Aldrich  G8270 
L-glutamine Sigma Aldrich  G3126 
L-arginine Sigma Aldrich  A5006 
D20 Sigma Aldrich  151882 
Trimethylsilyl Propanoic acid Sigma Aldrich  269913 
Sodium azide Sigma Aldrich  S2002 
LPS Sigma Aldrich O111:B4 L2630 
Foetal calf serum Labtech, UK Single FB-1001T 
Penicillin-Streptomycin-Glutamine Gibco Invitrogen, UK 10378 
CD14+ Microbeads Miltenyi, Germany  130-050-201 
Phosphate buffered saline Oxoid, UK  BR0014 
Nunc® MaxiSorpTM96 well plates Nunc, Denmark  44-2404-21 
Percoll GE Healthcare, UK  17-0891-01 
Hanks buffered salt solution Invitrogen, USA  14025092 
Corning™ Cell Culture Treated 
T75 flasks  Corning, Fisher Scientific 10-126-37 
Corning® Costar® cell culture 
plates (6, 96 well) Corning, Fisher Scientific 
08-772-33 
08-772-3B 
Table	 2.	 Chemicals	 and	 reagents	 including	 all	 products,	 suppliers	 and	 batch	
numbers	used	in	this	study.	
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3 DEVELOPMENT	OF	METABOLOMIC	ANALYSIS	
METHODS	
3.1 Introduction	
Standardisation of sample handling, processing, data acquisition and curation have 
contributed to improved reproducibility in metabolomics [332]. In contrast, at the start 
of this project methods for the analysis of metabolomic data were less well defined. 
Published studies commonly use a combination of multivariate analysis methods such 
as PCA and PLS, yet differ on data processing, normalisation and metabolite 
identification. Further, there has been limited progress in extracting meaningful 
biological information from the experimental data. This is not an issue in clinical 
biomarker identification where the goal is sample discrimination, not necessarily 
increased understanding of the disease. However, for our study it was necessary to be 
able to relate observed metabolic changes to underlying biological processes.  
 
To streamline data analysis and maximise reproducibility of results a standardised 
analysis workflow was developed. This was built on established standards within our 
group, but extended to include novel processing approaches where necessary. 
Metabolic pathway analysis algorithms and visualisations were developed to help aid 
the interpretation of results in their biological context. The development of this 
workflow and associated tools is outlined in this chapter. 
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3.2 Methods	
Algorithms were developed on both MATLAB (R2011a, The Math Works, Natick MA) 
and Python (2.7). MATLAB algorithms have been released via the github source code 
repository and are made available for install as zip files. Python (2.7; 3.4) packages 
have been released via the PyPi Python package server. Source code is available under 
the 2-clause BSD license.  
 
A number of standard samples were created for algorithm development including — 
urine at pH 7.0 serially diluted ± glucose spike 20 gL-1 glucose, RPMI pH at 7.0 serially 
diluted ± lactate spike, RPMI pH in the range 6.2-8.2. For development of analysis 
approaches appropriate to cell cultures, a sample dataset was generated from the culture 
of THP-1 cells under 20% and 1% O2 for 24 hours. Intracellular metabolites were 
isolated by methanol-chloroform extraction [333] and endpoint tissue culture media 
collected. For all test samples, 1D and 2D J-resolved 1H NMR spectra were acquired 
on a 600MHz Bruker NMR instrument. The resulting 2D JRES spectra were quantified 
and metabolites identified using the Field Independent Metabolite Analysis (FIMA) 
service from the Birmingham Metabolite Library (BML) at bml-nmr.org. 
3.3 Results	
Having explored the existing tools and standard approaches to analysis of metabolomic 
data, we sought to optimise and standardise key steps in our analysis workflow. The 
key areas for consideration were as follows — 
• Optimisation	
• Alignment	—has	implications	for	both	spectral	binning	and	PQN	scaling	
• Normalisation	—	TSA	vs.	PQN	
• Quantification	—	FIMA,	Chenomx	and	Metabohunter	
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• Multivariate	methods	—	PCA	vs.	PLS,	genetic	algorithms	
• Pathway	identification	and	visualisation	
3.3.1 Data	optimisation	
NMR metabolomics produces a large quantity of data —each full-resolution processed 
spectrum approximately 512kB in size — which in large-scale studies can quickly 
become unmanageable. However, successful analysis or biomarker identification rarely 
requires full-resolution spectra. Metabolomics is concerned with the quantification of 
metabolites — represented via the area of peaks in spectra. Regions between peaks, 
peak shape and variation in peak position are all artefacts of acquisition that do not 
contribute to metabolomic analysis. There are two common methods used for the 
reduction of spectral data to the important elements — binning and peak picking.  
 
Peak picking is based on the principle that the peaks — metabolites — are the important 
part of the data. If peaks can be accurately isolated, the remainder of the data can 
therefore be discarded.. There are a number of approaches to peak identification from 
spectra, from localisation of higher regions surrounded by lower regions to the analysis 
of the harmonics in the NMR signal. In practical use with 1D 1H NMR spectra the 
former is usually sufficient to identify the key peaks and exclude noise. However, any 
peaks that fall below determined thresholds will be lost from the data. Since confident 
identification of metabolites often depends on the identification of multiple resonant 
peaks this can pose problems during subsequent analysis. Similarly, if thresholds are 
set too loosely background noise can be wrongly identified as data. 
 
Spectral binning is a simpler approach in which spectra are sub-divided into a number 
of regions of a standard size (~0.05 ppm). Maximum intensities or AUC are then 
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calculated for each bin and used for subsequent analysis. This effectively discards 
irrelevant variation while retaining minor peaks that may go undetected by a peak-
finding algorithm. Binning is preferred due to the simplicity of use — which can be 
consistently applied across multiple studies without configuration. However, while 
binning eliminates variation arising from minor misalignments of peaks, it is also 
susceptible to false variation where peaks fall on bin-edges. Quality alignment is 
therefore key to achieving meaningful results with binning. 
3.3.2 Spectral	alignment	
Spectral alignment is one of the single most important steps in the data pre-processing 
workflow. Misalignment of spectra can result in binning artefacts and spurious peak 
variation between samples, resulting in erroneous results. The established standard of 
spectral shifting was icoshift, an algorithm that uses a fast fourier transform (FFT) 
implementation of cross correlation to simultaneously identify and correct offsets 
between multiple spectra [334]. The result is an ability to rapidly and accurately align 
complex signals, even where overlap and extraneous peaks exist. However, this 
algorithm was not without its limitations. Because clusters in different regions of the 
spectra can shift differently in response to pH variation, shifting must be performed in 
segments across the spectra. To avoid two peak clusters with differential pH behaviour 
occurring within a single segment and rendering alignment impossible, these segments 
are typically set to fractions of a ppm. However, artefacts can be introduced where 
segments land in the middle of peaks or peak clusters.  
 
First, a number of naïve alignment approaches were attempted, including iteratively 
increasing or decreasing bins with 2-fold changes and offsets. However, while 
minimising the occurrence of edge-peak collisions, they did not eliminate them and 
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artefacts were still seen in the resulting spectra. To resolve this issue a simple algorithm 
was developed to search for the optimal local site of bin edges. Following the principal 
that the tops of peaks were the area of most interest and most variation in an NMR 
spectrum the algorithm searched for the lowest variation minima in the locality of the 
default bin edge. To limit the search space the adjustment threshold was set to 1/3 of 
the total spectrum size in both directions, meaning each segment can be automatically 
adjusted from 1/3 to 1 1/3 its original size. The resulting outputs using the minimally 
improved spectral alignment (MISA) algorithm (Figure 3.1) give a representative view 
of icoshift alignment in pH-variable samples. The standard 50 segments show spectral 
artefacts at the location of the segment edges. By shifting segment edges out of the 
clusters MISA successfully eliminates the artefacts from the spectra. The effect on 
subsequent multivariate analysis (PCA) is seen in Figure 3.2 showing the improved 
clustering of the samples.  
 
 
Figure 3.1. Minimally Improved Segmental Alignment eliminates
segment-edge artefacts in icoshift aligned spectra. Samples ofglutamine-free RPMI were diluted 3 parts to 1 part 4x NMR buffer and pHadjusted to pH 6.2, 6.4, 7.2 and 7.4 in duplicates. Spectra were acquired andprocessed with NMRLab using standard methodology excepting theomission of segmental alignment. Spectra were globally aligned withoutsegments prior to application of MISA algorithm. Resulting spectrafollowing MISA-optimised alignment are shown (A) unaligned, (B) icoshiftaligned and (C)MISA-icoshift aligned spectra from deliberately pH-variablesamples ranging from pH 6.2-8.2. Segment-edges (blue) falling in peakclusters prevent alignment and introduce artefacts (see cluster @1.45).MISA optimisation of segment edges (red) eliminates this problem andresults in well aligned artefact-free spectra.
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C
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Figure 3.2. MISA-optimisation reduces within-group variation
following PCA. Samples of glutamine-free RPMI were diluted 3 parts to 1part with 4x NMR buffer and pH adjusted to pH 6.2, 6.4, 7.2 and 7.4 induplicates. Spectra were acquired and processed with NMRLab usingstandard methodology excepting the omission of segmental alignment.Principal Component Analysis (PCA) was performed on spectra with (A) nosegmental alignment (cyan), icoshift 50-segment alignment (red) andMISA-icoshift 50-segment alignment (green) in samples with a pH range of6.2-8.2. MISA optimisation reduces variation between otherwise identicalsamples. Separate PCA models were generated for (B) of non-MISAoptimised aligned samples only (C) and MISA-optimised samples only.Samples have grouped into pH<7 and pH>7 groups, with minimal within-group variation in PC 1.
CB
A
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3.3.3 Normalisation	
Metabolomic samples are particularly prone to confounding variation. Urine 
concentration varies considerable from sample to sample dependent on subject, 
hydration and diseases affecting urine output. Other bio-fluids such as plasma are 
relatively stable but can be affected by medical interventions such as the administration 
of saline. Metabolite extracts from solid materials including tissue or cultured cells are 
typically extracted into solvent and therefore may also be affected by tissue size, extract 
efficiency or volume. The adjustment of pH — occurring after sample loading with 
phosphate buffer and 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) or 
trimethylsilyl propionic acid (TMSP or TSP) — by addition of NaOH or HCl further 
dilutes samples. Finally, data may show inter-sample variation arising from the 
acquisition itself, due to effects of the NMR apparatus. Minimisation of these errors is 
key to accurate quantification of metabolites and to the success of subsequent analyses. 
This is commonly achieved by the application of standard scaling and normalisation 
methods in the pre-processing of metabolomic data.  
 
Scaling to a DSS or TMSP calibration standard is the simplest method to account for 
sample dilution after the addition of phosphate buffer. The standard is commonly added 
to the phosphate buffer to act as both a volume and spectral shift standardisation marker 
in acquired spectra [335]. By scaling the resulting spectra by the calibration peak it is 
possible to eliminate variation introduced during the sample pH adjustment or 
acquisition. However, as the standard is added after initial sample preparation any prior 
variation is unaccounted for and other methods must also be used. 
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For urinary biomarkers it is common to reference to urinary creatinine. Creatinine is 
freely and consistently filtered at the glomerulus — with a rate of production 
proportional to the subjects muscle mass [336]. Since creatinine excretion is constant, 
the concentration in urine falls in direct proportion to the rate of urine production. 
Normalisation of other metabolites by the creatinine concentration can therefore be 
used to adjust for their dilution. The main peaks for creatinine are well isolated on the 
NMR spectra (4.0 ppm and 3.0 ppm) allowing scaling on either peak. However, this 
method is only applicable to urinary metabolomics and no equivalent “housekeeping” 
metabolite exists for consistent scaling of other bio-fluids, tissues or cell extracts. 
 
In these cases algorithmic methods are used that attempt to normalise multiple spectra 
against a computed standard — including total spectral area (TSA) and probabilistic 
quotient normalisation (PQN). TSA is a straightforward algorithm that naively scales 
each spectrum to a standard area under the curve. This method is robust where dilution 
is the only cause of variation, however it is susceptible to scaling error in the presence 
of additional peaks or large changes in individual peak magnitude [337]. PQN 
normalisation attempts to avoid this limitation by calculating the ideal scale factor on a 
point-by-point basis for each spectrum [337]. The median of these point-wise scaling 
factors is considered to be the mostly likely scaling factor for a given spectrum and 
applied to the whole spectrum. This method relies on the principle that spectra from the 
same type of biological source will be fundamentally similar and functions well if that 
is the case. However, the point-by-point scaling makes PQN normalisation particularly 
susceptible to spectral misalignment. 
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PQN normalisation was therefore preferred due to the resilience of the algorithm to 
variable or new peaks in the spectra — a strong possibility in our cell extract analysis. 
Initial testing showed that it was less capable than TSA normalisation on standardised 
pH adjusted RPMI samples with considerable pH induced peak shifting Figure 3.3. 
Although pH variation is not a concern for cell extracts, we expected to see rising lactic 
acid in the cell culture media based on our pilot experiments. The MISA-improved 
icoshift alignment was shown to be capable of compensating for pH-induced shift 
within normal limits and to enable PQN normalise to function optimally. With all 
culture media samples being pH adjusted prior to analysis, the combination of MISA 
and PQN was deemed sufficient to produce consistent results for this study. 

Figure 3.3 1D NMR normalisation by TSA and PQN with and without
alignment. Samples of healthy urine were serially diluted 1, ½, ¼ intriplicate and then diluted 3 parts to 1 part with 4x NMR buffer and pHadjusted to pH 7.0 prior to acquisition of NMR spectra. Spectra wereacquired and processed with NMRLab using standard methodologyexcepting the omission of segmental alignment and spectral scaling(TSA/PQN normalisation). Resulting spectra are plotted, showing thecitrate peak, selected due to the presence of segmentation effects. TSA andPQN attempt to remove dilution effects on spectra scaling, therefore underoptimal conditions all lines should be equal. PQN is optimised at the ppmlevel, therefore misalignment can lead to improper scaling. In (A) TSAnormalisation performs better on poorly-aligned spectra than (B) PQN.The zoomed in view (C) of the poorly scaled PQN-normalised spectrashows alignment issues. (D) Repeating the PQN normalisation followingMISA-icoshift alignment gives a well aligned and scaled spectra.
AB
C
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3.3.4 Multivariate	analysis	methods	
Because of the potential for large numbers of quantified metabolites or peaks, the 
analysis of metabolomic data is commonly based on multivariate methods. Principal 
component analysis (PCA) is an unsupervised analysis technique that allows the major 
variation in a dataset to be projected into a series of correlated principal components. 
This is useful for identifying unknown sources of variation, particularly in complex 
multi-sample studies where the important groupings may not be known. Partial least 
squares (PLS) is a related supervised analysis where the data is correlated against a 
provided variable — either a continuous variable in partial least squares regression 
(PLS-R) or a binary classifier in partial least squares discriminant analysis (PLS-DA). 
These have the advantage of isolating the variation of interest but are prone to over-
fitting and require cross-validation to determine if the resulting model is generalisable. 
 
In addition to these established methods our group has previously explored using 
genetic algorithms to identify biomarkers [338]. The underlying principle of genetic 
algorithms is the iterative improvement towards a given maximal fitness — as 
calculated by a fitness function — through the random assortment and selection of 
genes. For the analysis of metabolomic data individual genes represent individual bins 
or peaks and fitness is defined by the ability of a given set of genes to predict a target 
group. Starting populations are generated and each population is judged according to 
the ability of its genes to predict the target classification or variable. Those that fall 
below the fitness threshold are culled and replaced with re-randomised sets. Over 
multiple generations the population moves towards local maxima of fitness. In order to 
find the global maxima it is necessary to repeat the algorithm a number of times. The 
result is the set of optimal organisms, which may be further interrogated to produce the 
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set of optimal genes — metabolites — to predict the sample groups. Genetic algorithms 
have the advantage that they do not require co-correlation of predictive variables and 
so have the potential to identify more complex patterns in the data. However, this is at 
the expense of speed with a typical run taking over 24 hours on a desktop computer. 
 
Because the goal of this study was to identify the metabolic differences between 
specific groups — of macrophage subsets — supervised analysis was preferred to 
extract variation with minimal noise. Partial least squares discriminant analysis (PLS-
DA) was selected for identification of inter-group differences, while partial least 
squares regression (PLS-R) analysis was used for correlation of macrophage metabolic 
profiles against cytokine expression levels. The latter was performed using a MATLAB 
script developed by John Byrne, University of Birmingham. We also explored genetic 
algorithms as an alternative approach following our previous success with the method 
in the search for biomarkers. However, we found that for this study with well-controlled 
tissue-cultured samples orthogonal PLS-DA was sufficient to integrate all the relevant 
variation in our samples. Sample analyses using the galgo genetic algorithm method 
took considerably longer than standard PLS-DA yet returned the same peak results. 
 
While the standard methods are sufficient for pairwise comparisons of macrophage 
subsets, we found that above 3 groups it became difficult to interpret the resulting 
weights and scores plots that are produced by PLS-DA. To simplify multiple-group 
analysis a novel algorithm was developed which iteratively performed pairwise 
comparisons between groups in the data. The inverse of the regression co-efficient (1-
r2) was used to define sample group distances in a unified 2-dimensional projection of 
all groups. By applying a force-directed layout algorithm class groups automatically 
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position themselves to match as far as possible the differences between the groups in 
the original. Metabolite concentrations can be overlaid on the resulting maps with 
gradient plotting to show the major distinguishing features of the samples in question. 
The result is a single map showing the key features of a complex multiple sample 
experiment Figure 3.4. This method is applied in our analysis of macrophage 
differentiation/activation in hypoxic environments in Chapter 7. 
 
 
 
 
 
 
 

Figure 3.4. Force-projected PLS-DA maps showing clustering between
groups of differentiated macrophages. Media were collected from 6 wellplates following monocyte differentiation with GM-CSF (M1), M-CSF (M2)and GM-CSF/IL-4 (DC) conditions and subsequent stimulation with LPS,under normoxia, hypoxia and reperfusion conditions. Samples were diluted3 parts to 1 part with 4x NMR buffer and pH adjusted to pH 7.0 prior toacquisition by 2D JRES NMR. Metabolites were quantified from 2D JRESspectra using the Field Independent Metabolite Analysis (FIMA) service ofthe Birmingham Metabolite Library (BML-NMR). Quantified metaboliteswere analysed using a PLS-DA clustering algorithm to determine globalrelationships between groups. Increased distances indicate increaseddifferences between samples. Samples from (A) M1, M2, DC populationsgroup together, as do samples cultured under normoxia, hypoxia orreperfusion conditions. (B) Simplified PLS-DA map grouping all M1, M2and DC classes overlaid withmetabolite change data as quantified by FIMA.Alterations in metabolites +/- are shown relative to direction of the arrow,e.g. Arginine increases from DCs to M2s. Significant changes (as tested byStudent’s t-test) are indicated by stars (*=0.05, **=0.01, ***=0.005,****=0.001). (C) Contour maps allow overlay of metabolite concentrationsto aid visualisation of the metabolic basis of group separation. For example,myo-Inositol is shown to be raised in M1/M2 macrophages underreperfusion and LPS-stimulation. (D) Multiple metabolites may be plottedon the samemap to visualise similarities in distribution.
A B
C D
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3.3.5 Metabolite	identification	and	quantification		
The identification of metabolites is a key to extracting meaningful information from 
NMR data. The analysis was typically performed blind, with comparisons between 
peaks —or bins — performed prior to identification of the metabolites those peaks 
represent. This was necessary when identification required manual matching of peaks 
to public databases of standard spectra. However, during the course of this project a 
number of automated approaches have become available that enable faster 
identification — and quantification — of metabolites from 1D and 2D NMR spectra. 
These methods invert the process, and allow analysis to be performed directly on 
quantified data. The set of tools considered for this study are shown in Table 3. 
 	
Source NMR Ident Quant Notes 
HMDB 1D 905  Manual search per compound 
MetaboHunter  
(HMDB & MMCD) 1D 867+448  Automated whole-spectra search 
Chenomx 1D 372 372 Manual identification, automated quantification for multiple spectra 
FIMA 2D 208 208 Automated multi-spectra identification and quantification 
Table	3.	1H	NMR	metabolite	identification	and	quantification	tools	Selection	of	tools	considered	for	use	in	this	study,	available	at	the	outset	of	the	project.	
 
Accurate identification and quantification of metabolites from NMR spectra was 
essential to the success of this project. The complexity of complete culture media and 
cell extract samples rendered manual identification via HMDB unusable for this 
purpose. The alternatives considered for use were —  
• Metabohunter	—automated	fitting	algorithms	against	a	subset	of	the	HMDB	
• Chenomx	—	automated	fitting	based	on	a	manually-fit	initial	spectra	
• FIMA	(BML-NMR)	—	an	entirely	automated	fitting	service	using	2D	JRES	spectra	
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To determine the quantification capabilities of each method a series of serially diluted 
pH 7.0 RPMI spectra were processed and quantified using each method. The results 
(Figure 3.5) showed that manual identification and automated quantification with 
Chenomx was the optimum approach for both accuracy of identification and 
quantification of metabolites in the spectra (R2 = 0.989). FIMA was reasonably accurate 
at quantification (R2 = 0.771) but failed to identify a number of metabolites known to 
be in the media and — more problematically — misidentified others. Metabohunter 
automated matching using default parameters set for mammalian metabolites on 
600MHz at pH 7.0 was the worst performer, incorrectly identifying a number of 
metabolites, and with a poor accuracy score on quantification (R2 = 0.053). On the basis 
of these results Chenomx was selected as the preferred method for quantification and 
identification, with FIMA being reserved for rapid quantification and identification for 
preliminary or exploratory work where Chenomx would be too time consuming. 
 
As the identification and quantification method was selected using culture media, we 
next needed to re-test and optimise the method for cell extracts. In particular, it was 
necessary to calculate the minimum number of cells at which meaningful identification 
could be made as this would determine the number of experimental conditions that 
could be tested per donor. To explore this a series of cell extracts and NMR acquisitions 
were performed using an increasing number of M-CSF differentiated monocytes, 
including 0.5x106, 1x106, 2x106 to 3x106 (Figure 3.6). Higher numbers offered higher 
quantification reliability, reaching 35 metabolites with 3x106 cells and including major 
metabolites of the glycolytic and TCA cycle. This number was therefore taken as the 
baseline minimum for future metabolomics experiments, however many were 
performed on higher (10x106) cell numbers. 
Figure 3.5. Metabolite identification and quantification by
Metabohunter, FIMA and Chenomx. Three alternative methods ofmetabolite identification and quantification from NMR spectra were testedfor accuracy using a known-concentration complex mixture. Samples ofglutamine-free RPMI were diluted 3 parts to 1 part 4x NMR buffer and pHadjusted to pH 7.0 in triplicate. Both 1D and 2D JRES spectra were acquiredby NMR. (A) 1D spectra were processed with NMRLab using standardmethodology. Binned, aligned spectra were submitted to Metabohunter foranalysis. Metabohunter correctly matched and quantified a number ofmetabolites, but also identified a number of metabolites not in the mixture.Quantified values correlated poorly with known values (=0.05) (B)Metabolites were quantified from 2D JRES spectra using the FieldIndependent Metabolite Analysis (FIMA) service of the BirminghamMetabolite Library (BML-NMR). Identification coverage was improvedcompared to Metabohunter, and quantification correlated highly withknown values (>0.7) but contained incorrect metabolites. (C) Chenomxmanual identification with automated quantification was performed onraw unprocessed spectra. This method produced the most accurate resultsfinding the majority of RPMI metabolites with the exception of cystine,choline, glutathione, serine and tryptophan. Chenomx quantified valuescorrelated highly (>0.98) with known concentrations.
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Figure 3.6. Cell number optimisation for metabolite extract
quantification. Optimal macrophage cell numbers for metabolitequantification from cell extracts was determined using a series of testsamples at 0.5x106, 1x106, 2x106 and 3x106. Monocytes were differentiatedin T25 culture flasks for 7 days in triplicate. Intracellular metabolites wereextracted at endpoint of differentiation by standard methanol extractionand dried extracts were resuspended in 1x NMR buffer and pH adjusted topH 7.0. 2D JRES spectra were acquired by NMR and quantified by the FieldIndependent Metabolite Analysis (FIMA) service of the BirminghamMetabolite Library (BML-NMR). The optimal cell number was determinedby coverage of quantification. (A) Quantification of top abundantmetabolites fromNMR of 3x106 to 0.5x106 cell extracts. 3x106 cells enabledquantification of 25+ metabolites. Note, the missing value (quantified highat 2x106 cells) is a misidentification. (B) Close up view of spectra generatedfrom multiple cell quantifications, showing a general agreement betweensamples, but reduced noise at increasing cell numbers. Based on these dataa cell number of 3x106 was chosen as a minimum baseline level for allmacrophage experiments.
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3.3.6 Metabolic	pathway	visualisation	
The analysis methods outlined so far are as equally applicable to biomarker 
identification from bio-fluids as they are the analysis of cell extracts. However, in order 
to achieve useful insights from this study it was important to be able to interpret 
detected changes in metabolite concentrations in their biological context. Previously 
interpretation of metabolic findings was a completely manual process. Metabolite 
databases such as the Human Metabolome Database [339] — catalogues of 
metabolomic data and clinical associations and normal ranges — were interrogated 
with identified metabolites, looking for disease or biological associations. Metabolic 
pathway maps from KEGG provide biological pathway contextual information while 
tools such as PathVisio [340] or Cytoscape [341] allow pathway-based visualisation. 
However, both of these tools required a target pathway to be known and identified and 
available tools did not yet support pathway searching or construction from available 
data. Therefore, analysis was artificially restricted to those pathways and reactions most 
studied. 
 
To enable visualisation of non-standard metabolic pathways and aid our understanding 
of relationships between them in the macrophage system, a metabolic pathway 
visualisation library MetaViz was developed for Python using the Graphviz graph 
visualisation system. The visualisation system is driven by data derived from the 
HumanCyc database, including all metabolites, proteins and genes involved. The layout 
automatically excludes a number of metabolites considered ‘secondary’ such as energy 
carriers (ATP, ADP, etc.) and ions (Mg+), but annotates reactions as necessary. 
Metabolite, gene and protein data can all be visualised on the pathway using 
configurable colour scales. Pathway enzyme gene or protein changes are shown on 
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reaction links. The tool allows rapid visualisation of data with integrated annotations of 
pathway connections and sub-pathways (Figure 3.7). The maps are not without their 
limitations — for example multiple-intersecting pathways can become unreadable — 
but offer a useful first step in exploring metabolic changes in a system. 
 
The automated visualisation of metabolic pathways removed one limitation on our 
ability to explore metabolic changes. However, we found that when facing the 
multitude of pathways available there remained a tendency to focus on central pathways 
— e.g. glycolysis, or TCA cycle metabolism — that while well understood may not be 
the most relevant. In order to remove this bias from our discovery a simple pathway-
mining algorithm pathminer was developed to identify key variation in metabolic 
pathways using an unbiased approach. In the algorithm pathways are scored based on 
metabolite change, metabolite change +/- only and metabolite difference between 
adjacent reactions. For a given input dataset a ranked list of metabolic pathways are 
produced, indicating where the largest regulation is occurring. Scaling allows scores to 
be adjusted for pathway size to remove tendency towards large pathways or metabolite 
network importance — number of pathways a metabolite is in — depending on 
application. The algorithm provides a simple method to isolate and focus on potentially 
important areas of cellular metabolism (Figure 3.8). The algorithm was validated using 
simulated datasets containing up- and downregulated pathways over configurable 
background noise. It was able to correctly identify key pathways up to a noise level at 
one log10 below real data mean (Figure 3.9). Beyond this level encroaching noise 
affected the selection of low-scoring pathways, but higher scored pathways remained 
intact. The resulting algorithm was used to explore our metabolic findings in 
macrophage subsets. 
Figure 3.7. An overview of MetaViz pathway-exploration features.MetaViz performs automatic layout, annotation and colouring ofoverlapping metabolic pathways. (A) Mapping of HumanCyc metabolicpathways. Reaction colours indicate parent pathways an individualreaction is a member of. Reactions in more than one pathway are striped.
(B) Network analysis of database pathways, with metabolites present inmore pathways highlighted with thicker lines– changes in thesemetabolites are more significant, representing alterations in multiplesystems. (C) Hidden pathway links (grey arrows) show relationshipsbetween metabolites via currently hidden pathways. (D) Databaseinformation, one-click add & remove pathways, protein and enzymeslistings and database unification links are all available from the MetaVizinterface.
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Figure 3.8. Pathminer algorithm identifies most regulated pathways in
data. To demonstrate pathway-mining capabilities of the pathmineralgorithm triplicate T75 flasks containing 10x106 THP-1 cells werecultured under 1% oxygen (hypoxic) and 20% oxygen (normoxic) for 24 h.Intracellular metabolites were extracted at endpoint of differentiation bystandard methanol extraction and dried extracts were resuspended in 1xNMR buffer and pH adjusted to pH 7.0. 2D JRES spectra were acquired byNMR and quantified by the Field Independent Metabolite Analysis (FIMA)service of the Birmingham Metabolite Library (BML-NMR). Quantifiedmetabolites were used to calculate log2 fold change between hypoxic andnormoxic cultures, which was subsequently analysed using the pathmineralgorithm. The algorithm identified the TCA cycle as one of the most down-regulated pathways.
log2(fc) 1-1
Figure 3.9. Resilience of pathminer algorithm to increasing levels of
background noise. The response of the pathminer algorithm toquantification error was assessed. Simulated data was generatedcontaining values for metabolites in the TCA cycle and glycolysismetabolites over a series of concentration ranges. Random noise wasadded to the control values in a constant 10-4 to 10-6 range to simulatequantified values falling into noise floor (A) Control data in the range 10-4to 10-6, results in clear distinction of intended pathways (repeatable). (B)With control data in the range 10-3 to 10-7 pathway identification continuesto function. (C) Repeat in range 10-3 to 10-7, pathway identification hassuggested citrulline biosynthesis instead of tyrosine degradation, yet keypathways glycolysis and TCA cycle persist. (D) Control data in the range 10-2 to 10-8. TCA cycle identification swamped by background noise, yetglycolysis still recognised.
log2(fc) 1-1
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3.4 Conclusions	
The methods described in this chapter were developed to resolve analysis issues as they 
occurred throughout this study. The standardised workflow which resulted from this 
work was used for the remainder of this thesis — 
• 1D	1H	NMR	
• 2D	1H	JRES	NMR	spectra	for	pilot	experiments	
• Pre-processing	with	NMRLab/MetaboLab	
• icoshift	+	MISA	for	spectral	alignment	
• PQN	normalisation	
• Spectral	binning	at	0.06ppm	
• Chenomx	for	identification	+	quantification	
o +	Chenomx	library	peak	matching	for	binned	spectra	peak	identification	
o +	FIMA	identification	and	quantification	for	2D	JRES	
• Pathminer	pathway	mining	and	MetaViz	pathway	visualisation	
 
The completed pipeline is illustrated in Figure 3.10.  
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Figure 3.10. The completed analysis pipeline. Metabolomic samples areacquired via 1D 1HNOESY NMRwith optional 2D JRES NMR. 1D data are processedwith NMRLab then icoshift aligned with MISA optimisations. Spectra are PQNnormalised and peaks identified by Chenomx. Simultaneously, spectra areidentified and quantified by Chenomx directly to produce non-normalised per-metabolite concentrations. Resulting data are analysed using PLS-DA, multi-wayPLS-DA and PLS-R to integrate with other data sources such as cytokines. PLS-DAmaps and pathminer identified pathways support hypothesis generation to informfurther analysis and subsequent experiments.
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4 PATHOMX:	A	WORKFLOW-BASED	TOOL	FOR	
METABOLOMIC	ANALYSIS	
4.1 Introduction	
The standardisation of our workflow was successful in simplifying the analysis process. 
However, the process still required a large amount of manual data handling through 
multiple formats, from raw NMR data to comma-separated files to MATLAB data 
frames and models. While manageable for single runs, this quickly became 
unmanageable for large-scale and more complex experiments. The learning curve 
associated with each of the tools — including at least some programming experience 
— also placed a barrier on non-experts performing metabolomic analysis. The 
workflow outlined in the previous chapter demonstrates this well, combining 5 separate 
applications and platforms: MATLAB-based NMRLab and MetaboLab for processing, 
PLS Toolbox (Eigenvector Research, Wenatchee WA USA) for multivariate analysis, 
Chenomx (Edmonton, Alberta, Canada) for metabolite identification and Excel for 
identified peak annotation [330].  
 
Scientific workflow tools have emerged as a powerful approach for the adaptable 
analysis of large datasets, with a number of platforms available [342]. Taverna and 
Galaxy are of particular note, having established themselves as platforms of choice for 
transcriptomic data analysis [343,344]. Both feature step-wise workflow construction 
paired with server-based batch processing, yet differ on the level of abstraction of their 
components. Taverna is a low-level workflow creator, requiring programming 
knowledge and with a particular focus on integration with remote services. Galaxy in 
contrast offers high-level components that perform common bioinformatics tasks 
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wholesale, with a focus on local-service integration without the need for programming 
knowledge. However, both platforms lacked support for the analysis of metabolomic 
data and the batch-processing paradigm limited their application to the automatable 
steps of data analysis — making them poorly suited to the iterative analysis and 
visualisation common in our metabolomic studies. 
 
In view of the benefits that workflow-based analysis provides, yet hoping to overcome 
the limitations of batch processing, an application was developed — Pathomx — to 
support real-time workflow-based analysis of metabolomic and other data.  
4.2 Implementation	
Pathomx is an open source and cross-platform analysis tool. It is built as a graphical 
user interface (GUI) application written in Python (v2.7; Python Software Foundation), 
with a user interface based on Qt (5.1; Digia) and graphing powered by Matplotlib 
(v1.1.1) [345]. Plugins support data import, processing, analysis, visualisation and 
export. Pathomx ships with a base set of plugins for metabolomics processing and 
analysis based on NumPy (v1.7.1), SciPy (v.0.12.0), SkiKit-Learn (v.0.14.1) and 
NMRGlue (v.0.4) [346–348]. Pathway layout in the MetaViz plugin is via pydot 
(v1.0.28) interface to Graphviz (v2.12) [349]. The functionality described in this paper 
relates to the base plugins provided with Pathomx 2.3. Pathomx is distributed with a 
standard set of focused on the analysis of NMR-derived metabolomic data. Many of 
the tools developed for the Pathomx workflows were subsequently released 
independently as Python (2.7; 3.4) library packages to enable their use outside of the 
software, including biocyc, pyqtconfig, metabohunter, mplstyler, MetaViz, icoshift, 
gpml2svg. 
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In Pathomx nomenclature plugins provide tools that are used for construction of 
workflows. Data analysis workflows are constructed using a drag-and-drop interface, 
allowing tool inputs and outputs to be rearranged, connected and disconnected 
dynamically (Figure 4.1). Recalculation and regeneration of figures is automatic and 
the current run-state is visualised within the workflow editor. Tool execution occurs on 
a separate thread and supports multithreaded processing, allowing efficient execution 
of complex workflows on large datasets on a standard modern desktop machine. This 
is particularly useful when applying interactive adjustments to data, exploring the 
effects of binning approaches on subsequent analysis or quantification accuracy. 
Recalculation and regeneration of figures occurs automatically, with execution state 
visualised in the workflow editor (blue=complete, red=error, green=active). Tools can 
make use of parallel processing for efficient execution on standard desktop machines. 
Errors return complete Python backtraces for debugging, together with descriptive error 
messages. To support development of custom tools an application-programming 
interface (API) was developed to give tools access to data visualisation, report 
generation and configuration management by default. Tool scripts can be edited inline 
to customise behaviour for specific workflows and the IPython server backend provides 
interfaces to MATLAB® and R that can be used interchangeably. Pathomx supports 
data import from a number of tools and public databases, including BML-NMR, 
Chenomx (Chenomx Inc.), the Gene Expression Omnibus (GEO) format, 
MetaboLights, raw Bruker NMR, PeakML and PRIDE [350–354]. There is also a 
general text/CSV file importer tool and support for MATLAB and Excel files, which 
can handle more complex format requirements. The default toolkit includes a number 
of tools for standard 1D NMR data processing and analysis (Figure 4.2). 
 
Figure 4.1 The Pathomx application interface. The main windowcontains the current workspace with (A) the workflow editor showing thecurrent analysis workflow, centre, and the toolkit panel on the sidebar. (B)Tool interface with configuration options in the sidebar and live figurevisualisation in centre. Data tables are accessible through the tabbedinterface on the bottomof the window.
AB
Figure 4.2 Graphical interface for two common 1D NMR processing
tools. Tool configuration is performed using standardised settings panels(left) while outputs, including figures and data tables, are updatedautomatically (right) (A) 1D spectral binning with configurable bin width(in ppm) and offset. (B) spectral normalisation offering TSA or PQN scaling
AB
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4.3 Discussion	
To demonstrate the functions of Pathomx a sample workflow and metabolomic dataset 
will be discussed below. Sample data is derived from the culture of THP-1 human 
macrophage cell line as described in the previous chapter. Briefly, THP-1 macrophages 
were cultured under 20% (normoxic) and 1% (hypoxic) conditions for 24 hours. 
Intracellular metabolites were methanol-chloroform extracted and resulting samples 
analysed using 1D and 2D J-resolved (JRES) 1H NMR on a 600 MHz B600 Bruker 
Avance III spectrometer with TCI 1.7 mm z-PFG cryogenic probe. Resulting 2D JRES 
spectra were quantified and identified using the the Field Independent Metabolite 
Analysis (FIMA) Birmingham Metabolite Library (BML) at bml-nmr.org. The 
processed quantified metabolites and the raw 1D Bruker NMR FID files were loaded 
into Pathomx and a workflow constructed using the default toolkit. 
4.3.1 Spectral	processing	
Prior to the analysis of 1D NMR data there are a number of processing steps that are 
performed to ensure that any observed variation in data is reflective of biology. The 
Pathomx toolkit is designed to replicate as far as possible the capabilities of the 
NMRLab/MetaboLab toolset available in in MATLAB [334,355]. It provides baseline 
correction, TMSP peak alignment and scaling, segmental alignment using the icoshift 
Python library, both TSA and PQN spectral normalisation and spectral binning [337].  
 
For demonstration purposes, the sample 1D data were peak-aligned using a TMSP 
reference peak, followed by icoshift segmental alignment. Spectra were then binned at 
0.015 ppm bin widths and assigned to experimental groups my matching spectra 
number to an important experimental class table (Figure 4.3 and Figure 4.4).   

Figure 4.3 Graphical representation of the Pathomxworkflows used in
the generation of figures in this thesis.Workflows are constructed usinga drag and drop interface from multiple independently configurable tools.Tools take input data and process it, depending on their configuration, togenerate outputs and visualisations. Workflows can be saved and re-usedfor novel data in future, allowing for standardisation of workflows. (A) 1D1H Bruker NMR analysis workflow. (B) 2D JRES BML-NMR analysisworkflow.

Figure 4.4 Example outputs from the 1D processing workflow. NMRspectra processed using the Pathomx workflow system, with step-wisevisualisation of spectral processing. Triplicate T25 flasks containing 10x106THP-1 cells were cultured under 1% oxygen (hypoxic) and 20% oxygen(normoxic) for 24 h. Intracellular metabolites were extracted at endpointof differentiation by standard methanol extraction and dried extracts wereresuspended in 1x NMR buffer and pH adjusted to pH 7.0. 1D NMR spectrawere acquired and analysed using the previously described Pathomxworkflow. (A) Raw1H NMR spectra. (B) TMSP and water regionsare excluded. (C) Spectral binning to 0.06 ppm. (D) Aligned usingIcoshift. (E) PQN normalisation. (F) Mapped to experimental groups byspectra number— normoxia (orange) hypoxia (blue).
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4.3.2 Metabolite	identification	
Identification and quantification of 2D JRES data is supported using the BML-NMR 
service. The returned data from BML-NMR includes a metabolite name and InChI 
identifier that uniquely identifies the metabolite [356]. These identifiers can be 
converted to more useful BioCyc or HMDB identifiers through the ‘Map to Biocyc’ 
tool [357,358]. Pathomx is distributed with a subset of the BioCyc/HumanCyc Homo 
sapiens pathway data under license from SRI International [357], as part of the 
separately released BioCyc Python package. Database cross-referencing is supported 
for KEGG, HMDB and a number of other biological databases, using a combination of 
BioCyc annotations and the MNXref database [359,360]. There is support for custom 
database mappings, supplied as a comma-separated text file. This capability to map 
identifiers to database entities is also available for gene and protein identifiers. 
Identification of 1D NMR data is more complicated however Pathomx supports direct 
peak annotation for manual peak assignment, as well as support for importing 
automated metabolite quantification from the Chenomx software. Fully automatic 
assignment is also supported with the MetaboHunter, a freely-available web service for 
1D NMR spectra identification [361]. This approach is prone to mis-identification but 
is used here in place of manual assignment for demonstration. The resulting annotated 
1D and 2D data are shown in Figure 4.5. 
 
 
 
  

Figure 4.5 Metabolite identification generated from MetaboHunter
and BML-NMR. Triplicate T25 flasks containing 10x106 THP-1 cells werecultured under 1% oxygen (hypoxic) and 20% oxygen (normoxic) for 24 h.Intracellular metabolites were extracted at endpoint of differentiation bystandard methanol extraction and dried extracts were resuspended in 1xNMR buffer and pH adjusted to pH 7.0. 1D NMR spectra were acquired andprocessed using a Pathomx workflow. 2D JRES spectra were acquired byNMR and quantified by the Field Independent Metabolite Analysis (FIMA)service of the Birmingham Metabolite Library (BML-NMR). (A) 1D NMRspectra with peaks matched to HMDB identifiers by MetaboHunter and 2DJRES BML-NMR quantified metabolites. The default toolkit also supportsmanual peak assignment and import of quantification data from Chenomx.Identified metabolites can be annotated onto all subsequent plots and usedfor pathway analysis. (B) 2D JRES FIMA-identified metabolites visualizedon GPML/Wikipathways pathway. Log2 fold change is shown on a red-bluescale, showing up- and down-regulated metabolites respectively. Themajority of metabolites of the TCA cycle are reduced under hypoxia.
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4.3.3 Multivariate	analysis	
Pathomx includes standard multivariate analysis methods in the default tools, including 
PCA and PLS-DA. These tools are themselves based on the scikit-learn machine-
learning libraries [347]. The capabilities and configuration of these tools was modelled 
on that available in our existing manual workflow. Relevant plots include scores, 
loadings and weightings are generated automatically. Since our test dataset includes 
two distinct groups (normoxia, hypoxia) we here used PLS-DA to identify differences 
between them. The resulting loadings plots show contributions of each peak (1D) or 
metabolite (2D) to the separation of the two groups (Figure 4.6). 
  

Figure 4.6 The default Pathomx toolkit includes support for
multivariate analysis. Triplicate T25 flasks containing 10x106 THP-1 cellswere cultured under 1% oxygen (hypoxic) and 20% oxygen (normoxic) for24 h. Intracellular metabolites were extracted at endpoint of differentiationby standard methanol extraction and dried extracts were resuspended in1x NMR buffer and pH adjusted to pH 7.0. 2D JRES spectra were acquiredby NMR and quantified by the Field Independent Metabolite Analysis(FIMA) service of the Birmingham Metabolite Library (BML-NMR). (A)PLS-DA of FIMA-quantified metabolites shows separation between thenormoxia (orange) hypoxia (blue) class groups. (B) The first two latentvariables are shown alongside, with metabolite annotations visible. THP-1cells under hypoxia producemore lactate.
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4.3.4 Metabolic	pathway	analysis	
Visualisation of metabolic pathways is supported by integrated support for MetaViz 
library. Metabolite, gene and protein concentrations or fold-change scores may be 
displayed on the maps using a colour scale. This ability to visualise multiple types of 
data in a single figure is particularly useful when integrating multiple -omics data. 
There is support for metabolic pathway analysis via the pathminer library. The output 
of pathminer analysis can be used directly to drive MetaViz for immediate visualisation 
of the top altered pathways as determined by the algorithm. In situations where 
traditional pathway representation is preferred there is also support for KEGG or 
WikiPathways/GPML manually laid-out pathways [362,363].  
 
The generate pathway maps for the demonstration data, fold change values for 
identified metabolites were calculated between normoxic and hypoxic cultures. These 
were visualised directly using standard GPML/Wikipathways pathway maps (Figure 
4.5B). Additionally, the included pathway mining tools were used to select and 
visualise the most up- and down- regulated pathways based on analysis of the data. The 
resulting top 5 pathways are passed to the MetaViz pathway drawing tool for 
visualisation, with fold-change data represented on a blue-red colour scale (Figure 4.7). 
  

Figure 4.7 Pathway mined metabolites as visualised by the MetaViz
plugin. Triplicate T25 flasks containing 10x106 THP-1 cells were culturedunder 1% oxygen (hypoxic) and 20% oxygen (normoxic) for 24 h.Intracellular metabolites were extracted at endpoint of differentiation bystandard methanol extraction and dried extracts were resuspended in 1xNMR buffer and pH adjusted to pH 7.0. 2D JRES spectra were acquired byNMR and quantified by the Field Independent Metabolite Analysis (FIMA)service of the Birmingham Metabolite Library (BML-NMR). Regulatedpathways were identified from quantified metabolites using the PathomxPathway Mining plugin and rendered using the MetaViz pathway plugin.Log2 fold change is shown on a red-blue scale, showing up- and down-regulated metabolites respectively. Analysis showed down-regulation ofTCA cycle metabolites and low NAD as an indicator of oxygen-dependentelectron-transport chain failure.
log2(fc) 1-1
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Under normal oxygenated conditions, glucose is metabolised through the glycolytic 
pathway ending in pyruvate. Subsequently pyruvate is transformed to acetyl-CoA to 
feed the TCA cycle. However, the TCA cycle is dependent on NADH recycling to NAD 
by the oxygen-dependent electron-transport chain to function. Under hypoxic 
conditions downregulation of the TCA cycle would be expected and the pathway-
mining analysis correctly identifies this change, ranking the TCA cycle as the most-
altered pathway in the system. Pathway visualisation shows downregulation of a 
majority of TCA cycle metabolites, together with low NAD concentration. In the 
absence of the feed forward into the TCA cycle, excess pyruvate is excreted as lactate. 
 
The results of this analysis can be exported to standard formats including text/CSV 
files, Excel or MATLAB workspace files.  
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4.4 Conclusions	
Pathomx is a workflow-based tool for the analysis and visualisation of data. The 
standard tools provide a complete metabolomic processing workflow through data 
import, processing, analysis and visualisation. I made extensive use of Pathomx to 
optimise and speed up the analysis of my results in subsequent chapters. However, the 
main driver for it development was my realisation of the complexity of the analysis of 
metabolomic data. If metabolomics is to be made accessible as a mainstream approach 
to the systems biology of cells or disease such tools are likely to become increasingly 
important. Using Pathomx for workflow construction requires no programming 
knowledge, and resulting workflows and datasets can be shared and re-used. The plugin 
system allows it to be readily extended with new tools, and other research groups have 
exploited this in order to add support for non-metabolomic analysis. The core 
application and default plugins are open-sourced under the GNU Public License v3. 
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5 METABOLOMICS	OF	MACROPHAGE	
DIFFERENTIATION	
5.1 Introduction	
Under the established nomenclature differentiated, activated macrophages are broadly 
classified into M1 or M2, representing “classical” cellular and “alternative” humoral 
immune responses respectively [164]. Recent work has expanded the M2 classification 
with sub-classifications M2a-c reflecting the activating stimulus [170]. In this study we 
were primarily interested in macrophages matching the M1 and M2a activation profiles 
— activated with LPS or LPS+IFNγ and IL-4, which are commonly differentiated on a 
background of M-CSF. However, GM-CSF is also used to differentiate M1-like 
macrophages in the Verreck model (M-CSF alone produces the corresponding M2 
phenotype). Given the high concentration of GM-CSF in the rheumatoid synovium we 
wanted to explore what effect differentiation with M-CSF and GM-CSF had on 
macrophage metabolism and subsequent activation [179].  
 
To explore this we differentiated blood derived monocytes under M-CSF and GM-CSF 
differentiation conditions for 6 days (Table 4). The analysis of the metabolomic and 
transcriptomic data from differentiated macrophages is outlined in this chapter. 
 
Differentiation Activation Mantovani Model Verreck Model 
GM-CSF — — M1 polarised 
M-CSF — — M2 polarised 
Table	4.	Macrophage	differentiation	treatments.	Established	macrophage	differentiation	methods	and	expected	polarisation.	
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5.2 Results	
We sought to determine whether M-CSF/GM-CSF differentiated macrophages were 
distinguishable at the endpoint of differentiation. The analysis of the metabolomics of 
macrophage differentiation was approached in four stages: Firstly, differentiation 
media were analysed to determine metabolic changes during the differentiation process. 
Secondly, endpoint media metabolites were analysed to identify overall changes during 
differentiation. Thirdly, endpoint cellular extracts were analysed, which in combination 
with media findings should provide an overview of cellular metabolic behaviours. 
Finally, endpoint transcriptional data were analysed for pathway analysis.  
 
The differentiation experiment was performed using multiple donors and technical 
replicates. Isolated peripheral blood monocytes (1x107) were differentiated in T75 
flasks with 12 mL standard culture media (RPMI+GPS+10% FCS) containing M-CSF 
(10 ng/ml) or GM-CSF (10 ng/ml) for 6 days. Endpoint intracellular RNA was 
extracted using Qiagen RNeasy MiniKit and quantified using Agilent 8x60K array. 
Endpoint culture media was collected and intracellular metabolites extracted by 
standard methanol extraction was collected. Resulting samples were analysed by 1D H1 
NMR. Spectra were processed using a standard NMRLab workflow. Following the 
assessment of relative performance of FIMA and Chenomx for metabolite 
quantification it was decided to perform the quantification from 1D only NMR spectra 
using Chenomx. Analysis of the resulting spectra was performed using both processed 
and quantified Chenomx data to account for metabolites not in the Chenomx library.  
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5.2.1 Macrophage	metabolic	output	changes	during	differentiation	under	
M-CSF	or	GM-CSF	
To quantify metabolic changes during macrophage differentiation longitudinal culture 
media samples were taken under differentiation with GM-CSF (n=4) or M-CSF (n=8). 
1D 1H NMR spectra were acquired and quantified using the Chenomx software. The 
time course concentration of each metabolite was plotted for M-CSF and GM-CSF 
wells. Samples started with the same baseline RPMI media therefore decreases from 
the initial concentration are indicative of metabolite uptake by differentiating cells, 
while increases are indicative of production and excretion. Transiently occurring 
metabolites, or those with high quantification error were not included. Longitudinal 
plots of metabolite concentrations are given in Figure 5.1—Figure 5.6. 
 
Glucose followed a downward trend throughout differentiation, with GM-CSF 
macrophage consumption outstripping M-CSF macrophages in the initial stages of 
differentiation. Between day 2 and 3, glucose consumption by GM-CSF macrophages 
slowed temporarily, before continuing at pace from day 4 onwards. In contrast glucose 
consumption by M-CSF macrophages was slower, but consistent throughout the 
differentiation period. By end point, GM-CSF macrophages had consumed 
significantly more glucose than their M-CSF counterparts. GM-CSF macrophages also 
consumed glutamine up to day 3 and produced a spike of glutamate at day 2. 
 
Citraconate was consumed in both cultures, however consumption by GM-CSF 
macrophages was much more rapid, with the entire media depleted by day 3. The 
metabolite remained undetectable thereafter in GM-CSF macrophages. Similarly, 3-
hydroxyisovalerate was consumed rapidly by both macrophage subsets in the first 3 
days of differentiation, falling from 0.035 µM to 0.015 µM by day 2, and then 
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plateauing. Arginine, asparagine, isoleucine, leucine, methylguanidine and valine were 
all consumed at a low but consistent rate during differentiation, with similar profiles in 
both M-CSF and GM-CSF macrophages. Similarly, creatine followed a downward 
trend in both macrophage subsets, albeit more rapidly consumed under GM-CSF. 
 
Lactate followed a trend upwards from day 1-6, peaking at 15 µM for GM-CSF and 
12 µM for M-CSF differentiated macrophages. The separation between the 
differentiation media occurs around day 3, and remained consistent thereafter without 
widening or shrinking. A similar trend upwards form the low media baseline of 0.2 µM 
was observed for amino acid alanine, but only under GM-CSF differentiation. In M-
CSF differentiation conditions the concentration of alanine remained almost completely 
unchanged.  
 
Histidine was excreted by both GM-CSF and M-CSF macrophages at day 6. As an 
essential amino acid this suggests protein turnover. Both ornithine and pyroglutamate 
were excreted in the later stages with GM-CSF macrophages excreting larger quantities 
than M-CSF. Phenylalanine, myo-inositol, pyruvate and tyrosine concentrations 
fluctuated during differentiation remaining broadly unchanged over the timecourse. 
 
 
 
  

Figure 5.1. Quantified media metabolite concentrations during M-CSF
and GM-CSF differentiation. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Longitudinal culture media (20 µl) collected oneach day were analysed by 1D H1 NMR. No media was added during thedifferentiation process. Metabolites were identified and quantified fromraw spectra with Chenomx. Results showed 3-Hydroxyisovalerate wasconsumed readily in the first 3 days of differentiation in both GM-CSF (n)and M-CSF (n) macrophages and plateaued thereafter. Alanine wasproduced by GM-CSF macrophages starting from day 3 and wassignificantly upregulated related to M-CSF macrophages by the end ofdifferentiation. 3-hydroxyisovalerate levels decreased significantly albeitonly slightly over the course of the entire differentiation. Arginineconcentrations cycled during differentiation with arginine in the media ofGM-CSF differentiatedmacrophages significantly raised at day 2.
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Figure 5.2. Quantified media metabolite concentrations during M-CSF
and GM-CSF differentiation. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Longitudinal culture media (20 µl) collected oneach day were analysed by 1D H1 NMR. No media was added during thedifferentiation process. Metabolites were identified and quantified fromraw spectra with Chenomx. Citraconate was consumed by both GM-CSF (n)and M-CSF (n) macrophages. In GM-CSF macrophages consumption wasmuch more rapid, with the entire media concentration depleted by day 3and remaining undetectable thereafter. Aspartate and creatine wereconsumed by both at comparable rates in both differentiation conditions,while formate was detectable at day 6.
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Figure 5.3. Quantified media metabolite concentrations during M-CSF
and GM-CSF differentiation. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Longitudinal culture media (20 µl) collected oneach day were analysed by 1D H1 NMR. No media was added during thedifferentiation process. Metabolites were identified and quantified fromraw spectra with Chenomx. Media glucose was consumed during thedifferentiation process in both GM-CSF (n) and M-CSF (n), with GM-CSFmacrophages consuming at a higher rate, with a concentration significantlybelow that of M-CSF macrophages from day 2. GM-CSF macrophages alsoconsumed glutamine up to day 3 and produced glutamate, withconcentrations significantly raised relative to M-CSF throughout thetimecourse. Histidine (an essential amino acid) was initially depleted andthen excreted by both GM-CSF andM-CSFmacrophages at day 6.
Glucose
Glutamate
Glutamine
Histidine
n GM-CSF
n M-CSF
Figure 5.4. Quantified media metabolite concentrations during M-CSF
and GM-CSF differentiation. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Longitudinal culture media (20 µl) collected oneach day were analysed by 1D H1 NMR. No media was added during thedifferentiation process. Metabolites were identified and quantified fromraw spectra with Chenomx. Lactate was excreted by both GM-CSF (n) andM-CSF (n) macrophages during differentiation, with GM-CSF macrophagecultures excreting significantly more at later timepoints. Leucine,isoleucine and methylguanidine were are all consumed during thedifferentiation process, with GM-CSF macrophages having consumedsignificantlymore leucine fromday 3 onwards.
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Figure 5.5. Quantified media metabolite concentrations during M-CSF
and GM-CSF differentiation. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Longitudinal culture media (20 µl) collected oneach day were analysed by 1D H1 NMR. No media was added during thedifferentiation process. Metabolites were identified and quantified fromraw spectra with Chenomx. Phenylalanine and myo-inositol concentrationsfluctuated during differentiation of both GM-CSF (n) and M-CSF (n)macrophages but remain broadly unchanged over the completetimecourse. However, myo-inositol was significantly higher in the media ofGM-CSF differentiating macrophages. Both ornithine and pyroglutamatewere excreted in the later stages, with GM-CSF macrophages excretingsignificantly larger quantities of pyroglutamate thanM-CSFmacrophages.
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Figure 5.6. Quantified media metabolite concentrations during M-CSF
and GM-CSF differentiation. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Longitudinal culture media (20 µl) collected oneach day were analysed by 1D H1 NMR. No media was added during thedifferentiation process. Metabolites were identified and quantified fromraw spectra with Chenomx. Tyrosine cycled during differentiation withincreases and decreases in both GM-CSF (n) and M-CSF (n) macrophages,but with no significant difference between the groups. Pyruvate cycledsimilarly, but with overall little change in concentration. Valine wasconsumed during the differentiation process, with GM-CSF macrophagesconsuming more rapidly and being significantly reduced relative to M-CSFdifferentiatedmacrophages by day 4.
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Figure 5.7. PLS-DA of endpoint culture media for macrophage
differentiation conditions. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=9) or GM-CSF(10 ng/nl; n=8) for 6 days. Endpoint culture media was collected andanalysed by 1D H1 NMR. A) Spectra were processed using a standardNMRLab workflow. Principal component analysis (PCA) was performed onprocessed binned data. M-CSF (¡) and GM-CSF (r) groups separatedclearly with high cross-validated sensitivity/specificity (Sensitivity: 1.0Specificity: 0.857). Bins responsible for this separation were mapped tospectral peaks and identified by reference to the Chenomx library. Resultsshowed increased lactate and decreased glucose in GM-CSF differentiatedmacrophages. B) Metabolites were identified and quantified from rawspectra with Chenomx. PCA was performed on quantified metabolites. M-
CSF (¡) and GM-CSF (r) groups separated well, but with lower cross-validated sensitivity/specificity (Sensitivity: 0.667 Specificity: 0.625).Results showed increased acetate, alanine, lactate and decreased glucose,methionine, phenylalanine in GM-CSF differentiatedmacrophages
AB
r GM-CSF
¡ M-CSF
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5.2.2 Differentiated	 macrophages	 can	 be	 distinguished	 by	 end-point	
media	metabolic	profiles	
Analysis of the end-point media for M-CSF (n=9) and GM-CSF (n=8) differentiation 
by PLS-DA successfully confirmed the ability to distinguish the two groups by media 
metabolite concentration alone, with the majority of difference in glucose and lactate 
concentrations alone. Scores and weights for the orthogonal PLS-DA analysis of 
processed spectra are shown in Figure 5.7. Due to the predominance of both lactate and 
glucose in the endpoint media other signals were largely undetectable in the PLS model. 
There are variance-stabilisation methods capable of mitigating this, however the 
Chenomx-quantified metabolites side step this issue and were therefore preferred for 
the media analysis. Results showed increased lactate production and increased glucose 
consumption in GM-CSF vs. M-CSF differentiated macrophages in line with 
differentiation media findings. Sensitivity and specificity of the cross-validated models 
was 1.0 and 0.857 respectively. 
5.2.3 Quantified	endpoint	culture	metabolites	show	profile	tendencies	for	
macrophage	subsets	
An equivalent orthogonal PLS-DA analysis was performed using the Chenomx-
quantified metabolites. In total 30 metabolites were identified and quantified for each 
sample. Metabolite concentrations were auto-scaled before analysis to avoid the model 
being dominated by high concentration metabolites. The resulting model scores and 
weightings plots are shown in Figure 5.7. Sensitivity and specificity of the cross-
validated models was 0.667 and 0.625 respectively. In an orthogonal PLS-DA between 
M-CSF (n=9) and GM-CSF (n=8) differentiated macrophages culture media alanine, 
proline, isoleucine and threonine was lower under M-CSF differentiation while 
methionine, phenylalanine, valine, asparagine and tyrosine are lower under GM-CSF 
differentiation. Lactate excretion is associated with GM-CSF differentiation as is 
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glucose consumption. The metabolite concentration changes identified by the weights 
plots were difficult to interpret in this format; therefore metabolites were plotted for M-
CSF and GM-CSF macrophages, alongside baseline media concentrations for each 
metabolite (Figure 5.8—Figure 5.9). The inclusion of baseline media makes it possible 
to determine whether relative reduced concentrations in one group reflect consumption 
or lowered production. Metabolite plots are arranged in alphabetical order, with 
significance calculated by Student’s t-test relative to baseline media concentrations.  
 
Glucose, glutamine, glutamate, acetate, 3-hydroxyisovalerate, arginine, asparagine, 
methylguanidine, methionine, leucine, isoleucine, phenylalanine, myo-inositol, 
tyrosine and valine were all significantly reduced in both macrophage subsets, relative 
to baseline media, indicating consumption during the differentiation process. 
Citraconate was significantly reduced under GM-CSF differentiation alone. Significant 
excretion of ornithine and histidine were also seen in both macrophage subsets. GM-
CSF macrophages produced more lactate and consumed more glucose than M-CSF 
macrophage during differentiation, while M-CSF macrophages excreted significant 
quantities of pyruvate. 
  
 
  
Figure 5.8. Chenomx-quantified metabolite concentrations for
endpoint culture. Peripheral bloodmonocytes (1x107) were differentiatedin T75 flasks with 12ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/ml; n=8) or GM-CSF (10 ng/nl; n=4) for 6 days.Endpoint culture media was collected and analysed by 1D H1 NMR.Metabolites were identified and quantified from raw spectra withChenomx. Significantly altered metabolites were calculated relative toaveraged repeated measurements of baseline media using a one-sample t-test (* p<0.05 ** p<0.01 *** p<0.001). Histidine and 2-hydroxyisovaleratewere significantly increased in both GM-CSF (n) and M-CSF (n)macrophage conditions, while 3-hydroxyisovalerate, acetate, arginine,asparagine, glucose, glutamine, glutamate and isoleucine were allsignificantly reduced.
2-Hydroxybutyrate 3-Hydroxyisovalerate Acetate
Alanine Arginine Asparagine
Citraconate Glucose Glutamate
Glutamine Histidine Isoleucine
☐ Baseline	media		n GM-CSF nM-CSF
Figure 5.9. Chenomx-quantified metabolite concentrations for
endpoint culture media. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Endpoint culture media was collected andanalysed by 1D H1 NMR. Metabolites were identified and quantified fromraw spectra with Chenomx. Significantly altered metabolites werecalculated relative to averaged repeated measurements of baseline mediausing one-sample t-test (* p<0.05 ** p<0.01 *** p<0.001). Ornithine wassignificantly increased in both GM-CSF (n) and M-CSF (n) macrophageconditions, while leucine, myo-Inositol, methylguanidine, methionine,phenylalanine, tyrosine and valine were all reduced. Lactate was increasedunder GM-CSF macrophage differentiation at endpoint of differentiation,but was non-significant relative to baseline due to the large measurementerror. Pyruvate and pyroglutamate were significantly raised under M-CSFdifferentiation.
2-Hydroxybutyrate 3-Hydroxyisovalerate Acetate
Methylguanidine Methionine Ornithine
Phenylalanine Pyroglutamate Pyruvate
Tyrosine Valine
☐ Baseline	media		n GM-CSF nM-CSF
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5.2.4 Differentiated	 macrophages	 can	 be	 distinguished	 by	 end-point	
metabolic	profiles	of	cell	extracts	
Endpoint intracellular metabolites for M-CSF (n=8) and GM-CSF (n=4) macrophages 
were quantified from methanol cell extracts. Analysis was performed from 1D 1H NMR 
spectra using both processed raw spectra, and Chenomx-quantified metabolite 
concentrations. To observe general global patterns in the macrophage subsets a PLS-
DA was performed for the two differentiation conditions. The scores and weightings 
plots for the orthogonal PLS-DA analysis of individual groups’ processed spectra are 
shown in Figure 5.10. The concentrations of intracellular metabolites were within the 
same range, and therefore there were no consistently dominating metabolites. 
Orthogonal PLS-DA (Sensitivity: 0.750 Specificity: 1.0) of M-CSF differentiation 
macrophages against GM-CSF differentiated macrophages showed that lactate was 
increased under GM-CSF differentiation, as was myo-inositol and taurine, while 
dimethylamine was reduced. Orthogonal PLS-DA of Chenomx-quantified metabolites 
showed the same regulation (Sensitivity: 0.875 Specificity: 0.250) with additionally 
intracellular ornithine, tyrosine, serine and glucose shown to be higher in M-CSF 
macrophages, while alanine, fumarate, histidine were all raised in GM-CSF 
macrophages. 
 
Quantified metabolites were plotted as previously. There is no baseline concentration 
available as for the media results; therefore significant differences were determined 
between the M-CSF and GM-CSF macrophage groups. Intracellular arginine, ornithine 
and tyrosine were raised significantly under M-CSF differentiation while glucose, 
leucine and pyruvate were all raised but not significantly. In contrast, GM-CSF 
differentiation was associated with significantly increased alanine, arginine, creatine 
phosphate, glycine, isocitrate, lactate, myo-inositol, threonine and tyrosine.

Figure 5.10. PLS-DA of endpoint cell extracts for macrophage
differentiation conditions. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Endpoint intracellular metabolites werecollected by standard methanol extraction and analysed by 1D H1 NMR. A)Spectra were processed using a standard NMRLab workflow. Principalcomponent analysis (PCA) was performed on processed binned data.MCSF
(¡) and GM-CSF (r) groups separated clearly with high cross-validatedsensitivity/specificity (Sensitivity: 0.750 Specificity: 1.0). GM-CSFdifferentiation was associated with increased intracellular lactate, myo-inositol, taurine and decreased dimethylglycine. B) Metabolites wereidentified and quantified from raw spectra with Chenomx. PCA wasperformed on quantified metabolites. M-CSF (¡) and GM-CSF (r) groupsseparated less well, with poor cross-validated sensitivity/specificity(Sensitivity: 0.875 Specificity: 0.250). Results showed increased myo-inositol, lactate, glycine, alanine and decreased ornithine, GTP, glucose inGM-CSF differentiatedmacrophages.
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Figure 5.11 Chenomx-quantified metabolite concentrations for
endpoint cell extracts. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Endpoint intracellular metabolites werecollected by standard methanol extraction and analysed by 1D H1 NMR.Metabolites were identified and quantified from raw spectra withChenomx. Significantly altered intracellular metabolites were calculatedbetween macrophage differentiation conditions using a two-sample t-test(GM-CSF n M-CSF n) (* p<0.05 ** p<0.01 *** p<0.001). Arginine wassignificantly raised in M-CSF macrophages (or reduced in GM-CSFmacrophages). In contrast alanine, creatine phosphate, glycine, isocitrateand lactate were significantly raised following GM-CSF differentiation.
Alanine Arginine Carnitine
Creatine Creatine phosphate Glucose
Glutamate Glutamine Glycine
Isocitrate Lactate Leucine
n GM-CSF nM-CSF
Figure 5.12. Chenomx-quantified metabolite concentrations for
endpoint cell extracts. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) for 6 days. Endpoint intracellular metabolites werecollected by standard methanol extraction and analysed by 1D H1 NMR.Metabolites were identified and quantified from raw spectra withChenomx. Significantly altered intracellular metabolites were calculatedbetween macrophage differentiation conditions using a two-sample t-test(GM-CSF n M-CSF n) (* p<0.05 ** p<0.01 *** p<0.001). Ornithine andtyrosine were both significantly increased following M-CSF differentiation(or reduced following GM-CSF), while myo-inositol and threonine weresignificantly increased in GM-CSFmacrophages.
Methylguanidine myo-Inositol Ornithine
Pyroglutamate Pyruvate Threonine
Tyrosine Valine
n GM-CSF nM-CSF
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5.2.5 Differentiated	 macrophages	 can	 be	 distinguished	 by	 end-point	
transcriptional	profiles	To	determine	 the	 role	of	 transcriptional	 regulation	 in	differentiation,	RNA	was	quantified	 from	 endpoint	 differentiated	 unstimulated	 macrophages	 (day	 6)	cultured	in	parallel	to	the	cultures	for	metabolomic	analysis.	Experiments	were	performed	 in	 biological	 triplicate	 (3	 donors)	 for	 each	 differentiation	 condition	with	monocytes	cultured	in	6	well	plates	at	a	density	of	6.25x104	cells	/	cm2	.	RNA	expression	was	quantified	by Oxford Gene Technologies using an Agilent 8x60K 
gene expression array using the global human male reference transcription profile as 
background. Data was analysed with Agilent GeneSpring v12.6. Intra-array 
normalisation was performed by Lowess during feature extraction and again by median 
scaling during analysis. The resulting distribution of sample data is shown in Figure 
5.13A. The group variation was visualised using PCA shown in Figure 5.13B showing 
a degree of clustering between samples in each group. Regulated genes were filtered 
using one-way ANOVA with p<0.05 between groups and log2 fold-change >1 relative 
to background. 	
 
Differentiation of macrophages under GM-CSF (n=3) and M-CSF (n=3) resulted in 
different transcriptional profiles. Genes were classified by gene ontology information 
and log2 fold change values relative to baseline plotted to identify the most regulated 
genes. The interesting gene ontology groups are shown in Figure 5.14 and Figure 5.15. 
The key regulated genes were found to be those involved in immune function and 
responses, regulated genes were found to be involved in immune function, although a 
number of metabolic, signalling, channel and motor activity genes were also regulated. 
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To clarify interpretation, the genes showing a greater than 2-fold change (~2000) were 
manually categorised according to their role in macrophage differentiation and/or 
metabolism. Groups were determined manually based on GeneCards and UniProt 
reference data [364,365]. Gene ontology information was considered for classification 
but was found to be too generic for our uses. Selected genes were bundled into named 
grouped and then filtered by sum regulation to give the top up or down regulated gene 
groups for each macrophage subset. Gene regulation changes associated with 
differentiation under GM-CSF or M-CSF are considered below. The complete gene 
tables are given in Appendix I. 
  
Figure 5.13. Quality Control analysis for transcriptomics data.Peripheral blood monocytes (6x106 per plate) were differentiated in 6-wellplates with 2ml standard culture media (RPMI+GPS+10% FCS) containingM-CSF (10 ng/ml; n=3) or GM-CSF (10 ng/nl; n=3) for 6 days. Endpointintracellular RNA was extracted using Qiagen RNeasy MiniKit andquantified using Agilent 8x60K array. A) Box and whisker plot of allquantifications generated using Agilent’s GeneSpring v12.6. Arrays wereintra-array normalised by Lowess during feature extraction and inter-arraynormalised by scaling to the median value of all samples during loadinginto GeneSpring. B) Principal component analysis of normalised, processedtranscriptomics data showing clusteringwithin experimental groups.
AB
Figure 5.14. M-CSF differentiated macrophages transcriptional log2
fold change from base human transcriptome. Peripheral bloodmonocytes (6x106 per plate) were differentiated in 6-well plates with 2mlstandard culture media (RPMI+GPS+10% FCS) containing M-CSF(10 ng/ml; n=3) or GM-CSF (10 ng/nl; n=3) for 6 days. Endpointintracellular RNA was extracted using Qiagen RNeasy MiniKit andquantified using Agilent 8x60K array. Highlighted genes are grouped by GO(Gene Ontology) terms. A) Biological Process; up-regulation of CADM1 aCa2+ dependent cell-cell adhesionmolecule, ITGADwhich encodes integrinalpha-D and DNM3 a microtubule binding and transport protein. TLR5which recognises bacterial flagellin is also upregulated. CD35 (ComplementReceptor 1) is down-regulated. B) Enzymes; PDK4 is up-regulated. Thisenzyme inactivates pyruvate dehydrogenase via phosphorylated. IncreasedPDK4 should therefore be associated with reduced glycolysis. C)Transporters; up-regulation of fatty acid transport FABP4, FABP5 D)Activity; up-regulation of anti-inflammatory soluble receptor IL1R1.
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Figure 5.15. GM-CSF differentiated macrophages transcriptional log2
fold change from base human transcriptome. Peripheral bloodmonocytes (6x106 per plate) were differentiated in 6-well plates with 2mlstandard culture media (RPMI+GPS+10% FCS) containing M-CSF(10 ng/ml; n=3) or GM-CSF (10 ng/nl; n=3) for 6 days. Endpointintracellular RNA was extracted using Qiagen RNeasy MiniKit andquantified using Agilent 8x60K array. Highlighted genes are grouped by GO(Gene Ontology) terms. A) Process; up-regulation of CCL26 a eosinophiland basophil chemoattractant, CCL13 chemotactic for monocytes,lymphocytes, basophils and eosinophils, but not neutrophils FOXQ1 aregulator of cell the cell cycle. In contrast IL1B, IL2RA and IL5 are all down-regulated. B) Enzymes; up-regulation of glycine amidinotransferase(GATM) a gene involved in creatine synthesis, and monoamine oxidase A(MAOA). C) Transporters; up-regulation of FABP4 (fatty acid uptake) andRAMP1 a CGRP receptor and down-regulation of SLC11A1 which encodesfor an iron and manganese transporter) D) Action; down-regulation ofMYH11/MYO1Bmyosin involved in cell contraction andmovement.
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5.2.6 Regulation	of	genes	associated	with	macrophage	differentiation	
Genes associated with macrophage differentiation were selected from those found 
during literature review of established markers for monocytes and M1/M2a 
macrophages. These genes were filtered to include those significantly regulated 
between experimental groups and regulated at >2 fold change relative to the baseline 
human gene expression profile. 
 
The resulting genes were grouped according to function/class and gene groups were 
ranked according to fold-change. As the up- or down- regulation of these genes is 
relative to a generic baseline genes in common between groups may not reflect change 
during differentiation but rather characteristic features of cells of the monocyte-
macrophage lineage. The importance of downregulated genes is also difficult to assess 
without knowledge of baseline expression levels in monocytes. Therefore, the 
description below deals primarily with gene upregulation or with uniquely regulated 
genes when comparing between groups. The list of detected up- and down-regulated 
genes is given in Table 10 and Table 11 in Appendix I. 
5.2.6.1 Transcriptional	 changes	 common	 to	 both	 M-CSF	 and	 GM-CSF	
differentiation	
Upregulated genes common to both M-CSF and GM-CSF macrophages included a 
number genes previously reported to be associated with alternative activation of 
macrophages, including F13A1, CCL13, CCL26 and CD209/DC-SIGN [167]. The 
strongest upregulated of these was F13A1 (Factor XIII) the final zymogen coagulation 
factor in the blood coagulation cascade responsible for clot stabilisation [366]. 
Chemokines CCL13 and CCL26 are chemoattractant for monocytes, lymphocytes, 
basophiles and eosinophils. Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (CD209/DC-SIGN) is a C-type lectin receptor found on the 
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surface of macrophages and dendritic cells which binds to mannose carbohydrate 
PAMPS commonly found on viruses, bacteria and fungi, initiating phagocytosis. 
 
CD1 (CD1, CD1B, CD1C, CD1E) which has previously been reported in response to 
GM-CSF stimulation alone was found to be upregulated in both M-CSF and GM-CSF 
differentiated macrophages [367]. CD1s are glycoproteins related to class I HLA and 
involved in presentation of lipid and glycolipid antigens to T cells. Insulin-like growth 
factor 1 (IGF1) an enhancer of tissue regeneration previously reported in monocytes 
and macrophages was also found to be upregulated in both conditions [368]. Two 
receptors for pro-inflammatory cytokine IL-1 (IL1R1/IL1R2) were also upregulated. 
IL-1 is commonly produced by M1-polarised macrophages and is raised in the 
rheumatoid synovium [134,256]. Here we saw downregulation of IL-1 (IL1A, IL1B) 
after differentiation (prior to activation). Similarly downregulated were CXCL10 — a 
macrophage activator — and T cell co-stimulatory receptor CD80. AKT3, a 
serine/threonine protein kinase (AKT kinase) involved in responses to growth factors 
(including PDGF and IGF1) was also downregulated under both 7 conditions.  
 
Both M-CSF and GM-CSF macrophages were found to upregulate never in mitosis 
kinase 10 (NEK10) a marker of replication arrest, indicating that replication is halted 
by the macrophage differentiation process. 
5.2.6.2 Transcriptional	changes	unique	to	M-CSF	differentiation	
The differentiation of M-CSF macrophages also resulted in a number of uniquely 
regulated genes. There was unique upregulation of toll-like receptor 5 (TLR5) a PAMP 
receptor which recognises bacterial flagellin previously reported to be upregulated 
following M2 polarization [369]. C-type lectin domain family 13 member A (CD302) 
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a protein involved in endocytosis and phagocytosis; chemokine CXCL12 a 
chemoattractant for T cells and monocytes and CCR2, the receptor for monocyte 
chemoattractant protein-1 (CCL2); were all upregulated. The latter has been previously 
reported to be downregulated during differentiation of M1/M2 macrophages and is 
implicated in monocyte infiltration/recruitment in rheumatoid arthritis [167,308]. 
 
In contrast, toll like receptors for viral PAMPS were downregulated — including TLR8, 
which recognizes guanine-rich single-stranded RNA (ssRNA) while TLR3 recognises 
double-stranded RNA (dsRNA) in endosomes. 
 
Both colony-stimulating factor 3 (CSF3) also known as G-CSF and colony-stimulating 
factor 2 receptor B (CSF2RB) — which is the receptor for GM-CSF — were 
downregulated uniquely during M-CSF differentiation. The latter suggests a 
mechanism for M-CSF differentiating macrophages to sustain M-CSF polarisation 
during differentiation. There were other indications of reduced sensitivity to signalling 
with downregulation of JAK-STAT protein kinases associated with cytokine signalling 
(JAK2, JAK3) and of CD40 a costimulatory protein found on macrophages which binds 
the secondary T cell signalling molecule CD40L (CD154) found on Th1 cells. 
5.2.6.3 Transcriptional	changes	unique	to	GM-CSF	differentiation	
GM-CSF differentiated macrophages uniquely upregulated expression of IFNγ (IFNG) 
which is a key priming signal for macrophage responses to LPS. Though commonly 
thought to be an indicator of T cell contamination in macrophage cultures, IFNγ has 
been shown to be expressed by human macrophages [370]. This would provide a 
mechanism for paracrine/autocrine priming of macrophages to subsequent LPS 
exposure. The common subunit of pro-inflammatory cytokines IL-12/IL-23 (IL12B) 
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was also up-regulated, however the corresponding alpha subunits were absent. The 
beta-2 subunit of the IL-12 receptor (IL12RB2) was also upregulated without its 
corresponding beta-1 binding partner. GM-CSF macrophages also uniquely 
upregulated CCL14 and CXCL13 which are activating for monocytes and chemotactic 
for B cells respectively. 
 
There was further indications of responsiveness to pro-inflammatory signalling with 
upregulation of members of the mitogen-activated protein kinase (MAPK) family 
(MAP3K9, MAP3K13) which regulate cellular proliferation and differentiation via 
JNK, NF-kappa-B and IKK activation. TNF receptor associated factor 5 (TRAF5) 
which mediates signal transduction from TNF receptors was also upregulated following 
GM-CSF. However, conversely, GM-CSF macrophages uniquely downregulated 
protein kinase C eta (PRKCH) which is involved in signalling responses to LPS via 
TLR4 and generation of pro-inflammatory cytokines [371,372]. 
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5.2.7 Distinctive	 metabolic	 pathway	 regulation	 accompanies	
differentiation	by	M-CSF	or	GM-CSF	
 
Metabolic pathways help place quantified intracellular metabolite changes in their 
biological context. In order to form a complete picture of pathway regulation, we 
employed a pathway-mining approach to find the most up- and down- regulated 
metabolic pathways on the basis of constituent metabolites. The selection process was 
performed twice — once biasing for larger pathways, the second biasing for smaller — 
and the resulting pathways were selected for visualisation. This process was performed 
first using metabolomic data only, then using transcriptomic data only and finally using 
a combination of the two. Where possible combinations of pathways were selected for 
visualisation together to help build additional context. The resulting figures are shown 
in Figure 5.16—Figure 5.23. Due to the absence of a normalised base metabolic profile 
metabolite ratios are calculated relative to the opposite group — that is GM-CSF/M-
CSF or M-CSF/GM-CSF. The same ratio was used for transcriptomics data for clarity. 
The resulting images are therefore identical but oppositely regulated, however both are 
included for clarity and discussed as a unit. The raw metabolic gene changes have 
already been discussed.  
 
First, we looked at the central metabolism of differentiated macrophages (Figure 5.16; 
Figure 5.17). GM-CSF differentiation was associated with an upregulation of 
glycolysis- genes relative to M-CSF. The transcription of pyruvate kinase, regulating 
the step from phosphoenolpyruvate was downregulated, however pyruvate 
dehydrogenase catalysing the reaction to acetyl-CoA, was up. Intracellular lactate was 
raised in GM-CSF macrophages as previously reported. Fumarate and 2-oxoglutarate 
were increased in the TCA cycle and early genes of the TCA cycle were isoform 
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switched, rather than directly up- or down- regulated. Metabolites of the urea cycle, 
including L-aspartate, L-arginine, L-ornithine, were all down relative to M-CSF. 
Quantified levels of ATP, ADP and NAD were all increased in GM-CSF macrophages.  
 
Specifically mined pathways for M-CSF vs. GM-CSF differentiation included the 
mitochondrial L-carnitine shuttle, creatine biosynthesis & creatine-phosphate 
biosynthesis, protein citrullination, inositol phosphate biosynthesis, fatty acid β-
oxidation, glutamate biosynthesis and degradation, asparagine biosynthesis and 
degradation, and prostanoid biosynthesis. 
 
The mitochondrial carnitine shuttle is responsible for the transport of long-chain fatty 
acids into the mitochondrial matrix. Mitochondrial carnitine concentration is the 
limiting factor in acylcarnitine/carnitine exchange and long-chain fatty acid uptake 
[373]. L-carnitine was raised under M-CSF differentiation, and reduced under GM-CSF 
(Figure 5.18). Transcriptional changes showed reduced expression of genes involved 
in L-carnitine biosynthesis, but increased in recycling from acetyl-CoA-carnitine to 
produce acetyl-CoA. However, the fatty acid β-oxidation pathway— only measured at 
the transcriptional level — offered an alternative view. Fatty acid β-oxidation is the 
mechanism by which fatty acids are broken down in mitochondria to generate acetyl-
CoA, additionally producing NADH and FADH2 co-enzymes for the electron transport 
chain. Steps in the cycle were predominantly gene-switched, however there was a 
notable difference saturated fatty acyl-CoA synthetase and dodecanoyl-CoA delta 
isomerase between M-CSF and GM-CSF differentiated macrophages, with strong 
upregulation in GM-CSF macrophages (Figure 5.19). The former catalyses the 
metabolism of saturated fatty acids, while the latter is the route into the cycle for 
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unsaturated fatty acids. The changes suggest that M-CSF macrophages favour saturated 
fatty acid degradation and GM-CSF preferentially metabolise unsaturated fatty acids. 
Given the roles for fatty acids in signalling and inflammation this imbalance is also 
worth notable for potential pro- or anti- inflammatory effects. 
 
The asparagine biosynthesis and degradation pathways in conjunction with threonine 
degradation were identified by pathway mining from the metabolomic data (Figure 
5.20). Culture media results showed a small decrease in asparagine under GM-CSF but 
that appeared to be un-related to the regulation of these pathways. Glutamine was 
slightly raised at the cellular level under GM-CSF reflecting the previously described 
uptake from culture media, as was downstream product glutamate and further product 
2-oxoglutarate, a component of the TCA cycle. 
 
Creatine phosphate (phosphocreatine) functions as an energy store of high-energy 
phosphate. Creatine is phosphorylated by creatine kinase in the presence of ATP to 
produce phosphocreatine. The reverse reaction releases ATP into the cell during periods 
of high ATP requirements. Creatine is synthesised from arginine, glycine and 
methionine. The data showed a clear distinction between M-CSF and GM-CSF 
differentiated macrophages, with GM-CSF macrophages associated with much higher 
concentrations of creatine and creatine-phosphate (Figure 5.21). The final-step enzyme 
guanidinoacetate N-methyltransferase was relatively downregulated in GM-CSF by 
the endpoint of differentiation, perhaps indicating a feedback effect. Notably GM-CSF 
macrophages were associated with higher levels of ATP and ADP, perhaps indicating 
a higher energy turnover associated with this subtype.  
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Although not a metabolic process per se protein protein citrullination was identified by 
the pathway mining algorithm from the transcriptomic data (Figure 5.21). While there 
was a degree of isotype switching occurring, the general tendency was of an 
upregulation of PAD genes under M-CSF differentiation.  
 
Inositol phosphates (IP) are important secondary messenger molecules used in signal 
transduction and signalling. The general trend was towards upregulation of genes in 
this pathway under M-CSF differentiation relative to GM-CSF differentiated 
macrophages (Figure 5.22). The phosphorylated versions of inositol were not 
detectable with NMR however the depletion of myo-inositol was suggestive that the 
upregulation at the gene level was driving a conversion to downstream products.  
 
Prostanoid biosynthesis was also regulated between M-CSF and GM-CSF 
differentiated macrophages (Figure 5.23). The methanol-chloroform processing of cell 
extract samples excludes lipids from the sample therefore prostaglandins were not 
quantified. However, the regulation at the gene level indicated a relative increase in 
prostaglandin I2 and E2 converting enzymes under GM-CSF, and a converse increase 
in prostaglandin D2 and thromboxane A2 under M-CSF. Prostaglandin I2 inhibits 
platelet aggregation while E2 supresses T cell receptor signalling while both have 
vasodilatory effects [374]. Thromboxane A2 is pro-thrombotic, stimulating platelet 
aggregation and an active vasoconstrictor, while prostaglandin D2 is a vasodilator most 
associated with allergic responses [374].  
Figure 5.16. Central metabolism glycolysis, TCA and urea cycle
following M-CSF differentiation. Peripheral blood monocytes (1x107 perflask; 6x106 per plate) were concurrently differentiated for 6 days in T75flasks and 6-well plates with 12ml and 2ml standard culture media(RPMI+GPS+10% FCS) respectively. Endpoint intracellular metabolites ofmonocytes differentiated with M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) were collected from T75 cultures by standard methanolextraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Endpoint intracellular RNA ofmonocytes differentiated with M-CSF (10 ng/ml; n=3) or GM-CSF(10 ng/nl; n=3) was extracted from 6 well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60K array. Colours indicate meanlog2 fold-change of stimulated M-CSF macrophage intracellular metabolitesand RNA relative to GM-CSF macrophages. Metabolites of the TCA cyclewere reduced, while those of the urea cycle were raised. Lactate wasreduced relative to GM-CSF. Transcriptional changes showed switchedtranscription of genes relative to GM-CSF — see the changed pattern ofgene up/down regulation (shown as red/blue lines) in phosphoglyceratephosphorylation for example — in glycolysis and the TCA cycle, while
pyruvate dehydrogenase enzymes converting pyruvate to acetyl-coA weredown.
log2(fc) 1.0-1.0
M-CSF
Figure 5.17. Central metabolism glycolysis, TCA and urea cycle
following GM-CSF differentiation. Peripheral blood monocytes (1x107per flask; 6x106 per plate) were concurrently differentiated for 6 days inT75 flasks and 6-well plates with 12ml and 2ml standard culture media(RPMI+GPS+10% FCS) respectively. Endpoint intracellular metabolites ofmonocytes differentiated with M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) were collected from T75 cultures by standard methanolextraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Endpoint intracellular RNA ofmonocytes differentiated with M-CSF (10 ng/ml; n=3) or GM-CSF(10 ng/nl; n=3) wasextracted from 6 well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60K array. Colours indicate meanlog2 fold-change of stimulated GM-CSF macrophage intracellularmetabolites and RNA relative to M-CSF macrophages. Metabolites of theTCA cycle were increased, while those of the urea cycle were lowered.Lactate was increased relative to M-CSF. Transcriptional changes showedswitched transcription of genes relative to GM-CSF — notice the changedpattern of gene up/down regulation (shown as red/blue lines) inphosphoglycerate phosphorylation for example— in glycolysis and the TCAcycle, while pyruvate dehydrogenase enzymes converting pyruvate toacetyl-coAwere up.
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Figure 5.18. Mitochondrial L-carnitine shuttle, L-carnitine
biosynthesis. Peripheral blood monocytes (1x107 per flask; 6x106 perplate) were concurrently differentiated for 6 days in T75 flasks and 6-wellplates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)respectively. Endpoint intracellular metabolites of monocytesdifferentiated with M-CSF (10 ng/ml; n=8) or GM-CSF (10 ng/nl; n=4) werecollected from T75 cultures by standard methanol extraction and analysedby 1D H1 NMR. Metabolites were identified and quantified from rawspectra with Chenomx. Endpoint intracellular RNA of monocytesdifferentiated with M-CSF (10 ng/ml; n=3) or GM-CSF (10 ng/nl; n=3) wasextracted from 6 well plates using Qiagen RNeasy MiniKit and quantifiedusing Agilent 8x60K array. Colours indicate mean log2 fold-change ofstimulated M-CSF macrophage intracellular metabolites and RNA relativeto GM-CSF macrophages and vice versa. L-carnitine was raised under M-CSF differentiation, and reduced under GM-CSF. Transcriptional changesshowed reduced expression of genes involved in L-carnitine biosynthesis,but increased in recycling from acetyl-CoA-carnitine to produce acetyl-coA.Pre-cursor 2-oxoglutarate was depleted inM-CSFmacrophages.
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Figure 5.19. Fatty acid β-oxidation. Peripheral blood monocytes (1x107per flask; 6x106 per plate) were concurrently differentiated for 6 days inT75 flasks and 6-well plates with 12ml and 2ml standard culture media(RPMI+GPS+10% FCS) respectively. Endpoint intracellular metabolites ofmonocytes differentiated with M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) were collected from T75 cultures by standard methanolextraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Endpoint intracellular RNA ofmonocytes differentiated with M-CSF (10 ng/ml; n=3) or GM-CSF(10 ng/nl; n=3) was extracted from 6 well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60K array. Colours indicate meanlog2 fold-change of stimulated M-CSF macrophage intracellular metabolitesand RNA relative to GM-CSFmacrophages and vice versa. The breakdown offatty acids in the mitochondria to produce acetyl-coA is a key step inmetabolism. M-CSF macrophages showed up-regulation of the saturatedfatty acid metabolites route, while GM-CSF macrophages showed up-regulation the dodecenoyl-coA route, promoting preferential metabolism ofunsaturated fatty acids.
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Figure 5.20. Glutamate biosynthesis and degradation, asparagine
biosynthesis and degradation. Peripheral blood monocytes (1x107 perflask; 6x106 per plate) were concurrently differentiated for 6 days in T75flasks and 6-well plates with 12ml and 2ml standard culture media(RPMI+GPS+10% FCS) respectively. Endpoint intracellular metabolites ofmonocytes differentiated with M-CSF (10 ng/ml; n=8) or GM-CSF(10 ng/nl; n=4) were collected from T75 cultures by standard methanolextraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Endpoint intracellular RNA ofmonocytes differentiated with M-CSF (10 ng/ml; n=3) or GM-CSF(10 ng/nl; n=3) was extracted from 6 well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60K array. Colours indicate meanlog2 fold-change of stimulated M-CSF macrophage intracellular metabolitesand RNA relative to GM-CSF macrophages and vice versa. Pathways areshown for asparagine biosynthesis and degradation (opposite) andglutamate biosynthesis and degradation (over). Glutamine consumptionfrom culture media under GM-CSF differentiation was reflected here byassociated increase glutamine at the cellular level, and down-streamproduct glutamate. Product 2-oxoglutarate and precursor L-alanine werealso raised under GM-CSF.
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Figure 5.21. Creatine and creatine phosphate biosynthesis, protein
citrullination. Peripheral blood monocytes (1x107 per flask; 6x106 perplate) were concurrently differentiated for 6 days in T75 flasks and 6-wellplates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)respectively. Endpoint intracellular metabolites of monocytesdifferentiated with M-CSF (10 ng/ml; n=8) or GM-CSF (10 ng/nl; n=4) werecollected from T75 cultures by standard methanol extraction and analysedby 1D H1 NMR. Metabolites were identified and quantified from rawspectra with Chenomx. Endpoint intracellular RNA of monocytesdifferentiated with M-CSF (10 ng/ml; n=3) or GM-CSF (10 ng/nl; n=3) wasextracted from 6 well plates using Qiagen RNeasy MiniKit and quantifiedusing Agilent 8x60K array. Colours indicate mean log2 fold-change ofstimulated M-CSF macrophage intracellular metabolites and RNA relativeto GM-CSF macrophages and vice versa. GM-CSF macrophages wereassociated with higher concentrations of both creatine and creatinephosphate, reflecting a reserve of high energy phosphate. Genes involved inprotein citrullination were down-regulated under GM-CSF differentiationrelative to M-CSF macrophages, albeit with up-regulation of a single PADisoform.
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Figure 5.22. myo-Inositol metabolism. Peripheral blood monocytes(1x107 per flask; 6x106 per plate) were concurrently differentiated for 6days in T75 flasks and 6-well plates with 12ml and 2ml standard culturemedia (RPMI+GPS+10% FCS) respectively. Endpoint intracellularmetabolites of monocytes differentiated with M-CSF (10 ng/ml; n=8) orGM-CSF (10 ng/nl; n=4) were collected from T75 cultures by standardmethanol extraction and analysed by 1D H1 NMR. Metabolites wereidentified and quantified from raw spectra with Chenomx. Endpointintracellular RNA of monocytes differentiated with M-CSF (10 ng/ml; n=3)or GM-CSF (10 ng/nl; n=3) was extracted from 6 well plates using QiagenRNeasy MiniKit and quantified using Agilent 8x60K array. Colours indicatemean log2 fold-change of stimulated M-CSF macrophage intracellularmetabolites and RNA relative to GM-CSF macrophages and vice versa.Pathways are shown for both M-CSF (opposite) and GM-CSF (over).Inositol phosphates are important secondary messengers in signaltransduction. Only myo-Inositol was detectable at the metabolite level, butchanges in enzymes were detectable in transcriptional data. Precursormyo-Inositol was increased under GM-CSF differentiation, while mostgenes involved in forward conversion to secondary messengers weredown-regulated.
log2(fc) 1.0-1.0
M-CSF
GM-CSF
log2(fc) 1.0-1.0
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Figure 5.23. Prostanoid biosynthesis. Peripheral blood monocytes(1x107 per flask; 6x106 per plate) were concurrently differentiated for 6days in T75 flasks and 6-well plates with 12ml and 2ml standard culturemedia (RPMI+GPS+10% FCS) respectively. Endpoint intracellularmetabolites of monocytes differentiated with M-CSF (10 ng/ml; n=8) orGM-CSF (10 ng/nl; n=4) were collected from T75 cultures by standardmethanol extraction and analysed by 1D H1 NMR. Metabolites wereidentified and quantified from raw spectra with Chenomx. Endpointintracellular RNA of monocytes differentiated with M-CSF (10 ng/ml; n=3)or GM-CSF (10 ng/nl; n=3) was extracted from 6 well plates using QiagenRNeasy MiniKit and quantified using Agilent 8x60K array. Colours indicatemean log2 fold-change of stimulated M-CSF macrophage intracellularmetabolites and RNA relative to GM-CSFmacrophages and vice versa. Gene-level regulation showed a tendency towards prostaglandin I2 and E2 underGM-CSF differentiation, in contrast to D2 and thromboxane A2 under M-CSF. Prostanoids have multiple overlapping functions, however the biashere was towards platelet aggregation under M-CSF differentiationconditions.
M-CSF
GM-CSF
log2(fc) 1.0-1.0
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5.2.8 Regulation	of	metabolic	genes	during	differentiation	
Metabolic genes were defined broadly as those transcribing proteins involved in 
metabolic reactions, or those involved in uptake or excretion of metabolic products. 
The function of genes specific to metabolic pathways has been covered in the previous 
section, therefore these are excluded here.  
5.2.8.1 Metabolic	gene	expression	following	M-CSF	differentiation	
In M-CSF differentiated macrophages selenium uptake selenoprotein (SEPP1) was 
strongly upregulated. Selenium is a trace nutrient involved in the reduction of 
antioxidant enzymes and an integral component of glutathione peroxidase [375]. There 
was also upregulation of a number of heparan sulphate transferases (HS3ST1, HS3ST2, 
HS6ST1) that catalyse the transfer of sulphate groups during heparin sulphate 
biosynthesis. Heparan sulphates have multiple functions, including angiogenesis, 
coagulation and as competitive binding analogues for IFNγ [376]. Fatty acid uptake is 
supported by the upregulation of fatty acid binding proteins (FABP4, FABP5) [377]. 
Interestingly, there was a coordinated upregulation of malic enzyme 1 (ME1) 
responsible for the generation of NADPH for fatty acid biosynthesis [378]. 
Transcription of insulin-like growth factor 1 (IGF1), which promotes anabolic 
metabolism, was also upregulated following M-CSF. 
 
A number of solute carriers were upregulated, supporting transport of multiple 
compounds including: lactate, pyruvate and branch-chain oxo-acid export (SLC16A8), 
zinc (SLC39A10), amino-acid proton antiport (SLC38A6), iron export (SLC40A1), 
vesicular storage and exocytosis of ATP (SLC17A9), glucose (SLC2A8, SLC45A3), 
acylcarnitines (SLC25A48), K-Cl co-transport (SLC12A5), Na-HCO3 co-transport 
(SLC4A7), chloride and iodide transport (SLC26A4), Na-H antiporter (SLC981), 
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chloride, sulphate and oxalate (SLC26A9), ornithine and palmitoylcarnitine 
(SLC25A29) and folate (SLC46A1). The upregulation of the proton-linked lactate-
BCAA transporter (SLC16A8) supports BCAA uptake and lactate excretion along 
concentration gradients. 
 
Strongly downregulated were indoleamine 2,3-dioxygenase 1&2 (IDO1, IDO2) which 
catalyse the first, rate-limiting, step in tryptophan catabolism (kyneurine pathway).  
5.2.8.2 Metabolic	gene	expression	following	GM-CSF	differentiation	
There was much overlap with macrophages differentiated under GM-CSF conditions 
and those under M-CSF. For example selenoproteins (SEPP1; upregulated), 
transporters (SLC17A9, SLC25A48, SLC26A9 and SLC16A3 upregulated; 
SLC22A15 downregulated), heparan sulphates (HS3ST1, HS3ST2; upregulated), fatty 
acid binding proteins (FABP4, FABP5; upregulated). However, there were still notable 
differences in gene regulation between the subsets. For example, GM-CSF 
differentiation was uniquely associated with upregulation of UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 4 (GALNTL4) 
which catalyses O-linked oligosaccharide biosynthesis. Arachidonate 15-lipoxygenase 
(ALOX15) involved in the metabolism of fatty acid hydroperoxidases from arachidonic 
acid and linoleic acid was also upregulated.  
 
A number of transport-associated genes were also upregulated transport including those 
involved in vesicular amine transport of amines (SLC18A2), GABA export 
(SLC6A13), zinc sequestration in vesicles (SLC30A4), Na+/Ca2+ antiporter in 
multiple compartments sequestering and reducing cytoplasmic Ca2+ (SLC8A3), 
oligopeptide uptake of 2-4 amino acids for products of protein digestion (SLC15A1). 
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ATP binding cassette family C members which transport nucleotide analogs (ABCC5), 
K+ (ABCC8) and export cAMP and cGMP (ABCC11) were also upregulated. 
 
Aldehyde oxidase (AOX1) involved in hydrogen peroxide and superoxide production, 
was downregulated in GM-CSF macrophages. This has been identified as a possible 
nitric oxide (NO) producer via reduction of nitrite with NADH or aldehyde as an 
electron donor. Conversely, dual oxidase maturation factor (DUOXA1) which supports 
transport of ROS-producing DUOX enzymes to membranes, was upregulated [379]. 
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5.3 Discussion	
Macrophages have roles in both immune responses and homeostasis [144]. 
Macrophages migrate into sites of inflammation, releasing both pro- and anti- 
inflammatory signals to mediate the immune response. Given the diverse environments 
in which macrophage differentiate, and the various functions they undertake  we sought 
to determine whether differentiated macrophages would display distinct macrophage 
metabolic profiles. Due to the low numbers of tissue resident macrophages in tissues, 
studying these subsets in or ex vivo was not feasible [129]. Instead we used two in vitro 
differentiation conditions based on current understanding of macrophage biology. 
Blood derived monocytes were differentiated for 6 days under tissue culture conditions 
in the presence of either M-CSF or GM-CSF. M-CSF is the differentiation background 
for macrophage subsets in the M1/M2a-c nomenclature proposed by Matovani et al., 
but also the basis for Verreck et al. M2 macrophages. GM-CSF in contrast is associated 
with Verreck’s M1 macrophages. We hoped that by differentiating macrophages using 
these two alternative methods we would produce a more complete overview of 
macrophage metabolic behaviour. 
 
Following differentiation we performed metabolomic analysis of both intracellular and 
extracellular (media) metabolites from macrophage cultures. To provide additional 
longitudinal information on metabolism during differentiation, samples of 
differentiation media were also taken daily during the differentiation process. All 
metabolomic samples were analysed by 1H NMR, quantified and analysed as described 
in the preceding methods. Simultaneous endpoint transcriptional profiles were taken to 
add further information to metabolic pathways and provide phenotypic data on our 
differentiated macrophages.  
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Analysis of endpoint metabolic profiles demonstrated that it was possible to distinguish 
macrophages differentiated using M-CSF or GM-CSF — using either intracellular or 
extracellular metabolites. The strongest differentiator between the groups was the 
concentration of lactate, which was raised under GM-CSF differentiation. GM-CSF 
macrophages were also observed to consume larger quantities of glucose and glutamine 
during differentiation and to promote metabolism of saturated fatty acids. This 
combination of energy sources suggests that GM-CSF differentiated macrophages are 
highly ATP dependent.  
 
Transcriptional regulation was considered primarily in the context of metabolic 
changes and genes previously associated with macrophage differentiation or activation. 	
Differentiation with both M-CSF and GM-CSF resulted in upregulation of a number of 
genes associated with alternative activation including F13A1, CCL13, CCL26 and 
CD209/DC-SIGN with strongest upregulation of F13A1 (Factor XIII) responsible for 
clot stabilisation [167,366]. CD209/DC-SIGN is a C-type lectin receptor which binds 
to mannose PAMPS commonly on viruses, bacteria and fungi, to facilitate 
phagocytosis. There was also upregulation of chemokines CCL13 and CCL26 which 
are chemoattractant for monocytes, lymphocytes, basophiles and eosinophils. Multiple 
CD1 molecules (CD1, CD1B, CD1C, CD1E) which have previously been reported in 
response to GM-CSF were also upregulated in both M-CSF and GM-CSF macrophages 
[367]. CD1s are glycoproteins related to class I HLA and involved in presentation of 
lipid and glycolipid antigens to T cells. IL-1, a common product of M1-polarised 
macrophages — and raised in the rheumatoid synovium — was downregulated (IL1A, 
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IL1B) [134,256]. However, receptors for IL-1 were upregulated in both subsets 
(IL1R1/IL1R2). CXCL10 — a macrophage activator — and T cell co-stimulatory 
receptor CD80 were both also downregulated. Both M-CSF and GM-CSF macrophages 
strongly upregulated selenoprotein SEPP1 which has a role in selenium uptake. 
Selenium reduces antioxidant enzymes and forms an integral component of glutathione 
peroxidase [375]. Interestingly, both M-CSF and GM-CSF macrophages were found to 
upregulate never in mitosis kinase 10 (NEK10) indicating replication arrest was 
induced by the macrophage differentiation process.  
 
M-CSF macrophages uniquely upregulated toll-like receptor 5 (TLR5) a PAMP 
receptor recognising flagellin — and associated with M2 polarization — and C-type 
lectin domain family 13 member A (CD302) a protein involved in endocytosis and 
phagocytosis [369]. Toll like receptors for viral PAMPS were downregulated — 
including TLR8 (recognising ssRNA) and TLR3 (recognising dsRNA). M-CSF 
macrophage fatty acid metabolism was supported by the upregulation of fatty acid 
binding proteins (FABP4, FABP5) and of malic enzyme 1 (ME1) which generates 
NADPH for fatty acid biosynthesis [377,378]. Downregulation	 of	 JAK-STAT 
pathway members (JAK2, JAK3) may indicate reduced cytokine responsiveness. 
 
GM-CSF differentiated macrophages were found to uniquely upregulate expression of 
IFNγ (IFNG) providing a paracrine/autocrine priming mechanism for subsequent 
responses to LPS. Chemokines CCL14 and CXCL13 — activating for monocytes and 
chemotactic for B cells respectively — were all upregulated even in the absence of 
stimulation. However, GM-CSF macrophages downregulated protein kinase C eta 
(PRKCH) which transduces responses to LPS via TLR4 [371,372]. 
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An overview of detected M-CSF and GM-CSF transcriptional phenotypes is given in 
Table 5. 
 
 
 M-CSF GM-CSF 
Replication Inhibited Inhibited 
Recruitment T cells Monocytes 
T cells, monocytes, (-) 
neutrophils 
Adhesion 
Degrade collagen 
Degrade matrix 
Cell-cell interactions 
Degrade collagen 
Cell-matrix interactions 
Signalling Increased Ca
2+ signalling 
 (-) JAK/STAT 
Ca2+ exocytosis vesicles 
 (-) PI-3K 
Table	5.	Summary	of	gene	regulation	following	M-CSF/GM-CSF	differentiation.	Potential	functional	implications	of	transcriptional	changes	resulting	from	differentiation	under	M-CSF	and	GM-CSF	polarising	conditions.	
		
Metabolic profiles and gene regulation were also analysed in the context of the most 
regulated metabolic pathways — as identified using the pathminer algorithm. 
 
Differentiation with GM-CSF was associated with increased glycolysis, glucose 
consumption and lactate production. However, there was no strong upregulation of 
glucose transporters at the gene level relative to M-CSF macrophages. TCA cycle 
metabolites were also increased in spite of the excretion of lactate and this appeared to 
be due to utilisation of alternative energy sources. The previously identified glutamine 
and aspartate consumption, alongside glutamate and alanine production, suggested that 
glutamine was being metabolised by GM-CSF macrophages to produce 2-oxoglutarate 
in the process of glutaminolysis. Similarly, GM-CSF macrophages showed 
transcriptional upregulation of the mitochondrial carnitine shuttle. The availability of 
carnitine is the limiting factor in long chain fatty acid translocation for metabolism and 
lower levels are seen under GM-CSF macrophages — however synthesis of L-carnitine 
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was upregulated [373]. This may be an artefact of the extraction method used for the 
intracellular metabolite preparation which removes non-polar molecules from the NMR 
preparation may have removed fatty-acid bound L-carnitine. Rather than the total L-
carnitine content therefore, the intracellular quantification may reflect the free L-
carnitine. Differences in fatty acid metabolism were however also apparent at the 
transcriptional level, with β-oxidation showing a preference for saturated fatty acids in 
M-CSF and unsaturated fatty acids in GM-CSF differentiated macrophages. 
 
Both M-CSF and GM-CSF macrophages differentially regulated a number of small 
molecule transporters, upregulating uptake of fatty acids, amino acids, metal ions, and 
glucose. Transporter regulation favoured uptake of glucose (SLC2A8, SLC45A3), fatty 
acids (FABP4, FABP5), and branched chain amino acids (BCAAs; SLC16A8). 
Notably, BCAAs leucine, isoleucine and valine where all depleted from the culture 
media in both conditions. Despite the observed increase in glucose consumption, GM-
CSF macrophages did not further increase expression of GLUT transporters. A 
summary of regulated solute transporters is shown in Table 6 while full details of 
regulated metabolic genes are given in Table 12 and Table 13 in Appendix I. 
 
In this chapter we have demonstrated that differentiated macrophages do in fact display 
distinct metabolic profiles. We have demonstrated that GM-CSF macrophages appear 
to be have higher energy requirements and use multiple energy sources including 
glucose, fatty acids and glutamine to meet those requirements, while M-CSF 
macrophages are comparatively metabolically quiescent. Further, we have used 
transcriptional profiling to confirm phenotypic profiles of the two macrophage subsets. 
In the next chapter we will use these same methods and apply them to macrophage 
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activation, to determine whether these observed changes are persistent or transient, and 
whether they have functional implications for subsequent responses. 
 
 
 
 
M-CSF GM-CSF 
Cellular 
Selenium 
Fatty acids 
Zinc 
Glucose 
Folate 
Polar amino acids 
Neutral amino acids 
Copper 
Glucose (Na+ antiport) 
Glutamate 
 
Intracellular 
ATP storage 
Zinc storage 
 
 
 
Mitochondrial 
Acyl-carnitines 
(mitochondrial) 
Ornithine 
Pamotylcarnitine 
Iron 
Cellular 
Selenium 
Fatty acids 
Iron 
Manganese 
Branch chain amino acids 
Anionic amino acids 
cysteine, glutamate 
Aromatic amino acids 
 
 
 
Intracellular 
ATP storage 
Amine storage 
Zinc storage 
Ca2+ storage 
 
Mitochondrial 
Acyl-carnitines (mitochondrial) 
 
Table	6.	Solute	transporter	regulation	in	M-CSF	and	GM-CSF	differentiation.	Summary	of	the	most	upregulated	transporter	genes	in	differentiated	macrophages.		
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6 METABOLOMICS	OF	MACROPHAGE	
ACTIVATION	
6.1 Introduction	
As previously described, the standard nomenclature classifies differentiated, activated 
macrophages are classified into M1 or M2 subsets, linked to pro-inflammatory cell-
mediated or extracellular/parasitic immunity respectively [164]. The recent expansion 
of the M2 nomenclature (M2a-c) describes multiple macrophage subsets with variable 
phenotypes at the level of transcriptomics, surface markers, cytokines and behaviours 
[218]. Cellular processes have distinctive metabolic requirements that must be met 
either externally from the tissue environment or from turnover of existing cellular 
biomass. Given the range of tissues in which macrophages are found, and the range of 
functions macrophage-like cells perform, we hypothesised that differentiated 
macrophages must be able to regulate their metabolism to suit cellular requirements 
[144]. Further, we hypothesised that these changes in metabolism would be tied to the 
differentiation programme and change in line with other established markers.  
 
To determine whether this was the case we performed a series of controlled 
differentiation experiments using monocytes isolated from the peripheral blood of 
healthy donors. Monocytes were differentiated to macrophages matching the 
established subset from the existing literature, selected particularly for potential 
relevance to inflammatory disease and the process of resolution. In this study we were 
primarily interested in macrophages matching the M1 and M2a activation profiles — 
activated with LPS or LPS+IFNγ and IL-4. However, for completeness and in light of 
the high levels of GM-CSF in the rheumatoid synovium, we also explored M1-like 
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macrophages based on the Verreck et al. GM-CSF model [179]. The complete set of 
differentiation conditions are outlined in Table 7.  
 
Differentiation Activation Mantovani Model Verreck Model 
M-CSF LPS M1 M2 
M-CSF IFNγ + LPS M1 — 
M-CSF IL-4 M2a — 
GM-CSF LPS — M1 
GM-CSF — — M1 polarisation 
M-CSF — — M2 polarisation 
Table	7.	Differentiation	and	activation	treatments	Established	macrophage	activation	methods	and	polarisation	from	literature.	
 
The differentiated macrophages were analysed using a combination of intra- and extra-
cellular metabolomics, in conjunction with transcriptomics and cytokine assays. 
Simultaneous comparison of metabolic changes with differentiation markers and 
altered gene expression, we enable us to determine whether differentiation drives 
changes in macrophage metabolism and further explore the extent to which this 
variation was regulated as an integral part of the differentiation programme.  
6.2 Results	
The analysis of the metabolomics of macrophage differentiation was approached in four 
stages as per the previous chapter — endpoint cell culture media, endpoint intracellular 
metabolite extracts and transcriptional data. The activation experiment was performed 
using multiple donors and technical replicates. Isolated peripheral blood monocytes 
(1x107) were differentiated in T75 flasks with 12 mL standard culture media 
(RPMI+GPS+10% FCS) containing 10 ng/ml M-CSF or 10 ng/ml GM-CSF for 6 days. 
On day 6 differentiated macrophage cultures were activated with 20 ng/ml IL-4, 
100 ng/ml LPS or 100 ng/ml LPS + 20 ng/ml IFNγ and incubated for 18 h to give 
cultures of unstimulated M-CSF/GM-CSF and stimulated M-CSF+LPS, GM-
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CSF+LPS, M-CSF+IL-4, M-CSF+LPS or M-CSF+LPS+IFNγ macrophages. Endpoint 
intracellular RNA was extracted using Qiagen RNeasy MiniKit and quantified using 
Agilent 8x60K array. Endpoint culture media was collected and intracellular 
metabolites extracted by standard methanol extraction. Resulting samples were 
analysed by 1D H1 NMR. Spectra were processed using a standard NMRLab workflow. 
Spectra analysis was performed using both processed and quantified Chenomx data to 
account for metabolites not in the Chenomx library.  
6.2.1 Differentiated	 macrophages	 can	 be	 distinguished	 by	 end-point	
media	metabolic	profiles	
Macrophages were activated under GM-CS+LPS (n=8), M-CSF+LPS (n=8), M-
CSF+LPS+IFNγ (n=6) and M-CSF+IL-4 (n=7) conditions. Data were analysed using 
PLS-DA with scores and weightings plots for the orthogonal PLS-DA analysis of 
processed raw spectra is shown Figure 6.1—Figure 6.3. 
 
 As for the previous chapter, the predominance of both lactate and glucose in the 
endpoint media meant other signals were largely undetectable in the PLS model. 
However, the group-wise comparisons by PLS-DA successfully confirmed the ability 
to distinguish each macrophage group by differentiation media concentrations alone. 
Even with the majority of variation in lactate or glucose, these variations persisted 
between each macrophage subset, and did so consistently. The cross-validated 
sensitivity and specificity of the PLS-DA models were GM-CSF vs. GM-CSF+LPS 
(0.857 /1.0), M-CSF+LPS vs. GM-CSF+LPS (0.875/0.714), M-CSF vs. M-CSF+IL-4 
(1.0/1.0), M-CSF vs. M-CSF+LPS+IFNγ (1.0/1.0), M-CSF+IL-4 vs. M-
CSF+LPS+IFNγ (1.0/1.0) and M-CSF+LPS vs. M-CSF+LPS+IFNγ (0.889/1.0). The 
tendency across the board was to increased lactate production and glucose consumption 
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in LPS activated macrophages. In contrast IL-4 activation drove increased lactate 
production, but with reduced glucose consumption. Finally, IFNγ+LPS activation of 
M-CSF macrophages produced more lactate, yet consumed less glucose when 
compared to LPS alone.  
6.2.2 Quantified	endpoint	media	metabolites	show	profile	tendencies	for	
macrophage	subsets	
An equivalent orthogonal PLS-DA analysis was performed using the Chenomx-
quantified metabolites. In total 30 metabolites were identified and quantified for each 
sample. Metabolite concentrations were autoscaled before analysis, to avoid the model 
being dominated by high concentration metabolites. The resulting model scores and 
weightings plots are shown in Figure 6.4—Figure 6.6. The cross-validated sensitivities 
and specificities of the models were GM-CSF vs. GM-CSF+LPS (0.750/0.667), M-
CSF+LPS vs. GM-CSF+LPS (1.0/1.0), M-CSF vs. M-CSF+IL-4 (0.667/0.444), M-
CSF vs. M-CSF+LPS (0.750/0.667), M-CSF vs. M-CSF+LPS+IFNγ (0.778/0.500), M-
CSF+IL-4 vs. M-CSF+LPS+IFNγ (0.556/0.333) and M-CSF+LPS vs. M-
CSF+LPS+IFNγ (0.833/0.667). 
 
The high number of identified metabolites and number of differentiation subsets was 
difficult to consider in this format. For clarity, only the major metabolites for each 
subset will be highlighted, with the remainder left for consideration later in the context 
of metabolic pathways. It is important to note also that due to the scaling of metabolites, 
the highest ranked metabolites in the weightings plots reflect those that were most 
consistently altered between the control and test groups in each comparison. Note also 
that by its nature PLS-DA comparison are between groups and so an apparent increase 
in one, may also be a decrease in its paired sample. 
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Activation of differentiated macrophages with LPS produced notable changes in culture 
media overnight. For example, M-CSF differentiation followed by LPS activation saw 
increased asparagine, lysine, proline and myo-inositol (Figure 6.5B) (Sensitivity: 0.750 
Specificity: 0.667). Similarly GM-CSF differentiation and GM-CSF+LPS treated 
macrophages (Figure 6.4A) (Sensitivity: 0.750 Specificity: 0.667) showed activation 
with LPS was accompanied by increased lactate, however there was also increased 
myo-inositol, proline, lysine and decreased glutamate, 2-hydroxybutyrate and 
methylguanidine in endpoint media.  
 
The cross-wise comparison PLS-DA between M-CSF differentiated LPS activated and 
GM-CSF differentiated LPS activated macrophages, showed increased alanine, acetate, 
3-hydroxyisovalerate and decreased 2-hydroxybutyrate, glutamine. During 
differentiation and activation GM-CSF+LPS macrophages consume glutamine and 
glutamate, while M-CSF+LPS macrophages consume profile, lysine and alanine.  
 
In other macrophage subsets, an orthogonal PLS-DA between M-CSF differentiated 
unstimulated macrophages and M-CSF differentiated macrophages stimulated with IL-
4 (Sensitivity: 0.667 Specificity: 0.444; low predictive strength) (Figure 6.5A) showed 
increased proline, histidine and acetate and decreased methylguanidine, glutamine, 
tyrosine following IL-4 activation. In contrast activation with LPS+IFNγ (Figure 6.5A) 
(Sensitivity: 0.778 Specificity: 0.500) showed increases in media citraconate, alanine, 
leucine and pyroglutamate relative to unstimulated M-CSF macrophages. 
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The crosswise PLS-DA comparisons for the IL-4 and LPS+IFNγ subsets showed 
(Figure 6.5) increased citraconate, alanine, pyroglutamate and decreased lysine, 
threonine, Histidine in LPS+IFNγ activated macrophages. However, the sensitivity and 
specificity of this model was low (Sensitivity: 0.556 Specificity: 0.333) indicating that 
the differences are not consistent enough to be predictive of group membership. Finally, 
to determine the effect of IFNγ on macrophage activation PLS-DA was performed 
between M-CSF+LPS and M-CSF+LPS+IFNγ (Figure 6.5B) (Sensitivity: 0.833 
Specificity: 0.667) showing increased pyruvate, methionine, glucose and decreased 
formate, arginine, histidine following activation with the LPS with the addition of IFNγ. 
 
The absolute metabolite quantifications performed by Chenomx are shown, arranged 
in alphabetical order in Figure 6.7 and Figure 6.8. Results showed that activation of M-
CSF differentiated macrophages with LPS was associated with consumption of glucose 
from the media, while other M-CSF activation conditions saw limited reduction from 
their unstimulated baseline, and GM-CSF+LPS saw reduced consumption compared to 
GM-CSF alone. Similarly, LPS activation was associated with reduced glutamate — 
also seen in GM-CSF macrophages albeit nonsignificant —as well as significant 
increases in media lactate. Methylguanidine was significantly reduced in all M-CSF 
activated subsets. Pyruvate and tyrosine were both significantly reduced following LPS 
activation of M-CSF macrophages but not in any other subsets. Ornithine was 
significantly increased following LPS activation of GM-CSF macrophages. 
  

Figure 6.1. PLS-DA of endpoint culture media for macrophage activation
conditions. Peripheral blood monocytes (1x107) were differentiated in T75 flaskswith 12ml standard culture media (RPMI+GPS+10% FCS) containing M-CSF (10ng/ml) or GM-CSF (10 ng/ml) for 6 days. On day 6 a subset of the differentiatedmacrophage cultures were stimulated with LPS and incubated overnight to givecultures of unstimulated M-CSF (n=9) GM-CSF (n=8) and stimulated M-CSF+LPS(n=8) GM-CSF+LPS (n=8) macrophages. Endpoint culture media was collected andanalysed by 1D H1 NMR. Spectra were processed using a standard NMRLabworkflow. Partial least squares discriminant analysis (PLS-DA) was performed onprocessed binned data. High-weighted bins responsible for separation betweenexperimental groups were mapped to spectral peaks and identified by reference tothe Chenomx library. A) GM-CSF (r) vs. GM-CSF+LPS () Groups separated withstrong cross-validated sensitivity/specificity (Sensitivity: 0.857 Specificity: 1.0).Results showed increased lactate and decreased glucose in GM-CSF differentiatedLPS activated macrophages B) M-CSF+LPS (=) vs. GM-CSF+LPS () Groupsseparated with strong cross-validated sensitivity/specificity (Sensitivity: 0.875Specificity: 0.714). Results showed increased lactate and decreased glucose in GM-CSF differentiated LPS activatedmacrophages
AB
r GM-CSF  GM-CSF+LPS
= M-CSF+LPS
Figure 6.2. PLS-DA of endpoint culture media for macrophage
activation conditions. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml) for 6 days. On day 6 asubset of the differentiated macrophage cultures were stimulated with IL-4(n=7), LPS (n=8) or LPS+IFNγ (n=6) and incubated overnight to givecultures of activated and unactivated M-CSF (n=9) macrophages. Endpointculture media was collected and analysed by 1D H1 NMR. Spectra wereprocessed using a standard NMRLab workflow. Partial least squaresdiscriminant analysis (PLS-DA) was performed on processed binned data.High-weighted bins responsible for separation between experimentalgroups were mapped to spectral peaks and identified by reference to theChenomx library. A) M-CSF (¡) vs. M-CSF+IL-4 (=) Groups separatedwith strong cross-validated sensitivity/specificity (Sensitivity: 1.0Specificity: 1.0). Results showed increased lactate and glucose in IL-4activated macrophages B) M-CSF (¡) vs. M-CSF+LPS (=) Groupsseparated with strong cross-validated sensitivity/specificity (Sensitivity:1.0 Specificity: 1.0). Results showed increased lactate and decreasedglucose in M-CSF differentiated LPS activated macrophages C) M-CSF (¡)
vs. M-CSF+LPS+IFNγ (=) Groups separated with strong cross-validatedsensitivity/specificity (Sensitivity: 1.0 Specificity: 1.0 ). Results showedincreased lactate and decreased glucose in LPS+IFNγ activatedmacrophages
AB
C
¡ M-CSF = M-CSF+LPS
= M-CSF+LPS+IFNγ
= M-CSF+LPS+IL-4
Figure 6.3. PLS-DA of endpoint culture media for macrophage
activation conditions. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml) for 6 days. On day 6the differentiated macrophage cultures were stimulated with IL-4 (n=7),LPS (n=8) or LPS+IFNγ (6) and incubated overnight to give cultures ofactivatedmacrophages. Endpoint culture media was collected and analysedby 1D H1 NMR. Spectra were processed using a standard NMRLabworkflow. Partial least squares discriminant analysis (PLS-DA) wasperformed on processed binned data. High-weighted bins responsible forseparation between experimental groups were mapped to spectral peaksand identified by reference to the Chenomx library. A) M-CSF+IL-4 (=) vs.
M-CSF+LPS+IFNγ (=) Groups separated with strong cross-validatedsensitivity/specificity (Sensitivity: 1.0 Specificity: 1.0). Results showedincreased lactate and decreased glucose in LPS+IFNγ activatedmacrophages B) M-CSF+LPS (=) vs. M-CSF+LPS+IFNγ (=) Groupsseparated with strong cross-validated sensitivity/specificity (Sensitivity:0.889 Specificity: 1.0). Results showed increased lactate and decreasedglucose in LPS+IFNγ activatedmacrophages
AB
= M-CSF+LPS
= M-CSF+LPS+IFNγ
= M-CSF+LPS+IL-4
Figure 6.4. PLS-DA of Chenomx-quantified endpoint culture media for
macrophage activation conditions. Peripheral blood monocytes (1x107)were differentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10%FCS) containingM-CSF (10 ng/ml) or GM-CSF (10 ng/ml)for 6 days. On day 6 the differentiated macrophage cultures werestimulated with LPS and incubated overnight to give cultures ofunstimulated M-CSF (n=9) GM-CSF (n=8) and stimulated M-CSF+LPS (n=8)GM-CSF+LPS (n=8) macrophages. Endpoint culture media was collectedand analysed by 1D H1 NMR. Metabolites were identified and quantifiedfrom raw spectra with Chenomx. Partial least squares discriminant analysis(PLS-DA) was performed on quantified data. A) GM-CSF (r) vs. GM-
CSF+LPS () Groups separated with moderate cross-validatedsensitivity/specificity (Sensitivity: 0.750 Specificity: 0.667). Resultsshowed increased myo-inositol, proline, lysine and decreased glutamate, 2-hydroxybutyrate, methylguanidine in GM-CSF differentiated LPS activatedmacrophages B) M-CSF+LPS (=) vs. GM-CSF+LPS () Groups separatedwith strong cross-validated sensitivity/specificity (Sensitivity: 1.0Specificity: 1.0). Results showed increased alanine, acetate, 3-hydroxyisovalerate and decreased 2-hydroxybutyrate, glutamine in GM-CSFdifferentiated LPS activatedmacrophages
AB
r GM-CSF  GM-CSF+LPS
= M-CSF+LPS
Figure 6.5. PLS-DA of Chenomx-quantified endpoint culture media for
macrophage activation conditions. Peripheral blood monocytes (1x107)were differentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml) for 6 days. On day 6 asubset of the differentiated macrophage cultures were stimulated with IL-4(n=7), LPS (n=8) or LPS+IFNγ (n=6) and incubated overnight to givecultures of activated and unactivated M-CSF (n=9) macrophages. Endpointculture media was collected and analysed by 1D H1 NMR. Metabolites wereidentified and quantified from raw spectra with Chenomx. Partial leastsquares discriminant analysis (PLS-DA) was performed on quantified data.
A) M-CSF (¡) vs. M-CSF+IL-4 (=) Groups separated with poor cross-validated sensitivity/specificity (Sensitivity: 0.667 Specificity: 0.444).Results showed increased proline, histidine, acetate and decreasedmethylguanidine, glutamine, tyrosine in IL-4 activated macrophages B) M-
CSF (¡) vs. M-CSF+LPS (=) Groups separated with moderate cross-validated sensitivity/specificity (Sensitivity: 0.750 Specificity: 0.667).Results showed increased glucose, glutamate, pyruvate and decreasedlactate, proline, glutamine in M-CSF differentiated LPS activatedmacrophages C) M-CSF (¡) vs. M-CSF+LPS+IFNγ (=) Groups separatedwith moderate cross-validated sensitivity/specificity (Sensitivity: 0.778Specificity: 0.500). Results showed increased methylguanidine, glucose,glutamate and decreased proline, citraconate, lactate in LPS+IFNγ activatedmacrophages.
AB
C
¡ M-CSF = M-CSF+LPS
= M-CSF+LPS+IFNγ
= M-CSF+LPS+IL-4
Figure 6.6. PLS-DA of Chenomx-quantified endpoint culture media for
macrophage activation conditions. Peripheral blood monocytes (1x107)were differentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10% FCS) containing M-CSF (10 ng/ml) for 6 days. On day 6the differentiated macrophage cultures were stimulated with IL-4 (n=7),LPS (n=8) or LPS+IFNγ (n=6) and incubated overnight to give cultures ofactivatedmacrophages. Endpoint culture media was collected and analysedby 1D H1 NMR. Metabolites were identified and quantified from rawspectra with Chenomx. Partial least squares discriminant analysis (PLS-DA)was performed on quantified data. A) M-CSF+IL-4 (=) vs. M-
CSF+LPS+IFNγ (=) Groups separated with poor cross-validatedsensitivity/specificity (Sensitivity: 0.556 Specificity: 0.333). Resultsshowed increased citraconate, alanine, pyroglutamate and decreasedlysine, threonine, histidine in LPS+IFNγ activated macrophages B) M-
CSF+LPS (=) vs. M-CSF+LPS+IFNγ (=) Groups separated with strongcross-validated sensitivity/specificity (Sensitivity: 0.833 Specificity: 0.667).Results showed increased pyruvate, methionine, glucose and decreasedformate, arginine, histidine in LPS+IFNγ activatedmacrophages.
AB
= M-CSF+LPS
= M-CSF+LPS+IFNγ
= M-CSF+LPS+IL-4
Figure 6.7. Chenomx-quantified metabolite concentrations for
endpoint culture media. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10%FCS) containingM-CSF (10 ng/ml) or GM-CSF (10 ng/ml)for 6 days. On day 6 a subset of the differentiated macrophage cultureswere stimulated with LPS and incubated overnight to give cultures ofunstimulatedM-CSF (n=9) GM-CSF (n=8) and stimulatedM-CSF+IL-4 (n=7)M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) and GM-CSF+LPS (n=8)macrophages. Endpoint culture media was collected and analysed by 1D H1NMR. Metabolites were identified and quantified from raw spectra withChenomx. Significantly regulated metabolites in activated macrophageswere calculated relative to matched unstimulatedmacrophages (GM-CSF orM-CSF) using a two-sample t-test (* p<0.05 ** p<0.01 *** p<0.001). Mediaglucose, 3-hydroyisovalerate and glutamate were significantly reducedfollowing LPS activation of M-CSFmacrophages, but not affected with otherM-CSF activation conditions. Citraconate was depleted for all activationconditions except for LPS+IFNγ where concentrations were raised. Therewere no significant changes in alanine, arginine, asparagine, histidine,glutamine or isoleucine following activation (GM-CSF ⧄, M-CSF □;ActivationnNonen LPSn IL-4n LPS+IFNγ)
3-Hydroxyisovalerate Acetate Alanine
Arginine Asparagine Citraconate
Glucose Glutamate Glutamine
Histidine Isoleucine
Differentiation ⧄ GM-CSF		□ M-CSF	
Activation n None	n LPS	n LPS+IFNϒ	n IL-4
Figure 6.8. Chenomx-quantified metabolite concentrations for
endpoint culture media. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10%FCS) containingM-CSF (10 ng/ml) or GM-CSF (10 ng/ml)for 6 days. On day 6 a subset of the differentiated macrophage cultureswere stimulated with LPS and incubated overnight to give cultures ofunstimulatedM-CSF (n=9) GM-CSF (n=8) and stimulatedM-CSF+IL-4 (n=7)M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) and GM-CSF+LPS (n=8)macrophages. Endpoint culture media was collected and analysed by 1D H1NMR. Metabolites were identified and quantified from raw spectra withChenomx. Significantly regulated metabolites activated macrophages werecalculated relative to matched unstimulated macrophages (GM-CSF or M-CSF) using a two-sample t-test (* p<0.05 ** p<0.01 *** p<0.001). Medialactate concentrations had significant variation/measurement error.Lactate was increased following LPS activation of M-CSF differentiatedmacrophages alone. Methylguanidine was significantly depleted in allactivated macrophages except IL-4, while methionine was reducedfollowing both LPS activation of GM-CSF macrophages and raised followingLPS activation of GM-CSF. Proline was significantly increased under allactivation conditions. Pyruvate and tyrosine were significantly reducedfollowing LPS activation of M-CSF macrophages alone. There were nosignificant changes in media myo-inositol, phenylalanine, pyroglutamate orvaline following activation. (GM-CSF ⧄, M-CSF □; Activation n None n LPS
n IL-4n LPS + IFNγ)
Lactate Leucine Methylguanidine
Methionine myo-Inositol Ornithine
Phenylalanine Proline Pyroglutamate
Pyruvate Tyrosine Valine
Differentiation ⧄ GM-CSF		□ M-CSF	
Activation n None	n LPS	n LPS+IFNϒ	n IL-4
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6.2.3 Differentiated	 macrophages	 can	 be	 distinguished	 by	 end-point	
metabolic	profiles	of	cell	extracts	
Post-activation intracellular metabolites were quantified from methanol cell extracts for 
GM-CS+LPS (n=5), M-CSF+LPS (n=5), M-CSF+LPS+IFNγ (n=6) and M-CSF+IL-4 
(n=3) macrophages. Spectra were analysed using both quantified Chenomx data and 
processed raw spectra to account for metabolites not in the Chenomx library. The scores 
and weights for the orthogonal PLS-DA analysis of individual groups’ processed 
spectra is shown in Figure 6.9—Figure 6.11. The cross-validated sensitivities and 
specificities of the PLS-DA models were GM-CSF vs. GM-CSF+LPS (1.0/1.0), M-
CSF+LPS vs. GM-CSF+LPS (1.0/1.0), M-CSF vs. M-CSF+IL-4 (1.0/1.0), M-CSF vs. 
M-CSF+LPS (1.0/0.333), M-CSF vs. M-CSF+LPS+IFNγ (0.5/0.8), M-CSF+IL-4 vs. 
M-CSF+LPS+IFNγ (0.5/0.8) and M-CSF+LPS vs. M-CSF+LPS+IFNγ (0.667/0.800). 
The concentration of individual intracellular metabolites is within the same dynamic 
range, and so there were no consistently dominating metabolites. One of the IL-4 
samples unfortunately had to be excluded from all PLS-DA models due to a poor fit 
(high Hotelling's T2 and Q residuals) with the other data. 
 
GM-CSF differentiated macrophages stimulated with LPS (Sensitivity: 1.0 Specificity: 
1.0) showed increases in intracellular glucose, taurine, dimethylglycine and reduced 
myo-inositol and lactate concentrations relative to unstimulated GM-CSF 
macrophages. In contrast, M-CSF differentiated macrophages stimulated with LPS 
(Sensitivity: 0.5 Specificity: 0.8) showed increased intracellular lactate, glutamate, 
myo-inositol and phosphocholine, while dimethylamine and acetate was reduced. Peak 
interference made it impossible to conclusively identify whether a further increased 
peak was glutamine, glutamate or homoserine, and whether a reduced peak was 
dimethylglycine or methylhistidine, however these may be clarified in the quantified 
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results. M-CSF differentiated macrophages activated with LPS+IFNγ (Sensitivity: 1.0 
Specificity: 0.333) was likewise associated with decreased intracellular dimethylamine, 
and increased lactate and myo-inositol, broadly following results for LPS alone. 
 
Orthogonal PLS-DA of macrophages differentiated with M-CSF and activated with IL-
4 (Sensitivity: 1.0 Specificity: 0.333) identified a much more diverse increase in 
metabolites, including lactate, taurine, myo-inositol and phosphocholine, with 
reduction in only dimethylamine. The similarity of changes in intracellular metabolites 
for both pro-inflammatory and anti-inflammatory macrophages was surprising. 
 
Looking at comparisons across the activated macrophage subsets, it was apparent that 
quantitative differences persisted even after activation. Orthogonal PLS-DA of M-CSF 
differentiated LPS+IFNγ activated against IL-4 activated (Sensitivity: 0.5 Specificity: 
0.800) showed increased intracellular lactate, taurine and glucose following LPS+IFNγ 
activation, while alanine and acetate were all raised in IL-4. Conversely, orthogonal 
PLS-DA of M-CSF differentiated LPS activated against LPS+IFNγ (Sensitivity: 0.667 
Specificity: 0.8) activated macrophages showed the addition of IFNγ resulted in higher 
intracellular lactate, and reduced glucose, taurine and dimethylamine. Orthogonal PLS-
DA of GM-CSF differentiated and M-CSF differentiated macrophages both activated 
with LPS (Sensitivity: 1.0 Specificity: 1.0) showed that despite activation of GM-CSF 
macrophages resulting in a drop in intracellular lactate, levels were still higher 
compared to M-CSF macrophages. Likewise, intracellular dimethylglycine, taurine and 
glucose were all raised in GM-CSF differentiated LPS activated macrophages, while in 
M-CSF differentiated LPS activated macrophages myo-inositol was increased. 
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6.2.4 Quantified	 cell	 extract	 metabolites	 show	 profile	 tendencies	 for	
macrophage	subsets	
Differentiation endpoint intracellular metabolites were quantified from methanol cell 
extract using the Chenomx software and orthogonal PLS-DA analysis was performed 
using the Chenomx-quantified metabolites. In total 30 metabolites were identified and 
quantified. Metabolite concentrations were auto-scaled before analysis to avoid the 
model being dominated by high concentration metabolites. The scores and weightings 
plots for the orthogonal PLS-DA analysis of individual groups’ Chenomx-quantified 
metabolites is shown in Figure 6.12—Figure 6.14. The cross-validated sensitivity and 
specificity of the PLS-DA models were GM-CSF vs. GM-CSF+LPS (0.5/0.6), M-
CSF+LPS vs. GM-CSF+LPS (1.0/0.8), M-CSF vs. M-CSF+IL-4 (1.0/1.0), M-CSF vs. 
M-CSF+LPS (0.75/1.0), M-CSF vs. M-CSF+LPS+IFNγ (0.75/0.833), M-CSF+IL-4 vs. 
M-CSF+LPS+IFNγ (0.6/0.667) and M-CSF+LPS vs. M-CSF+LPS+IFNγ 
(0.667/0.667) High-scoring Chenomx-quantified metabolites for each activation subset 
were plotted for comparison and are shown in Figure 6.15 and Figure 6.16. Significant 
changes were calculated for each subset relative to the relevant unactivated 
macrophages.  
 
Results showed that activation of M-CSF differentiated macrophages was associated 
with increases in intracellular histidine, myo-inositol (non-significant for LPS+IFNγ). 
In contrast activation of GM-CSF macrophages with LPS saw reduced myo-inositol, 
alongside reduced pyruvate, 2-oxoglutarate and alanine. In contrast, histidine was 
reduced following LPS activation of GM-CSF macrophages. Arginine was reduced in 
all activated M-CSF macrophages. Intracellular glucose was increased in GM-CSF 
differentiated LPS activated and M-CSF differentiated LPS activated macrophages, but 
unaltered in all other subsets. IL-4 activation of M-CSF macrophages entirely depleted 
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intracellular glutamine, tyrosine and fumarate, while both were unchanged in other 
subsets. Methylguanidine, pryoglutamate, threonine, 2-oxoglutarate, acetate, alanine, 
formate and isoleucine were all significantly increased in IL-4 activated macrophages. 
Threonine was reduced following LPS activation and intracellular ornithine was 
significantly increased in all activated subsets. 
 
 
 
 
Figure 6.9. PLS-DA of endpoint cell extracts for macrophage activation
conditions. Peripheral blood monocytes (1x107) were differentiated in T75 flaskswith 12ml standard culture media (RPMI+GPS+10% FCS) containing M-CSF (10ng/ml) or GM-CSF (10 ng/ml) for 6 days. On day 6 a subset of the differentiatedmacrophage cultures were stimulated with LPS and incubated overnight to givecultures of unstimulated M-CSF/GM-CSF and stimulated M-CSF+LPS (n=5) GM-CSF+LPS (n=5) macrophages. Endpoint intracellular metabolites were collected bystandard methanol extraction and analysed by 1D H1 NMR. Spectra were processedusing a standard NMRLab workflow. Partial least squares discriminant analysis(PLS-DA) was performed on processed binned data. High-weighted binsresponsible for separation between experimental groups were mapped to spectralpeaks and identified by reference to the Chenomx library. A) GM-CSF (r) vs. GM-
CSF+LPS () groups separated clearly with high cross-validatedsensitivity/specificity (Sensitivity: 1.0 Specificity: 1.0 ). Results showed increasedintracellular glucose, dimethylglycine and taurine, and decreased myo-inositol andlactate in LPS activated macrophages. B) M-CSF+LPS (=) vs. GM-CSF+LPS ()groups separated clearly with high cross-validated sensitivity/specificity(Sensitivity: 1.0 Specificity: 1.0). Results showed increased intracellular lactate,dimethylglycine, glucose, glucitol and taurine, and decreased myo-inositol in GM-CSF differentiated LPS activatedmacrophages.
AB
r GM-CSF  GM-CSF+LPS
= M-CSF+LPS
Figure 6.10. PLS-DA of endpoint cell extracts for macrophage activation
conditions. Peripheral blood monocytes (1x107) were differentiated in T75 flaskswith 12ml standard culture media (RPMI+GPS+10% FCS) containing M-CSF (10ng/ml) for 6 days. On day 6 a subset of the differentiated macrophage cultureswere stimulated with IL-4 (n=3; one sample excluded), LPS (n=5) or LPS+IFNγ(n=6) and incubated overnight to give cultures of activated and unactivated M-CSF(n=8) macrophages. Endpoint intracellular metabolites were collected by standardmethanol extraction and analysed by 1D H1 NMR. Spectra were processed using astandard NMRLab workflow Partial least squares discriminant analysis (PLS-DA)was performed on processed binned data. High-weighted bins responsible forseparation between experimental groups were mapped to spectral peaks andidentified by reference to the Chenomx library. A) M-CSF (¡) vs. M-CSF+LPS (=)groups separated clearly with moderate cross-validated sensitivity/specificity(Sensitivity: 1.0 Specificity: 0.333 ). Results showed increased intracellular lactate,taurine, dimethylglycine, myo-inositol, phosphocholine and decreaseddimethylamine in IL-4 activated macrophages. B) M-CSF (¡) vs. M-CSF+IL-4 (=)groups separated clearly with high cross-validated sensitivity/specificity(Sensitivity: 1.0 Specificity: 1.0). Results showed increased intracellular lactate,myo-inositol, phosphocholine and decreased dimethylamine and dimethylglycinein M-CSF differentiated LPS activated macrophages. C) M-CSF (¡) vs. M-
CSF+LPS+IFNγ (=) groups separated clearly with moderate cross-validatedsensitivity/specificity (Sensitivity: 0.500 Specificity: 0.800 ). Results showedincreased intracellular lactate, myo-inositol and glutamate and decreaseddimethylamine, dimethylglycine and acetate in LPS+IFNγ activatedmacrophages.
AB
C
r GM-CSF = M-CSF+LPS
= M-CSF+LPS+IFNγ
= M-CSF+LPS+IL-4
Figure 6.11. PLS-DA of endpoint cell extracts for macrophage activation
conditions. Peripheral blood monocytes (1x107) were differentiated in T75 flaskswith 12ml standard culture media (RPMI+GPS+10% FCS) containing M-CSF (10ng/ml) for 6 days. On day 6 the differentiated macrophage cultures werestimulated with IL-4 (n=3; one sample excluded), LPS (n=5) or LPS+IFNγ (6) andincubated overnight to give cultures of activated macrophages. Endpointintracellular metabolites were collected by standard methanol extraction andanalysed by 1D H1 NMR. Spectra were processed using a standard NMRLabworkflow. Partial least squares discriminant analysis (PLS-DA) was performed onprocessed binned data. High-weighted bins responsible for separation betweenexperimental groups were mapped to spectral peaks and identified by reference tothe Chenomx library. A) M-CSF+LPS (=) vs. M-CSF+LPS+IFNγ (=) groupsseparated clearly with high cross-validated sensitivity/specificity (Sensitivity:0.667 Specificity: 0.800). Results showed increased intracellular dimethylgycine,taurine, dimethylamine, glucose and decreased lactate in IL-4 activatedmacrophages. B) M-CSF+IL-4 (=) vs. M-CSF+LPS+IFNγ (=) groups separatedwith moderate cross-validated sensitivity/specificity (Sensitivity: 0.500 Specificity:0.800). Results showed increased intracellular lactate, taurine, glucose anddecreased acetate and alanine in LPS activatedmacrophages.
AB
= M-CSF+LPS
= M-CSF+LPS+IFNγ
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Figure 6.12. PLS-DA of Chenomx-quantified endpoint cell extracts for
macrophage activation conditions. Peripheral blood monocytes (1x107)were differentiated in T75 flasks with 12ml standard culture media(RPMI+GPS+10%FCS) containingM-CSF (10 ng/ml) or GM-CSF (10 ng/ml)for 6 days. On day 6 a subset of the differentiated macrophage cultureswere stimulated with LPS and incubated overnight to give cultures ofunstimulated M-CSF (n=9) GM-CSF (n=8) and stimulated M-CSF+LPS (n=8)GM-CSF+LPS (n=8) macrophages. Endpoint intracellular metabolites werecollected by standard methanol extraction and analysed by 1D H1 NMR.Metabolites were identified and quantified from raw spectra withChenomx. Partial least squares discriminant analysis (PLS-DA) wasperformed on quantified data. A) GM-CSF (r) vs. GM-CSF+LPS ()groups separated with poor cross-validated sensitivity/specificity(Sensitivity: 0.500 Specificity: 0.600). Results showed increasedintracellular Glucose, ornithine, valine, leucine, decreased myo-inositol,pyruvate, glycine in LPS-activated macrophages. B) M-CSF+LPS (=) vs.
GM-CSF+LPS () groups separated clearly with high cross-validatedsensitivity/specificity (Sensitivity: 1.0 Specificity: 0.800). Results showedincreased intracellular ATP/ADP, creatine, pyruvate, myo-inositol in M-CSFdifferentiated LPS activated macrophages, while higher glucose, glutamine,threonine when GM-CSF differentiated LPS activation.
AB
r GM-CSF  GM-CSF+LPS
= M-CSF+LPS
Figure 6.13. PLS-DA of Chenomx-quantified endpoint cell extracts for
macrophage activation conditions. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media (RPMI+GPS+10%FCS) containing M-CSF (10 ng/ml) for 6 days. On day 6 a subset of thedifferentiated macrophage cultures were stimulated with IL-4 (n=3), LPS (n=8) orLPS+IFNγ (n=6) and incubated overnight to give cultures of activated andunactivated MC-CSF (n=9) macrophages. Endpoint intracellular metabolites werecollected by standardmethanol extraction and analysed by 1DH1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. Partial leastsquares discriminant analysis (PLS-DA) was performed on quantified data. A) M-
CSF (¡) vs. M-CSF+LPS (=) groups separated clearly with high cross-validatedsensitivity/specificity (Sensitivity: 0.750 Specificity: 1.0 ). Results showedincreased lactate, succinate, myo-inositol, ornithine and decreased threonine,isoleucine and caprate in IL-4 activated macrophages. B) M-CSF (¡) vs. M-CSF+IL-
4 (=) groups separated clearly with high cross-validated sensitivity/specificity(Sensitivity: 1.0 Specificity: 1.0). Results showed increased alanine, ATP, glycine,lactate, threonine and decreased GTP, glutamine, tyrosine, serine in M-CSFdifferentiated LPS activated macrophages. C) M-CSF (¡) vs. M-
CSF+LPS+IFNSg(=) groups separated clearly with high cross-validatedsensitivity/specificity (Sensitivity: 0.750 Specificity: 0.833). Results increasedsuccinate, valine, tyrosine, lactate and decreased dimethylamine, caprate, isocitratein LPS+IFNγ activatedmacrophages.
AB
C
¡ M-CSF = M-CSF+LPS
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Figure 6.14. PLS-DA of Chenomx-quantified endpoint cell extracts for
macrophage activation conditions. Peripheral blood monocytes (1x107) weredifferentiated in T75 flasks with 12ml standard culture media (RPMI+GPS+10%FCS) containing M-CSF (10 ng/ml) or GM-CSF (10 ng/ml) for 6 days. On day 6 thedifferentiated macrophage cultures were stimulated with IL-4 (n=7), LPS (n=8) orLPS+IFNγ (n=6) and incubated overnight to give cultures of activatedmacrophages.Endpoint intracellular metabolites were collected by standard methanol extractionand analysed by 1D H1 NMR. Metabolites were identified and quantified from rawspectra with Chenomx. Partial least squares discriminant analysis (PLS-DA) wasperformed on quantified data. A) M-CSF+LPS (=) vs. M-CSF+LPS+IFNγ (=)groups separated clearly with moderate cross-validated sensitivity/specificity(Sensitivity: 0.667 Specificity: 0.667). Results showed increased isoleucine,pyruvate, acetoin, ADP and decreased IMP, taurine, glucose, isocitrate in LPS+IFNγactivated macrophages. B) M-CSF+IL-4 (=) vs. M-CSF+LPS+IFNγ (=) groupsseparated clearly with high cross-validated sensitivity/specificity (Sensitivity: 0.6Specificity: 0.667). Results showed increased succinate, tyrosine, glucitol, fumarateand decreased glycine, carinitine, formate, creatine in LPS+IFNγ activatedmacrophages.
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Figure 6.15. Chenomx-quantified metabolite concentrations for endpoint cell
extracts. Peripheral blood monocytes (1x107) were differentiated in T75 flaskswith 12ml standard culture media (RPMI+GPS+10% FCS) containing M-CSF (10ng/ml) or GM-CSF (10 ng/ml) for 6 days. On day 6 a subset of the differentiatedmacrophage cultures were stimulated with LPS and incubated overnight to givecultures of unstimulated M-CSF (n=9) GM-CSF (n=8) and stimulated M-CSF+IL-4(n=7) M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) and GM-CSF+LPS (n=8)macrophages. Endpoint intracellular metabolites were collected by standardmethanol extraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Significantly regulated metabolitesactivated macrophages were calculated relative to matched unstimulatedmacrophages (GM-CSF or M-CSF) using a two-sample t-test (* p<0.05 ** p<0.01 ***p<0.001). Intracellular 2-oxoglutarate, acetate, alanine, formate, histidine andisoleucine were significantly raised in IL-4 activated M-CSF macrophages, whileglutamine and fumarate were almost entirely depleted. In contrast 2-oxoglutaratewas significantly reduced following LPS activation of GM-CSF macrophages. Lactatewas significantly increased following activation of all M-CSF macrophages. Glucosewas significantly raised in LPS stimulated GM-CSF macrophages but unalteredelsewhere. Glutamate was not significantly altered under any activation condition(GM-CSF ⧄, M-CSF □; ActivationnNonen LPSn LPS + IFNϒn IL-4)
2-Oxoglutarate Acetate Alanine
Arginine Formate Fumarate
Glucose Glutamate Glutamine
Histidine Isoleucine Lactate
Differentiation ⧄ GM-CSF		□ M-CSF	
Activation n None	n LPS	n LPS+IFNϒ	n IL-4
Figure 6.16. Chenomx-quantified metabolite concentrations for endpoint cell
extracts. Peripheral blood monocytes (1x107) were differentiated in T75 flaskswith 12ml standard culture media (RPMI+GPS+10% FCS) containing M-CSF (10ng/ml) or GM-CSF (10 ng/ml) for 6 days. On day 6 a subset of the differentiatedmacrophage cultures were stimulated with LPS and incubated overnight to givecultures of unstimulated M-CSF (n=9) GM-CSF (n=8) and stimulated M-CSF+IL-4(n=7) M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) and GM-CSF+LPS (n=8)macrophages. Endpoint intracellular metabolites were collected by standardmethanol extraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Significantly regulated metabolitesactivated macrophages were calculated relative to matched unstimulatedmacrophages (GM-CSF or M-CSF) using a two-sample t-test (* p<0.05 ** p<0.01 ***p<0.001). Myo-Inositol was significantly reduced in LPS activated GM-CSFmacrophages, but significantly increased in M-CSF differentiated LPS and IL-4activated macrophages. All activation conditions produced increases inintracellular ornithine. Tyrosine was significantly depleted following IL-4activation of M-CSF macrophages, while it was significantly increased under allother activation conditions. Intracellular valine was significantly increased in M-CSF+LPS+IFNγ macrophages. Methylguanidine and threonine were bothsignificantly increased following IL-4 activation of M-CSF macrophages. Leucinewas not significantly altered under any activation condition (GM-CSF ⧄, M-CSF □;ActivationnNonen LPSn LPS + IFNϒn IL-4)
Leucine Methylguanidine myo-Inositol
Ornithine Pyroglutamate Pyruvate
Succinate Threonine Tyrosine
Valine
Differentiation ⧄ GM-CSF		□ M-CSF	
Activation n None	n LPS	n LPS+IFNϒ	n IL-4
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6.2.5 Differentiated,	 activated	 macrophages	 can	 be	 distinguished	 by	
transcriptional	profiles	
As for the previous chapter, RNA	 was	 quantified	 from	 endpoint	 activated	macrophages	 (day	 7)	 cultured	 in	 parallel	 to	 the	 metabolomic	 analyses.	Experiments	 were	 performed	 in	 biological	 triplicate	 (3	 donors)	 for	 each	differentiation	condition	with	monocytes	cultured	in	6	well	plates	at	a	density	of	6.25x104	cells/cm2.	RNA	expression	was	quantified	by Oxford Gene Technologies 
using an Agilent 8x60K gene expression array using the global human male reference 
transcription profile as background. Transcriptional data were analysed with Agilent 
GeneSpring v12.6. Intra-array normalisation was performed by Lowess during feature 
extraction and again by median scaling during GeneSpring analysis. See Figure 5.13 in 
the previous chapter for QC analysis of this data. Regulated genes were filtered using 
one-way ANOVA with p<0.05 between groups and log2 fold-change >1 relative to the 
background. The non-specific nature of the background somewhat complicates 
interpretation, as observed changes may reflect baseline expression for 
monocytes/macrophages and not up- or down-regulation per se. However, comparisons 
between differentiation conditions should be informative. 
 
Activation of differentiated macrophages resulted in different transcriptional profiles. 
Genes were classified by gene ontology information and log2 fold change values 
relative to baseline to identify the most regulated genes. The interesting gene ontology 
groups are shown in Figure 6.17—Figure 6.20. To clarify interpretation of the data, 
genes with greater than 2-fold change (~2000) were manually categorised as before into 
groups relating to macrophage differentiation and/or metabolism. These groups were 
determined manually based on GeneCards and UniProt reference data [364,365]. 
Selected genes were bundled into named grouped and then filtered by sum regulation 
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to give the top 20 up or down regulated gene groups for each macrophage group. Gene 
regulation changes associated with activation under GM-CSF+LPS, M-CSF+LPS, M-
CSF+LPS+IFNγ, M-CSF+IL-4 are considered below. Summary gene tables are given 
in Appendix II. 
  
Figure 6.17. GM-CSF differentiated, LPS activated macrophages gene
transcription log2 fold change relative to unstimulated GM-CSF macrophages.Peripheral blood monocytes (6x106 per plate) were differentiated in 6-well plateswith 2ml standard culture media (RPMI+GPS+10% FCS) containing GM-CSF (10ng/nl) for 6 days. On day 6 a subset of the differentiated macrophage cultures werestimulated with LPS and incubated overnight to give cultures of unstimulated GM-CSF (n=3) and stimulated GM-CSF+LPS (n=3) macrophages. Endpoint intracellularRNA was extracted using Qiagen RNeasy MiniKit and quantified using Agilent8x60K array. Highlighted genes are grouped by GO (Gene Ontology) terms. A)Biological Process; up-regulation of CXCL11 a chemotactic attractant for T cells,CCL15 a chemotactic attractant for T cells and macrophages and MMP25 a matrix-metalloproteinase involved in extracellular matrix degradation. B) Transporters;
C) Activity; up-regulation of SLCO5A1 a anion transporter, FABP4 a fatty acidtransporter. Interestingly,FABP3 is down-regulated. D) down-reglation of HPGDwhich encodes for an enzyme involved in prostaglandinmetabolism.

Figure 6.18. M-CSF differentiated LPS stimulated macrophages gene
transcription log2 fold change relative to unstimulated M-CSF macrophages.Peripheral blood monocytes (6x106 per plate) were differentiated in 6-well plateswith 2ml standard culture media (RPMI+GPS+10% FCS) containing M-CSF (10ng/nl) for 6 days. On day 6 a subset of the differentiated macrophage cultures werestimulated with LPS and incubated overnight to give cultures of unstimulated M-CSF (n=3) and stimulated M-CSF+LPS (n=3) macrophages. Endpoint intracellularRNA was extracted using Qiagen RNeasy MiniKit and quantified using Agilent8x60K array. Highlighted genes are grouped by GO (Gene Ontology) terms. A)Biological Process; up-regulation of CXCL13, 6 and 3 responsible for B cell,neutrophil and monocyte chemotaxis respectively. IL-1A and IL-6, bothinflammatory cytokine, are also up-regulated. TLR5 is down-regulated. B)Enzymes; CD35 (complement receptor 1) is up-regulated while CIITA an MHC-IItranscription transactivator is down-regulated. C) Transporters; D) Activity;MYH11 and a number of other myosin encoding genes are up-regulated as is ADCwhich encodes for arginine decarboxylase.

Figure 6.19. M-CSF differentiated LPS+IFNγ stimulated macrophages
macrophages gene transcription log2 fold change relative to unstimulated M-
CSF macrophages. Peripheral blood monocytes (6x106 per plate) weredifferentiated in 6-well plates with 2ml standard culture media (RPMI+GPS+10%FCS) containingM-CSF (10 ng/nl) for 6 days. On day 6 a subset of the differentiatedmacrophage cultures were stimulated with LPS+IFNγ and incubated overnight togive cultures of unstimulated M-CSF (n=3) and stimulated M-CSF+LPS+IFNγ (n=3)macrophages. Endpoint intracellular RNA was extracted using Qiagen RNeasyMiniKit and quantified using Agilent 8x60K array. Highlighted genes are groupedby GO (Gene Ontology) terms. A) Biological Process; inflammatory cytokines IL-1A,IL6 and IL-5 are up-regulated while anti-inflammatory IL-1R is down-regulated.CCL20 a lymphocyte chemoattractant is also up-regulated. In contrast CCR2 amonocyte chemoattractant is down-regulated. B) Enzymes; CYP3A5, involved inlipid synthesis, is up-regulated. C) Transporters; D) Activity; SGPP2 a gene withsphingolipid-related functions (putatively pro-inflammatory) is up-regulated

Figure 6.20. M-CSF differentiated IL-4 stimulated macrophages macrophages
gene transcription log2 fold change relative to unstimulated M-CSF
macrophages. Peripheral blood monocytes (6x106 per plate) were differentiatedin 6-well plates with 2ml standard culture media (RPMI+GPS+10%FCS) containingM-CSF (10 ng/nl) for 6 days. On day 6 a subset of the differentiated macrophagecultures were stimulated with IL-4 and incubated overnight to give cultures ofunstimulated M-CSF (n=3) and stimulated M-CSF+IL-4 (n=3) macrophages.Endpoint intracellular RNA was extracted using Qiagen RNeasy MiniKit andquantified using Agilent 8x60K array. Highlighted genes are grouped by GO (GeneOntology) terms. A) Biological Process; up-regulation of ECSCR a regulator ofchemotaxis, RAP1GAP a GTPase-activating-protein and CD1B which mediatespresentation of lipids to T cells. IL10 is down-regulated, as is IL6 and IL2RA. CCL5which triggers the release of histamine from eosinophils is also down-regulated. B)Enzymes; C) Transporters; D) Activity; up-regulated of STMN1which encodes for aprotein involved in regulation of micro-tubular structure. Transcription factorSTAT4 is also down-regulated.
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6.2.6 Regulation	of	genes	associated	with	macrophage	differentiation	in	
activation	with	LPS,	LPS+IFNγ	and	IL-4	
As described in the previous chapter, genes associated with macrophage differentiation 
were selected from those found during literature review of established markers for 
monocytes and M1/M2a macrophages. These genes were filtered to identify those 
significantly regulated at >2 fold change between groups relative to the human baseline 
expression. 
 
The resulting genes were grouped according to function/class and gene groups were 
ranked according to fold-change. The up- or down-regulation of these genes is again 
relative to a generic baseline therefore may not reflect directly the change during 
activation. To address this, unique gene expression — where genes are up- or down-
regulated only in specific subsets — is also discussed. Genes upregulated during 
differentiation and then also post-activation are not considered features of activation. 
The list of detected up- and down-regulated genes are given in Table 14-Table 17 in 
Appendix II. 
6.2.6.1 Transcriptional	changes	across	different	activation	treatments	
There was notably no overlap in the up- or down-regulated genes across all macrophage 
activation/polarization treatments. On closer inspection it was apparent that the IL-4 
macrophages were the most distinctive subset having no overlap in up- or down- 
regulated genes with any other M-CSF subset under study, and no overlap with 
upregulated genes under GM-CSF+LPS activation. However, GM-CSF+LPS and M-
CSF+IL4 macrophages did share downregulation of MMP1, IL-8 and IL-2RA.  
 
All macrophages activated with LPS (M-CSF+LPS, M-CSF+LPS+IFNγ, GM-
CSF+LPS) showed upregulation of pro-inflammatory cytokine IL-6 and T cell co-
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stimulatory receptor CD80. Interferon-responsive cytokines were also upregulated in 
all LPS treated macrophages. These included interferon gamma-induced protein 10 
(CXCL10/IP10) which is secreted by monocytes in response to IFNγ and is chemotactic 
for monocytes/macrophages, T, NL and dendritic cells; and interferon gamma inducible 
protein 9 (CXCL11/I-TAC/IP9) which is strongly induced by IFNγ and IFNb, and is 
chemotactic for activated T cells. These cytokines were upregulated in treatments 
without exogenous IFNγ (M-CSF+LPS/GM-CSF+LPS) — however, IFNγ 
transcription was upregulated in all LPS treated macrophages. Macrophage 
inflammatory protein 3 (CCL20/MIP-3A) the expression of which has been previously 
reported to be induced by LPS was also upregulated [380]. 
 
Mannose receptor 1 (MRC1) a C-type lectin present on macrophages which recognises 
glycans on the surface of yeast and protozoa (MRC1) was the only downregulated gene 
common to all LPS treatments. 
 
The majority of gene regulation changes observed in M-CSF+LPS and GM-CSF+LPS 
activation were also found in M-CSF+LPS+IFNγ macrophages. However, the two 
LPS-alone activation treatments did produce novel upregulation of CCL19, 
chemotactic for dendritic cells, activated B cells and memory T cells, and monokine 
induced by gamma interferon (CXCL9/MIG) which signals to activated T cells. 
Similarly, the M-CSF differentiated macrophages stimulated with LPS alone 
upregulated the majority of genes commonly with those stimulated with LPS and IFNγ 
(IFNG), sharing 26 up- and 7 down- regulated genes respectively.  
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6.2.6.2 Transcriptional	changes	unique	to	LPS	activation	of	M-CSF	macrophages	
There were some notable differences between GM-CSF differentiated and M-CSF 
differentiated macrophages following subsequent LPS activation. The changes unique 
to M-CSF+LPS macrophages are described below. 
 
LPS activation of M-CSF macrophages produced a wide upregulation of cytokines and 
chemokines including the pro-inflammatory IFNγ (IFNG) and members of the IL-1 
family (IL1A, IL1B) commonly produced by macrophages in response to LPS 
stimulation [381].  
 
Also upregulated following LPS treatment were IL-8 (IL8), which induces chemotaxis 
in neutrophils, IL-12 (IL12B) which promotes the differentiation of naïve T cells into 
Th1 cells, IL-15 (IL15) which regulates T and NK cell activation and proliferation; and 
IL-23 (IL23A) a proinflammatory cytokine driving activation of T, NK and 
macrophage cells via JAK/STAT signalling cascade. CCL5 a chemoattractant for blood 
monocytes, memory T cells and eosinophils was also upregulated. The pattern of 
upregulation was therefore biased towards a Th1-like response as would be expected 
for the activation stimuli. Chemokine receptors, including those for IL-2, IL-12, IL-15, 
IL-17 were also upregulated (IL2RA, IL12RB1, IL15RA, IL17RD) — interestingly 
including receptors for a number of cytokines M-CSF+LPS macrophages have 
themselves upregulated. Tumour-necrosis factor-alpha induced proteins (TNFAIP6, 
TNFAIP3) which increase expression rapidly in the presence of TNFα were also 
upregulated, although TNFα itself was not present in our transcriptomics data. 
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Following LPS activation M-CSF macrophages also upregulated expression of GM-
CSF (CSF2) and G-CSF (CSF3). The biological implication of GM-CSF production 
following LPS activation of M-CSF macrophages is unclear. Somewhat unexpectedly, 
stimulation with LPS also uniquely drove upregulation of toll-like receptor 3 (TLR3; 
CD283) responsible for responses to viral-associated dsRNA. 
 
Thrombospondin 4 (THBS4) an adhesive glycoprotein mediating cell-to-cell and cell-
to-matrix adhesion — and with an established role in macrophage recruitment in RA 
— was also upregulated [311,382]. 
6.2.6.3 Transcriptional	 changes	 unique	 to	 LPS	 activation	 of	 GM-CSF	
macrophages	
GM-CSF differentiated macrophages activated with LPS uniquely upregulated a 
number of HLA class molecules including HLA class II histocompatibility antigen, DO 
beta chain (HLA-DOB) which is localised to intracellular vesicles inhibits HLA-DM 
supressing loading of peptides onto HLA class II molecules. Major Histocompatibility 
Complex, Class II, DR Beta 6 (HLA-DRB6). HLA class I, L (HLA-L) was also 
uniquely upregulated. This suggests that GM-CSF+LPS activation strongly promotes 
antigen presentation.  
 
Monocyte activating cytokine CCL14 was upregulated and responsiveness to IL-12 
was indicated with upregulation of the beta-2 subunit of the IL-12 receptor (IL12RB2) 
which is commonly upregulated in response to IFNγ [383]. Interestingly, IFNγ was 
expressed in all GM-CSF macrophages, both before and after stimulation with LPS. 
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There were also indications of downregulation or modulation of signalling following 
LPS activation. For example, MAP2K6, a member of the mitogen-activated protein 
kinase (MAPK) family essential for STAT4 activation in response to IL-12 is 
downregulated. GMCSF-LPS macrophages also uniquely downregulated receptors for 
IL-1 and IL-2 (IL1R1, IL2RA). Transcription of M-CSF (CSF1) was also 
downregulated suggesting — as observed in M-CSF+LPS macrophages — of a bias 
towards GM-CSF differentiation in response to LPS. 
6.2.6.4 Transcriptional	changes	between	LPS	and	LPS+IFNγ	activation	of	M-CSF	
macrophages	
Upregulation of IFNγ (IFNG) by M-CSF+LPS macrophages may provide a mechanism 
for paracrine/autocrine priming of other macrophages. IFNγ expression in macrophage 
is a common indicator of T cell contamination, however expression has been shown in 
macrophages before [370]. Further, we do not detect expression in cultures including 
IFNγ in the activation stimulus. Monokine induced by gamma interferon 
(CXCL9/MIG) was here upregulated, indicating responsiveness to IFNγ. CCL19, 
which is chemotactic for dendritic cells, activated B cells and memory T cells, was also 
upregulated uniquely in this subset. In contrast, CD1-alpha (CD1A) was uniquely 
downregulated following LPS activation alone, but not in M-CSF+LPS+IFNγ 
macrophages. 
 
Activation of M-CSF macrophages with LPS+IFNγ resulted in a number of uniquely 
upregulated genes relative to M-CSF with LPS alone. Receptors/receptor subunits for 
cytokines IL-7, Th2-response associated IL-13 and pro-inflammatory IL-17 (IL7R, 
IL13RA2, IL17RB) were all upregulated. Interleukin 1 receptor associated kinase 2 
(IRAK2), commonly expressed in macrophages, was also uniquely upregulated [384]. 
This kinase associates with IL1 receptor upon stimulation, with a role in signal 
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transduction and NF-kappaB upregulation. M-CSF macrophages treated with LPS and 
IFNγ together also uniquely upregulated two matrix metallopeptidases (MMP12, 
MMP3) which were not changed following LPS alone.  
 
6.2.6.5 Transcriptional	changes	following	IL-4	activation	of	M-CSF	macrophages	
IL-4 activation produced unique gene up- and down- regulation profiles, with no genes 
in common with LPS activated M-CSF macrophages. In contrast to the strong gene 
regulation noted in the LPS-activated macrophages, activation with IL-4 activation 
resulted in relatively few up- or down- regulated genes. Upregulated genes included 
lysozyme-like genes 1 & 2 (LYZL1, LYZL2); transcription factor Myb proto-oncogene 
(MYB); peroxisome proliferator-activated receptor gamma (PPAR-γ/PPARG) which 
regulates fatty acid storage and glucose metabolism; and marker of cellular 
proliferation Ki67 (MKI67). 
 
The majority of significantly regulated genes following IL-4 activation were 
downregulated. For example, monokine induced by gamma interferon (CXCL9/MIG), 
previously seen upregulated in LPS-stimulated cells, was here downregulated reflecting 
the absence of IFNγ production in IL-4 activated macrophages. The beta-subunit of 
pro-inflammatory IL-12 (IL12B) and receptor subunit beta-1 (IL12RB1) were also 
downregulated. IL-12 and IL-4 function antagonistically in production of IFNγ by 
macrophages [385] therefore downregulation of these receptors likely supports the Th2 
response. Anti-inflammatory cytokine IL-10 (IL10), associated with the regulatory 
macrophage (M2c) phenotype rather than the model used here (M2a), was also 
downregulated following IL-4. Further, a number of TNF receptor associated factors 
(TRAF1, TRAF2, TRAF5) which mediate signal transduction from members of the 
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TNF receptor family were also downregulated, suggesting loss of responsiveness to 
TNF in these cells. 
 
Signalling pathway proteins were also directly downregulated including AKT1 
substrate 1 (AKT1S1) a subunit of mTORC and HIF-1α (HIF1A) a key protein involved 
in cellular responses to hypoxia. The reduced expression of HIF-1α may therefore make 
IL-4 activated macrophages less able to respond transcriptionally to low oxygen 
environments. 
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6.2.7 Distinctive	metabolic	pathway	regulation	accompanies	macrophage	
activation	
Metabolic pathway analysis using cell extract metabolites highlighted key differences 
between the metabolite profiles of different subsets. Results for the core metabolic 
pathways (Figure 6.21—Figure 6.24) showed that LPS activation of GM-CSF 
differentiated macrophages drove downregulation of glycolysis and TCA cycle while 
an increase of metabolites in the urea cycle. Two steps in glycolysis were upregulated 
at the gene level. In contrast activation of M-CSF macrophages with LPS drove 
increases of TCA cycle metabolites, while the TCA cycle was downregulated at the 
transciptional level. Also downregulated was pyruvate dehydrogenase, the linking step 
from pyruvate to the TCA cycle. Citrate, 2-oxoglutarate and succinate were all 
upregulated however. M-CSF macrophage activation with LPS+IFNγ produced a very 
similar profile with upregulation of glycolysis, a tendency towards downregulation of 
the TCA cycle and downregulation of the urea cycle. In contrast IL-4 activation saw 
upregulation of TCA cycle genes relative to M-CSF differentiation alone. Fumarate in 
the TCA cycle was also increased, while pyruvate was reduced. The final pyruvate 
kinase step of glycolysis was also downregulated at the transcriptional level.  
 
Away from the core metabolic pathway a striking pattern appeared in the metabolomic 
data for M-CSF differentiated macrophages. Activation — whether LPS, LPS+IFNγ or 
IL-4 — resulted very similar metabolic profiles across each of the most regulated 
pathways. While differences did exist between subsets in the degree of up- or down- 
regulation, the direction was consistently the same. This suggested that for all M-CSF–
differentiated macrophages subsets there were common metabolic requirements to 
subsequent activation processes. However, this agreement was not necessarily reflected 
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at the transcriptional level. The general trends of GM-CSF against the similar M-CSF 
subsets will be described later, together with cross-comparisons of M-CSF subsets. 
 
Levels of intracellular creatine and creatine phosphate (Figure 6.25) in GM-CSF/LPS 
activated macrophages was reduced relative to inactivated GM-CSF macrophages, 
while creatine biosynthesis was downregulated at the gene level. It was notable that 
cellular ATP and ADP levels were also reduced. In contrast all M-CSF differentiated 
macrophages — regardless of activation — showed an increase in creatine and creatine 
phosphate, though creatine biosynthesis remained downregulated. Therefore M-CSF 
activated macrophages appeared to storing high-energy phosphate.  
 
There was a similar pattern for the carnitine shuttle/biosynthesis, responsible for 
shuttling of long-chain fatty acids into mitochondria (Figure 6.26), with barely changed 
levels of carnitine in GM-CSF/LPS macrophages vs. differentiation, while increased 
levels in all M-CSF subsets. Biosynthesis of carnitine was downregulated at the gene 
level in GM-CSF macrophages, but upregulated in all M-CSF subsets. Notably, in 
LPS+IFNγ activated macrophages carnitine acetylase was downregulated. Fatty acid β-
oxidation (Figure 6.27) was shown to be strongly upregulated at the gene level in IL-4 
activated M-CSF macrophages, with upregulation of all steps in the cycle and 
upregulation of intake for both saturated and unsaturated fatty acids. In contrast LPS 
and LPS+IFNγ stimulated macrophages subsets showed downregulation of initial 
saturated fatty acid steps of the oxidation cycle. LPS-alone also upregulated acetyl-CoA 
dehydrogenase for saturated fatty acid metabolism without hydrogen peroxide 
production. In GM-CSF+LPS macrophages the fatty acid β-oxidation pathway was 
completely downregulated.  
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Protein citrullination (Figure 6.29) was shown to be upregulated most in IL-4 
stimulated macrophages, while strongly downregulated in LPS+IFNγ macrophages. 
LPS activation of M-CSF macrophages was associated with more upregulation of PAD 
genes than for the GM-CSF differentiated macrophage subset. Myo-inositol (Figure 
6.30) was reduced following LPS activation of GM-CSF macrophages, while raised in 
all M-CSF subsets. Both LPS activation treatments had similar profiles at the 
transcriptional level, and LPS+IFNγ. In contrast IL-4 activation of M-CSF 
macrophages showed unique upregulation of the IP3 synthesis step at the transcriptional 
level. 
 
Prostanoid biosynthesis (Figure 6.31) was differentially regulated at the transcriptional 
level between all activated macrophage subsets. GM-CSF differentiated LPS activated 
macrophages showed a bias towards prostaglandin D2, E2 and thromboxane A2, and 
away from prostaglandin I2. In contrast, the activation of M-CSF macrophages with 
LPS upregulated prostaglandin I2 and D2 only, with an isotype switch on E2. Further 
addition of IFNγ resulted in I2 alone being upregulated. Activation of M-CSF 
macrophages with IL-4n in contrast resulted in upregulation of all routes to produce 
prostaglandin D2, E2 and I1 and thromboxane A2. 
 
To highlight the unique features of the differentiation background under identical 
activation we performed a cross-comparison of the GM-CSF+LPS and M-CSF+LPS 
subsets (Figure 6.31—Figure 6.36). In this comparison M-CSF+LPS was used as the 
control, and features will be described relative to it. The comparison demonstrated that 
GM-CSF differentiated LPS activated macrophages upregulated early TCA genes but 
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had relative reduction in metabolites of both glycolysis and TCA pathways. 
Intracellular lactate was slightly increased and pyruvate dehydrogenase was 
upregulated — promoting conversion of pyruvate to acetyl-CoA. Creatine and creatine 
phosphate were down in GM-CSF macrophages as already demonstrated, as were 
cellular ADP and ATP levels, while biosynthesis was upregulated at the transcriptional 
level. Intracellular glutamine and threonine were all raised in GM-CSF+LPS 
macrophages, relative to M-CSF+LPS macrophages, while glutamate and aspartate 
were reduced. Fatty acid β-oxidation was also increased at a transcriptional level, 
promoting preferential oxidation of saturated fatty acids. However, carnitine was 
reduced, as were genes involved in carnitine synthesis and the carnitine shuttle, which 
suggests long-chain fatty acid metabolism is not a key metabolic energy source for 
LPS-activated GM-CSF macrophages. Finally, prostaglandin biosynthesis was biased 
towards PGE2 and TxA2 and away from D2 and I2. 
 
Having identified metabolic and transcriptional changes, we sought to correlate the 
changes in metabolism directly with cytokine output. LPS activated GM-CSF (n=3) 
and M-CSF (n=3) macrophage IL-6 output was quantified by ELISA and correlated 
using PLSR against quantified intracellular metabolites (Figure 6.37). IL-6 was 
selected due to consistency of measurement and the established expression of IL-6 by 
in active RA [284]. Results showed that IL-6 production was associated with increases 
in TCA and urea cycle metabolites, mimicking our findings for LPS activation of M-
CSF macrophages. The former may reflect the increased energy demands of activation 
and the latter the catabolism of amino acids, either as an energy source or resulting from 
protein degradation, results in accumulation of ammonia (NH3) which must be 
converted to urea for excretion [386].  
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Figure 6.21. Central metabolism in GM-CSF+LPS vs. GM-CSF macrophages.Peripheral blood monocytes (1x107 per flask; 6x106 per plate) were concurrentlydifferentiated for 6 days in T75 flasks and 6-well plates with 12ml and 2mlstandard culture media (RPMI+GPS+10% FCS) containing GM-CSF (10 ng/nl) for 6days. On day 6 a subset of the differentiated macrophage cultures were stimulatedwith LPS and incubated overnight to give cultures of unstimulated GM-CSF (n=3)and stimulated GM-CSF+LPS (n=3) macrophages. Endpoint intracellularmetabolites were collected by standard methanol extraction and analysed by 1D H1NMR. Metabolites were identified and quantified from raw spectra with Chenomx.Endpoint intracellular RNA of differentiated macrophages (each group; n=3) wereextracted from 6 well plates using Qiagen RNeasy MiniKit and quantified usingAgilent 8x60K array. Pathway maps were generated using the metaviz algorithm.Colours indicate mean log2 fold-change of stimulated GM-CSF+LPS macrophageintracellular metabolites and RNA relative to unstimulated GM-CSF macrophages.Metabolites of the urea cycle were raised following LPS stimulation, while those ofthe TCA cycle and glycolysis were relatively reduced. Transcription of enzymesinvolved in the final step of glycolysis and the conversion of pyruvate to acetyl-coAwere downregulated, while earlier enzymeswere up-regulated at the gene level.
GM-CSF+LPS
log2(fc) 1.0-1.0
Figure 6.22. Central metabolism in M-CSF+LPS vs. M-CSF macrophages.Peripheral blood monocytes (1x107 per flask; 6x106 per plate) were concurrentlydifferentiated for 6 days in T75 flasks and 6-well plates with 12ml and 2mlstandard culture media (RPMI+GPS+10% FCS) containing M-CSF (10 ng/nl) for 6days. On day 6 a subset of the differentiated macrophage cultures were stimulatedwith LPS and incubated overnight to give cultures of unstimulatedM-CSF (n=9) andstimulated M-CSF+LPS (n=8) macrophages. Endpoint intracellular metaboliteswere collected by standard methanol extraction and analysed by 1D H1 NMR.Metabolites were identified and quantified from raw spectra with Chenomx.Endpoint intracellular RNA of differentiated macrophages (each group; n=3) wereextracted from 6 well plates using Qiagen RNeasy MiniKit and quantified usingAgilent 8x60K array. Pathway maps were generated using the metaviz algorithm.Colours indicate mean log2 fold-change of stimulated M-CSF+LPS macrophageintracellular metabolites relative to unstimulated M-CSF macrophages. LPSstimulation of M-CSF differentiated macrophages produced strong up-regulation ofmetabolites and transcription of glycolysis. Metabolites of the TCA cycle were alsolargely up-regulated, however genes associated with both the TCA cycle and
pyruvate dehydrogenase genes were down-regulated. Intracellular lactate wasincreased, while pyruvate was reduced.
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Figure 6.23. Central metabolism in M-CSF+LPS+IFNγ vs. M-CSF. Peripheralblood monocytes (1x107 per flask; 6x106 per plate) were concurrentlydifferentiated for 6 days in T75 flasks and 6-well plates with 12ml and 2mlstandard culture media (RPMI+GPS+10% FCS) containing M-CSF (10 ng/nl) for 6days. On day 6 a subset of the differentiated macrophage cultures were stimulatedwith LPS+IFNγ and incubated overnight to give cultures of unstimulated M-CSF(n=9) and stimulated M-CSF+LPS+IFNγ (n=8) macrophages. Endpoint intracellularmetabolites were collected by standard methanol extraction and analysed by 1D H1NMR. Metabolites were identified and quantified from raw spectra with Chenomx.Endpoint intracellular RNA of differentiated macrophages (each group; n=3) wereextracted from 6 well plates using Qiagen RNeasy MiniKit and quantified usingAgilent 8x60K array. Pathway maps were generated using the metaviz algorithm.Colours indicate mean log2 fold-change of stimulated M-CSF+LPS+IFNγmacrophage intracellular metabolites relative to unstimulatedM-CSFmacrophages.LPS+IFNγ stimulation of M-CSF differentiated macrophages produced strong up-regulation of metabolites of both glycolysis and the TCA cycle. Early steps of theTCA cycle were down-regulated at the transcriptional level. While the final step ofglycolysis was down-regulated, earlier genes were up-regulated. Intracellularlactate was increased, as was pyruvate.
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Figure 6.24. Central metabolism in M-CSF+IL-4 vs. M-CSF. Peripheral bloodmonocytes (1x107 per flask; 6x106 per plate) were concurrently differentiated for 6days in T75 flasks and 6-well plates with 12ml and 2ml standard culture media(RPMI+GPS+10%FCS) containingM-CSF (10 ng/nl) for 6 days. On day 6 a subset ofthe differentiated macrophage cultures were stimulated with IL-4 and incubatedovernight to give cultures of unstimulated M-CSF (n=9) and stimulated M-CSF+IL-4(n=8) macrophages. Endpoint intracellular metabolites were collected by standardmethanol extraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Endpoint intracellular RNA ofdifferentiated macrophages (each group; n=3) were extracted from 6 well platesusing Qiagen RNeasy MiniKit and quantified using Agilent 8x60K array. Pathwaymaps were generated using themetaviz algorithm. Colours indicate mean log2 fold-change of stimulated M-CSF+IL-4 macrophage intracellular metabolites relative tounstimulated M-CSF macrophages. Endpoint intracellular metabolites werecollected by standardmethanol extraction and analysed by 1DH1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. IL-4 stimulation ofM-CSF differentiated macrophages produced up-regulation of metabolites ofglycolysis and the early steps of TCA cycle. Transcription of TCA-cycle associatedgenes was also up-regulated, as were pyruvate dehydrogenase complex genesinvolved in themetabolism of pyruvate to acetyl-coA.
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Figure 6.25. Creatine biosynthesis. Peripheral blood monocytes (1x107 per flask;6x106 per plate) were concurrently differentiated for 6 days in T75 flasks and 6-well plates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6 a subset ofthe differentiated macrophage cultures were stimulated with cytokines andincubated overnight to give cultures of unstimulated M-CSF (n=9) GM-CSF (n=8)and stimulated M-CSF+IL-4 (n=7) M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) andGM-CSF+LPS (n=8) macrophages. Endpoint intracellular metabolites werecollected by standardmethanol extraction and analysed by 1DH1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. Endpointintracellular RNA of differentiated macrophages (each group; n=3) were extractedfrom 6well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60Karray. Pathway maps were generated using themetaviz algorithm. Colours indicatemean log2 fold-change of stimulated macrophage intracellular metabolites relativeto matched unstimulated macrophages following activation of differentiatedmacrophages with (opposite) GM-CSF+LPS, (opposite) M-CSF+LPS, (over) M-CSF+LPS+IFNγ or (over) M-CSF+IL-4. Activation of GM-CSF differentiatedmacrophages resulted in reduced creatine and creatine phosphate, andupregulation of creatine synthesis at the transcriptional level. Activation of all M-CSF differentiated macrophages resulted in increased creatine and creatinephosphate and downregulation of creatine synthesis at the gene level.
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Figure 6.26. The carnitine shuttle. Peripheral blood monocytes (1x107 per flask;6x106 per plate) were concurrently differentiated for 6 days in T75 flasks and 6-well plates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6 a subset ofthe differentiated macrophage cultures were stimulated with cytokines andincubated overnight to give cultures of unstimulated M-CSF (n=9) GM-CSF (n=8)and stimulated M-CSF+IL-4 (n=7) M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) andGM-CSF+LPS (n=8) macrophages. Endpoint intracellular metabolites werecollected by standardmethanol extraction and analysed by 1DH1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. Endpointintracellular RNA of differentiated macrophages (each group; n=3) were extractedfrom 6well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60Karray. Pathway maps were generated using themetaviz algorithm. Colours indicatemean log2 fold-change of stimulated macrophage intracellular metabolites relativeto matched unstimulated macrophages following activation of differentiatedmacrophages with (opposite) GM-CSF+LPS, (opposite) M-CSF+LPS, (over) M-CSF+LPS+IFNγ or (over)M-CSF+IL-4. Activation of GM-CSF macrophages with LPSproduced no change in the concentration of carnitine. Biosynthesis wasdownregulated at the gene level, yet the enzymes of the shuttle remainupregulated. Activation of all M-CSF derived subsets resulted in increasedintracellular carnitine, and up-regulation of carnitine biosynthesis. However, therewere transcriptional differences at the level of the carnitine shuttle.
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Figure 6.27. Fatty acid acid β-oxidation. Peripheral blood monocytes (1x107 perflask; 6x106 per plate) were concurrently differentiated for 6 days in T75 flasks and6-well plates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6 a subset ofthe differentiated macrophage cultures were stimulated with cytokines andincubated overnight to give cultures of unstimulated M-CSF (n=9) GM-CSF (n=8)and stimulated M-CSF+IL-4 (n=7) M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) andGM-CSF+LPS (n=8) macrophages. Endpoint intracellular metabolites werecollected by standardmethanol extraction and analysed by 1DH1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. Endpointintracellular RNA of differentiated macrophages (each group; n=3) were extractedfrom 6well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60Karray. Pathway maps were generated using themetaviz algorithm. Colours indicatemean log2 fold-change of stimulated macrophage intracellular metabolites relativeto matched unstimulated macrophages following activation of differentiatedmacrophages with (opposite) GM-CSF+LPS, (opposite) M-CSF+LPS, (over) M-CSF+LPS+IFNγ or (over) M-CSF+IL-4. LPS and LPS+IFNγ stimulation of M-CSFmacrophages produced near identical results with down-regulation of the enzymesfor metabolism of saturated fatty acids. The unsaturated fatty acid route was up-regulated however. LPS stimulation of GM-CSF macrophages showed a similarprofile, yet with up-regulation of the acetyl-coA dehydrogenase shunt. IL-4activated macrophages showed up-regulation of all steps of the cycle and of uptakefor both saturated and unsaturated fatty acids.
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Figure 6.28. Glutamate biosynthesis and degradation, asparagine
biosynthesis and degradation. Peripheral blood monocytes (1x107 per flask;6x106 per plate) were concurrently differentiated for 6 days in T75 flasks and 6-well plates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6 a subset ofthe differentiated macrophage cultures were stimulated with cytokines andincubated overnight to give cultures of unstimulated M-CSF (n=9) GM-CSF (n=8)and stimulated M-CSF+IL-4 (n=7) M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) andGM-CSF+LPS (n=8) macrophages. Endpoint intracellular metabolites werecollected by standardmethanol extraction and analysed by 1DH1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. Endpointintracellular RNA of differentiated macrophages (each group; n=3) were extractedfrom 6well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60Karray. Pathway maps were generated using themetaviz algorithm. Colours indicatemean log2 fold-change of stimulated macrophage intracellular metabolites relativeto matched unstimulated macrophages following activation of differentiatedmacrophages with (opposite) GM-CSF+LPS, (over) M-CSF+LPS, (iii) M-CSF+LPS+IFNγ or (iv) M-CSF+IL-4. All subsets of activated macrophages showbroadly similar profiles, with the only notable differences being between levels of2-oxoglutarate, glutamate, asparagine and aspartate.
asparagine	biosynthesis	
and	degradation
glutamate	biosynthesis	
and	degradation	
GM-CSF+LPS
log2(fc) 1.0-1.0
asparagine	biosynthesis	
and	degradation
glutamate	biosynthesis	
and	degradation	
M-CSF+LPS
log2(fc) 1.0-1.0
asparagine	biosynthesis	
and	degradation
glutamate	biosynthesis	
and	degradation	
M-CSF+LPS+IFNγ
log2(fc) 1.0-1.0
asparagine	biosynthesis	
and	degradation
glutamate	biosynthesis	
and	degradation	
M-CSF+IL-4
log2(fc) 1.0-1.0

Figure 6.29. Protein citrullination. Peripheral blood monocytes (1x107 per flask;6x106 per plate) were concurrently differentiated for 6 days in T75 flasks and 6-well plates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6 a subset ofthe differentiated macrophage cultures were stimulated with cytokines andincubated overnight to give cultures of unstimulated M-CSF (n=9) GM-CSF (n=8)and stimulated M-CSF+IL-4 (n=7) M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) andGM-CSF+LPS (n=8) macrophages. Endpoint intracellular metabolites werecollected by standardmethanol extraction and analysed by 1DH1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. Endpointintracellular RNA of differentiated macrophages (each group; n=3) were extractedfrom 6well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60Karray. Pathway maps were generated using themetaviz algorithm. Colours indicatemean log2 fold-change of stimulated macrophage intracellular metabolites relativeto matched unstimulated macrophages following activation of differentiatedmacrophages with GM-CSF+LPS, M-CSF+LPS, M-CSF+LPS+IFNγ or M-CSF+IL-4.Transcriptional data shows increase in PAD enzyme transcription is highestfollowing LPS and IL-4 activation of both GM-CSF and M-CSF differentiatedmacrophages. Notably macrophages activated with both LPS+IFNγ show apparentdown-regulation of most PAD genes.
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Figure 6.30. myo-Inositol metabolism. Peripheral blood monocytes (1x107 perflask; 6x106 per plate) were concurrently differentiated for 6 days in T75 flasks and6-well plates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6 a subset ofthe differentiated macrophage cultures were stimulated with cytokines andincubated overnight to give cultures of unstimulated M-CSF (n=9) GM-CSF (n=8)and stimulated M-CSF+IL-4 (n=7) M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) andGM-CSF+LPS (n=8) macrophages. Endpoint intracellular metabolites werecollected by standardmethanol extraction and analysed by 1DH1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. Endpointintracellular RNA of differentiated macrophages (each group; n=3) were extractedfrom 6well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60Karray. Pathway maps were generated using themetaviz algorithm. Colours indicatemean log2 fold-change of stimulated macrophage intracellular metabolites relativeto matched unstimulated macrophages following activation of differentiatedmacrophages with (opposite) GM-CSF+LPS, (over) M-CSF+LPS, (iii) M-CSF+LPS+IFNγ or (iv) M-CSF+IL-4. Myo-inositol is reduced following LPSactivation of GM-CSF macrophages, but raised in all M-CSF differentiated subsets.LPS and LPS+IFNγ stimulation of M-CSF macrophage, and LPS stimulation of GM-CSF macrophages produces a very similar profile at the transcriptional level. IL-4activated M-CSF differentiated macrophages show unique up-regulation of IP3synthesis step at the transcriptional level.
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Figure 6.31. Prostanoid biosynthesis. Peripheral blood monocytes (1x107 perflask; 6x106 per plate) were concurrently differentiated for 6 days in T75 flasks and6-well plates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6 a subset ofthe differentiated macrophage cultures were stimulated with cytokines andincubated overnight to give cultures of unstimulated M-CSF (n=9) GM-CSF (n=8)and stimulated M-CSF+IL-4 (n=7) M-CSF+LPS (n=8) M-CSF+LPS+IFNγ (n=6) andGM-CSF+LPS (n=8) macrophages. Endpoint intracellular metabolites werecollected by standardmethanol extraction and analysed by 1DH1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. Endpointintracellular RNA of differentiated macrophages (each group; n=3) were extractedfrom 6well plates using Qiagen RNeasyMiniKit and quantified using Agilent 8x60Karray. Pathway maps were generated using themetaviz algorithm. Colours indicatemean log2 fold-change of stimulated macrophage intracellular metabolites relativeto matched unstimulated macrophages following activation of differentiatedmacrophages with (opposite) GM-CSF+LPS, (opposite) M-CSF+LPS, (over) M-CSF+LPS+IFNγ or (over) M-CSF+IL-4. LPS activation of GM-CSF macrophagesshowed a bias towards prostaglandin D2, E2 and thromboxane A2, and away fromprostaglandin I2. LPS activation of M-CSF macrophages up-regulated prostaglandinI2 and D2 only, with an isotype-switch on E2. Further addition of IFNγ resulted inI2 alone being up-regulated. IL-4 activation in contrast resulted in up-regulation ofall pathways including prostaglandin D2, E2 and I1 and thromboxane A2.
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Figure 6.32. Central metabolism in GM-CSF+LPS vs. M-CSF+LPS macrophages.Peripheral blood monocytes (1x107 per flask; 6x106 per plate) were concurrentlydifferentiated for 6 days in T75 flasks and 6-well plates with 12ml and 2mlstandard culture media (RPMI+GPS+10%FCS) containingM-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6 differentiated macrophage cultures werestimulated with LPS and incubated overnight to give cultures of stimulated M-CSF+LPS (n=8) and GM-CSF+LPS (n=8) macrophages. Endpoint intracellularmetabolites were collected by standard methanol extraction and analysed by 1D H1NMR. Metabolites were identified and quantified from raw spectra with Chenomx.Endpoint intracellular RNA of differentiated macrophages (each group; n=3) wereextracted from 6 well plates using Qiagen RNeasy MiniKit and quantified usingAgilent 8x60K array. Pathway maps were generated using the metaviz algorithm.Colours indicate mean log2 fold-change of the two stimulated macrophage subsetsintracellular metabolites relative to one another. Metabolites of glycolysis werereduced in GM-CSF+LPS vs. M-CSF+LPS macrophages, as was intracellular lactate.Metabolites of the TCA cycle were reduced, while genes encoding enzymes in thisarea were upregulated. Transcription of genes in glycolysis were also increased onbalance, aas themetabolism of pyruvate to acetyl-coA.
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Figure 6.33. Creatine biosynthesis in GM-CSF+LPS vs. M-CSF+LPS
macrophages. Peripheral bloodmonocytes (1x107 per flask; 6x106 per plate) wereconcurrently differentiated for 6 days in T75 flasks and 6-well plates with 12ml and2ml standard culture media (RPMI+GPS+10%FCS) containing M-CSF (10 ng/nl) orGM-CSF (10 ng/nl) for 6 days. On day 6 differentiated macrophage cultures werestimulated with LPS and incubated overnight to give cultures of stimulated M-CSF+LPS (n=8) and GM-CSF+LPS (n=8) macrophages. Endpoint intracellularmetabolites were collected by standard methanol extraction and analysed by 1D H1NMR. Metabolites were identified and quantified from raw spectra with Chenomx.Endpoint intracellular RNA of differentiated macrophages (each group; n=3) wereextracted from 6 well plates using Qiagen RNeasy MiniKit and quantified usingAgilent 8x60K array. Pathway maps were generated using the metaviz algorithm.Colours indicate mean log2 fold-change of the two stimulated macrophage subsetsintracellular metabolites relative to one another. Biosynthesis of creatine was up-regulated in GM-CSF+LPS macrophages at the transcriptional level, whileintracellular concentrations of creatine and creatine phosphate were bothdepleted.
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Figure 6.34. Glutamate biosynthesis and degradation, asparagine
biosynthesis and degradation. Peripheral blood monocytes (1x107 per flask;6x106 per plate) were concurrently differentiated for 6 days in T75 flasks and 6-well plates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6differentiated macrophage cultures were stimulated with LPS and incubatedovernight to give cultures of stimulated M-CSF+LPS (n=8) and GM-CSF+LPS (n=8)macrophages. Endpoint intracellular metabolites were collected by standardmethanol extraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Endpoint intracellular RNA ofdifferentiated macrophages (each group; n=3) were extracted from 6 well platesusing Qiagen RNeasy MiniKit and quantified using Agilent 8x60K array. Pathwaymaps were generated using themetaviz algorithm. Colours indicate mean log2 fold-change of the two stimulatedmacrophage subsets intracellular metabolites relativeto one another. Intracellular glutamine, asparagine and aspartate was raised in GM-CSF+LPS macrophages relative to M-CSF+LPS macrophages, while glutamate wasreduced.
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Figure 6.35. Fatty acid oxidation and carnitine biosynthesis in GM-CSF+LPS
vs. M-CSF+LPSmacrophages. Peripheral blood monocytes (1x107 per flask; 6x106per plate) were concurrently differentiated for 6 days in T75 flasks and 6-wellplates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6differentiated macrophage cultures were stimulated with LPS and incubatedovernight to give cultures of stimulated M-CSF+LPS (n=8) and GM-CSF+LPS (n=8)macrophages. Endpoint intracellular metabolites were collected by standardmethanol extraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Endpoint intracellular RNA ofdifferentiated macrophages (each group; n=3) were extracted from 6 well platesusing Qiagen RNeasy MiniKit and quantified using Agilent 8x60K array. Pathwaymaps were generated using themetaviz algorithm. Colours indicate mean log2 fold-change of the two stimulatedmacrophage subsets intracellular metabolites relativeto one another. Fatty acid oxidation was increased at the transcriptional level inGM-CSF+LPS relative to M-CSF+LPS, with up-regulation of the saturated fatty acidmetabolism route, yet down-regulation of unsaturated fatty acid metabolism. Incontrast carnitine was depleted, as was precursor 2-oxoglutarate, and stronglydown-regulated at the transcriptional level, including enzymes of the carnitineshuttle.
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Figure 6.36. Protein citrullination and prostaglandin biosynthesis in GM-
CSF+LPS vs. M-CSF+LPS macrophages Peripheral blood monocytes (1x107 perflask; 6x106 per plate) were concurrently differentiated for 6 days in T75 flasks and6-well plates with 12ml and 2ml standard culture media (RPMI+GPS+10% FCS)containing M-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6differentiated macrophage cultures were stimulated with LPS and incubatedovernight to give cultures of stimulated M-CSF+LPS (n=8) and GM-CSF+LPS (n=8)macrophages. Endpoint intracellular metabolites were collected by standardmethanol extraction and analysed by 1D H1 NMR. Metabolites were identified andquantified from raw spectra with Chenomx. Endpoint intracellular RNA ofdifferentiated macrophages (each group; n=3) were extracted from 6 well platesusing Qiagen RNeasy MiniKit and quantified using Agilent 8x60K array. Pathwaymaps were generated using themetaviz algorithm. Colours indicate mean log2 fold-change of the two stimulatedmacrophage subsets intracellular metabolites relativeto one another. GM-CSF+LPS activation was generally associated with down-regulation of PAD enzymes involved in protein citrullination. Prostanoidbiosynthesis was biased towards prostaglandin E2 and thromboxane A2, and awayfromprostaglandins D2 and I2, relative toM-CSF+LPS activatedmacrophages.
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Figure 6.37. Metabolic profile of macrophage activation correlated by
PLS-R against IL6 production by LPS activated macrophages.Peripheral blood monocytes (6x106 per plate) were differentiated in 6-wellplates with 2ml standard culture media (RPMI+GPS+10% FCS) containingM-CSF (10 ng/nl) or GM-CSF (10 ng/nl) for 6 days. On day 6 a subset of thedifferentiated macrophage cultures were stimulated with LPS andincubated overnight to give cultures of unstimulated M-CSF (n=9) GM-CSF(n=8) and stimulated M-CSF+LPS (n=8) and GM-CSF+LPS (n=8)macrophages. Endpoint intracellular metabolites were collected bystandard methanol extraction and analysed by 1D H1 NMR. Metaboliteswere identified and quantified from raw spectra with Chenomx. Quantifiedmetabolites were used to build a partial least squares regression (PLS-R)model against IL-6 concentration. The resulting model was able to predictIL-6 output frommetabolic profile with moderate accuracy (R2=0.66). PLS-R weights (metabolite importance estimations) were used to mineregulated pathways using pathminer algorithm and the weights plottedusingmetaviz. The resulting plots showmetabolic changes associated withproduction of cytokines, namely increased TCA cycle and urea cycleactivity. The former is associatedwith increased energy demands, the latterwith protein breakdown and nitrogen recycling, perhaps indicative ofprotein recycling via autophagy.
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	328	
6.2.8 Regulated	genes	associated	with	cellular	metabolism	
Metabolic genes were defined as those transcribing proteins involved in metabolic 
reactions or in uptake or excretion of metabolic products (Table 18—Table 21). Again, 
as the function of genes specific to metabolic pathways has been covered in the previous 
section, these are excluded here. 
 
Following activation with LPS (Table 19) there was a wide alteration in metabolic gene 
expression compared to non-activated differentiated M-CSF macrophages. The 
previously strongly upregulated selenoprotein 1 (SEPP1) insulin-like growth factor 1 
(IGF1), malic enzymes (ME1, ME3) and fatty acid binding proteins 4 & 5 (FABP4, 
FABP5) were no longer upregulated. There was however an increase in the free fatty 
acid receptor 2 & 3 (FFAR2, FFAR3). The expression of a number of solute carriers 
was altered following LPS activation. Solute carriers previously upregulated and now 
downregulated included folate (SLC46A1), glucose (SLC45A3), zinc (SLC39A10) and 
an amino-acid proton antiporter (SLC38A6). Solute carriers previously downregulated 
and now upregulated included copper (SLC1A2), mitochondrial iron (SLC25A37), 
neutral amino acid-proton antiporter (SLC38A5) and zinc uptake and storage 
(SLC39A8). Metal uptake was also upregulated with genes encoding metallothioneins 
(MT1DP, MT2A, MT1L, MT1M, MT1X, MT1H, MT1E, MT1F, MT1G, MT1A, 
MT1B) and ferritin (FTH1) both increased. There were no strongly downregulated 
metabolic genes in the selected set. 
 
Activation of M-CSF macrophages with the combination of LPS+IFNγ (Table 20) 
again produced a broadly similar profile to M-CSF+LPS, but with a few notable 
exceptions. For example carbonic anhydrase (CA12) previously strongly upregulated 
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was no longer among the top genes. Indoleamine 2,3-dioxygenases were not previously 
seen but were now strongly upregulated (IDO1, IDO2). Similarly arginine 
decarboxylase (ADC) was also upregulated. 2'-5'-oligoadenylate synthetase 2 & 3 
(OAS2, OAS3) which were downregulated in M-CSF+LPS alone activation were now 
upregulated. 
 
Activation of GM-CSF differentiated macrophages with LPS (Table 21) resulted 
predominantly in metabolic gene downregulation, particularly of solute carriers. Of the 
genes strongly upregulated under GM-CSF differentiation only selenoprotein P 
(SEPP1) remained upregulated after LPS. There was switching of cytochrome P450 
enzymes with upregulation (CYP3A7, CYP7B1) and downregulation (CYP4F22, 
CYP19A1) of different family members. Downregulated genes included 
phosphoglucomutase 5 (PGM5), glucose-fructose oxidoreductase domain containing 1 
(GFOD1), glycerol-3-phosphate acyltransferase 2 (GPAT2), inositol-
tetrakisphosphate 1-kinase (ITPK1) and aldehyde dehydrogenases (ALDH5A1, 
ALDH1A2). Only a small number of solute transporters including those for neutral 
amino acids (SCL38A5), Na+/Mg2+ (SL41A1), glycine (SLC6A9) and organic cations 
(SLC22A14) were upregulated. Only a single Na+/Ca2+ antiporter (SLC8A3) 
upregulated under GM-CSF remained upregulated after activation.  
 
Activation of M-CSF macrophages with IL-4 (Table 18) again produced a notably 
distinct gene profile. Interestingly however, among the downregulated genes there was 
strong agreement with those seen under M-CSF differentiation without activation. The 
few notable exceptions were the absence of downregulation of glycerol kinase (GK, 
GK3P), carboxylesterase 1 (CES1), cytochrome P450s (CYP3A7, CYP27B1) and GTP 
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cyclohydrolase 1 (GCH1). However, there were a number of uniquely up-regulated 
genes, including ST6-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 
(ST6GALNAC3), sarcosine dehydrogenase (SARDH), leukotriene A4 hydrolase 
(LTA4H), ATPases (ATP8B3, ATP8B1, ATP9A) and aldehyde dehydrogenases 
(ALDH5A1, ALDH7A1, ALDH1A2, ALDH1L2). Cytochrome P450 family members 
(CYP4F22, CYP3A5, CYP4F35P, CYP19A1) were also upregulated — the reverse of 
what was seen with M-CSF alone, yet affecting a distinct set of genes. As before, many 
solute carriers were altered by activation. However, the majority of regulated genes 
were not seen under M-CSF alone. Those that were upregulated in common were zinc 
(SLC39A10), glucose (SLC45A3), lactate, pyruvate, branch-chain oxo-acids (derived 
from leucine, valine and isoleucine) uptake (SLC16A8), iron-export (SLC40A1). 
Novel upregulated solute carriers under IL-4 activation included an iron and manganese 
transporter (SLC11A1), cation and chloride cotransporter (SLC12A8), choline 
transporter (SLC44A2), Ca2+ & K+:Na+antiporter Na+ (SLC24A3), and oligopeptide 
uptake transporter (SLC15A1). Also upregulated were organic anion transporters 
SLCO4C1, SLCO2B1.  
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6.3 Discussion	
Having successfully demonstrated that differentiation with M-CSF and GM-CSF 
produce macrophages with distinct metabolic profiles, we next investigated the 
metabolic effects of the activation with LPS, LPS+IFNγ or IL-4. The activation with 
these cytokines reflects M1 (LPS or LPS+IFNγ) and M2a (IL-4) respectively. 
Comparisons were made relative to the macrophage subsets’ differentiation 
background (e.g. M-CSF+LPS vs. M-CSF) and between M-CSF and GM-CSF 
differentiated LPS stimulated macrophages to compare the lasting effects of 
differentiation on activated macrophages. Further comparisons were made between M-
CSF macrophages activated with LPS and with LPS+IFNγ to determine whether this 
drove noticeable changes in the response. Macrophages were activated following 6 days 
of differentiation with M-CSF or GM-CSF and cultured overnight alongside control 
unstimulated macrophages on both differentiation backgrounds. Resulting culture 
media, cell extracts and transcriptional profiles were determined as before. 
 
Results demonstrated that it was possible to distinguish activated macrophage subsets 
by metabolic profiles alone. However, while there are were significant differences 
between subsets in intracellular metabolites of the central metabolic pathways 
(pyruvate, glucose, lactate, 2-oxoglutarate) these differences were generally not seen 
elsewhere. Notable exceptions to this were acetate (upregulated) alanine (upregulated) 
threonine (upregulated), tyrosine (downregulated) and glutamine (downregulated) that 
were strongly and independently altered in the IL-4 subset alone. There was yet more 
agreement between the M-CSF subsets at the culture media level, with only pyruvate 
— significantly down in M-CSF+LPS — differing significantly. Activation of all M-
CSF macrophage subsets was associated with increased glutamate consumption from 
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the media. LPS or LPS+IFNγ stimulation also drove further consumption of glucose, 
methylguanidine and methionine. In contrast LPS activation of GM-CSF macrophages 
was associated with increased excretion of myo-inositol, arginine and asparagine. 
 
Transcriptional results showed a lack of commonality between differentiation and 
activation. Many genes that were upregulated under differentiation were downregulated 
following activation and vice versa. These changes are summarised in Table 8. The 
distinctiveness of activated macrophage subsets was underlined by the fact that there 
was no overlap in up- or down- regulated metabolic, or differentiation-associated, genes 
across all macrophage activation/polarisation treatments. The M-CSF+IL-4 subset was 
the most unique of all treatments, with no overlap in up- or down- regulation of genes 
with any other M-CSF subset. These findings reinforce the observation of Murray et al. 
that the Verreck/Mantovani M2 models are not comparable [178]. Surprisingly, M-
CSF+IL-4 macrophages did share common downregulation of MMP1, IL-8 and IL-
2RA with GM-CSF+LPS macrophages. However, as previously noted downregulation 
of genes is difficult to interpret due to the baseline used for this analysis.  
 
Macrophages activated with LPS (M-CSF+LPS, M-CSF+LPS+IFNγ, GM-CSF+LPS) 
all showed a common pro-inflammatory profile, with upregulation of IL-6 and T cell 
costimulatory receptor CD80 as previously reported [155]. In those LPS-treated 
macrophages not treated with additional IFNγ there was strong upregulation of IFNγ 
(IFNG) expression providing a mechanism for paracrine/autocrine priming in the 
absence of exogenous IFNγ. Responsiveness to this was demonstrated by the presence 
of interferon-responsive cytokine expression (CXCL9/MIG, CXCL10/IP10, 
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CXCL11/I-TAC/IP9) in all subsets. LPS-responsive macrophage inflammatory protein 
3 (CCL20/MIP-3A) was also upregulated [380].  
 
LPS activation of M-CSF macrophages uniquely saw upregulation of members of the 
IL-1 cytokine family (IL1A, IL1B) commonly seen in macrophage responses to LPS 
stimulation [381]. A number of other pro-inflammatory cytokines including IL-8, IL-
12, IL-15 and IL-23 were also upregulated, collectively promoting Th1 polarisation and 
T/NK cell proliferation and activation. Transcriptional changes in response to LPS 
stimulation were therefore biased towards proinflammatory Th1 responses — the 
expected M1 polarisation response to bacterial LPS [155]. Interestingly, LPS activation 
of M-CSF also drove expression of GM-CSF (CSF2). GM-CSF can drive 
differentiation of both macrophage-like and dendritic-like cells in vitro, therefore the 
expression of GM-CSF following LPS activation of M-CSF macrophages may 
therefore reflect promotion of GM-CSF macrophages as better able to respond to 
LPS/bacterial pathogens, or promotion of dendritic cell differentiation to support 
antigen-presentation and initiation of the adaptive response.  
 
LPS activation of GM-CSF differentiated macrophages in contrast was notable for the 
unique upregulation of a number of HLA class molecules including Major 
Histocompatibility Complex, Class II, DR Beta 6 (HLA-DRB6) and HLA class I, L 
(HLA-L) indicating an increased capacity for antigen presentation. Upregulation of 
HLA-DR is a feature of synovial macrophages in RA [250]. Monocyte activating 
CCL14 was also upregulated uniquely here, which promotes activation of monocytes 
but not chemotaxis. The upregulation of IL-12 reported by Vereck et al. as a feature of 
this GM-CSF M1 model was also seen here although we also detected upregulation 
	334	
prior to LPS stimulation [176]. Interestingly there appeared to be indications of self-
regulation, with downregulation of a MAPK signalling pathway member (MAP2K6) 
essential for STAT4 activation and responses to IL-12, as were receptors for IL-1 and 
IL-2 [387]. The transcription of M-CSF (CSF1) was also downregulated following LPS 
activation of GM-CSF macrophages, again suggesting that LPS activation biases 
towards further differentiation of GM-CSF macrophages or dendritic cells. At the 
metabolic level we discovered that LPS activation of GM-CSF macrophages resulted 
predominantly in transcriptional downregulation, which matches with observations at 
the metabolite level. Only selenoprotein P (SEPP1) remained upregulated after LPS, 
and there was upregulation of solute transporters for neutral amino acids (SCL38A5), 
Na+/Mg2+ (SL41A1), glycine (SLC6A9) and organic cations (SLC22A14). Only a 
single solute carrier — a Na+/Ca2+ antiporter (SLC8A3) — remained upregulated from 
GM-CSF differentiation.  
 
M-CSF differentiated macrophages stimulated with LPS+IFNγ shared the majority of 
regulated genes with those stimulated with LPS alone (26 up- and 7 down-regulated 
genes). However, there remained a number of uniquely regulated genes unique to this 
subset. For example, receptors for cytokines IL-7, Th2-associated IL-13 and pro-
inflammatory IL-17 were all upregulated. Also upregulated was an interleukin 1 
receptor kinase (IRAK2) which is involved in IL-1 signal transduction, and commonly 
expressed on macrophages [384]. Metabolically there was strong upregulation of 
indoleamine 2,3-dioxygenases (IDO1, IDO2), arginine decarboxylase (ADC) and 2'-
5'-oligoadenylate synthetase 2 & 3 (OAS2, OAS3) which were downregulated in M-
CSF+LPS. 
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Activation with IL-4 produced the most distinctive transcriptional profile, sharing no 
genes in common with LPS activated M-CSF macrophages. Further, there were 
relatively few up- or down- regulated genes novel to IL-4 activation that were not 
expressed during differentiation with M-CSF. The similarity may indicate the parallels 
in the literature between the M2a phenotype and Verreck’s unstimulated M2 [176]. 
Notably however IL-4 activated subset did upregulate marker of cellular proliferation 
Ki67 (MKI67) and never expressed in mitosis kinase 1 (NEK1) — upregulated during 
differentiation — was now absent. IL-4 has been previously reported to induce 
macrophage proliferation in tissues— although it reportedly causes G1/S arrest in mice 
bone marrow derived macrophages [224,225,388]. IL-4 activation did not induce 
production of IFNγ and response markers including monokine induced by gamma 
interferon (CXCL9/MIG) were downregulated here. Anti-inflammatory cytokines IL-
10 — associated with the regulatory macrophage (M2c) phenotype rather than the 
model used here (M2a) — was also downregulated, confirming that the phenotype of 
IL-4 macrophages was not directly anti-inflammatory. 
 
Activation of M-CSF macrophages with IL-4 also resulted in downregulation of HIF-
1α, the key regulator of cellular responses to hypoxia. Stabilisation of HIF in low 
oxygen results in the induction of transcription of a number of genes including a number 
of glycolytic enzymes. As previously described, HIF-1α also has a role in pro-
inflammatory signalling, including for example driving IL-1β [193]. HIF-1α deficient 
macrophages are impaired in M1 activation, including glycolysis and glucose uptake 
[113]. Downregulation following (M2a polarising) IL-4 stimulation is therefore logical. 
However reduced HIF-1α may also indicate a reduced ability of these macrophages to 
respond to low oxygen conditions and have implications for tissue repair in the 
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rheumatoid synovium. Peroxisome proliferator-activated receptor gamma (PPAR-
γ/PPARG) which regulates fatty acid storage and glucose metabolism — and 
previously shown to be induced in IL-4 macrophages — was upregulated here 
[232,233]. Downregulated genes interestingly showed strong agreement with those 
seen under M-CSF differentiation without activation, suggesting that IL-4 macrophages 
share a similarly inactive phenotype. There were however a number of uniquely up- 
and down- regulated metabolic genes, and unique regulation particularly in metabolic 
pathways (see later). Upregulation was also present in transporters for zinc 
(SLC39A10), glucose (SLC45A3), lactate, pyruvate, branch-chain oxo-acids (derived 
from leucine, valine and isoleucine) uptake (SLC16A8), iron-export (SLC40A1).  
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 GM-CSF +LPS M-CSF +LPS 
M-CSF 
+IFNγ 
M-CSF 
+IL-4 
Inflammatory Pro Pro Pro Non 
Replication Inhibited Inhibited Inhibited Active 
Recruitment 
B cells 
Dendritic 
cells 
T cells 
Monocytes 
NK cells 
 
B cells 
Dendritic cells 
Monocytes 
NK cells 
Neutrophils 
T cells 
Monocytes 
NK cells 
Neutrophils 
B cells 
Dendritic cells 
Lymphocytes 
N/A 
Adhesion Cell-cell interactions 
Cell-cell 
interactions 
Cell-cell 
interactions 
Matrix-cell 
interactions 
Signalling  GPCR JAK/STAT GPCR 
JAK/STAT 
GPCR 
(-) JAK/STAT 
 
Table	8.	Functional	outcomes	of	gene	transcription	changes	in	activation.	Functional	implications	of	transcriptional	changes	resulting	from	differentiation	and	activation	under	various	polarising	conditions.	
 
 
Metabolic pathway analysis showed agreement between all subsets of M-CSF 
macrophages, with the exception of the central metabolic pathways. The activation of 
GM-CSF macrophages with LPS led to reductions in glycolytic and TCA cycle 
metabolites, while activation of M-CSF macrophages with IL-4 led to increases in the 
TCA cycle. The increase of glycolytic metabolites was broadly mimicked in other M-
CSF macrophage subsets, with only LPS showing reduced pyruvate. In the central 
pathways M-CSF+LPS and M-CSF+LPS+IFNγ were most in agreement at the 
metabolic and transcriptional level. These results demonstrate however that the 
majority of macrophage metabolic differences are in place at the end of differentiation, 
and while activation of macrophages elicited metabolic change, this was largely 
dependent on differentiation background and not activation itself.  
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Prostanoid biosynthesis was particularly notable for the degree of transcriptional 
regulation across subsets. IL-4 activation saw upregulation of prostaglandin D2, E2 and 
I2 and thromboxane A2 synthesis while GM-CSF differentiated LPS activated 
macrophages transcriptionally supported all except I2. M-CSF differentiated LPS 
activated macrophages gene expression supported D2, I2 and reduced E2 synthesis 
while addition of IFNγ reduced this to I2, with lower E2. The similarity between GM-
CSF+LPS and M-CSF+IL4 macrophages at this level was interesting. 
 
A cross-comparison of GM-CSF+LPS vs. M-CSF+LPS allowed us to isolate the effect 
of the differentiation background in the resulting metabolic profiles. Results showed 
again that LPS activation of GM-CSF macrophages resulted in a reduction in glycolytic 
and TCA cycle metabolites, and a reduction in creatine and creatine phosphate. 
Metabolites of the urea cycle were increased, as was glycolysis, the TCA cycle and 
fatty acid β-oxidation at a transcriptional level, with a bias towards saturated fatty acids. 
However, carnitine, genes encoding carnitine synthesis enzymes and the carnitine 
shuttle were all lower suggesting that long-chain fatty acids are not the main source of 
energy for GM-CSF+LPS macrophages. Extra- and intra-cellular glucose was reduced 
following LPS activation of GM-CSF macrophages, while extra-cellular lactate was 
unchanged. Taken together, the evidence suggests that LPS activation of GM-CSF 
macrophages may drive a metabolic depletion of intracellular metabolites — including 
for example creatine/creatine phosphate sequestered during differentiation.  
 
In summary, in this chapter we determined that — 
• Activated	M-CSF	differentiated	macrophages	were	largely	indistinguishable	at	the	metabolic	level,	with	the	exception	of	central	metabolic	pathways	
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• LPS	 and	 LPS+IFNγ	 activation	 of	 M-CSF	 macrophages	 were	 almost	indistinguishable	at	both	the	metabolic	and	transcriptional	level.		
• IL-4	 activated	 M-CSF	 macrophages	 had	 a	 number	 of	 unique	 metabolic	 and	transcriptional	features,	notably	including	evidence	of	ongoing	replication	
• LPS	activation	of	GM-CSF	macrophages	drove	a	strong	depletion	of	intracellular	metabolites,	in	contrast	LPS	activation	of	M-CSF	macrophages
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7 MACROPHAGE	RESPONSES	TO	THE	METABOLIC	
ENVIRONMENT	
7.1 Introduction	
Tissue macrophages are associated with distinct niches within the body related to their 
function. However, in the rheumatoid synovium both tissue macrophages and 
infiltrating inflammatory macrophages are exposed to uniquely aggressive metabolic 
environment [48,55,81,297]. Having successfully established that macrophage 
differentiation is associated with subset specific metabolic profiles and behaviour, we 
next considered how the processes of differentiation and activation would be affected 
by an altered metabolic environment.   
 
In particular we were interested to discovered whether differentiated macrophages 
would be able to adapt to hypoxic conditions, or whether this environment would 
promote or impair normal functions. For example, activation of GM-CSF macrophages 
was associated with increased oxygen-dependent TCA cycle activity — does this 
impact activation under hypoxia? Cells do not exist in isolation from their environment. 
The metabolism of macrophages within the inflammatory site contributes to the 
metabolic profile of the site in which they reside, which in turn may affect other cells, 
and vice versa. This is particularly the case when the environment is relatively closed 
or poorly perfused — such as with the rheumatoid synovium. Therefore we further 
explored what effect changing the balance of metabolites in the culture environment 
would have on differentiation and activation. For example, synovial fibroblasts produce 
high levels of lactate [48,55]. What effect would this production of lactate have on other 
cells, including macrophages, and their activation/differentiation?  
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7.2 Results	
For these experiments only M-CSF and GM-CSF macrophages with LPS activation 
were considered due to the similarities between all M-CSF activated subsets observed 
in the previous chapter. GM-CSF differentiated monocytes stimulated with IL-4 — an 
in vitro model of dendritic cells [389] — was also included to provide a non-
inflammatory subset for comparison with the activated macrophage populations. This 
work was carried out prior to the expanded use of the Mantovani model M1/M2a 
macrophages. While a GM-CSF based model of IL-4 activation is likely relevant to the 
synovium, given the high concentrations of synovial GM-CSF, inclusion of M-
CSF+IL-4 macrophages would have been beneficial [390].  
 
The experiment was performed using multiple donors. Isolated peripheral blood 
monocytes were differentiated in 6 well plates at a density of 6.25x104 cells/cm2 in 
standard culture media (RPMI+GPS+10% FCS) containing 10 ng/ml M-CSF, 10 ng/ml 
GM-CSF or 10 ng/ml GM-CSF+20 ng/ml IL-4 for 6 days. On day 6 differentiated 
macrophage cultures were activated with 100 ng/ml LPS and incubated for 18 h. 
Culture media was replaced on day 3 and 5.  
7.2.1 Macrophage	 subsets	 remain	 distinguishable	 under	 hypoxia,	
normoxia,	reperfusion	conditions	
We first tested broadly whether the effects of differentiation and activation under 
normoxia, hypoxia or reperfusion conditions were sufficiently disruptive as to render 
the different macrophage and dendritic cells indistinguishable. To determine these 
effects, we performed macrophage differentiation experiments in biological triplicate 
(n=3) under normoxic (20% O2), hypoxic (1% O2) and reperfusion (1% O2 with 
intermittent 20% O2) conditions. The selected values for hypoxic (1% O2) are at the 
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lower end of measured oxygen perfusion in chronically inflamed tissues such as the 
rheumatoid synovium [102–104]. Normoxic values (20% O2) are above most 
physiological levels, aside from arterial blood, yet were selected due to technical 
limitations. Reperfusion conditions were designed to model reported reperfusion injury 
in the synovium as vessels in the inflamed synovium are intermittently occluded [391]. 
Hypoxic cells were fed on day 3 and 5 with media maintained at 1% O2, while 
reperfusion was modelled by feeding hypoxic cells with media conditioned at 20% O2. 
Normoxia cells received normal oxygenated media. Endpoint intracellular metabolites 
were extracted as per the established protocol previously described. 
 
Quantified 2D JRES FIMA metabolites were used to construct multiple PLS-DA 
models between each group. The calculated coefficient of correlation (r2) was then used 
to construct a multi-way PLS-DA map as previously described. In these maps the 
distance between experimental groups reflects the similarity (near) or dissimilarity (far) 
between them. 
 
Following the mapping it was discovered that the grouping clustered together in two 
distinct ways. Firstly, the different subsets — GM-CSF and M-CSF macrophages; and 
GM-CSF+IL-4 dendritic cells — clustered into their respective populations irrespective 
of subsequent treatment with LPS or culture under different perfusion conditions 
(Figure 7.1). Secondly, for the macrophage populations there was clustering between 
LPS stimulated and unstimulated subsets (Figure 7.2). In contrast GM-CSF+IL-4 
dendritic cells were unaffected by LPS activation, with all groups being almost entirely 
metabolically inactive. Interestingly, it was also apparent that LPS stimulated 
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macrophages and macrophages cultured under reperfusion conditions clustered on the 
basis of their metabolic profiles. 
  

Figure 7.1. PLS-DA space mapping for experiment with GM-CSF, M-CSF, GM-
CSF+IL-4 differentiated macrophages ± LPS stimulation. Peripheral bloodmonocytes (6x106 per plate) were differentiated in 6-well plates with 2ml standardculture media (RPMI+GPS+10% FCS) containing M-CSF (10ng/nl) or GM-CSF(10ng/nl) for 6 days. Media was replaced on day 3, and day 6. Cultures wereincubated under normoxia (20% O2), hypoxia (1% O2) and reperfusion (1% O2,with 20% O2 conditioned media feed). On day 6 a subset of the differentiatedmacrophage cultures were stimulated with LPS or IL-4 and incubated overnight togive cultures of unstimulated M-CSF (n=3) or GM-CSF (n=3) and stimulated M-CSF+LPS (n=3), GM-CSF+LPS (n=3) and GM-CSF+IL-4 (n=3) macrophages.Endpoint intracellular metabolites were collected by standard methanol extractionand analysed by 2D H1 JRES NMR. Metabolites were identified and quantified fromraw spectra with the BML-NMR service. Samples are labelled as follows: M1=GM-CSF, M2=M-CSF; N=normoxia, H=hypoxia, R=reperfusion; O=unstimulated, L=LPSstimulated. Mapping was performed using PLS-DA r2 between compared groups,with each line representing a comparison. Longer lines indicate larger differenceswith a force-directed algorithm used to find the optimum distance for mappedobjects. Each subtype of cell segregated within the plot with GMCSF+IL-4 (DCs)top-right, M-CSF (M2) central, GM-CSF (M1) bottom left. This suggested that testedsubsets were sufficiently metabolically distinct that they remained similar evenfollowing activation (LPS) or culture under reperfusion or hypoxia.
KEY
M1=GM-CSF N=Normoxia O=Unstimulated	(control)
M2=M-CSF H=Hypoxia L=LPS	stimulated
R=Reperfusion
Figure 7.2. PLS-DA space mapping showing the segregation between un-
stimulated and LPS stimulated M-CSF and GM-CSF macrophages. Peripheralblood monocytes (6x106 per plate) were differentiated in 6-well plates with 2mlstandard culture media (RPMI+GPS+10% FCS) containing M-CSF (10ng/nl) or GM-CSF (10ng/nl) for 6 days. Media was replaced on day 3, and day 6. Cultures wereincubated under normoxia (20% O2), hypoxia (1% O2) and reperfusion (1% O2,with 20% O2 conditioned media feed). On day 6 a subset of the differentiatedmacrophage cultures were stimulated with LPS or IL-4 and incubated overnight togive cultures of unstimulated M-CSF (n=3) or GM-CSF (n=3) and stimulated M-CSF+LPS (n=3), GM-CSF+LPS (n=3) and GM-CSF+IL-4 (n=3) macrophages.Endpoint intracellular metabolites were collected by standard methanol extractionand analysed by 2D H1 JRES NMR. Metabolites were identified and quantified fromraw spectra with the BML-NMR service. Samples are labelled as follows: M1=GM-CSF, M2=M-CSF; N=normoxia, H=hypoxia, R=reperfusion; O=unstimulated, L=LPSstimulated. Mapping was performed using PLS-DA r2 between compared groups,with each line representing a comparison. Longer lines indicate larger differenceswith a force-directed algorithm used to find the optimum distance for mappedobjects. Each culture condition segregated with reperfusion treatments clusteringon the left, interestingly together with those treated with LPS. This suggested thatLPS activation produced similar metabolic profiles to culture under reperfusion.Unstimulated normoxia and hypoxia samples clustered together on the right, whileGM-CSF+IL-4 DCs clustered independently, irrespective of culture treatments.
KEY
M1=GM-CSF N=Normoxia O=Unstimulated	(control)
M2=M-CSF H=Hypoxia L=LPS	stimulated
R=Reperfusion
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7.2.2 Central	metabolism	of	GM-CSF	macrophages	under	hypoxia	
GM-CSF macrophages were differentiated and LPS activated under hypoxia (1% O2) 
conditions and intracellular metabolites extracted using established methods. GM-CSF 
macrophages cultured under hypoxia had an expected reduction in metabolites of the 
TCA cycle (Figure 7.3) with lowered 2-oxoglutarate, oxaloacetate and cis-aconitate. In 
contrast succinate and pyruvate are increased. Also upregulated under hypoxia was 
creatine phosphate — a store of high-energy phosphate for quick release. 
7.2.3 Central	metabolism	of	M-CSF	macrophages	under	hypoxia	
M-CSF macrophages were differentiated and LPS activated under hypoxia (1% O2) 
conditions and intracellular metabolites extracted using established methods. M-CSF 
macrophages cultured under hypoxia saw a modest reduction in TCA cycle metabolites, 
but also of lactate and pyruvate (Figure 7.4). Of the detected and quantified metabolites 
under hypoxia, all were downregulated, suggesting a general downregulation of 
metabolism for M-CSF macrophages under these conditions.  
 
In M-CSF macrophages there was also a reduction in cis-aconitate, 
phosphoenolpyruvate and 3-phospho-D-glycerate. Essential amino acids (not plotted) 
including ketogenic leucine, were reduced under hypoxia, while carnitine, required for 
transport of fatty acids into the mitochondria for oxidation, was raised. 
  

Figure 7.3. GM-CSF+LPS macrophages under normoxia and 1% oxygenPeripheral blood monocytes (6x106 per plate) were differentiated in 6-well plateswith 2ml standard culture media (RPMI+GPS+10% FCS) containing GM-CSF(10ng/nl) for 6 days. Media was replaced on day 3, and day 6. Cultures wereincubated under normoxia (20% O2), hypoxia (1% O2). On day 6 a subset of thedifferentiated macrophage cultures were stimulated with LPS and incubatedovernight to give cultures of unstimulated GM-CSF (n=3) and stimulated GM-CSF+LPS (n=3) macrophages under normoxia and hypoxia. Endpoint intracellularmetabolites were collected by standard methanol extraction and analysed by 2D H1JRES NMR. Metabolites were identified and quantified from raw spectra with theBML-NMR service. (A; opposite) Intracellular metabolism of GM-CSF+LPSmacrophages under normoxia showing increases in TCA cycle metabolites. Coloursindicate log2 fold-change of stimulated GM-CSF+LPS macrophage intracellularmetabolites relative to matched unstimulated GM-CSF macrophages undernormoxia. (B; over) Intracellular metabolism of GM-CSF+LPS macrophages under1% oxygen. Colours indicate log2 fold-change of stimulated GM-CSF+LPSmacrophage intracellular metabolites relative to matched unstimulated GM-CSFmacrophages under hypoxia. Low oxygen was associated with the expectedreduction in metabolites of the oxygen-dependent TCA cycle. Creatine-phosphatewas increased, reflecting either an inability to activate under hypoxia, or storage ofenergy for future function.
A
log2(fc) 1.0-1.0
log2(fc) 1.0-1.0
B
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Figure 7.4. M-CSF+LPS macrophages under normoxia and 1% oxygenPeripheral blood monocytes (6x106 per plate) were differentiated in 6-well plateswith 2ml standard culture media (RPMI+GPS+10% FCS) containing M-CSF(10ng/nl) for 6 days. Media was replaced on day 3, and day 6. Cultures wereincubated under normoxia (20%O2) and hypoxia (1%O2). On day 6 a subset of thedifferentiated macrophage cultures were stimulated with LPS and incubatedovernight to give cultures of unstimulated M-CSF (n=3) and stimulated M-CSF+LPS(n=3) macrophages under normoxia and 1% oxygen. Endpoint intracellularmetabolites were collected by standard methanol extraction and analysed by 2D H1JRES NMR. Metabolites were identified and quantified from raw spectra with theBML-NMR service. (A; opposite) Intracellular metabolism of M-CSF+LPSmacrophage under normal oxygen conditions. Colours indicate log2 fold-change ofstimulated M-CSF+LPS macrophage intracellular metabolites relative to matchedunstimulated M-CSF macrophages, under normoxia. (B; over) Intracellularmetabolism of M-CSF+LPS macrophages under under 1% oxygen. Colours indicatelog2 fold-change of stimulated M-CSF+LPS macrophage intracellular metabolitesrelative to matched unstimulated M-CSF macrophages, under hypoxia. Low oxygenwas associated with reduction in TCA cycle metabolites but also lactate andpyruvate. The overall picture was of a reduction in metabolic function andthroughput.
A
log2(fc) 1.0-1.0
B
log2(fc) 1.0-1.0
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7.2.4 GM-CSF	macrophage	culture	under	reperfusion	conditions	results	in	
an	LPS	activated-like	metabolic	profile	
The similarity between GM-CSF differentiated, LPS activated macrophages noted in 
the PLS-DA space map was recapitulated at the pathway level, particularly in the 
central metabolic pathways (Figure 7.5). Here both LPS activation and culture under 
reperfusion conditions was associated with increases in metabolites of the TCA cycle, 
including succinate, fumarate, cis-aconitate and oxaloacetate, and of lactate and 
glucose-6-phosphate. Reduced under both conditions was 2-oxoglutarate. The 
similarity between the two conditions suggested that both LPS activation and 
reperfusion were metabolically activating in similar ways, perhaps reflecting a general 
macrophage activation response to environmental shock.  
 
 
 
  
Figure 7.5. GM-CSF+LPS macrophages compared to GM-CSF macrophages
under reperfusion conditions. Peripheral blood monocytes (6x106 per plate)were differentiated in 6-well plates with 2ml standard culture media(RPMI+GPS+10% FCS) containing GM-CSF (10ng/nl) for 6 days. Media wasreplaced on day 3, and day 6. Cultures were incubated under normoxia (20% O2)and reperfusion (1% O2, with 20% O2 conditioned media feed). On day 6 a subsetof the differentiated macrophage cultures were stimulated with LPS and incubatedovernight to give cultures of unstimulated GM-CSF (n=3) and stimulated GM-CSF+LPS (n=3) macrophages cultured under normoxia and reperfusion conditions.Endpoint intracellular metabolites were collected by standard methanol extractionand analysed by 2D H1 JRES NMR. Metabolites were identified and quantified fromraw spectra with the BML-NMR service. (A; opposite) Colours indicate log2 fold-change of stimulated GM-CSF+LPS macrophage intracellular metabolites relative tomatched unstimulated GM-CSF macrophages. (B; over) Colours indicate log2 fold-change of unstimulated GM-CSF macrophage intracellular metabolites underreperfusion relative to matched unstimulated GM-CSF macrophages undernormoxia. At the central metabolism level both processes are similar, with up-regulation of TCA cycle metabolites, reduction in 2-oxoglutarate and increasedoutput of lactate. Reperfusion allows macrophages cultured under hypoxia toutilise stored—oxygen dependent—energy sources such as fatty acids.
A
log2(fc) 1.0-1.0
B
log2(fc) 1.0-1.0
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7.2.5 Conditioned	 fibroblast	 media	 from	 RA	 patients	 increased	 IL-6	
output	
Having established an effect on macrophage metabolism from culture under hypoxia 
and reperfusion conditions, we next sought to determine whether the metabolic 
environment, that is the content and concentration of metabolites in the differentiation 
media, can alter macrophage differentiation and activation behaviours. As we were 
trying to identify possible metabolic influences in the rheumatoid environment, we used 
conditioned media from cultured human synovial fibroblasts to provide this complex 
metabolite mixture. Fibroblast cultures were used specifically due to the important role 
of fibroblasts in RA and the abundance of fibroblasts in the rheumatoid synovium [6].  
 
The specific fibroblast cultures used to generate this media were derived from synovial 
tissue biopsies from healthy and rheumatoid patients cultured within our group. Isolated 
fibroblasts were seeded at 5x105 cells per T175 flask and cultured in RPMI 1640 with 
10% FCS (non-heat inactivated), 1% MEM non-essential amino acids (Sigma M 7145) 
and  1% sodium orthopyruvate (Sigma S 8636). Media was collected as a waste product 
during splitting of confluent cells. Samples were collected blinded.  
 
Media was analysed by NMR as previously described to quantify the constituent 
metabolites. Media for culture was filtered to remove protein content and exclude the 
influence of cytokines or other signalling molecules. The resulting culture media was 
spiked at increasing concentrations into standard differentiation media. M-CSF and 
GM-CSF macrophages were differentiated as per the standard protocol and stimulated 
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with LPS on day 6. The response to LPS activation was quantified by IL-6 ELISA. IL-
6 was chosen for the readout (in place of TNFα) due to it giving a strong consistent 
signal for both GM-CSF and M-CSF macrophages and having high expression in active 
RA [284]. Conditioned media derived from two rheumatoid fibroblast cell lines and 
one healthy control were used for the analysis (Figure 7.6). 
 
The effect, if any, was slight with a small increase in detected IL-6 for GM-CSF 
macrophages at higher concentrations of RA fibroblast conditioned media.  We decided 
to follow this up, selecting specific metabolites from the conditioned media to 
determine if we could multiply any effect at higher concentrations. 
  

Figure 7.6. GM-CSF and M-CSF macrophages with conditioned fibroblast
culture media. Peripheral blood monocytes (6x106 per plate) were differentiatedin 6-well plates with 1ml standard culture media (RPMI+GPS+10% FCS) and 1mlfiltered conditioned fibroblast media, serially diluted in RPMI. Cells were culturedtogether with M-CSF (10ng/nl) or GM-CSF (10ng/nl) for 6 days. On day 6 a subsetof the differentiated macrophage cultures were stimulated with LPS and incubatedovernight to give cultures of unstimulated M-CSF (n=3) or GM-CSF (n=3) andstimulated M-CSF+LPS (n=3), GM-CSF+LPS (n=3) macrophages for each of the 3media mixtures, at 4 dilutions. Endpoint media was collected and IL-6concentration assayed by ELISA. Unstimulated controls (M-CSF or GM-CSF) areshown as horizontal lines with shading indicating 2sd. GM-CSF (M1) and M-CSF(M2) macrophages were differentiated in filtered conditioned waste media fromcultured fibroblasts. Media were serially diluted with standard RPMI culture mediaand IL-6 responses to LPS stimulation following differentiation plotted. Culturewith RA patient-derived fibroblasts (A) and (B) resulted in increased IL-6 output athighest concentrations.
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C
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7.2.6 Metabolite	content	of	fibroblast	conditioned	media	
To identify the potential metabolite content of the conditioned media that was having 
the stimulating effect on macrophage activation, the conditioned media samples (n=11) 
were analysed by NMR. Processed spectra were analysed by principal component 
analysis, showing separation between the rheumatoid and healthy groups (Figure 7.7). 
The key differentiating metabolites were lactate, alanine and 2-hydroxyisobutyrate, 
which were raised in rheumatoid condition media and glucose and myo-inositol, which 
were reduced relative to healthy control media. Selections of these metabolites were 
taken forward for subsequent direct testing by assay in media culture. 
 
  

Figure 7.7. Principal component analysis of conditioned fibroblast media.Conditioned media from RA (★) and non-RA (l) fibroblast cultures (n=11) wasanalysed by 1D H1 NMR to determine the potential metabolic content that may beexerting effects on macrophage behaviour. Spectra were processed using astandard NMRLab workflow. Principal component analysis (PCA) was performedon processed binned data. High-weighted bins responsible for separation betweenexperimental groups were mapped to spectral peaks and identified by reference tothe Chenomx library. A) RA and non-RA fibroblast media separated along principalcomponent 1. B)Most increased metabolites in the RA group were lactate, alanine,2-hydroxyisobutyrate. Sarcosine and glucose were reduced. On the basis of all up-regulated metabolites detected by PCA a panel of metabolites including lactate,glucose and a complete set of amino acids were selected for direct testing.
AB
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7.2.7 IL-6	 production	 in	 response	 to	 stimulation	 following	 metabolite	
spiking	
 
Metabolites identified from the spectra of conditioned media were tested directly by 
spiking into culture media. Spiked metabolites were selected based on importance in 
earlier experiments. Top concentrations of spiked metabolites were x10 concentrations 
in standard culture media or quantified from previous NMR, and serially diluted (½) 
thereafter. Top concentrations used for each were 20 gL-1 glucose, 3 gL-1 glutamine, 
133 µM lactate, BCAA (containing 0.5 gL-1 leucine, gL-1 valine, and 0.5 gL-1 
isoleucine) and 0.2 gL-1 arginine. As with the previous experiment, following 
differentiation of M-CSF and GM-CSF macrophages in the spiked media they were 
activated with LPS. Relative IL-6 production by the macrophage subsets and different 
concentrations of spiked metabolite were quantified by IL-6 ELISA and plotted (Figure 
7.8). As previously described, IL-6 was chosen for the readout for consistency in 
outputs for both macrophage subsets. 
 
Spiking of the culture media with glutamine showed a reduction in IL-6 production, 
however as concentrations increased it was toxic to the culture. Mixed branch chain 
amino acids, arginine and glucose had negligible effects on IL-6 production. Notably 
while high concentrations of lactate were toxic to the culture, at the lowest 
concentration there was a large increase in IL-6 production, even for unstimulated 
macrophages. IL-6 production following lactate spiking is shown individually in Figure 
7.9.  

Figure 7.8. IL-6 production in response to stimulation following metabolite
spiking. Peripheral blood monocytes (6x106 per plate) were differentiated in 6-well plates with 2ml standard culture media (RPMI+GPS+10% FCS) spiked withserial dilutions of arginine, glucose, glutamine, lactate, branched chain amino acids(BCAA). Cells were cultured together with M-CSF (10ng/nl) or GM-CSF (10ng/nl)for 6 days. On day 6 a subset of the differentiated macrophage cultures werestimulated with LPS and incubated overnight to give cultures of unstimulated M-CSF (n=3) or GM-CSF (n=3) and stimulated M-CSF+LPS (n=3), GM-CSF+LPS (n=3)macrophages for each of the 5 spiked media mixtures, at 4 dilutions. Endpointmedia was collected and IL-6 concentration assayed by ELISA. GM-CSF (n) M-CSF(n) macrophages are shown as solid lines, with LPS stimulated cultures indicatedwith dashed lines. Controls cultured in unspiked media are shown in backgroundas horizontal lines with shading indicating 2sd. Each point on the x-axis indicates a½ serial dilution, in standard media. Increases in glutamine and lactate showed areduction in IL-6 production, however at upper concentrations both were toxic tothe culture. Mixed branch chain amino acids, arginine and glucose had negligibleeffects. Interestingly, at the bottom concentrations lactate appeared to promote IL-6 production in both stimulated and unstimulatedmacrophages.
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Figure 7.9. IL-6 production in response to stimulation following lactate
spiking. Peripheral blood monocytes (6x106 per plate) were differentiated in 6-well plates with 2ml standard culture media (RPMI+GPS+10% FCS) spiked with10μM lactate. Cells were cultured together with M-CSF (10ng/nl) or GM-CSF(10ng/nl) for 6 days. On day 6 a subset of the differentiated macrophage cultureswere stimulated with LPS and incubated overnight to give cultures of unstimulatedM-CSF (n=3) or GM-CSF (n=3) and stimulated M-CSF+LPS (n=3), GM-CSF+LPS(n=3) macrophages, both spiked and unspiked with lactate. Endpoint media wascollected and IL-6 concentration assayed by ELISA. Resulting IL-6 production isshown following the addition the addition of lactate (⧄) to both GM-CSF (n) andM-CSF (n)media had a non-significant effect on IL-6. Error bars shown 2SD frommean.
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7.2.8 Metabolic	effects	of	macrophage	culture	in	lactate	spiked	media	
Having explored the effects of lactate on macrophage activation via cytokine 
production, we next explored whether increased culture lactate induced any changes in 
metabolism. Serial concentrations of lactate were spiked into standard culture media 
and macrophages differentiated as normal. Endpoint differentiation culture media (n=3) 
were collected for both GM-CSF macrophages and GM-CSF differentiated with 
subsequent LPS activation (Figure 7.10—Figure 7.12). 
 
Results showed that as concentration of lactate increased, media 2-hydroxyisovalerate 
and alanine were increasingly depleted while 3-hydroxyisovalerate was increased. 
Endpoint media creatine was also reduced, while media glucose increased. 
Interestingly, the depletion of glucose associated with LPS activation was resilient to 
increasing lactate, perhaps suggesting that activated macrophages are less impacted by 
the conditions. Other metabolites, including asparagine and glutamine were broadly 
unchanged. Media isoleucine, leucine and valine were notably reduced at lower 
concentrations of lactate, but later increased. Ornithine and pyruvate show the reverse 
trend moving upwards as lactate concentrations increase, but falling again at the highest 
concentrations. Both of these results suggest that toxicity of lactate at higher levels is 
killing macrophages and/or preventing metabolism. Of all measured intracellular 
metabolites only taurine showed a consistent increase in line with lactate.  
  

Figure 7.10. Endpoint culture media metabolite concentrations under
increasing lactate. Peripheral blood monocytes (1x107) were cultured in T75flasks with 12ml standard culture media (RPMI+GPS+10% FCS) spiked with serialdilutions of lactate. Cells were differentiated with GM-CSF (10ng/ml) for 6 days. Onday 6 a subset of differentiated macrophage cultures were stimulated with LPS andincubated overnight to give cultures of inactivated GM-CSF (n; n=3) and GM-CSF+LPS (n; n=3) macrophages. Endpoint culture media was collected andanalysed by 1D H1 NMR. Metabolites were identified and quantified from rawspectra with Chenomx. At higher concentrations of lactate, 2-hydroxyisovalerateand alanine were all depleted, while 3-hydroxyisovalerate was increased in bothLPS stimulated and unstimulated macrophages. Asparagine was broadlyunchanged throughout.
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Figure 7.11. Endpoint culture media metabolite concentrations under
increasing lactate. Peripheral blood monocytes (1x107) were cultured in T75flasks with 12ml standard culture media (RPMI+GPS+10% FCS) spiked with serialdilutions of lactate. Cells were differentiated with GM-CSF (10ng/ml) for 6 days. Onday 6 a subset of differentiated macrophage cultures were stimulated with LPS andincubated overnight to give cultures of inactivated GM-CSF (n; n=3) and GM-CSF+LPS (n; n=3) macrophages. Endpoint culture media was collected andanalysed by 1D H1 NMR. Metabolites were identified and quantified from rawspectra with Chenomx. LPS stimulated macrophages saw lower media glucose andcreatine as normal. Creatine consumption increased under higher lactateconcentrations, while media glucose consumption by LPS stimulated macrophagesreduced. Glutamine was unchanged except at higher concentrations, with a spike inLPS stimulated macrophages. Isoleucine was reduced as the concentration oflactate increased, however at higher concentrations it rose again.
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Figure 7.12. Endpoint culture media metabolite concentrations under
increasing lactate Peripheral blood monocytes (1x107) were cultured in T75flasks with 12ml standard culture media (RPMI+GPS+10% FCS) spiked with serialdilutions of lactate. Cells were differentiated with GM-CSF (10ng/ml) for 6 days. Onday 6 a subset of differentiated macrophage cultures were stimulated with LPS andincubated overnight to give cultures of inactivated GM-CSF (n; n=3) and GM-CSF+LPS (n; n=3) macrophages. Endpoint culture media was collected andanalysed by 1D H1 NMR. Metabolites were identified and quantified from rawspectra with Chenomx. Leucine and valine were both reduced as the concentrationof lactate increased, however at higher concentrations both rose again. Ornithineand pyruvate show the reverse trend moving upwards as lactate concentrationsincrease, but falling again at the highest concentrations.
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7.2.9 Differentiation	timecourse	effects	of	lactate	spiked	media		
To explore the effect of lactate spiking during macrophage differentiation we cultured 
GM-CSF macrophages under a series of spiked media conditions (n=3; each group), 
sampling culture media on each day of differentiation. These samples were analysed by 
NMR to give a longitudinal indication of metabolite changes during differentiation for 
each concentration of lactate (Figure 7.13—Figure 7.15). 
 
The results showed that lactate in the culture media suppressed the late-differentiation 
production of 2-hydroxybutyrate by GM-CSF macrophages. Previous results showed 
that higher concentrations of lactate in the media reduced glucose consumption in 
endpoint media. However, the longitudinal results indicate that initially the reverse is 
true – more glucose is consumed early in the higher concentration lactate media. This 
may reflect early activation triggered by the lactate concentration. Notably, media 
glutamine followed a broadly similar profile, while glutamate did not. 
 
Media isoleucine and methylguanidine were both reduced in response to increasing 
lactate, while methionine was unaffected. Lactate concentrations continued to increase 
further beyond the spiked concentrations during differentiation. Lower concentrations 
increased faster, with the concentrations of all groups reaching the same level by day 
4. This confirms our earlier suggestion that macrophages would be able to regulate their 
metabolic environment and therefore affect subsequently differentiating cells. 
 
Levels of ornithine, pyruvate, succinate and formate were all reduced by the addition 
of lactate to the culture media.  
 

Figure 7.13. Longitudinal differentiation metabolite concentrations in lactate
spiked media. Peripheral blood monocytes (1x107) were cultured in T75 flaskswith 12ml standard culture media (RPMI+GPS+10% FCS) spiked with serialdilutions of lactate. Cells were differentiated with GM-CSF (10ng/ml) for 6 days.Longitudinal culture media (20µl) collected on each day were analysed by 1D H1NMR. No media was added during the differentiation process. Metabolites wereidentified and quantified from raw spectra with Chenomx. Significance at eachtimepoint is calculated by Student’s t-test between 10µM and control groups.Lactate in the culture media suppressed the late differentiation production of 2-hydroxybutyrate by GM-CSF macrophages. Media glutamine and glucose werereduced during differentiation in response to increasing lactate.
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Figure 7.14. Longitudinal differentiation metabolite concentrations in lactate
spiked media. Peripheral blood monocytes (1x107) were cultured in T75 flaskswith 12ml standard culture media (RPMI+GPS+10% FCS) spiked with serialdilutions of lactate. Cells were differentiated with GM-CSF (10ng/ml) for 6 days.Longitudinal culture media (20µl) collected on each day were analysed by 1D H1NMR. No media was added during the differentiation process. Metabolites wereidentified and quantified from raw spectra with Chenomx. Significance at eachtimepoint is calculated by Student’s t-test between 10µMand control groups. Mediaisoleucine and methylguanidine were both reduced in response to increasinglactate, while methionine was unaffected. Lactate concentrations continued toincrease further during differentiation, with lower concentrations increasing faster,reaching the same concentration in all groups by day 4.
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Figure 7.15. Longitudinal differentiationmetabolite concentrations in
lactate spiked media. Peripheral blood monocytes (1x107) were culturedin T75 flasks with 12ml standard culture media (RPMI+GPS+10% FCS)spiked with serial dilutions of lactate. Cells were differentiated with GM-CSF (10ng/ml) for 6 days. Longitudinal culture media (20µl) collected oneach day were analysed by 1D H1 NMR. No media was added during thedifferentiation process. Metabolites were identified and quantified fromraw spectra with Chenomx. Significance at each timepoint is calculated byStudent’s t-test between 10µM and control groups. Differentiation mediapyruvate, succinate and tyrosine were all reduced by the addition of lactateto the culturemedia.
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7.3 Discussion	
In the preceding chapters we have established that macrophage metabolism is affected 
by GM-CSF and M-CSF differentiation. We also demonstrated that macrophage 
activation was accompanied by metabolic changes, but these changes were relatively 
limited in comparison to differentiation. Given the varied metabolic niches in which 
macrophages differentiate we next sought to explore whether the metabolic 
environment itself would have measurable effects on macrophage differentiation. The 
effect of oxygen concentration was assessed through the differentiation of macrophages 
under a range of oxygen concentrations — including hypoxia (1% O2), reperfusion (1% 
O2 with 20% O2 feed) and 20% O2 constant. Further, the effect of local metabolite 
concentrations on macrophage behaviour was studied through culture with media 
spiked with a range of metabolites. Metabolites were selected based on metabolomic 
analysis of conditioned media from healthy and rheumatoid synovial fibroblasts. 
 
The combined effects of oxygen concentration and LPS activation of metabolism was 
first asses using a novel global PLS-DA mapping approach. Here we showed that 
despite activation macrophages differentiated under different conditions remained 
distinctive. Further, macrophages activated with LPS of both types clustered together. 
Interestingly, macrophages exposed to reperfusion conditions also clustered in this 
same group indicating that macrophage metabolic responses to LPS activation or 
reperfusion were similar. This relationship was also apparent at the pathway level, 
particularly in the pathways of central metabolism. The previously described 
relationship between HIF-1α and pro-inflammatory responses, together with HIF-1α 
responsiveness to lactate, may explain the basis for the observed behaviour. 
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GM-CSF macrophages differentiated and activated with LPS under hypoxia conditions 
showed the expected reduction in the oxygen dependent pathways of central 
metabolism. However, there was also upregulation of energy storage molecule creatine 
phosphate. This was interesting in light of the similar metabolic profiles observed under 
reperfusion conditions, suggesting that under hypoxia GM-CSF macrophages sequester 
energy allowing for rapid re-activation and function. In contrast, M-CSF+LPS 
macrophages under hypoxia showed almost complete downregulation of central 
metabolism. These findings may have interesting implications for the behaviour of 
these two macrophage subsets under hypoxic and reperfusion conditions in the 
rheumatoid synovium. 
 
The effect of local metabolite concentration of macrophage behaviours was studied by 
spiking standard culture media with conditioned media — derived from fibroblast 
cultures of healthy and rheumatoid patients — and specifically selected spiked 
metabolites. Initial spiking with fibroblast media showed that media conditioned with 
fibroblasts derived from patients with rheumatoid arthritis produced a non-significant 
increase in IL-6 production in activated M-CSF and GM-CSF macrophages. Hoping 
that higher concentrations may elicit a stronger response we identified a number of 
potential contributing metabolites for direct testing via spiking of culture media at serial 
dilutions. Of the tested metabolites only lactate had a notably strong stimulatory effect 
on IL-6 production and was selected for follow up. However, on repeat we found the 
effect to be non-significant. 
 
We next decided to explore the effects of increasing lactate concentrations on the 
metabolic behaviours of differentiating macrophages. Increasing concentrations of 
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lactate in differentiation media was shown to result in depletion of 2-
hydroxyisovalerate and alanine and increase in 3-hydroxyisovalerate. We observed 
reduced consumption of glucose as the concentration of lactate increased. In LPS 
activated macrophages consumption was higher at lower concentrations of lactate, as 
in un-spiked experiments, but fell as the concentration of lactate increased. Results for 
other metabolites, both consumed and excreted, suggested that observed changes at 
higher concentrations were likely due to cell death. 
 
These findings were recapitulated in longitudinal differentiation experiments, culturing 
GM-CSF macrophages under different concentrations of lactate. However, we also 
demonstrated that the suppressed glucose consumption in increasing lactate was only 
true towards the endpoint of differentiation, while at the beginning of differentiation 
glucose consumption is higher. Glutamine — another energy source — followed the 
same profile. This may be an indication of promoted differentiation/activation of 
macrophages via the previously described lactate-HIF-1α interaction [127,248]. 
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8 GENERAL	DISCUSSION	
Rheumatoid arthritis (RA) is a common chronic autoimmune disease, affecting up to 
1% of the population [392]. In this complex disease the normal processes of 
inflammation and resolution are dysregulated, leading to the establishment of a chronic 
inflammatory state. The characteristic swollen joints associated with the disease result 
from increased synovial fluid volume and thickening of the synovial membrane driven 
by both fibroblast proliferation and immune cell infiltration [6]. Both innate and 
adaptive immune processes are thought to be involved in the disease process, while a 
combination of multiple genetic polymorphisms, gender, age and environmental factors 
are implicated in incidence [1,6,19,32–34]. The multi-factorial nature of the disease has 
made it difficult to understand the disease process and there has been an increasing 
interest in using ‘omics’ methods — including metabolomics— to tackle this problem. 
We found RA particularly interesting from a metabolomic perspective for a number of 
reasons. Firstly, previous studies have successfully applied global metabolomic 
techniques to the study of the disease, showing clear differences in the metabolomic 
profile of patients [61]. Synovial fluid of RA patients contains increased asparagine, 
citrulline, glutamine, lactate, lysine and succinate, tryptophan and tyrosine and reduced 
glucose and fatty acid concentrations [48,55,82,393]. Secondly, the rheumatoid 
synovium has been shown to be a metabolically distinctive site, with low and 
intermittent perfusion driving both local hypoxia and generation of reactive oxygen 
species which may depolymerise hyaluronic acid causing cartilage destruction [69,79–
81,102]. Finally, it has been shown that in RA the metabolism of synovial fibroblasts 
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is permanently altered by disease providing a potential mechanism for disease 
persistence [394]. 
 
Models of RA pathogenesis implicate multiple cell types in disease pathogenesis, 
including T and B cells, macrophages, dendritic cells and osteoclasts. However, for this 
study we chose to focus on macrophages due to their potential for both pro-
inflammatory destructive tissue remodelling and resolution and repair, which make 
them strong candidates as promoters and mediators of chronic disease [128]. 
Macrophage infiltration in the synovium has been shown to correlate directly with RA 
severity and joint destruction [128,129]. Multiple susceptibility loci for RA are 
associated with monocyte/macrophage function or homeostasis [130–132]. There is 
also a direct association between clinical improvement and altered macrophage 
function and biological therapies which specifically targeting macrophage-associated 
cytokines (TNFα) have demonstrated remarkable efficacy [133–141].  
 
Macrophages are an incredibly diverse family of cells, inhabiting various niches around 
the body [145]. The origin of synovial macrophages remains an open question however 
there is evidence for blood monocyte recruitment during inflammation leading to 
persistent populations [148–151,160,161]. The established nomenclature of 
differentiated, activated macrophages describes a binary classification of ‘classical’ or 
‘alternative’ macrophages, later termed M1 or M2 respectively [164,168]. Classically 
activated (M1) macrophages are pro-inflammatory effector cells activated in response 
in IFNγ or LPS. Once activated they secrete pro-inflammatory cytokines including 
TNFα and IL-6 and upregulate phagocytosis and expression of HLA class II, TLRs and 
CD86 [155,180,184–186]. In contrast, alternatively activated (M2) macrophages are 
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derived in response to Th2 cytokines IL-4 and/or IL-13. Recently, the nomenclature for 
M2 macrophages has been expanded (M2a-c) to distinguish macrophages stimulated 
with IL-4/IL-13, immune complexes and IL-10 respectively [144,155,170]. In this 
system ‘alternative activation’ is defined as M2a. Confusingly a parallel nomenclature 
has also developed, describing M1/M2 classification on the basis of differentiation 
background with M-CSF or GM-CSF [175,176]. The relationship between these in 
vitro macrophage model subsets and macrophage behaviour in the tissues is not clear, 
not least since macrophages differentiating in tissues may be exposed to multiple 
polarising signals. To account for this potential variability it has been suggested that 
macrophage classifications should instead be considered as points on a spectrum of 
possibilities and that in vivo macrophages likely have mixed phenotypes [170]. For the 
purposes of this study we chose to differentiate macrophages using both systems, but 
use a naming convention that describes the entire treatment to avoid ambiguity. 
Therefore, in this work we have used models reflecting Mantovani’s M1 (M-CSF+LPS, 
M-CSF+LPS+IFNγ), Mantovani’s M2a (M-CSF+IL-4), Verreck’s M1 (GM-
CSF±LPS) and Verreck’s M2 (M-CSF±LPS) phenotypes.  
 
Macrophage differentiation has previously been shown to have metabolic features. 
Classical activation (M1) of macrophages is associated with increases in glycoltic 
metabolism mediated through PFKFB3 [84], Akt phosphorylation of hexokinase and 
upregulation of Glut1 glucose transport [187,188]. This bias towards glycolysis may 
provide M1 macrophages with an energetic advantage in hypoxic inflamed sites such 
as the rheumatoid synovium [190]. In contrast M2a alternative activation is associated 
with reduced glycolytic activity and instead oxidative metabolism of both glucose (via 
pyruvate) and fatty acids in the mitochondria [238,239]. M2a macrophages express no 
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PFKB3 instead upregulating weak glycolytic activator PFKB1 [84]. The relationship 
between M2a and fatty acid metabolism is further emphasised by the finding that 
inhibition of fatty acid β-oxidation directly attenuates the M2a programme [189]. An 
interesting observation for macrophages in the rheumatoid synovium is that hypoxia 
and lactic acid has previously been shown to polarise tumour macrophages towards 
M2a yet also promote M1-associated pro-inflammatory IL-1, IL-6, IFNγ and TNFα 
signalling [113,127,210–214,248]. 
 
In this study we looked to explore this relationship between macrophage differentiation, 
activation and metabolism, aiming to gain novel insights into potential mechanisms 
underlying chronic inflammatory conditions such as RA. 
8.1 Analysis	methods,	software	development	and	Pathomx	
The use of standardised sample handling, processing and data acquisition methods is 
essential for reproducibility, and has been successfully applied in many ‘—omics’ 
fields including metabolomics [332]. However, the methods for analysing and 
interpreting metabolomic data were less well developed at the outset of this project. 
Metabolomics as applied here is a hypothesis forming approach whereby analysis of 
untargeted experimental data is used collectively to construct models of cellular or 
systemic behaviour. Success in this approach is dependent on making correct biological 
inferences from the data, requiring reproducible outputs across multiple experiments 
and often for large sample numbers. 
 
To support this and streamline the analysis of data from our experiments, a standardised 
workflow was constructed using a combination of established and novel approaches. 
Central to this approach was the development of the Pathomx software a GUI-based 
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tool which supports iterative development of data analysis and visualisation workflows 
[395]. The completed analysis workflow included pre-processing with 
NMRLab/MetaboLab, and an optimised icoshift algorithm (MISA) for the alignment 
of processed spectra. Identification and quantification was also performed on raw 
spectra using the Chenomx software. The Chenomx library was also used for manual 
peak matching from binned spectra, while the FIMA platform was used for 
quantification from 2D JRES NMR. Analysis of quantified metabolites in the pathway 
context was performed using the novel pathminer and metaviz algorithms allowing for 
rapid identification and visualisation of the areas of most regulation. The workflow was 
subsequently extended to integrate transcriptomic data into the analysis.  
8.2 Metabolic	 and	 transcriptional	 phenotypes	 of	macrophage	
differentiation	
As previously described, the established nomenclature for macrophages describes M1 
and M2a-c phenotypes — most commonly differentiated on the background of M-CSF 
[164]. However, in the Verreck et al. macrophage system GM-CSF is used to 
differentiate M1 macrophages while all M-CSF differentiation is classified as M2 
[176]. Since high levels of GM-CSF have been reported in the RA synovium this 
distinction was particularly important to potential interpretation of our findings in vivo 
[179]. This was explored through the metabolomic and transcriptomic analysis of blood 
derived monocytes under GM-CSF and M-CSF differentiating conditions. 
 
Our transcriptional data confirmed existing published markers of macrophage 
differentiation under GM-CSF and M-CSF, but also displayed transcriptional features 
associated with both M1 and M2a subsets. There was also significant commonality 
between the two differentiation conditions, with both GM-CSF and M-CSF 
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macrophages upregulating a number of genes associated with alternative macrophage 
activation. The strongest upregulated gene in both subsets was coagulation factor XIII 
responsible for clot stabilisation and an established marker of alternative activation 
[167,366]. C-type lectin receptor DC-SIGN which binds to mannose PAMPS on 
viruses, bacteria and fungi, to facilitate phagocytosis and CD1 previously reported in 
response to GM-CSF and involved in the presentation of lipid and glycolipid antigens 
to T cells were also upregulated in both subsets [167,367]. Receptors for pro-
inflammatory IL-1 were upregulated too, suggesting that any M1/M2 polarization 
present at this stage may be reversible in response to an inflammatory signal. Both GM-
CSF and M-CSF differentiating macrophages showed inhibition of replication via 
upregulation of never in mitosis kinase 10 which mediates C2/M cell cycle arrest [396]. 
This inhibition remained in place for all subsets during subsequent activation, with the 
exception of IL-4 (M2a) macrophages. 
 
There were however differences between the two subsets of differentiated 
macrophages, as would be expected in light of the established literature. Due to the 
absence of a monocyte transcriptomic/metabolomic profile comparisons between our 
GM-CSF and M-CSF macrophages are made directly with their polarised opposites.  
 
GM-CSF macrophages uniquely upregulated IFNγ providing a mechanism for both 
paracrine and autocrine priming for responses to LPS (Figure 8.1). However, there was 
also indications of reduced activity in the downregulation of protein kinase C eta which 
transduces responses to LPS and aldehyde oxidase (AOX1) which synthesises reactive 
oxygen species [371,372]. Metabolically, GM-CSF macrophages were far more active, 
appearing to utilise multiple energy sources, including glucose, fatty acids and 
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glutamine. Glutaminolysis in particular was uniquely upregulated in GM-CSF 
macrophages, with a coordinated reduction in media glutamine and increases in media 
glutamate throughout differentiation. Further metabolism of the glutamate in a 
transamination reaction with pyruvate to produce alanine and 2-oxoglutarate was 
evidenced by the unique excretion of the former into the media. Interestingly however, 
despite the increased glucose uptake in GM-CSF macrophages, there was no strong 
upregulation in glucose transporters at the cell surface relative to M-CSF macrophages. 
 
Upregulation of fatty acid β-oxidation has been previously noted in macrophages and 
was suggested here in GM-CSF macrophages at the transcriptional level with 
upregulation of the mitochondrial carnitine shuttle [192]. Carnitine is essential and the 
limiting factor translocation of fatty acids across the mitochondrial membrane for 
metabolism [373]. Briefly, fatty acids bind co-enzyme A in the cytoplasm and are 
carried across the outer membrane. CoA is replaced with carnitine by the enzyme 
carnitine palmitoyltransferase I, and the fatty-acid-carnitine complex undergoes 
facilitated diffusion by carnitine-acylcarnitine translocase into the mitochondrial 
matrix. The complex is broken down by carnitine palmitoyltransferase II releasing the 
fatty acid and carnitine into the matrix. Carnitine diffuses back into the matrix, while 
the fatty acid re-binds matrix coA and is oxidised and metabolised. Synthesis of 
carnitine was also transcriptionally upregulated in our macrophages, however the 
quantified intracellular concentration was lower. We suspect that this is an artefact of 
the chloroform-methanol extraction method removing lipid-bound carnitine from the 
solution and quantification therefore reflects the free unbound form of L-carnitine. 
Mass spectrometry-based lipidomics of the polar cellular extract fraction could be used 
to quantify lipids directly and remove this ambiguity. There was also strong 
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upregulation of fatty acid binding proteins (FABP) involved in fatty acid uptake [377]. 
Macrophages have been shown to store fatty acids, as triacylglycerol, to provide a 
backup source of energy for oxidation regardless of the extracellular supply [192].  
 
GM-CSF macrophages were also notable for the significant depletion of citraconate, 
(2-methyl-maleate) and essential BCAAs isoleucine, leucine and valine during 
differentiation. Leucine and isoleucine are both ketogenic amino acids. Later stages of 
differentiation were also associated with increased production of both ornithine and 
pyroglutamate. Interestingly, decarboxylation of ornithine is the first rate-limiting step 
in polyamine synthesis. There was no evidence of upregulation of this process in any 
pre- or post- activation subset, however the release of ornithine into the synovial 
environment may have implications for other cells. For example, activity of ornithine 
decarboxylase has previously been linked to cell transformation and has been proposed 
as a drug target in RA [397,398]. The concentration of polyamines in synovial 
mononuclear cells of patients with RA is 2-20 fold higher than normal [399]. 
 
M-CSF differentiated macrophages in contrast uniquely upregulated bacterial flagellin-
binding toll-like receptor 5 — targeting motile bacteria and previously linked to M2 
polarisation (Figure 8.2) [369]. As in GM-CSF macrophages endocytosis and 
phagocytosis is promoted, albeit here via upregulation of C-type lectin domain family 
13 member A (CD302). The reported features of M2 macrophages that the Verreck M-
CSF-alone model has been reported to generate — including secretion of TGFβ, IL-10 
and PGE-2— were not observed here [176]. Metabolically there was upregulation of 
both fatty acid binding proteins and of malic enzyme which generates NADPH for fatty 
acid biosynthesis [377,378]. Saturated fatty acid oxidation was also upregulated in 
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these macrophages. M-CSF macrophages consumed less glucose and glutamine and 
excreted less alanine, pyruvate and lactate than their GM-CSF counterparts. 
 
The observed markers of activation and metabolism following GM-CSF and M-CSF 
macrophage differentiation are summarised in Figure 8.1 and Figure 8.2. 
 
Figure 8.1 The metabolic and transcriptional phenotype of GM-CSF
differentiated macrophages. GM-CSF differentiated macrophages arehighly metabolically active, utilising glucose, fatty acids and glutamine togenerate ATP, which is stored as creatine phosphate. Upregulation of fattyacid binding protein (FABP) supports metabolism or storage of fatty acidsby these macrophages. GM-CSF macrophages also saw significantly higherexcretion of lactate, glutamine consumption and evidence of glutaminolysisat the transcriptional level.
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Figure 8.2 The metabolic and transcriptional phenotype of M-CSF
differentiated macrophages. M-CSF differentiated macrophages showupregulation of responses against LPS coated bacteria, promoting phagocytosis andIL-1 responsiveness. Metabolically, M-CSF macrophages were relatively quiescentwith up-regulation of fatty acid metabolism, and upregulation of fatty acid bindingprotein (FABP) transcriptionally. M-CSF differentiated macrophages producedsignificantly lower levels of lactate than GM-CSFmacrophages.
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8.3 Metabolic	 and	 transcriptional	 phenotypes	 of	macrophage	
activation	
Having established that M-CSF and GM-CSF differentiation produces macrophages 
with distinctive metabolic phenotypes we next explored the changes that occur 
following activation. We tested a number of established macrophage activation 
methods, associated with M1 and M2a subsets as previously described by Verreck, 
Mantovani and others [176,178,328]. Classically activated M1 macrophages were 
derived by activation with LPS on a background of either GM-CSF or M-CSF; or by 
activation with LPS+ IFNγ on M-CSF. Alternatively activated M2a macrophages were 
derived by activation of M-CSF differentiated macrophages with IL-4. As before, 
following activation macrophage intracellular metabolites, RNA and extracellular 
(media) metabolites were assayed to build a complete picture of the metabolic 
phenotype of the resulting cells. 
 
We found that it was indeed possible to distinguish differently activated macrophages 
by their metabolic profiles alone. However while there was considerable heterogeneity 
at the transcriptional level the metabolomic data was relatively uniform — with the 
exception of central metabolic pathways and some minor differences in IL-4 
macrophages. Metabolic differences between macrophages differentiated under M-
CSF and GM-CSF remained post-activation however there was considerably less 
variation between any of the M-CSF differentiated subsets, regardless of activation 
method. The transcriptional results for our activated macrophages were much more 
distinctive with no common up- or down- regulation in our selected genes across all 
subsets. M-CSF+IL-4 macrophages in particular showed a unique phenotype, with no 
overlap in up- or down- regulated genes in common with any other M-CSF subset. The 
common and unique features of each subset are described in detail below. 
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Classically activated (M1) macrophages are pro-inflammatory effector cells, with 
bacteriocidal and tumoricidal functions that differentiate in response to IFNγ or 
bacterial PAMPs including LPS [155,180]. For our activation experiments we used 
three LPS-based models (M-CSF+LPS, M-CSF+LPS+IFNγ, GM-CSF+LPS) matching 
the two existing classical activation systems. We found considerable overlap in these 
subsets at the transcriptional level, with all macrophages activated with LPS showing a 
common pro-inflammatory phenotype. All subsets showed the established upregulation 
of IL-6 and T cell costimulatory CD80 [155]. Both subsets not treated with exogenous 
IFNγ showed upregulation of IFNγ expression themselves providing a 
paracrine/autocrine priming mechanism. Further transcriptional support for the 
presence of IFNγ was seen in the upregulation of interferon-responsive MIG, IP9 and 
IP10 proteins in all LPS activated subsets [400,401]. Metabolically there was no 
overlap between all LPS subsets, largely due to the unique metabolic regulation of GM-
CSF+LPS macrophages when compared to other groups. 
 
M-CSF+LPS (and M-CSF+LPS+IFNγ) macrophages upregulated a number of pro-
inflammatory cytokines (Figure 8.4). Pro-inflammatory IL-1, commonly associated 
with macrophage LPS response [381]; IL-12 and IL-23 were all upregulated. This 
response matches the expected M1/Th1-like response to bacterial LPS [155]. Following 
LPS activation our M-CSF macrophages also upregulated GM-CSF (CSF2) as 
previously reported in monocytes [402]. This may have implications for the balance of 
macrophage phenotypes in the rheumatoid synovium, where GM-CSF levels are raised 
in active disease [390]. At the metabolic level, LPS activation was associated with an 
increase of TCA cycle and glycolysis at both the transcriptional and metabolic level. 
Genes of the pyruvate dehydrogenase complex, catalysing the conversion of pyruvate 
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to acetyl-CoA, were downregulated, as were the initial aconitase steps of the TCA 
cycle. Metabolites of later stages of the cycle, from 2-oxoglutarate onwards, were 
increased suggesting that M-CSF+LPS (and M-CSF+LPS+IFNγ) macrophages were 
using glutaminolysis to generate ATP. The only unique metabolic feature of M-CSF 
macrophages activated with LPS alone was reduced intracellular pyruvate. Culture 
media results showed that both LPS or LPS+IFNγ stimulation also drove consumption 
of glucose, methylguanidine and methionine. The majority of regulated genes in M-
CSF+LPS+IFNγ macrophages were shared with those treated with LPS alone. 
However, there were a number of unique features suggesting increased responsiveness 
including upregulation of receptors for IL-7, IL-13, IL-17 and an IL-1 receptor kinase 
commonly found in macrophages [384]. Retinol binding protein (RBP) was 
downregulated by the addition of IFNγ. Retinoic acid has been shown to upregulate 
GATA6 in tissue-resident macrophages, so this downregulation may further support 
the inflammatory LPS+IFNγ phenotype [403]. 
 
Activation of GM-CSF differentiated macrophages with LPS, matching the Verreck et 
al. activated M1 phenotype, produced macrophages with considerable differences at 
both the transcriptional and metabolic level (Figure 8.3). Activation resulted in 
upregulation of HLA class I/II, monocyte activating CCL14 and IL-12 — as reported 
previously [176]. However, signal attenuation was also suggested by downregulation 
of STAT4/IL-12 response mediating MAPK26 and receptors for pro-inflammatory IL-
1 [387]. Metabolically, activation of GM-CSF macrophages with LPS resulted in 
reduced glycolytic and TCA cycle metabolites, depletion of creatine and creatine 
phosphate and a drop in ADP-ATP. Concentrations of creatine phosphate have 
previously been shown to decrease during phagocytosis in both resident and blood 
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derived murine macrophages [404]. There was transcriptional upregulation of enzymes 
of both glycolysis and the TCA cycle, however interestingly LPS activation was 
associated with a significantly reduced consumption of glucose from the media (relative 
to unstimulated macrophages). The depletion of intracellular metabolites, including of 
creatine phosphate, suggests LPS activation of GM-CSF macrophages results in a 
short-term burst of energy with little replenishment. Genes encoding enzymes of the 
carnitine shuttle were downregulated relative to differentiation and carnitine levels 
themselves were also down, while fatty acid β-oxidation was also downregulated — in 
common with other LPS activation conditions. GM-CSF+LPS macrophages excreted 
significant methionine and ornithine following activation, while intracellular 
concentrations of urea cycle metabolites were raised. 
 
Alternatively activated macrophages (M2a) differentiate in response to Th2 cytokines 
IL-4 and/or IL-13 and have proposed roles in humoral immunity, revascularization of 
damaged tissues, and resolution of inflammation [170,218,219]. Transcriptionally, 
activation with IL-4 produced the most unique profile with no common genes with any 
other M-CSF subset (Figure 8.5). The majority of up- and down-regulated genes were 
also expressed during differentiation with M-CSF alone illustrating commonality 
between Mantovani’s M2a and Verreck’s unstimulated M2 macrophages. Some 
previously reported features of IL-4 (M2a) macrophages were not replicated here, 
including increased antigen processing or indications of increased pinocytosis or 
MRC1 dependent endocytosis [220–222]. Similarly, M2a macrophages have 
previously been reported to promote tissue healing and scar formation through the 
production of ornithine but this was not seen here, however there was production of 
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proline [243]. These differences may reflect the lack of IL-13 in our model, differences 
between human and mouse macrophages or the activation timescale.  
 
Activation with IL-4 resulted in upregulation of cellular proliferation marker Ki67 — 
alongside multiple cell cycle checkpoint and chromosome segregation genes 
— indicating active proliferation. IL-4 has been previously reported to induce 
macrophage proliferation in tissues [224,225]. The intracellular metabolic profiling of 
activated IL-4 macrophages showed also an almost complete depletion of glutamine. 
While initially suggesting glutaminolysis, glutamine is also consumed as a nitrogen 
donor for purine and pyrimidine biosynthesis including of the nucleotide bases that 
make up DNA and RNA [405,406]. The rapid and unusual glutamine consumption only 
observed in IL-4 macrophages may therefore result from replication of cellular DNA.  
 
Metabolically IL-4 activation resulted in upregulation of both the TCA cycle and 
glycolysis and of the pyruvate dehydrogenase reactions linking the two. IL-4 
macrophages therefore appear to utilise the linked glycolysis-TCA to provide ATP in 
an oxygen dependent manner. The upregulation of early TCA cycle enzymes also 
suggests that IL-4 macrophages are not utilising glutamine as an energy source but 
predominantly, as a source of nitrogen for replication and purine metabolism [194]. 
 
Finally, IL-4 activated macrophages also downregulated HIF-1α, the central regulator 
of cellular responses to hypoxia. As HIF-1α has a role in pro-inflammatory IL-1β 
signalling this reflects the non-inflammatory phenotype of IL-4 macrophages and 
biases these macrophages away from M1 activation [113,193]. However, as HIF-1α is 
essential for cellular responses to hypoxia, including upregulation of glycolysis and 
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uptake of glucose, this may leave M2a cells uniquely disadvantaged in hypoxic 
environments [113]. PPAR-γ which regulates fatty acid storage and glucose 
metabolism was also upregulated here, as previously reported [232,233]. 
 
To summarise, these results showed that the majority of metabolic differences between 
macrophage subsets are in place by the end of differentiation and the changes associated 
with activation are largely constrained to central metabolism. The changes in the energy 
generating metabolic pathways are summarised in Table 9. 
 
Energy GM-CSF M-CSF GM-CSF 
+LPS 
M-CSF 
+LPS 
M-CSF 
+LPS 
+IFNγ 
M-CSF 
+IL-4 
Glycolysis p q q p p p 
Acetyl-CoA synthesis p q q q q p 
TCA p q q q q p 
Fatty acid β-oxidation p p p q q p 
Glutaminolysis p q q p p = 
Creatine/+P p q q p p p 
Table	9.	Summary	of	metabolic	changes	in	differentiation	and	activation	
 
 
 
 
 
 
  
Figure 8.3 The metabolic and transcriptional phenotype of GM-CSF
differentiated LPS activated M1 macrophages. Activation of GM-CSFmacrophages with LPS results produced an actively pro-inflammatorymacrophage with release of IL-12 and IL-6, and promote recruitment of B,NK, T and dendritic cells. Activation was associated with depletion ofintracellular metabolites, including energy store creatine phosphate, andan associated downregulation of most metabolic pathways with theexception of β-oxidation. Transcriptional upregulation of fatty acid bindingprotein (FABP) was also noted.
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Figure 8.4 The metabolic and transcriptional phenotype of M-CSF
differentiated LPS or LPS+IFNγ activated M1 macrophages. Activationof M-CSF macrophages with LPS results in upregulation of multiple pro-inflammatory signals including IL-6, IL-12 and IL-1β. These macrophageswere found to be metabolically via glycolysis and glutaminolysis,consuming glutamine and excreting lactate and proline into themedia.
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Figure 8.5 The metabolic and transcriptional phenotype of M-CSF
differentiated IL-4 activated M2a macrophages. Activation of M-CSFmacrophages with IL-4 results in unique transcriptional phenotype, withevidence of cellular replication. Metabolically these are the most distinctiveof the M-CSF macrophages tested, yet still share many features with otherM-CSF subsets. M2a macrophages were the only subset found to be activelyreplicating, as previously reported. These activated macrophages uniquelyutilised all metabolic pathways for energy, with upregulation of glycolysis,β-oxidation, TCA and creatine phosphate synthesis. Complete depletion ofglutamine was observed, however this likely relates to purine andpyrimidine synthesis during replication.
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8.4 The	influence	of	the	metabolic	environment	
Having established metabolic differences between macrophage differentiation — and 
to a lesser degree activation — conditions, we next explored whether the metabolic 
environment could in turn alter macrophage behaviour. We hypothesised that 
macrophages would be either adapted to specific environmental conditions, reflecting 
their normal differentiated functions, or responsive to the environment as marker of 
inflammation or infection.  
 
Hypoxia is a key feature of the rheumatoid joint and other inflammatory sites and 
cellular mechanisms exist for responses to low oxygen conditions [69,206]. 
Physiological levels of oxygen are between 1-12% depending on tissue location and 
perfusion, however chronically inflamed tissues may reach as low as 0.5-2.5% [100–
103]. Hypoxia is an established driver of cell migration into the tissues and perfusion 
may act as a signalling mechanism to invading cells [69]. Cellular responses to hypoxia 
are regulated by members of the hypoxia-inducible factor (HIF) transcription factor 
family [109,112]. Low oxygen stabilises HIF which in turn induces transcription of 
various genes including glycolytic enzymes and other genes related to cellular 
metabolism including GAPDH and GLUT1 as well as pH regulation, erythropoiesis, 
angiogenesis and apoptosis [109,112,115]. As a result, we expected that culture of 
macrophage subtypes under hypoxia would result in altered cellular metabolism and 
behaviour. For the purpose of this study, hypoxic culture was performed at the low end 
of measured oxygen concentrations in active rheumatoid arthritis (1% O2). Additionally 
we studied the effects of reperfusion (1% O2 with 20% O2 feed) with normal 
atmospheric oxygen (20% O2 constant). It is worth noting that while this is the standard 
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oxygen concentration for tissue culture experiments, it is above the normal biological 
range in most tissues. 
 
The global PLS-DA map of M-CSF and GM-CSF macrophages differentiated and 
activated with LPS under normoxia, hypoxia and reperfusion conditions highlighted a 
number of interesting features of macrophage metabolism under these conditions. 
Firstly, the oxygenation conditions were not sufficient to overcome the clustering of 
differentiated macrophage populations — M-CSF and GM-CSF macrophages 
remained distinguishable from one another — mimicking our findings that LPS 
activation of macrophages did not overcome the differentiation background. However, 
a second level of clustering between the oxygenation groups was also present. 
Secondly, we observed that exposure of differentiating macrophages to reperfusion 
conditions produced a metabolic profile very similar to that of LPS activation at the 
level of central metabolism. 
 
Differentiation and activation of GM-CSF macrophages with LPS under hypoxia 
resulted in the expected reduction in metabolites of the oxygen-dependent TCA cycle. 
However, the increase in high-energy creatine phosphate may suggests energy storage. 
Reperfusion experiments demonstrated that when cultured in hypoxia and subsequently 
exposed to 20% O2, GM-CSF macrophages rapidly reactivate. In contrast M-CSF 
differentiated LPS macrophages under hypoxia showed a complete downregulation of 
central metabolism and no associated storage of ATP, suggesting quiescence rather than 
readiness. This may have implications for the relative balance of macrophage activity 
in low oxygen conditions, such as the rheumatoid synovium. TCA cycle function was 
reduced in the GM-CSF macrophages, with downregulation of a number of cycle 
	424	
metabolites including 2-oxoglutarate, oxaloacetate and cis-aconitate, together with an 
increase in pyruvate suggesting loss of the TCA cycle shunt. It was expected that this 
would be associated with an increase in lactate excretion as a waste by-product, but this 
was not observed. Succinate, which has recently been shown to have a signalling role 
in inflammatory processes, including sustaining IL-1β production in a HIF-1α 
dependent mechanism, was increased [193,407]. 
 
Both our experiments and existing literature have identified metabolites that are 
associated with inflammation and cellular activation. However, it remained unclear 
whether these metabolites are merely a by-product of processes, or are involved in 
regulation itself. To determine whether the local environment metabolite profile could 
have an effect on macrophage behaviours we spiked culture media with both complex 
mixtures — derived from RA patient and non-RA fibroblasts — and with single 
metabolites. The fibroblast conditioned media appeared to show an increase in 
macrophage IL-6 production following spiking with media conditioned with RA 
fibroblasts, but this was not significant. To explore whether higher concentrations of 
metabolites would drive a stronger and significant response, we proceeded to spike 
media with individual metabolites. The profile of these conditioned media showed a 
strong increase in lactate, and this, together with other potential metabolites was studied 
further. Specifically we looked at energy sources (glucose, glutamine), waste products 
(lactate), branch-chain amino acids, and arginine. Energy sources were intended to 
remove the checks on any metabolic processes, addition of lactate to test whether 
inhibition of lactate excretion (by increasing the gradient) could remove the glycolytic 
limitation on TCA cycle function, and supplementation with essential branch-chain 
amino acids has also been shown to drive an increase in Th1-like responses via IL-1, 
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IL-2, TNF and interferon [124]. Of the tested metabolites, only lactate had any notable 
effects. It was lethal to cultured macrophages at the top concentrations used, but at 
10µM showed a strong activating effect on the macrophages with a large increase in 
IL-6 production even in non-LPS activated macrophages.  
 
To explore this further, differentiating macrophages were also spiked with lactate at 
various concentrations to observe the effects on metabolic behaviours. Endpoint 
metabolites for a range of concentrations showed that as lactate concentrations 
increased, 2-hydroxyisovalerate and alanine were reduced, while 3-hydroxyisovalerate 
increased. Media glucose concentrations at endpoint were higher as lactate 
concentrations rose. Interestingly, the glucose consumption of LPS stimulated 
macrophages fell more quickly as lactate levels increased. 
 
The metabolic effects of lactate spiking on differentiation metabolism were observed 
by sampling spiked culture media and sampling media metabolic profiles over the 
differentiation timecourse. These results matched those in the endpoint analysis, but 
interestingly identified that suppressed consumption of glucose under increasing lactate 
only occurred towards the end of differentiation — at the beginning it was actually 
higher in spiked cultures. This may result from lactate promotion of macrophage 
differentiation/polarisation as previously described [127]. early activation of 
differentiating macrophages. Lactate concentrations in cultures continued to rise during 
differentiation to broadly equal levels by day 6. 
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8.5 A	 role	 for	 macrophage	 metabolism	 in	 the	 rheumatoid	
synovium	
In the previous sections we have outlined and summarised our findings of macrophage 
metabolism during differentiation and activation. We have also explored the effect of 
metabolic environment and oxygen perfusion on macrophage behaviour. Next, we will 
explore how these data support or refute our earlier hypotheses and attempt to put our 
findings in a larger context of the inflamed rheumatoid synovium. 
8.5.1 Differentiated	macrophages	display	distinct	metabolic	profiles		
We have successfully demonstrated that differentiated macrophages display distinctive 
metabolic profiles. Differentiation with M-CSF and GM-CSF produced populations of 
macrophages that had distinctive intracellular and extracellular metabolic profiles. The 
two groups could be separated with high sensitivity and specificity by their metabolic 
profiles alone and there were distinctive features both at the metabolite and pathway 
regulation level. GM-CSF macrophages were associated with upregulation of 
glycolysis and increased consumption of glucose and excretion of lactate relative to M-
CSF. Consumption of glutamine and upregulation of the carnitine shuttle suggests that 
GM-CSF macrophages also utilise glutaminolysis and fatty acid β-oxidation. 
 
However, our original hypothesis related to the established subsets of differentiation 
(activated) macrophages described by the M1/M2a models. These macrophage subsets 
were reflected in our data by the activated macrophages stimulated with LPS or IL-4 
respectively. Here the distinctiveness of macrophage subsets was not so clear. Post-
activation the strongest differences remained between macrophages differentiated on a 
background of M-CSF or GM-CSF and this difference persisted regardless of activation 
stimulus. For example classically activated M-CSF+LPS macrophages had more in 
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common with M-CSF+IL-4 than to classically activated GM-CSF+LPS macrophages 
at the metabolic level. These findings add weight to the suggestion by Murray et al. that 
these two M1 phenotypes are not comparable [178]. This is reflected clearly by the high 
sensitive/specificity between M-CSF+LPS and GM-CSF+LPS macrophages (1.0/1.0) 
but not between M-CSF+IL-4 and M-CSF+LPS+IFNγ (0.5/0.8). 
 
We did note upregulation of glycolysis in M-CSF+LPS and M-CSF+LPS+ IFNγ 
macrophages, as previously reported for M1 macrophages [84,187]. GLUT transporter 
expression upregulation was not detected however the increased surface expression in 
this subset is reported to occur via endocytic recycling of the transporters [188]. We 
also observed downregulation of TCA cycle metabolites (relative to M-CSF 
macrophages) in contrast to previous descriptions for these cells [192]. There was novel 
regulation in the IL-4 activated subset with unique upregulation of oxidative 
metabolism via TCA cycle and fatty acid β-oxidation [238,239]. We did not however 
measure downregulation of the glycolytic pathway that has been previously reported 
[84]. These macrophages therefore interestingly had more in common with GM-CSF 
differentiation than any other M-CSF subset. As IL-4 macrophages showed 
transcriptional evidence of replication this may simply reflect the metabolic 
requirements of this process. The complete depletion of glutamine at the cellular level 
in these macrophages likely indicates consumption for purine and pyrimidine 
biosynthesis, but this is not identifiable from our data. Glutaminolysis is a recognised 
energy source for M2a macrophages [84,194,241]. Aside from these features, the M-
CSF macrophage subsets were almost entirely uniformly regulated in their metabolism. 
 
	428	
Activation of GM-CSF macrophages with LPS was associated with a rapid depletion 
of metabolites from gylcolysis, the TCA cycle and creatine biosynthesis. Storage of 
high-energy phosphate in creatine phosphate and ATP is depleted relative to GM-CSF 
(and to M-CSF+LPS). The pattern suggested therefore rapid expenditure of stored 
energy, with no evidence in our data of replenishment. Only fatty acid metabolism was 
upregulated transcriptionally although due to our methods there was no metabolic 
evidence aside from carnitine depletion.  
8.5.2 Metabolic	profiles	of	differentiated/activated	macrophages	 reflect	
their	different	functions	
We hypothesised that the metabolic differences between differentiated macrophages 
would reflect unique features of their subset-specific functions. Our results showed that 
while that was the case to a degree – with notable differences in regulation of central 
metabolic pathways – the variation was not as broad as initially expected. For example, 
although our M-CSF subsets contained macrophages activated with both pro-
inflammatory and non-inflammatory stimuli (LPS and IL-4 respectively) the 
differences observed were for the most part in general energy generation/requirements 
rather than in specialised pathways that could be related to specific functions.  
 
Replication has previously been shown to be induced directly by IL-4 and we detected 
that here [224,225]. The replication of M-CSF+IL-4 macrophages puts novel metabolic 
demands on these cells, which was seen in the upregulation of all energy pathways 
including glycolysis, TCA cycle and fatty acid β-oxidation in this subset. It has been 
suggested that the energy efficiency of fatty acid β-oxidation is compatible with slow 
growth and responses to larger endemic parasites that M2a macrophages are thought to 
target and inhibition of fatty acid β-oxidation has been shown to attenuate the 
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transcriptional induction of the M2a programme [189]. The upregulation of PPARγ 
which promotes fatty acid storage and metabolism further supports this [232,233]. 
 
The diverse upregulation of central metabolic pathways in both GM-CSF differentiated 
and M-CSF+IL-4 activated macrophages may benefit both of these subsets in the 
rheumatoid synovium where high levels of ROS/NO may inhibit oxidative 
phosphorylation and glutaminolysis [194]. However, as M-CSF differentiation is 
primarily fatty acid β-oxidation dependent (which depends on a functioning TCA cycle 
to generate ATP) the M-CSF+IL-4 M2a subset may be at an energetic disadvantage. 
 
Any further analysis of the functional implications of metabolism was limited by the 
methods employed in the study. The use of metabolic spiking/hypoxia and cytokine 
assay provides only a limited a view of macrophage functional behaviours, and does 
not offer direct control over metabolism. This would therefore be best addressed by 
targeted inhibition of macrophage metabolic pathways with corresponding readout via 
functional assays. Specifically, on the basis of our existing results, it would be 
interesting to note the effects of direct inhibition of glycolysis, electron transport, 
glutaminolysis and fatty acid metabolism on cellular replication, phagocytosis, reactive 
oxygen production and pro- and anti-inflammatory cytokine release. Inhibitors for 
hexokinase (2-deoxyglucose), glucose uptake (WZB117), oxidative phosphorylation 
(2,4-DNP), glutaminolysis (BPTES) and fatty acid metabolism (cerulenin) are 
available, with targeting of non-oxidative metabolic pathways in particular of interest 
in cancer treatment [408,409]. Interestingly it has previously been shown that 2-
deoxyglucose selectively inhibits Fc and complement receptor mediated phagocytosis 
in murine peritoneal macrophages [410].  
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8.5.3 Metabolic	 differences	 between	 pro-	 and	 non-inflammatory	
macrophages	contribute	to	chronic	inflammation	in	the	synovium	
GM-CSF is secreted by activated macrophages, T cells, NK cells and fibroblasts, and 
has been found to be strongly upregulated in the synovium of patients with rheumatoid 
arthritis [390]. GM-CSF is produced by RA synovial cell cultures, and has been shown 
to be downregulated by TNFα blocking antibodies indicating that production is 
dependent on the continued presence of TNFα [390]. Therefore there is a circular 
interaction whereby fibroblasts produce GM-CSF in the presence of TNFα, 
differentiating macrophages that in turn produce TNFα. Success of anti-TNFα therapy 
in RA may be in part due to the indirect effect on macrophage differentiation. Blocking 
GM-CSF has been proposed as a potential drug target to reduce inflammation and 
damage associated with inflammatory disease, and is being actively explored in other 
diseases [411]. However, while GM-CSF promotes macrophage differentiation, a 
second activating signal is required to drive pro-inflammatory phenotypes. We wanted 
to explore whether metabolic signals both derived from and affecting macrophages may 
provide a route to persistence. 
 
The synovial fluid of RA patients has previously been described to contain high levels 
of lactate, low levels of glucose and increases in ketone bodies indicating utilisation of 
fats for energy [48,55]. While this profile of lactate production, glucose and fatty acid 
metabolism matches our results for macrophages under GM-CSF differentiation, 
similar metabolic profiles have been found in synovial fibroblasts [93]. Raised 
glutamine and succinate were also previously reported yet we did not detect this in our 
macrophage samples [82]. However, the metabolic environment of the rheumatoid 
synovium may itself bias macrophage differentiation or survival in favour of 
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inflammatory M1-like macrophages. We will address the most distinctive features of 
the rheumatoid synovium in turn — lactate, hypoxia and reactive oxygen species. 
 
Lactate has previously been shown to promote a M2-like differentiation of TAMs and 
U87/U251 cell lines [127,248]. However, conversely the IL-4 differentiation 
programme is thought to be dependent on fatty acid β-oxidation [189]. Our results 
suggested some degree of sensitivity of macrophages to lactate which, while not 
inducing significant increases in IL-6 production did promote increased glucose 
consumption during differentiation. Therefore, while not inducing a strong pro-
inflammatory phenotype neither did lactate promote M2a-like behaviour. 
 
Cellular responses to hypoxia are governed by the HIF transcription factor family 
members which regulate response to hypoxia [109,112]. Low oxygen stabilises HIF 
driving transcription of multiple genes supporting hypoxic survival — including 
increased glycolysis [113,114]. In the rheumatoid joint partial pressure of O2 (pp02) 
falls as low as 2-4% compared to 9-12% in non-RA patients therefore adaptability to 
low oxygen is key to cell survival [104,105]. HIF-1α has previously been shown to 
have a role in key features of M1 macrophage differentiation activation, including 
glycolysis, glucose uptake and IL-1β production [113]. Similarly, knockout of HIF-1α 
has been shown to promote M2a-like differentiation in TAMs [412]. Our transcriptional 
analysis identified downregulation of HIF-1α uniquely in the M2a (M-CSF+IL-4) 
subset. While logical in context of the role which HIF-1α plays in M1 differentiation, 
this may render these cells vulnerable to low oxygen conditions in vitro. Unfortunately, 
the effect of hypoxia on M2a macrophages was not explored directly in our follow up 
experiments. 
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The rheumatoid joint is rich in ROS resulting from a combination of activated 
macrophages, hypoxia and reperfusion [79,194,195]. Macrophages are reported to 
upregulate generation of glutathione (GSH) via the pentose phosphate pathway (PPP) 
to self-protect during M1 differentiation [84,199]. We did not detect glutathione in our 
metabolic data, nor metabolic/transcriptional changes in the PPP in either differentiated 
or activated macrophage populations.  However, the regulation of energy-producing 
metabolic pathways offers an alternative mechanism for ROS to alter the M1/M2a 
balance. Multiple enzymes of the TCA cycle and respiratory chain are sensitive to 
inhibition by ROS, as are those involved in glutaminolysis including α-ketoglutarate 
dehydrogenase and aconitase [413,414]. As we have previously demonstrated, during 
differentiation GM-CSF macrophages are metabolically promiscuous, utilising all 
available energy sources — and sequestering resulting ATP as creatine phosphate. In 
contrast, M-CSF macrophages primarily use fatty acid β-oxidation, only utilising other 
pathways following activation with IL-4. This energetic advantage may go some way 
to explaining the synovial bias towards M1-like macrophages [250]. 
8.5.4 Metabolic	 alteration	 of	 the	 synovium	 could	 offer	 a	mechanism	 to	
resolve	RA	
While metabolic regulation may play a role in macrophage differentiation and 
activation, the biasing effect of high concentrations of GM-CSF in the rheumatoid 
synovium cannot be ignored. Further, since the effect size of metabolic changes has not 
been calibrated against cytokine signalling is not possible to accurately evaluate 
combined signals. For simplicity sake therefore, the following discussion will assume 
that synovial GM-CSF can be attenuated pharmacologically as previously discussed 
[390]. Further, while our macrophage results may optimistically suggest that 
elimination of tissue hypoxia or removal of synovial lactate offer the most direct route 
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to metabolic intervention, no clinical or pharmacological method exists to achieve this 
in vitro. However, a number of metabolic inhibitors are available, targeting many of the 
metabolic pathways identified as unique to M1/M2a macrophages. 
 
The goal of the following theoretical intervention is to bias energetically against GM-
CSF/M1 macrophages, thereby promoting healing via the M2a subset. As previously 
described, during differentiation GM-CSF macrophages may receive an energetic 
advantage in the hypoxic, ROS-rich synovium, by being able to utilise multiple energy 
sources. In particular, oxidative metabolism is potentially inhibited by the presence of 
ROS. ROS production by macrophages can be inhibited directly using  N-acetyl-L-
cysteine (NAC) or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (APDC), however 
this would not eliminate ROS produced through the effects of hypoxia, reperfusion or 
metabolism [79,123,415–417]. Glutathione, a reducing agent commonly produced by 
macrophages themselves, could offer a means to mitigate these effects [418]. These 
changes would support M-CSF differentiation and metabolism via fatty acid β-
oxidation [189]. However, these approaches would not directly inhibit GM-CSF 
macrophage differentiation — and the associated consumption of glucose, glutamine 
and excretion of lactate into the synovium. This final step could be achieved through 
direct pharmacological inhibition of glycolysis via hexokinase with 2-deoxyglucose 
and/or targeted inhibition of HIF-1α, eliminating hypoxia responses and impairing M1 
activation [113,408]. Experiments based around combinations of these treatments 
would make for an interesting follow up in vitro. 
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8.6 Limitations	of	the	study	&	future	work	
The experimental and analytical methods used in this study were primarily built on 
available methods and expertise within the research group at the beginning of the 
project. By the completion of this project a number of these approaches were found to 
be less than-optimal for the question which we aimed to answer. Further, there are a 
number of logical next steps that follow from our existing findings. A brief review of 
these issues and suggested improvements follows. 
8.6.1 Metabolomics	
The metabolomic methods used in this study including the multivariate analyses were 
derived from established methods used for metabolic biomarker identification. 
Snapshots of cellular metabolism at experimental endpoints are informative for finding 
bulk differences and metabolic patterns. However, due to the interlinking of metabolic 
pathways this bulk metabolite quantification provided limited insight into metabolism 
at the functional level. The longitudinal metabolite uptake/excretion experiments were 
an attempt to supplement this information but interpretation of these was no simpler. 
 
Metabolic flux experiments where 13C labelled tracing metabolites are used to identify 
active routes of metabolic reactions would arguably have given more informative data 
for the scope of this study. This would particularly be the case if intracellular flux could 
be measured at multiple timepoints during the differentiation process. Though this 
would be difficult due to the limited monocyte numbers available, alternative methods 
for measuring live metabolic throughput are available. For example, the Seahorse 
(Seahorse Bioscience, USA) platforms allow direct, real-time quantification of cellular 
metabolism, energy substrate use and metabolic switching — under both normoxic and 
hypoxic conditions — with as little as 5,000 cells. 
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8.6.2 Macrophage	models	
The study was complicated by the use of multiple macrophage models (reflecting both 
the Verreck and Mantovani nomenclatures) which are not easily comparable. The 
Verreck M-CSF vs. GM-CSF model was selected for the initial phase of the work 
(Chapter 7) but it later became apparent that the consensus was moving away from this 
approach of differentiating macrophages. In retrospect covering both M-CSF and GM-
CSF subsets allowed us to identify the differences that were due to differentiation rather 
than activation. Without the multiple M-CSF models it would not have been possible 
to contrast the (few) metabolic differences arising from activation from those due to the 
differentiation background alone. The LPS+IFNγ subset was not notably different from 
LPS alone and it would likely have been more informative to switch this with IL-4 
activation on the background of GM-CSF. GM-CSF+IL-4 treatment of monocytes is 
drives a dendritic cell likely phenotype, although IL-4 in this model is typically used 
for differentiation not activation. Regardless, this would have offered a more balanced 
view of the relative of effects of differentiation and activation on both backgrounds. 
 
More generally, this study was based entirely on the differentiation and activation of 
blood derived monocytes. While the protocols used are well established, this is now 
known to generate non-homogenous populations of cells, with a spectrum of 
phenotypes within culture [155,419,420]. Further, the resulting populations — even if 
pure — are likely not good models of the tissue macrophages in the rheumatoid 
synovium, where cells are exposed to a complex mix of cytokines [20,21]. Analysis of 
tissue macrophages was considered early in the project, but small available cell 
numbers made this impractical for metabolomics. However, the aforementioned 
Seahorse platform may offer a route to assay these cells directly. Alternatively, 
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homogenous monocytes and macrophages have been successfully differentiated from 
human embryonic stem cells in vitro [419]. This would also eliminate the potential for 
contamination of cultures with T/NK cells which exists with current methods. 
8.6.3 Transcriptomics	
We attempted to address the limitation of our metabolomic methods by annotating 
enzymatic reactions of metabolic pathways with RNASeq transcriptomic data. This 
approach was broadly successful when combined with the developed pathway-mining 
approaches, however it was not without its own challenges.  
 
Firstly, the transcriptional analysis was limited by the use of the generic human 
expression background for significance and fold-change filtering prior to the analysis. 
This was necessary in part due to the large scale of the resulting data, but — together 
with the absence of undifferentiated monocyte data — limited the identification of true 
differentiation markers where they were not strongly altered between treatments. 
Secondly, inexperience in dealing with transcriptomic data and the addition of this data 
late in the project resulted in this data not being utilised to its full potential. The gene 
tables (Appendices I & II) are a naïve attempt to summarise these changes which would 
likely be better served using Gene Ontology (GO) analysis or other techniques. 
 
In hindsight, a simpler metabolic-gene array targeted approach would have been more 
appropriate and significantly simplified the subsequent analysis. However, this would 
have been at the expense of gene annotations on non-targeted pathways — restricting 
the results to core pathways including glycolysis, TCA cycle and some amino acid 
biosynthesis/degradation pathways. In selecting the approach for transcriptomic 
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analysis it was not clear that these pathways would likely be sufficient to explain the 
key differences between the macrophage subsets under study. 
8.6.4 Software	development	
The development of software and analysis algorithms consumed a large proportion of 
the time spent on this project. These tools were of varying success and application in 
the end result — unfortunately not always in proportion to the time investment. For 
example, while the Pathomx software was extremely useful for prototyping analyses, 
once the workflow was established these were more commonly exported as standalone 
Python scripts. The GUI workflow-construction interface was therefore used relatively 
little considering the development effort spent creating it. On a positive note, the core 
data analysis pipeline and GUI framework has subsequently been released as an open 
source project to accelerate the development of other scientific applications. 
  
Similarly, the Chenomx software used for quantification of the metabolites — as used 
in the majority of pathway plots — was also not initially available. As a result, 
considerable time was used attempting to solve data processing problems (alignment, 
pH shift) that were ultimately of limited concern with the automated quantification 
tools. The BML-NMR quantification service from 2D JRES spectra provided similar 
benefits earlier on, albeit with poorer metabolite resolution and quantification accuracy. 
However, once Chenomx was available these 2D JRES spectra was no longer useful. 
8.6.5 Cell	replication	
There was evidence of replication of IL-4 activated M-CSF macrophages at both the 
transcriptional and metabolic level however changes in cell numbers were not directly 
assayed in these experiments. Changes in cell numbers during the 18 hour activation 
window may have had effects on metabolism within a given culture. It would be 
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interesting to directly explore the degree to which the replication and differentiation 
process in M2a macrophages could be inhibited by glutamine starvation.  
8.7 Conclusions	
In this study we demonstrated that differentiated — and activated — macrophages do 
indeed display distinct metabolic profiles. Differentiation with GM-CSF and M-CSF 
produced two populations which were metabolically distinct, with GM-CSF 
macrophages generating energy from multiple sources, while M-CSF macrophages 
used primarily fatty acid β-oxidation alone. Activation of differentiated macrophages 
(with LPS, LPS+IFNγ or IL-4) in contrast had comparatively limited effects on 
metabolism outside of the central metabolic pathways. GM-CSF+LPS macrophages 
depleted intracellular metabolites and downregulated many pathways transcriptionally. 
M-CSF+IL-4 macrophages in contrast activated, with upregulation of multiple 
pathways and initiation of replication. We suggest that the metabolic adaptability of 
GM-CSF macrophages may put them at an energetic advantage in the hypoxic, ROS-
enriched rheumatoid synovium. Finally, we also explored macrophage responses to the 
metabolic environment. Here we showed  that exposure of GM-CSF macrophages to 
hypoxia led to the accumulation of ATP in creatine phosphate, and subsequent 
reperfusion drove a similar metabolic response to that seen in response to LPS.  
 
The completion of this work required the development of a number of software tools 
and methods for the analysis and visualisation of data, and these tools have been 
released as open source software for use in future work. 
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APPENDIX	I	
	
Genes	 Mean	log2(fc)	 Description	
F13A1	 4.70	 	 coagulation	factor	XIII,	A1	polypeptide	
IGF1	 2.69	 ±	0.69	 insulin-like	growth	factor	1	
IL1R1,	IL1R2	 2.51	 ±	0.24	 interleukin	1	receptor,	type	I	/	II	
TLR5	 2.47	 	 toll-like	receptor	5	
MS4A6A	 2.38	 ±	1.25	 membrane-spanning	 4-domains,	 subfamily	 A,	
member	6A	
CCL26,	CCL13	 2.27	 ±	0.06	 chemokine	ligand	(13;	26)	
NEK10	 1.94	 ±	0.44	 NIMA-related	kinase	10	
CCR2	 1.60	 ±	0.54	 chemokine	receptor	2	
CD209,	 CD1A,	 CD302,	 CD1C,	 CD1E,	
CD1B	
1.58	 ±	0.99	 CD	(1a;	1b;	1c;	1e;	209;	302)	molecule	
CXCL12	 1.34	 ±	0.08	 chemokine	ligand	12	
JAK2,	JAK3	 -1.29	 ±	0.25	 Janus	kinase	(2;	3)	
DUSP5,	DUSP8,	DUSP10	 -1.29	 ±	0.16	 dual	specificity	phosphatase	(10;	5;	8)	
TLR3,	TLR8	 -1.30	 ±	0.15	 toll-like	receptor	(3;	8)	
AKT3	 -1.30	 ±	0.05	 v-akt	murine	thymoma	viral	oncogene	homolog	3	
IRAK3,	IRAK2	 -1.30	 ±	0.05	 interleukin-1	receptor-associated	kinase	(2;	3)	
CSF2RB,	CSF3	 -1.66	 ±	0.13	 colony	 stimulating	 factor	 (2	 receptor,	 beta,	 low-
affinity;	3)	
TNFAIP3,	TNFAIP2,	TNFAIP6	 -1.80	 ±	0.55	 tumor	necrosis	factor,	alpha-induced	protein	(2;	3;	6)	
CXCL10,	CXCL11	 -1.80	 ±	0.50	 chemokine	ligand	1	(0;	1)	
CCL19,	CCL15,	CCL8,	CCL5,	CCL20	 -1.87	 ±	0.79	 chemokine	ligand	(15;	19;	20;	5;	8)	
CD40,	CD80	 -2.25	 ±	1.10	 CD	(40	molecule,	TNF	receptor	superfamily	member	5;	
80	molecule)	
IL17C,	IL1B,	IL15RA,	IL2RA,	IL8,	IL15,	
IL6,	IL1A	
-2.72	 ±	1.27	 interleukin	(1,	alpha;	1,	beta;	15;	15	receptor,	alpha;	
17C;	2	receptor,	alpha;	6;	8)		
Table	10.	Most	regulated	gene	groups	associated	with	macrophage	differentiation	
(M-CSF)	The	gene	groups	associated	with	macrophage	differentiation	that	were	most	up-	or	down-regulated	following	differentiation	under	M-CSF	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.	
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Genes	 Mean	log2(fc)	 Description	
F13A1	 5.00	 	 coagulation	factor	XIII,	A1	polypeptide	
CCL26,	CCL13,	CCL14	 3.87	 ±	1.50	 chemokine	ligand	(13;	14;	26)	
CD1C,	CD1A,	CD1B,	CD1E,	CD209	 2.16	 ±	1.20	 CD	(1a;	1b;	1c;	1e;	209)	molecule	
CXCL13	 2.15	 	 chemokine	ligand	13	
MMP25,	MMP12	 2.08	 ±	0.81	 matrix	metallopeptidase	(12;	25)	
IL12B,	IL12RB2,	IL1R1,	IL17RB,	IL1R2	 2.06	 ±	0.64	 interleukin	(12B;	12	receptor,	beta	2;	17	receptor	B;	
1	receptor,	type	I;	1	receptor,	type	II)	
DUOXA1	 2.02	 	 dual	oxidase	maturation	factor	1	
IFNG	 1.71	 	 interferon,	gamma	
NEK10	 1.61	 ±	0.24	 NIMA-related	kinase	10	
TRAF5	 1.49	 	 TNF	receptor-associated	factor	5	
IGF1	 1.28	 	 insulin-like	growth	factor	1	
MAP3K13,	MAP3K9	 1.09	 ±	0.03	 mitogen-activated	protein	kinase	kinase	kinase	 (13;	
9)	
AKT3	 -1.20	 ±	0.14	 v-akt	murine	thymoma	viral	oncogene	homolog	3	
TNFAIP6,	TNFAIP2	 -1.23	 ±	0.09	 tumor	necrosis	factor,	alpha-induced	protein	(2;	6)	
DUSP10	 -1.29	 	 dual	specificity	phosphatase	10	
PRKCH	 -1.32	 	 protein	kinase	C,	eta	
CD80	 -1.36	 	 CD80	molecule	
CCL19	 -1.63	 ±	0.54	 chemokine	ligand	19	
MMP2	 -1.80	 	 matrix	metallopeptidase	2	
IL17C,	IL7R,	IL1B,	IL15RA,	IL2RA,	IL8,	
IL1A	
-1.98	 ±	0.97	 interleukin	(1,	alpha;	1,	beta;	15	receptor,	alpha;	17C;	
2	receptor,	alpha;	7	receptor;	8)	
CXCL10	 -2.21	 ±	0.22	 chemokine	ligand	10	
TLR7	 -2.37	 	 toll-like	receptor	7	
 
Table	11.	Most	regulated	gene	groups	associated	with	macrophage	differentiation	
(GM-CSF)	The	gene	groups	associated	with	macrophage	differentiation	that	were	most	up-	or	down-regulated	following	differentiation	under	GM-CSF	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.	
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Genes	 Mean	log2(fc)	 Description	
SEPP1	 5.49	 ±	0.32	 selenoprotein	P,	plasma,	1	
GAL3ST4	 3.61	 		 galactose-3-O-sulfotransferase	4	
LTC4S	 3.51	 		 leukotriene	C4	synthase	
HS3ST2,	HS3ST1,	HS6ST1	 3.16	 ±	1.44	 heparan	 sulfate	 (3-O-sulfotransferase	 1;	 3-O-
sulfotransferase	2;	6-O-sulfotransferase	1)	
IGF1	 2.69	 ±	0.69	 insulin-like	growth	factor	1	
FABP4,	FABP5	(FABP4,	FABP5)	 2.04	 ±	1.19	 fatty	 acid	 binding	 protein	 (3,	 muscle	 and	 heart;	 4,	
adipocyte;	5)	
ME1,	ME3	 1.91	 ±	0.60	 malic	 enzyme	 (1,	 NADP(+)-dependent,	 cytosolic;	 3,	
NADP(+)-dependent,	mitochondrial)	
SLC16A8,	 SLC39A10,	 SLC38A6,	
SLC40A1,	 SLC17A9,	 SLC25A48,	
SLC2A8,	 SLC45A3,	 SLC12A5,	
SLC4A7,	 SLC26A4,	 SLC9B1,	
SLC26A9,	 SLC25A29,	 SLC46A2,	
SLC46A1	
1.57	 ±	1.63	 solute	carrier	family	(12;	16,	member	8;	17,	member	
9;	2;	25,	member	29;	25,	member	48;	26,	member	4;	
26,	 member	 9;	 38,	 member	 6;	 39;	 4,	 sodium	
bicarbonate	 cotransporter,	 member	 7;	 40;	 45,	
member	3;	46;	46,	member	2;	9,	subfamily	B)	
SLC38A5,	 SLC7A5,	 SLC22A15,	
SLC31A2,	 SLC39A8,	 SLC5A1,	
SLC25A37,	 SLC1A4,	 SLC30A7,	
SLC1A2	
-1.31	 ±	0.28	 solute	carrier	family	(1;	1;	22,	member	15;	25,	member	
37;	30;	31;	38,	member	5;	39;	5;	7)	
SAT1	 -1.58	 ±	0.09	 spermidine/spermine	 N1-acetyltransferase	 1	 (;	 )	
spermidine/spermine	N1-acetyltransferase	1	
CES1	 -1.63	 ±	0.50	 carboxylesterase	1	
GK,	GK3P	 -1.68	 ±	0.09	 glycerol	kinase	(;	3	pseudogen)	e	
OAS1,	OAS3	 -1.75	 ±	0.59	 2'-5'-oligoadenylate	synthetase	(1,	40/46;	3,	100)	kDa	
CYP3A7,	CYP27B1	 -1.86	 ±	0.58	 cytochrome	 P450,	 family	 (27,	 subfamily	 B,	
polypeptide	1;	3,	subfamily	A,	polypeptide	7)	
NAMPT	 -1.87	 ±	0.14	 nicotinamide	phosphoribosyltransferase	
GCH1	 -1.90	 ±	0.53	 GTP	cyclohydrolase	1	
HS3ST3B1	 -1.97	 ±	0.93	 heparan	sulfate	3-O-sulfotransferase	3B1	(;	)	heparan	
sulfate	3-O-sulfotransferase	3B1	
MT1DP,	 MT1X,	 MT1L,	 MT1M,	
MT1H,	 MT1E,	 MT2A,	 MT1F,	
MT1G,	MT1A,	MT1B	
-2.90	 ±	1.57	 metallothionein	(1A;	1B;	1D,	pseudogene;	1E;	1F;	1G;	
1H;	1L;	1M;	1X;	2A)	
SGPP2	 -3.24	 ±	0.22	 sphingosine-1-phosphate	 phosphatase	 2	 (;	 )	
sphingosine-1-phosphate	phosphatase	2	
IDO2,	IDO1	 -3.37	 ±	0.19	 indoleamine	2,3-dioxygenase	(1;	2)		
Table	12.	Most	regulated	gene	groups	associated	with	metabolism	(M-CSF)	The	gene	groups	associated	with	metabolism	that	were	most	up-	or	down-regulated	following	differentiation	under	M-CSF	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.		 	
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Genes	 Mean	log2(fc)	 Description	
GALNTL4	 4.15	 		 UDP-N-acetyl-alpha-D-galactosamine:polypeptide	 N-
acetylgalactosaminyltransferase-like	4	
ALOX15	 2.81	 ±	0.09	 arachidonate	15-lipoxygenase	
SEPP1	 2.35	 ±	0.08	 selenoprotein	P,	plasma,	1	
HS3ST2,	HS3ST1	 2.29	 ±	0.58	 heparan	sulfate	3-O-sulfotransferase	(1;	2)	
FABP4,	FABP5	 1.96	 ±	0.94	 fatty	acid	binding	protein	(4,	adipocyte;	5)	
SULT6B1,	SULT1C2P1	 1.84	 ±	0.35	 sulfotransferase	 family,	 cytosolic,	 (1C,	 member	 2	
pseudogene;	6B,	member)	1	
SLC17A9,	 SLC25A48,	 SLC26A9,	
SLC18A2,	 SLC6A13,	 SLC30A4,	
SLC8A3,	SLC15A1	
1.65	 ±	1.98	 solute	 carrier	 family	 (15;	 17,	 member	 9;	 18;	 25,	
member	48;	26,	member	9;	30;	6;	8)	
ABCC5,	ABCC8,	ABCC11	 1.18	 ±	0.41	 ATP-binding	cassette,	sub-family	C	
FTH1	 -1.11	 ±	0.02	 ferritin,	heavy	polypeptide	1	
SLC44A2,	 SLC22A15,	 SLC9A1,	
SLC11A1,	 SLC36A4,	 SLC7A11,	
SLC24A3,	 SLC4A5,	 SLC16A10,	
SLC12A8	
-1.35	 ±	0.35	 solute	 carrier	 family	 (11;	 12;	 16,	 member	 10;	 22,	
member	 15;	 24;	 36;	 4,	 sodium	 bicarbonate	
cotransporter,	member	5;	44,	member	2;	7;	9)	
CES1,	CES1P2	 -1.41	 ±	0.34	 carboxylesterase	1	(;	pseudogene	2)	
ALDH1A1	 -1.68	 ±	0.08	 aldehyde	dehydrogenase	1	family,	member	A1	
SGPP2	 -1.72	 ±	0.11	 sphingosine-1-phosphate	 phosphatase	 2	 (;	 )	
sphingosine-1-phosphate	phosphatase	2	
SAT1	 -1.77	 ±	0.05	 spermidine/spermine	N1-acetyltransferase	1	
MT1X,	 MT2A,	 MT1L,	 MT1M,	
MT1H,	 MT1E,	 MT1F,	 MT1G,	
MT1A,	MT1B	
-1.92	 ±	0.49	 metallothionein	 (1A;	1B;	1E;	1F;	1G;	1H;	1L;	1M;	1X;	
2A)	
HPSE	 -1.96	 ±	0.48	 heparanase	
IDO2,	IDO1	 -2.16	 ±	0.07	 indoleamine	2,3-dioxygenase	(1;	2)	
VNN2,	VNN1	 -2.29	 ±	0.74	 vanin	(1;	2)	
CSGALNACT1	 -2.30	 ±	0.19	 chondroitin	 sulfate	 N-
acetylgalactosaminyltransferase	1	
AOX1	 -2.72	 ±	0.35	 aldehyde	oxidase	1		
Table	13.	Most	regulated	gene	groups	associated	with	metabolism	(GM-CSF)	The	gene	groups	associated	with	metabolism	that	were	most	up-	or	down-regulated	following	differentiation	under	GM-CSF	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.	
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Genes	 Mean	log2(fc)	 Description	
MYB	 3.35	 	 v-myb	myeloblastosis	viral	oncogene	homolog	
MKI67	 2.80	 ±	0.21	 antigen	identified	by	monoclonal	antibody	Ki-67	
LYZL1,	LYZL2	 2.60	 ±	0.32	 lysozyme-like	(1;	2)	
CCL13	 2.32	 	 chemokine	ligand	13	
CCR2	 2.23	 ±	0.67	 chemokine	receptor	2	
CD1B,	CD1A,	CD1E,	CD1C	 1.80	 ±	1.14	 CD1	(a;	b;	c;	e)	molecule	
PPARG	 1.22	 ±	0.16	 peroxisome	 proliferator-activated	 receptor	
gamma	
CSF2RB,	CSF3	 -1.27	 ±	0.15	 colony	 stimulating	 factor	 (2	 receptor,	 beta,	 low-
affinity;	3)	
HIF1A	 -1.32	 ±	0.14	 hypoxia	inducible	factor	1,	alpha	subunit	
DUSP1,	DUSP10,	DUSP5P,	DUSP8	 -1.48	 ±	0.48	 dual	specificity	phosphatase	(1;	10;	5	pseudogene;	
8)	
TNFAIP6,	TNFAIP2,	TNFAIP3	 -1.76	 ±	0.11	 tumor	 necrosis	 factor,	 alpha-induced	protein	 (2;	
3;	6)	
MMP14,	MMP2,	MMP1,	MMP25	 -1.77	 ±	0.74	 matrix	metallopeptidase	(1;	14;	2;	25)	
JAK3	 -1.81	 ±	0.43	 Janus	kinase	3	
TRAF1,	TRAF2,	TRAF5	 -1.85	 ±	0.80	 TNF	receptor-associated	factor	(1;	2;	5)	
IL7R,	 IL12B,	 IL4I1,	 IL1B,	 IL15RA,	
IL12RB1,	IL10,	IL8,	IL2RA,	IL15,	IL6,	IL1A	
-2.32	 ±	1.27	 interleukin	(1,	alpha;	1,	beta;	10;	12	receptor,	beta	
1;	12B;	15;	15	receptor,	alpha;	2	receptor,	alpha;	
4	induced	1;	6;	7	receptor;	8)	
CD40LG,	CD80	 -2.44	 ±	1.43	 CD	(40	ligand;	80	molecule)	
IRAK2	 -2.66	 	 interleukin-1	receptor-associated	kinase	2	
CCL19,	 CCL8,	 CCL20,	 CCL15,	 CCL14,	
CCL5	
-2.79	 ±	1.51	 chemokine	ligand	(14;	15;	19;	20;	5;	8)	
AKT1S1	 -3.81	 	 AKT1	substrate	1	
CXCL10,	CXCL11,	CXCL9	 -4.42	 ±	1.84	 chemokine	ligand	(10;	11;	9)	
 
Table	14.	Most	regulated	gene	groups	associated	with	macrophage	differentiation	
(M-CSF+IL-4)	The	gene	groups	associated	with	macrophage	differentiation	that	were	most	up-	or	down-regulated	following	differentiation	under	M-CSF+IL-4	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.	
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Genes	 Mean	log2(fc)	 Description	
CXCL10,	CXCL11,	CXCL13,	CXCL9	 4.69	 ±	1.82	 chemokine	ligand	(10;	11;	13;	9)	
CD80	 3.35	 	 CD80	molecule	
TLR3	 2.98	 	 toll-like	receptor	3	
CSF3,	CSF2	 2.69	 ±	1.34	 colony	stimulating	factor	(2;	3)	
IL12B,	 IL17RD,	 IL1B,	 IL23A,	 IL15RA,	
IL2RA,	IL12RB1,	IL8,	IL15,	IL6,	IL1A	
2.33	 ±	2.40	 interleukin	 (1,	 alpha;	 1,	 beta;	 12	 receptor,	 beta	 1;	
12B;	 15;	 15	 receptor,	 alpha;	 17	 receptor	 D;	 2	
receptor,	alpha;	23,	alpha	subunit	p19;	6;	6;	8)	
CCL19,	CCL15,	CCL5,	CCL20	 2.29	 ±	0.95	 chemokine	ligand	(15;	19;	20;	5)	
IFNG	 1.95	 	 interferon,	gamma	
MMP10,	MMP2,	MMP1	 1.83	 ±	1.24	 matrix	metallopeptidase	(1;	10;	2)	
DUSP16,	DUSP8	 1.81	 ±	0.57	 dual	specificity	phosphatase	(16;	8)	
THBS4	 1.63	 	 thrombospondin	4	
TNFAIP6,	TNFAIP3	 1.48	 ±	0.11	 tumor	necrosis	factor,	alpha-induced	protein	(3;	6)	
CD1A,	CD302	 -1.35	 ±	0.33	 CD	(1a;	302)	molecule	
F13A1	 -1.49	 ±	0.24	 coagulation	factor	XIII,	A1	polypeptide	
PPARG	 -1.51	 ±	0.10	 peroxisome	proliferator-activated	receptor	gamma	
HLA-DOA	 -1.52	 	 major	histocompatibility	complex,	class	II,	DO	alpha	
MS4A6A	 -1.55	 ±	0.36	 membrane-spanning	 4-domains,	 subfamily	 A,	
member	6A	
MYC	 -1.74	 	 v-myc	myelocytomatosis	viral	oncogene	homolog	
CCR2	 -2.71	 	 chemokine	receptor	2	
MRC1	 -3.10	 	 mannose	receptor,	C	type	1	
TLR5	 -3.41	 	 toll-like	receptor	5	
	
Table	15.	Most	regulated	gene	groups	associated	with	macrophage	differentiation	
(M-CSF+LPS)	The	gene	groups	associated	with	macrophage	differentiation	that	were	most	up-	or	down-regulated	following	differentiation	under	M-CSF+LPS	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.	
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Genes	 Mean	log2(fc)	 Description	
CD80	 3.61	 	 CD80	molecule	
CXCL10,	CXCL11,	CXCL13	 3.36	 ±	0.42	 chemokine	ligand	1	(0;	1;	3)	
CSF3,	CSF2	 3.12	 ±	0.95	 colony	stimulating	factor	(2;	3)	
CCL15,	CCL5,	CCL20	 2.79	 ±	1.65	 chemokine	ligand	(15;	20;	5)	
TLR3	 2.55	 	 toll-like	receptor	3	
IL13RA2,	 IL7R,	 IL12B,	 IL17RD,	 IL1B,	
IL23A,	 IL15RA,	 IL17RB,	 IL2RA,	
IL12RB1,	IL8,	IL15,	IL6,	IL1A	
2.33	 ±	4.48	 interleukin	 (1,	 alpha;	 1,	 beta;	 12	 receptor,	 beta	 1;	
12B;	13	receptor,	alpha	2;	15;	15	receptor,	alpha;	17	
receptor	 B;	 17	 receptor	 D;	 2	 receptor,	 alpha;	 23,	
alpha	subunit	p19;	6;	6;	7	receptor;	8)	
MMP10,	MMP3,	MMP1,	MMP12	 2.20	 ±	1.64	 matrix	metallopeptidase	(1;	10;	12;	3)	
IRAK2	 1.96	 	 interleukin-1	receptor-associated	kinase	2	
DUSP5,	DUSP8	 1.95	 ±	0.33	 dual	specificity	phosphatase	(5;	8)	
TNFAIP6,	TNFAIP3	 1.42	 ±	0.37	 tumor	necrosis	factor,	alpha-induced	protein	(3;	6)	
HLA-DMA	 -1.18	 ±	0.06	 major	histocompatibility	complex,	class	II,	DM	alpha	
MRC1,	MRC2	 -1.24	 ±	0.16	 mannose	receptor,	C	type	(1;	2)	
CD302	 -1.37	 ±	0.12	 CD302	molecule	
PPARG	 -1.64	 ±	0.03	 peroxisome	proliferator-activated	receptor	gamma	
MPEG1	 -1.75	 	 macrophage	expressed	1	
PDGFC	 -1.85	 	 platelet	derived	growth	factor	C	
MS4A6A	 -2.68	 ±	0.35	 membrane-spanning	 4-domains,	 subfamily	 A,	
member	6A	
F13A1	 -3.01	 	 coagulation	factor	XIII,	A1	polypeptide	
CCR2	 -3.06	 ±	1.84	 chemokine	receptor	2	
TLR5	 -3.49	 	 toll-like	receptor	5	
 
Table	16.	Most	regulated	gene	groups	associated	with	macrophage	differentiation	
(M-CSF+LPS+IFNγ)	The	gene	groups	associated	with	macrophage	differentiation	that	were	most	up-	or	down-regulated	following	differentiation	under	M-CSF+LPS+IFNγ	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.	
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Genes	 Mean	log2(fc)	 Description	
CXCL10,	CXCL11,	CXCL13,	CXCL9	 2.49	 ±	0.94	 chemokine	ligand	(10;	11;	13;	9)	
HLA-L	 2.29	 	 major	histocompatibility	complex,	class	I,	L,	pseudogene	
IL12B,	IL6,	IL12RB2	 2.03	 ±	1.77	 interleukin	(12	receptor,	beta	2;	12B;	6)	
MMP25	 1.89	 	 matrix	metallopeptidase	25	
HLA-DOB	 1.73	 	 major	histocompatibility	complex,	class	II,	DO	beta	
NEK10	 1.57	 ±	0.03	 NIMA-related	kinase	10	
IFNG	 1.50	 	 interferon,	gamma	
HLA-DRB6	 1.50	 	 major	histocompatibility	complex,	class	II,	DR	beta	6	
CCL19,	CCL15,	CCL14,	CCL20	 1.49	 ±	0.84	 chemokine	ligand	(14;	15;	19;	20)	
IGF1	 1.44	 ±	0.35	 insulin-like	growth	factor	1	
CELA2B,	CELA1	 1.32	 ±	0.13	 chymotrypsin-like	elastase	family,	member	(1;	2B)	
CD40LG,	CD80	 1.30	 ±	0.02	 CD	(40	ligand;	80	molecule)	
IL8,	IL2RA,	IL1R1	 -1.23	 ±	0.16	 interleukin	(1	receptor,	type	I;	2	receptor,	alpha;	8)	
CCL22,	CCL17	 -1.33	 ±	0.31	 chemokine	ligand	(17;	22)	
LYZL1	 -1.37	 	 lysozyme-like	1	
MMP1,	MMP12	 -1.42	 ±	0.05	 matrix	metallopeptidase	1	(;	2)	
PDGFC	 -1.44	 	 platelet	derived	growth	factor	C	
CSF1	 -1.54	 ±	0.15	 colony	stimulating	factor	1	
MAP2K6	 -1.78	 	 mitogen-activated	protein	kinase	kinase	6	
CD209,	CD1B	 -1.90	 ±	0.33	 CD	(1b;	209)	molecule	
MRC1	 -3.47	 	 mannose	receptor,	C	type	1	
 
Table	17.	Most	regulated	gene	groups	associated	with	macrophage	differentiation	
(GM-CSF+LPS)	The	gene	groups	associated	with	macrophage	differentiation	that	were	most	up-	or	down-regulated	following	differentiation	under	GM-CSF+LPS	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.	
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Genes	 Mean	log2(fc)	 Description	
ST6GALNAC3	 2.22	 ±	0.24	 ST6-N-acetylgalactosaminide	alpha-2,6-sialyltransferase	3	
SARDH	 2.12	 ±	0.20	 sarcosine	dehydrogenase	
SLCO4C1,	SLCO2B1	 2.10	 ±	0.87	 solute	carrier	organic	anion	 transporter	 family,	member	
(2B;	4C)	1	
SORBS1	 2.06	 ±	0.08	 sorbin	and	SH3	domain	containing	1	
LTA4H	 2.06	 ±	0.09	 leukotriene	A4	hydrolase	
ATP8B3,	ATP8B1,	ATP9A	 1.70	 ±	0.27	 ATPase,	(aminophospholipid	transporter,	class	I,	type	8B,	
member	 1;	 aminophospholipid	 transporter,	 class	 I,	 type	
8B,	member	3;	class	II,	type	9A)	
PROS1	 1.55	 ±	0.69	 protein	S	
CYP4F22,	 CYP3A5,	 CYP4F35P,	
CYP19A1	
1.54	 ±	0.20	 cytochrome	P450,	family	(19,	subfamily	A,	polypeptide	1;	
3,	subfamily	A,	polypeptide	5;	4,	subfamily	F,	polypeptide	
22;	4,	subfamily	F,	polypeptide	35,	pseudogene)	
ALDH5A1,	 ALDH7A1,	 ALDH1A2,	
ALDH1L2	
1.51	 ±	0.98	 aldehyde	dehydrogenase	(1	family,	member	A2;	1	family,	
member	L2;	5	family,	member	A1;	7	family,	member	A1)	
HSPG2	 1.46	 ±	0.22	 heparan	sulfate	proteoglycan	2	
SLC7A8,	 SLC30A3,	 SLC37A2,	
SLC39A10,	 SLC11A1,	 SLC12A6,	
SLC12A8,	 SLC44A2,	 SLC38A1,	
SLC45A4,	 SLC24A4,	 SLC13A5,	
SLC45A3,	 SLC24A3,	 SLC27A5,	
SLC15A1,	 SLC16A8,	 SLC40A1,	
SLC35F3,	 SLC23A1,	 SLC1A5,	
SLC1A7,	SLC19A1	
1.39	 ±	0.95	 solute	carrier	family	(1;	11;	12;	13;	15;	16,	member	8;	19;	
23;	24;	27;	30;	35,	member	F3;	37;	38,	member	1;	39;	40;	
44,	member	2;	45,	member	3;	7)	
SLC38A5,	 SLC39A8,	 SLC41A2,	
SLC11A2,	 SLC10A6,	 SLC35F2,	
SLC2A6,	 SLC22A13,	 SLC2A1,	
SLC9A9,	 SLC4A5,	 SLC23A3,	
SLC5A11,	 SLC26A5,	 SLC9B1,	
SLC30A4,	 SLC9B2,	 SLC43A2,	
SLC1A2	
-1.53	 ±	0.53	 solute	carrier	family	(1;	10;	11;	2;	22;	23;	26,	member	5;	
30;	 35,	 member	 F2;	 38,	 member	 5;	 39;	 4,	 sodium	
bicarbonate	cotransporter,	member	5;	41,	member	2;	43,	
member	2;	5;	9;	9,	subfamily	B)	
OAS1,	OAS3,	OAS2	 -1.67	 ±	0.60	 2'-5'-oligoadenylate	 synthetase	 (1,	 40/46;	 2,	 69/71;	 3,	
100)	kDa	
MT1DP,	 MT2A,	 MT1L,	 MT1M,	
MT1H,	 MT1E,	 MT1X,	 MT1F,	
MT1G,	MT1A,	MT1B	
-1.75	 ±	0.53	 metallothionein	(1A;	1B;	1D,	pseudogene;	1E;	1F;	1G;	1H;	
1L;	1M;	1X;	2A)	
PFKFB3	 -2.05	 ±	0.02	 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase	3	
NAMPT	 -2.13	 ±	0.08	 nicotinamide	phosphoribosyltransferase	
SAT1	 -2.30	 ±	0.12	 spermidine/spermine	 N1-acetyltransferase	 1	 (;	 )	
spermidine/spermine	N1-acetyltransferase	1	
HS3ST3B1	 -2.48	 ±	1.31	 heparan	 sulfate	 3-O-sulfotransferase	 3B1	 (;	 )	 heparan	
sulfate	3-O-sulfotransferase	3B1	
SGPP2	 -3.92	 ±	0.05	 sphingosine-1-phosphate	phosphatase	2	(;	)	sphingosine-
1-phosphate	phosphatase	2	
IDO2,	IDO1	 -5.23	 ±	0.82	 indoleamine	2,3-dioxygenase	(1;	2)		
Table	18.	Most	regulated	gene	groups	associated	with	metabolism	(M-CSF+IL-4)	The	gene	groups	associated	with	metabolism	that	were	most	up-	or	down-regulated	following	differentiation	under	M-CSF+IL-4	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.	
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Genes	 Mean	log2(fc)	 Description	
CA12	 3.98	 	 carbonic	anhydrase	XII	
CP	 3.12	 ±	0.50	 ceruloplasmin	
MT1DP,	 MT2A,	 MT1L,	 MT1M,	
MT1X,	 MT1H,	 MT1E,	 MT1F,	
MT1G,	MT1A,	MT1B	
3.00	 ±	0.61	 metallothionein	(1A;	1B;	1D,	pseudogene;	1E;	1F;	1G;	1H;	
1L;	1M;	1X;	2A)	
FFAR2,	FFAR3	 2.89	 ±	1.58	 free	fatty	acid	receptor	(2;	3)	
CMPK2	 2.83	 ±	0.20	 cytidine	 monophosphate	 kinase	 2,	 mitochondrial	 (;	 ,	
mRNA)	
CES1P2,	CES1	 2.80	 ±	0.30	 carboxylesterase	1	(;	pseudogene	2)	
HS3ST3B1	 2.50	 ±	0.47	 heparan	 sulfate	 3-O-sulfotransferase	 3B1	 (;	 )	 heparan	
sulfate	3-O-sulfotransferase	3B1	
NAMPT	 2.38	 ±	0.01	 nicotinamide	phosphoribosyltransferase	
AOX1	 2.31	 ±	0.01	 aldehyde	oxidase	1	
ADC	 2.08	 ±	0.19	 arginine	decarboxylase	
SGPP2	 2.02	 ±	0.51	 sphingosine-1-phosphate	phosphatase	2	(;	)	sphingosine-
1-phosphate	phosphatase	2	
CYP2J2,	 CYP3A7,	 CYP3A5,	
CYP7A1	
1.81	 ±	0.64	 cytochrome	P450,	family	(2,	subfamily	J,	polypeptide	2;	3,	
subfamily	A,	polypeptide	5;	3,	subfamily	A,	polypeptide	7;	
7,	subfamily	A,	polypeptide	1)	
SLC38A5,	 SLC11A1,	 SLC24A3,	
SLC7A11,	 SLC39A8,	 SLC25A37,	
SLC16A10,	 SLC18A1,	 SLC8A3,	
SLC25A28,	SLC1A2,	SLC30A2	
1.70	 ±	0.74	 solute	 carrier	 family	 (1;	 11;	 16,	member	10;	 18;	 24;	 25,	
member	28;	25,	member	37;	30;	38,	member	5;	39;	7;	8)	
OAS3,	OAS2	 1.67	 ±	0.29	 2'-5'-oligoadenylate	synthetase	(2,	69/71;	3,	100)	kDa	
CYB5R3,	CYB5R2	 1.36	 ±	0.13	 cytochrome	b5	reductase	(2;	3)	
GK,	GK5,	GK3P	 1.32	 ±	0.44	 glycerol	kinase	(;	3	pseudogene;	5)	
FTH1	 1.21	 ±	0.11	 ferritin,	heavy	polypeptide	1	
SLC37A2,	 SLC39A10,	 SLC20A1,	
SLC7A8,	 SLC45A3,	 SLC25A5,	
SLC7A1,	 SLC22A5,	 SLC38A6,	
SLC16A7,	SLC46A1,	SLC19A1	
-1.37	 ±	0.24	 solute	carrier	family	(16,	member	7;	19;	20;	22;	25;	37;	38,	
member	6;	39;	45,	member	3;	46;	7;	7)	
FABP5	 -1.55	 ±	0.03	 fatty	acid	binding	protein	5	
SLCO4C1,	SLCO2B1	 -2.07	 ±	0.20	 solute	carrier	organic	anion	 transporter	 family,	member	
(2B;	4C)	1		
Table	19.	Most	regulated	gene	groups	associated	with	metabolism	(M-CSF+LPS)	The	gene	groups	associated	with	metabolism	that	were	most	up-	or	down-regulated	following	differentiation	under	M-CSF+LPS	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.		
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Genes	 Mean	log2(fc)	 Description	
CMPK2	 2.86	 ±	0.18	 cytidine	 monophosphate	 kinase	 2,	 mitochondrial	 (;	 ,	
mRNA)	
CP	 2.70	 ±	0.39	 ceruloplasmin	
FFAR2,	FFAR3	 2.45	 ±	1.51	 free	fatty	acid	receptor	(2;	3)	
MT1DP,	 MT2A,	 MT1L,	 MT1M,	
MT1X,	 MT1H,	 MT1E,	 MT1F,	
MT1G,	MT1A,	MT1B	
2.37	 ±	0.64	 metallothionein	(1A;	1B;	1D,	pseudogene;	1E;	1F;	1G;	1H;	
1L;	1M;	1X;	2A)	
HS3ST3B1	 2.35	 ±	0.06	 heparan	 sulfate	 3-O-sulfotransferase	 3B1	 (;	 )	 heparan	
sulfate	3-O-sulfotransferase	3B1	
CYP2J2,	 CYP4A11,	 CYP19A1,	
CYP27C1,	CYP3A7,	CYP3A5	
2.34	 ±	1.80	 cytochrome	P450,	family	(19,	subfamily	A,	polypeptide	1;	
2,	subfamily	J,	polypeptide	2;	27,	subfamily	C,	polypeptide	
1;	 3,	 subfamily	 A,	 polypeptide	 5;	 3,	 subfamily	 A,	
polypeptide	7;	4,	subfamily	A,	polypeptide	11)	
CES1,	CES1P2	 2.13	 ±	0.20	 carboxylesterase	1	(;	pseudogene	2)	
SGPP2	 2.10	 ±	0.62	 sphingosine-1-phosphate	phosphatase	2	(;	)	sphingosine-
1-phosphate	phosphatase	2	
IDO2,	IDO1	 1.92	 ±	0.12	 indoleamine	2,3-dioxygenase	(1;	2)	
NAMPT	 1.86	 ±	0.06	 nicotinamide	phosphoribosyltransferase	
GCH1	 1.83	 ±	0.52	 GTP	cyclohydrolase	1	
ADC	 1.82	 ±	0.09	 arginine	decarboxylase	
SAA2,	SAA1	 1.64	 ±	0.53	 serum	amyloid	A	(1;	2)	
SLC38A5,	 SLC9A4,	 SLC39A14,	
SLC24A3,	 SLC22A11,	 SLC39A8,	
SLC5A4,	 SLC25A27,	 SLC16A12,	
SLC26A9,	 SLC8A3,	 SLC25A28,	
SLC1A2	
1.47	 ±	0.83	 solute	 carrier	 family	 (1;	 16,	 member	 12;	 22;	 24;	 25,	
member	27;	25,	member	28;	26,	member	9;	38,	member	
5;	39;	5;	8;	9)	
OAS3,	OAS2	 1.42	 ±	0.52	 2'-5'-oligoadenylate	synthetase	(2,	69/71;	3,	100)	kDa	
FABP5	 -1.19	 ±	0.03	 fatty	acid	binding	protein	5	
PNPLA3,	PNPLA7,	PNPLA4	 -1.19	 ±	0.10	 patatin-like	phospholipase	domain	containing	(3;	4;	7)	
ABHD2,	ABHD6,	ABHD14A	 -1.21	 ±	0.18	 abhydrolase	domain	containing	(14A;	2;	6)	
SLC37A2,	 SLC39A10,	 SLC38A6,	
SLC6A7,	 SLC7A8,	 SLC46A1,	
SLC46A2,	 SLC45A3,	 SLC12A7,	
SLC25A5,	 SLC46A3,	 SLC22A5,	
SLC4A7,	 SLC20A1,	 SLC2A11,	
SLC47A1,	 SLC26A11,	 SLC27A1,	
SLC4A8,	SLC43A1,	SLC19A1	
-1.48	 ±	0.48	 solute	carrier	family	(12;	19;	2;	20;	22;	25;	26,	member	11;	
27;	 37;	 38,	 member	 6;	 39;	 4,	 sodium	 bicarbonate	
cotransporter,	 member	 7;	 4,	 sodium	 bicarbonate	
cotransporter,	member	8;	43,	member	1;	45,	member	3;	
46;	46,	member	2;	46,	member	3;	47,	member	1;	6;	7)	
RBP1,	RBP7	 -1.80	 ±	0.09	 retinol	binding	protein	(1;	7)	,	cellular		
Table	 20.	 Most	 regulated	 gene	 groups	 associated	 with	 metabolism	 (M-
CSF+LPS+IFNγ)	The	gene	groups	associated	with	metabolism	that	were	most	up-	or	down-regulated	following	differentiation	under	M-CSF+LPS+IFNγ	differentiating	conditions	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.		 	
	510	
Genes	 Mean	log2(fc)	 Description	
SLCO5A1	 3.38	 	 solute	carrier	organic	anion	 transporter	 family,	member	
5A1	
SEPP1	 2.30	 ±	0.09	 selenoprotein	P,	plasma,	1	
CYP3A7,	CYP7B1	 2.15	 ±	0.21	 cytochrome	P450,	family	(3,	subfamily	A,	polypeptide	7;	7,	
subfamily	B,	polypeptide	1)	
ACPP	 1.72	 ±	0.65	 acid	phosphatase,	prostate	
PPA1	 1.66	 ±	0.01	 pyrophosphatase	1	
IGF1	 1.44	 ±	0.35	 insulin-like	growth	factor	1	
SLC38A5,	 SLC41A1,	 SLC35F2,	
SLC6A9,	SLC8A3,	SLC22A14	
1.34	 ±	0.34	 solute	carrier	family	(22,	member	14;	35,	member	F2;	38,	
member	5;	41,	member	1;	6;	8)	
SAA2,	SAA1	 1.11	 ±	0.09	 serum	amyloid	A	(1;	2)	
GFOD1	 -1.07	 ±	0.01	 glucose-fructose	oxidoreductase	domain	containing	1	
ITPK1	 -1.11	 ±	0.07	 inositol-tetrakisphosphate	1-kinase	
ALDH5A1,	ALDH1A2	 -1.26	 ±	0.14	 aldehyde	dehydrogenase	(1	family,	member	A2;	5	family,	
member	A1)	
GPAT2	 -1.26	 ±	0.25	 glycerol-3-phosphate	acyltransferase	2,	mitochondrial	
PGM5	 -1.31	 ±	0.23	 phosphoglucomutase	5	
SLC39A10,	 SLC7A8,	 SLC11A1,	
SLC24A4,	 SLC3A1,	 SLC24A3,	
SLC7A11,	 SLC22A5,	 SLC12A1,	
SLC16A10,	 SLC47A1,	 SLC12A8,	
SLC30A3,	SLC30A2	
-1.36	 ±	0.33	 solute	carrier	family	(11;	12;	12;	16,	member	10;	22;	24;	3;	
30;	39;	47,	member	1;	7;	7)	
PROS1	 -1.47	 ±	0.10	 protein	S	
CYP4F22,	CYP19A1	 -1.59	 ±	0.44	 cytochrome	P450,	family	(19,	subfamily	A,	polypeptide	1;	
4,	subfamily	F,	polypeptide	22)	
CSGALNACT1	 -1.77	 ±	0.12	 chondroitin	sulfate	N-acetylgalactosaminyltransferase	1	
SLCO2B1	 -2.17	 	 solute	carrier	organic	anion	 transporter	 family,	member	
2B1	
HPGD	 -2.35	 	 hydroxyprostaglandin	dehydrogenase	15-(NAD)	
RETN	 -2.66	 ±	0.23	 resistin		
Table	21.	Most	regulated	gene	groups	associated	with	metabolism	(GM-CSF+LPS)	The	gene	groups	associated	with	metabolism	that	were	most	up-	or	down-regulated	following	differentiation	under	GM-CSF+LPS	differentiating	conditions.	Genes	from	the	same	family,	having	>	2	fold	positive	or	negative	regulation	and	having	similar	functions	were	grouped	prior	to	the	selection.	Listed	values	are	the	mean	log2	fold-change	of	the	grouped	genes,	±	the	range	of	measured	values	within	each	group.	Single	genes	with	multiple	isoforms	are	grouped	together.	
 
